


EAS



84th EAS CONGRESS

May 29 - June 1, 2016
Innsbruck, Austria



Innsbruck PROGRAMME BOOK

www.eas2016.kenes.com

EAS




EAS 2016 AT YOUR FINGERTIPS

Download the App for the Full Congress Experience Search "EAS 2016"

Your all-in-one guide for the duration of the Congress:

- Access the programme and venue maps
- Bookmark your preferred sessions and read about your favorite speakers
- Receive important notifications from the organisers
- Learn about exhibitors and sponsors, accreditation, and much more



EAS



84th EAS CONGRESS

May 29 - June 1, 2016
Innsbruck, Austria



PROGRAMME BOOK

Organised by



Rue François-Versonnex 7
1207 Geneva, Switzerland
Tel: +41 22 501 7420
Fax: +41 22 906 9140
Email: eas@kenes.com

CONTENTS

Welcome Letter	3
Committees	4
The European Atherosclerosis Society	6
About Innsbruck	8
EAS Keynote Lecture	9
The Anitschkow Prize	10
Young Investigator Awards	11
General Information	13
CME Accreditation	16
Information for Presenters	19
Poster Area Map	22
Programme at a Glance	24
Congress Floor Plan	28
Hall Name Eulogy of Distinguished Scientists	30
Scientific Programme	
Sunday, May 29, 2016	35
Monday, May 30, 2016	41
Tuesday, May 31, 2016	57
Wednesday, June 1, 2016	73
Science at a Glance Presentations	81
Poster Presentations, Monday May 30, 2016	99
Poster Presentations, Tuesday, May 31, 2016	137
Index of Authors	181
Recognition, Acknowledgements and Commercial Support	217
Acknowledgements	219
Industry Sponsored Sessions	222
Educational Grant	228
Exhibition Information	229
List of Sponsors and Exhibitors	231

DEAR FRIENDS AND COLLEAGUES,

On behalf of the European Atherosclerosis Society (EAS) and the Austrian Atherosclerosis Society (AAS) we are delighted to welcome you to Innsbruck for the 84th EAS Congress.

The congress committees have been working hard on preparing a programme of scientific excellence that will excite and inform the European and Global Atherosclerosis communities. We are particularly proud to announce the certainly inspiring Keynote Lecture by Nobel laureate Michael S. Brown entitled "How genes control cholesterol" and invaluable contributions by outstanding plenary speakers. The comfortable atmosphere of the congress venue and its impressive setting will provide a unique meeting place for high-level interdisciplinary exchange of newest research highlights and effective networking among participants from more than 70 countries from across the world.

The congress will be held at Congress Innsbruck, located next to the scenic river Inn and in walking distance to the city centre and all major hotels. Innsbruck is one of the most beautiful cities in the Alps, surrounded by impressive mountain peaks. Another attraction, of course, are the superb Tyrolean culinary highlights that will be offered during the unique Social Programme and throughout the meeting. Finally, for those with a few days to spare, there are many interesting opportunities to visit Innsbruck's cultural highlights before and after the congress.

The 84th EAS congress is accompanied by an International Satellite Symposium on Lp(a) two days ahead of the main congress, again bringing together world experts in this small but exciting and emerging field of an extraordinary atherogenic lipoprotein.

On behalf of the organising committee, we welcome you to Innsbruck for a memorable and inspiring congress.



Alberico L. Catapano
EAS President



Geesje Dallinga-Thie
Chair,
Programme
Scientific
Committee



Seppo Ylä-Herttua
Co-Chair,
Programme
Scientific
Committee



Hans Dieplinger
Congress Chair



Florian Kronenberg
Congress Chair

COMMITTEES

CONGRESS CHAIRS

Hans Dieplinger, Austria
Florian Kronenberg, Austria

EAS EXECUTIVE COMMITTEE

Alberico L. Catapano, Italy, **President**
Olov Wiklund, Sweden, **Vice President**
M. John Chapman, France, **Past President**
Petri Kovanen, Finland, **Secretary & Award Committee Chair**
Jan Borén, Sweden, **Treasurer**
Lale Tokgözoglu, Turkey, **President Elect**
Christoph J. Binder, Austria
Geesje Dallinga-Thie, The Netherlands
Børge Nordestgaard, Denmark
Arnold von Eckardstein, Switzerland
Michal Vrablik, Czech Republic

LOCAL ORGANISING COMMITTEE

Hans Dieplinger, Innsbruck, **Congress Chair**
Florian Kronenberg, Innsbruck, **Congress Co-Chair**
Christoph Binder, Vienna
Benjamin Dieplinger, Linz
Christoph Ebenbichler, Innsbruck
Bernhard Föger, Bregenz
Gerhard Kostner, Graz
Dagmar Kratky, Graz
Bernhard Paulweber, Salzburg
Ruth Prassl, Graz
Andreas Ritsch, Innsbruck
Wolfgang Schneider, Vienna
Herbert Stangl, Vienna
Ernst Steyrer, Graz
Gerd Utermann, Innsbruck
Rudolf Zechner, Graz

SCIENTIFIC PROGRAMME COMMITTEE

Geesje Dallinga-Thie, The Netherlands, **Chair**
Seppo Ylä-Herttua, Finland, **Co-Chair**
Eric Bruckert, France
Alberico L. Catapano, Italy
Hans Dieplinger, Austria
Jörg Heeren, Germany
Dimitris Kardassis, Greece
Florian Kronenberg, Austria
Chris Packard, UK
Erik Stroes, The Netherlands
Arnold von Eckardstein, Switzerland

COUNSELLING MEMBERS

Gerhard Kostner, Austria
Wolfgang Schneider, Austria

CONGRESS COMMITTEE

Marja-Ritta Taskinen, Finland, **Chair**
Jan Borén, Sweden
Hans Dieplinger, Austria
Danilo Norata, Italy
Chris Packard, UK

APPRECIATION AND THANKS

We would like to thank the reviewers of the submitted abstracts for their valuable help and assistance.

FACULTY LIST

Afonyuskin Taras, Austria
Alitalo Kari, Finland
Armitage Jane, UK
Assmann Gerd, Germany
Averna Maurizio, Italy
Banach Maciej, UK
Besseling Joost, The Netherlands
Binder Christoph J., Austria
Borén Jan, Sweden
Bossano Prescott Eva, Denmark
Boulanger Chantal M., France
Brouwer Ingeborg A., The Netherlands
Brown Mark J., USA
Brown Michael, USA
Bruckert Eric, France
Bujo Hideaki, Japan
Caligiuri Giuseppina, France
Carmeliet Peter, Belgium
Catapano Alberico, Italy
Chapman M. John, France
Colhoun Helen, UK
Dallinga-Thie Geesje, The Netherlands
de Meyer Guido R.C., Belgium
Després Jean-Pierre, Canada
Dieplinger Benjamin, Austria
Dieplinger Hans, Austria
Ebenbichler Christoph J., Austria
El-Osta Assam, Australia
Farinaro Eduardo, Italy
Ferri Nicola, Italy
Föger Bernhard, Austria
Fu Jingyuan, The Netherlands
Gaetano Carlo, Germany
Gaudet Daniel, Canada
Gordts Philip, USA
Graham Ian, Ireland
Herz Joachim, USA
Heeren Jörg, Germany
Hersberger Martin, Switzerland
Hobbs Helen, USA
Hoefler Imo, The Netherlands

Hoffmann Michael, Germany
Humphries Steve, UK
Hunt Steve, Qatar
Jauhainen Matti, Finland
Kararigas Georgios, Germany
Kardassis Dimitris, Greece
Karpe Fredrik, UK
Koenig Wolfgang, Germany
Kollerits Barbara, Austria
Kostner Gerhard, Austria
Kotseva Kornelia, UK
Kovanen Petri, Finland
Kratky Dagmar, Austria
Kronenberg Florian, Austria
Kuivenhoven Jan Albert, The Netherlands
Lambert Gilles, France
Lamina Claudia, Austria
Laufs Ulrich, Germany
Letourneur Didier, France
Luetjohann Dieter, Germany
Ley Klaus, USA
Lichtenstein Alice H., USA
Lutgens Esther, The Netherlands
Mach Francois, Switzerland
Maegdefessel Lars, Sweden
März Winfried, Germany
Malik Vasanti, USA
Mangelsdorf David, USA
Manolio Teri, USA
Marsche Gunther, Austria
Martinez Laurent O., France
Matsuzawa Yuji, Japan
McCormick Sally, New Zealand
Moschetta Antonio, Italy
Moulin Philippe, France
Müller Thomas, Austria
Nicholls Stephen, Australia
Norata Giuseppe Danilo, Italy
Nordestgaard Børge, Denmark
Öörni Katariina, Finland
Packard Chris, UK
Parini Paolo, Sweden
Pasterkamp Gerard, The Netherlands
Paulweber Bernhard, Austria

Pechlaner Raimund, Austria
Piepoli Massimo, Italy
Poirier Steve, Canada
Prassl Ruth, Austria
Ray Kausik K., UK
Reaven Peter D., USA
Ripatti Samuli, Finland
Ritsch Andreas, Austria
Rudling Mats, Sweden
Ryan Robert O., USA
Sanjana Neville, USA
Schmid Johannes, Austria
Schneider Markus, Germany
Schneider Wolfgang, Austria
Scharbagt Hubert, Austria
Scheja Ludger, Germany
Schunkert Heribert, Germany
Seed Mary, UK
Stangl Herbert, Austria
Steinhagen-Thiessen Elisabeth, Germany
Steyrer Ernst, Austria
Stojakovic Tatjana, Austria
Stroes Erik, The Netherlands
Suhre Karsten, Qatar
Stuling Thomas, Austria
Taskinen Marja-Riitta, Finland
Tawakol Ahmed, USA
Titze Jens M., Germany
Tokgözoglu Lale, Turkey
Tschöp Matthias, Germany
Ulmer Hanno, Austria
Utermann Gerd, Austria
van Gaal Luc, Belgium
von Eckardstein Arnold, Switzerland
Vrablik Michal, Czech Republic
Watts Gerald, Australia
Wiklund Olov, Sweden
Willeit Peter, UK
Ylä-Herttua Seppo, Finland
Yvant-Charvet Laurent, France
Zambon Alberto, Italy
Zechner Rudolf, Austria
Zelcer Noam, The Netherlands
Zimmermann Robert, Austria

THE EUROPEAN ATHEROSCLEROSIS SOCIETY

The European Atherosclerosis Society (EAS) was founded in 1964 with the aim of “advancing and exchanging knowledge concerning the causes, natural history, treatment and prevention of atherosclerotic disease”.

For more than 50 years the Society’s expertise has been used to teach clinicians how to manage lipid disorders and how to prevent atherosclerosis. By offering to our members access to educational materials, and opportunities to take part in Congress and courses, and by providing a forum in which new developments can be discussed, EAS contributes to the development of knowledge in the field, and ultimately to the improved treatment of persons with cardiovascular disease and lipid disorders.

In recent years the Society has made a particular effort to recruit young scientists and clinicians also from other related disciplines.

The European Atherosclerosis Society’s goal is to provide a framework for concerted scientific and clinical discussion of new developments in basic research, diagnosis and therapy of atherosclerosis.

WHAT WE DO – AT A GLANCE

- EAS is active in the publication of **Guidelines** and **Consensus Position Papers**, and its official **Journal** is *Atherosclerosis*. Through a regular series of **Featured Commentaries** EAS puts into perspective topical issues of relevance to our members.
- The Society organizes an annual **Congress** for approximately 2000 delegates, and runs a programme of **Advanced Courses** for both basic scientists and clinicians.
- **EAS Academy** is the Society’s online e-Learning resource, containing a range of educational material and self-teaching programmes.
- EAS is co-organiser of the **European Lipoprotein Club** (ELC) annual Scientific meeting.
- EAS coordinates the **FH Studies Collaboration**, working to establish an international registry of observational studies on FH.

WHY SHOULD I BECOME AN EAS MEMBER?

CONTINUE YOUR PROFESSIONAL DEVELOPMENT WITH EAS EDUCATIONAL ACTIVITIES - ADVANCED COURSES & EAS ACADEMY

EAS membership offers opportunities to deepen your theoretical skills and/or practical knowledge, which you can then apply in your own research or clinical practice. The Society organises educational activities such as Advanced Courses (many CME accredited by EBAC), and offers a wealth of online learning material, such as webcasts, videos and quizzes, on the Society’s educational platform, EAS Academy. As an EAS member, you have access to the very latest uploaded material, EAS Academy’s Premium content.

STAY WELL INFORMED WITH EAS PUBLICATIONS

EAS membership makes it easier for those working in the field to stay abreast of the latest developments in the field. In addition to access to the Society’s own publications of Consensus position papers and Guidelines, EAS membership includes complimentary access to *Atherosclerosis Journal* (worth ca. 300 €), and members receive by email newsletters and featured commentaries on topical issues.

INTERACT WITH LEADING EXPERTS IN THE FIELD AT EAS CONGRESS

The participants at EAS annual Congress are world leaders in atherosclerosis research and clinical practice, and the size and format of the Congress lends itself to networking and interaction. EAS members are encouraged to submit their findings as an abstract to Congress, where they can participate at significantly reduced registration fee (savings of up to 100 € compared to non-member fees).

APPLY FOR GRANTS AND PRIZES AS AN EAS MEMBER

EAS members may apply for the Society’s travel grants to attend Congress, and, where eligible, may apply for the Society’s Prizes.

GREAT VALUE MEMBERSHIP BENEFITS AT AFFORDABLE ANNUAL SUBSCRIPTION RATES

EAS’ aim is to provide access to learning that will help our members to manage lipid disorders and to prevent and treat atherosclerosis. We keep our annual membership subscription rates low – 40 € (persons over 35) or 20 € (persons 35 or younger) – so that as many as possible can afford to become members.

HOW TO BECOME AN EAS MEMBER

If you’re not an EAS member and would like to become one, you should complete the application form and pay the annual subscription fee. Once your application is approved, and the subscription payment processed, you become eligible for membership benefits for one year at www.eas-society.org.



ABOUT INNSBRUCK

Innsbruck is the capital city of the federal state of Tyrol in western Austria. It is located in the Inn Valley at the junction with the Wipptal (Sill River), which provides access to the Brenner Pass, some 30 kilometers (19 mi) south of Innsbruck. Located in a broad valley between high mountains, it is an internationally renowned winter sports centre.

Innsbruck serves as an ideal place for skiing in winter, and mountaineering in summer. There are several ski resorts around Innsbruck as well as nearby, which include the Axamer Lizum, Patscherkofel, Igls, Seefeld, Tulfes and Stubai Valley.

The city of Innsbruck is suffused with the spirit of the Habsburg dynasty.

The Habsburgs' legacy in Innsbruck is sumptuous and palatial majestic and has left many architectural landmarks in the city.

EAS KEYNOTE LECTURE

The Keynote Lecture at EAS Congress 2016 is given by **Michael S. Brown, Paul J. Thomas Professor of Molecular Genetics and Director of the Jonsson Center for Molecular Genetics at University of Texas Southwestern, Dallas, USA.**



Dr. Brown and his long-time colleague, Dr. Joseph L. Goldstein, are recognised as the discoverers of the low density lipoprotein (LDL) receptor, which controls the level of cholesterol in blood and in cells. Drs. Brown and Goldstein have received many awards for this work, including the U.S. National Medal of Science and the Nobel Prize for Medicine or Physiology in 1985.

Working together, Drs. Brown and Goldstein showed that familial hypercholesterolaemia is caused by genetic defects in the LDL receptor, which disrupt the normal regulation of cholesterol metabolism. Their studies led to the elucidation of the mechanism by which this receptor carries LDL particles into cells through coated pits and coated vesicles. These LDL receptor studies provided clear evidence for selective uptake of macromolecules into cells, giving rise to the concept of receptor-mediated endocytosis.

More recently, study of another genetic disease called Niemann-Pick C (NPC), has provided insights into how cholesterol is transported from one organelle to another, which underlie the consistency in cholesterol concentration in the plasma membrane. Extensive studies showed that both the NPC1 and NPC2 proteins have the capacity for binding LDL cholesterol. Whereas binding of cholesterol to NPC2 is rapid, occurring within minutes, binding to NPC1 is extremely slow, requiring several hours to reach equilibrium. However, this process can be accelerated when cholesterol is delivered by NPC2. Based on these findings, it was proposed that NPC2 extracts cholesterol from LDL in the lysosome and then transfers it to the N-terminal domain of membrane-bound NPC1 for insertion into the lysosomal membrane, currently being tested in the laboratory of Professor Brown.

The work of Drs. Brown and Goldstein has not only been the stimulus for new thinking about cholesterol homeostasis, but also has led to the development of new concepts in biology. Specifically, these include selective sorting of proteins within the plasma membrane, a prerequisite for receptor-mediated endocytosis; receptor-mediated endocytosis and receptor recycling; and, finally, the concept of feedback regulation of receptors.

Michael Brown graduated in 1962 from the College of Arts and Sciences of the University of Pennsylvania, with chemistry as his major subject, and subsequently obtained his M.D. degree in 1966 at the same university. He was an intern and resident at the Massachusetts General Hospital, where he met Joseph L. Goldstein, a fellow intern; the two established the friendship and mutual respect that led to their long-term scientific collaboration. Dr. Brown subsequently completed a postdoctoral fellowship at the National Institutes of Health, before moving to UT Southwestern, becoming Professor in 1976. The remainder of this story has been instrumental in changing how hypercholesterolaemia is managed, and paving the way for innovative new therapeutic agents targeting LDL cholesterol.

THE ANITSCHKOW PRIZE



THE ANITSCHKOW PRIZE RECIPIENT 2016 IS PROFESSOR PETER CARMELIET, PROFESSOR AT THE KATHOLIEKE UNIVERSITEIT LEUVEN (LEUVEN, BELGIUM).

The Anitschkov lecture entitled *Endothelial Cell Metabolism: A Novel Player in Atherosclerosis? Basic Principles and Therapeutic Opportunities* will be part of the Congress Opening Ceremony.

PROFESSOR PETER CARMELIET



Peter Carmeliet is a physician and professor at the Katholieke Universiteit Leuven (Leuven, Belgium). He is former director (2008-2015) of the Vesalius Research Center, VIB - KU Leuven and is heading the Laboratory of Angiogenesis and Vascular Metabolism at the VRC. His research interests are vasculogenesis, angiogenesis, and vascular endothelial growth factors. His research group has sought to elucidate the molecular basis of angiogenesis with the aim of translating their findings to therapeutic concepts and ultimately novel treatments. Latest findings indicate that the efficacy of current anti-angiogenic therapy in cancer is limited by intrinsic refractoriness and acquired drug resistance. To overcome this problem, his research

team pioneered the study of endothelial cell metabolism during vessel sprouting. Professor Carmeliet is the recipient of numerous awards, including InBev-Baillet Latour health prize (2010), Ernst Jung-Priz für Medizin (2010), the Blaise Pascal Medal in Medicine and Life Sciences by the European Academy of Sciences (2011), the Münster Heart Center Award (2015), and award of the Noble title of Baron, granted by King Filip of Belgium (2015).

YOUNG INVESTIGATOR AWARDS

THESE ANNUAL AWARDS ARE PRESENTED BY EAS FOR OUTSTANDING PUBLICATIONS BY YOUNG SCIENTISTS IN THE FIELD OF ATHEROSCLEROSIS

STEVE POIRIER



In 2003, Steve joined the team of Dr. Nabil Seidah at the Clinical Research Institute of Montreal the same year the laboratory published the identification of PCSK9 and its link to familial hypercholesterolemia. Over the years, he actively designed and performed key experiments as well as collaborated with international researchers to accomplish important studies in the highly competitive field of PCSK9 biology in cardiovascular diseases. Cited by more than 850 publications, those manuscripts have questioned and revisited published papers that supported the fact

that PCSK9 had only one target and that it was acting exclusively via an extracellular route. He was the first to show that PCSK9 has other important targets towards LDLR family members and revealed the existence of an intracellular route for PCSK9-induced LDLR degradation. In addition, he also made many other significant contributions in the field of PCSK9 such as the identification of the two known natural inhibitors of PCSK9 namely AnxA2 (extra-hepatic) and GRP94 (hepatic) now used as precursors for the design of lipid-lowering agents with high therapeutic potentials. He also showed that the cytosolic adaptor AP-1A is directly implicated in the intracellular trafficking of Niemann-Pick type C proteins and revealed the first evidence and mechanism by which the cancer drug 5-Azacytidine favorably perturbs lipid and cholesterol metabolism. Together with his great scientific partner Dr. Gaëtan Mayer (CSO), he is the co-founder and CEO of Monogenic Pharmaceuticals a Montreal Heart Institute-based biotech primarily developing 4 distinct unprecedented and highly innovative therapeutic pipelines to lower circulating LDL-Cholesterol and cardiovascular diseases by specifically targeting PCSK9.

YOUNG INVESTIGATOR AWARDS

JOOST BESSELING



Dr. Besseling started Med School at the University of Amsterdam (the Academic Medical Center) in 2004 and obtained his medical degree in 2012. Subsequently, he started his PhD research under the guidance of Prof. Kastelein, Dr. Hovingh and Dr. Hutten.

He worked on studies focused on different aspects of familial hypercholesterolemia and published in highly cited peer reviewed journals, such as Lancet and JAMA. He specifically focused on the diagnosis, consequence and treatment of FH and as such showed that FH patients are relatively protected from diabetes mellitus.

Moreover, he developed a new prediction model for carriership

of an FH mutation, and investigated the consequence of CETP inhibition in these patients. In January 2016, he started his residency to become a board certified specialist in internal medicine, and in October 2016, he will defend his PhD thesis on familial hypercholesterolemia.

GENERAL INFORMATION

VENUE

Congress und Messe Innsbruck GmbH
Rennweg 3
6020 Innsbruck, Austria
www.cmi.at

OFFICIAL LANGUAGE

The official language of the Congress is English. All presentations will be made in English.

CLOTHING

Clothing is informal for all occasions.

REGISTRATION DESK HOURS

The Registration Desk will be situated at the North Entrance, ground level of the convention center, as follows:

Sunday, May 29	10:00 – 21:00
Monday, May 30	07:30 – 19:40
Tuesday, May 31	08:00 – 18:30
Wednesday, June 1	08:00 – 12:30

EXHIBITION OPENING HOURS

Sunday, May 29	17:30 – end of Welcome Reception
Monday, May 30	10:00 – 17:30
Tuesday, May 31	10:00 – 17:30
Wednesday, June 1	10:00 – 12:30

CONGRESS NAME BADGE

Upon registration you will receive your name badge. You are kindly requested to wear your badge during all sessions and events.

EAS 2016 APP

Install the EAS 2016 interactive mobile App to your smartphone and portable devices to access all the Congress information you could need during the Congress:

- See the overview of sessions, speakers and exhibitors
- Create your own programme for the event, including bookmarking the sessions you wish to attend
- Receive real-time updates

Download the EAS App now to enhance your congress experience! (available on the App Store or Google Play).



EAS 2016 E-BOOK

EAS 2015 Final Programme E-Book is available online and can be viewed and downloaded at: www.eas2016.kenes.com

This e-book offers a 'green alternative' to the printed programme book, provides delegates a convenient and enjoyable way to access congress content on the move and is designed to provide a user friendly interface on any mobile device. EAS is dedicated to implementing innovative and environmentally-friendly technology. The programme book can be downloaded as a PDF file from the congress website.

REFRESHMENTS

Coffee and refreshments will be served to Congress participants in the Exhibition Area from May 29-June 1, as indicated in the Programme.

Cash Bars will be available next to the Exhibition Area.

INTERNET ACCESS

WiFi is available for congress participants throughout the public areas. In order to log in please use the following user name and password:

User name: **eas-2016**

Password: **eas-2016**

Free internet and email facilities will be available in the exhibition area during the exhibition opening hours only. Congress abstracts will also be available for viewing from these stations. Please be considerate of fellow participants when using these facilities.

CONGRESS ABSTRACTS

The congress abstracts will be published online in the Atherosclerosis Journal following the congress.

MOBILE PHONES AND PHOTOGRAPHY

Participants are kindly requested to keep their mobile phones switched off in session halls and refrain from taking pictures during sessions.

SMOKING POLICY

The 84th EAS Congress is a Non-Smoking event and participants are requested to refrain from smoking in the venue.

CLOAK ROOM

A cloak room will be available for participants on Wednesday, June 1st at the Innfoyer.

LIABILITY AND INSURANCE

The Congress Secretariat and Organisers cannot accept liability for personal accidents or loss of or damage to private property of participants. Participants are advised to take out their own personal travel and health insurance for their trip.

SAFETY AND SECURITY

Please do not leave bags or suitcases unattended at any time, whether inside or outside the session halls. Hotels strongly recommend that you use their safety deposit boxes for your valuables.



WEBCASTING

A selection of sessions will be webcast and will be available on the Society website after the Congress.

CONGRESS ORGANISERS



84th EAS Congress
Rue François-Versonnex 7,
1207 Geneva,
Switzerland
Tel: +41 22 501 7420
Fax: +41 22 906 9140
E-mail: eas@kenes.com

CME ACCREDITATION

EDUCATIONAL OBJECTIVES

After participating in this educational event, learners should be able to:

- Address individual needs in compliance with their Continuous Professional Development (CPD) plan.
- Exchange ideas and knowledge in the field of Atherosclerosis and related cardiovascular conditions across continents, institutions, and individuals.
- Discuss the innovative new therapeutic agents targeting LDL cholesterol.
- Identify possible programmatic collaborations to more effectively address regional, national and local responses to Atherosclerosis around the world and overcome barriers that limit access to prevention, care and services.
- Discuss the latest scientific advantages in the field of Atherosclerosis and related cardiovascular conditions.
- Summarise the latest research outcomes in the field of Atherosclerosis and related cardiovascular conditions.

TARGET AUDIENCE

Specialists in the field of atherosclerosis, clinical chemistry, diabetes, endocrinology, primary care and more.

ACCREDITATION STATEMENT AND CREDIT DESIGNATION EUROPEAN BOARD FOR ACCREDITATION IN CARDIOLOGY (EBAC)

An application was made to the European Board for Accreditation in Cardiology (EBAC) for CME accreditation of this event. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

AMERICAN MEDICAL ASSOCIATION (AMA)

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

ROYAL COLLEGE OF PHYSICIANS AND SURGEONS OF CANADA

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada. For more information, visit: www.royalcollege.ca.

CREDIT BREAKDOWN

Day	Monday, May 30	Tuesday, May 31	Wednesday, June 1	Total Credits:
Maximum Credits	6	6	3	15

EBAC ACCREDITED EDUCATIONAL PROGRAMME

EBAC Accredited Educational Programmes will be taking place during the Congress as follows:

- EBAC Accredited Educational Programme: Diet and prevention of cardiovascular disease. Symposium at EAS 2016 Innsbruck Sunday, May 29, 2016, 14:00-15:30
This session is supported by an unrestricted educational grant from BASF, Raisio and Unilever.
- EBAC Accredited Educational Programme: Gene therapy and lipoprotein lipase deficiency. Symposium at EAS 2016 Innsbruck Sunday, May 29, 2016, 14:00-15:00
This session is supported by an unrestricted educational grant from Chiesi.
- EBAC Accredited Educational Programme: Gene therapy and lipoprotein lipase deficiency. Symposium at EAS 2016 Innsbruck Monday, May 30, 2016, 13:00-14:00
This session is supported by an unrestricted educational grant from Meda (Rottapharm).
- EBAC Accredited Educational Programme: Low HDL high triglyceride, diabetic dyslipidaemia. Symposium at EAS 2016 Innsbruck Tuesday, May 31, 2016, 13:00-14:00
This session is supported by an unrestricted educational grant from Mylan.
- EBAC Accredited Educational Programme: Lysosomal Acid Lipase Deficiency. Symposium at EAS 2016 Innsbruck Tuesday, May 31, 2016, 13:00-14:00
This session is supported by an unrestricted educational grant from Alexion.

In compliance with EBAC/ EACCME guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest that might cause a bias in the presentations. The Organizing Committee is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

CREDIT BREAKDOWN

Day	Sunday, May 29	Monday, May 30	Tuesday, May 31	Total Credits:
Maximum Credits	2	1	2	5

TO RECEIVE YOUR CME/CPD CERTIFICATE

The CME/CPD certificate will be available after completing the online evaluation and credit claiming procedure. The process takes about 5 minutes. We thank you for your feedback as it is an important part of CME/CPD accreditation and helps improve future educational offerings.

Before June 29, 2016:

1. Access the online system via any of the following
 - Please note that web browsers Mozilla Firefox 2.X or higher, or Google Chrome are recommended
 - Visit the CME/CPD Accreditation page on the event website
 - Follow the link in the email sent at the end of the event
2. Complete the anonymous online evaluation
3. Complete the credit claim form and submit
4. The CME/CPD certificate will be available for download; fill-in and retain for your personal records

DISCLOSURE AND RESOLUTION OF PERSONAL CONFLICTS OF INTEREST

In accordance with CME/CPD accreditation criteria and standards for commercial support to ensure balance, independence, objectivity, and scientific rigor, those in control of the educational content must disclose potential or actual conflicts of interest. Disclosure information is evaluated and conflicts of interest resolved. Disclosure is made to participants prior to the activity. Participants will be asked on the evaluation to assess the objectivity and independence of the event.

INDUSTRY SUPPORT DISCLOSURE

This event is supported, in part, by funding from industry. All support is managed in strict accordance with CME/CPD accreditation criteria and standards for commercial support. Appropriate acknowledgement of all supporting organizations is made in the Programme guide, on the event website, and with signage during the event. Disclosure is made to participants prior to the activity.

Aegerion Pharmaceuticals	Akcea Therapeutics	Alexion	Amgen	BASF
Chiesi	Denka Seiken	European FH Network	FH Score	Fuji Film/Sonosite
IBL	Kaneka Pharma	Kowa	Meda Pharma	Merck MSD
Mercodia	Mylan	Numares	Pfizer	Raisio
Randox	Regeneron	Sanofi	Unilever	Wisepress

INFORMATION FOR PRESENTERS

ORAL PRESENTATIONS

DATA PRESENTATION:

A speakers' ready room will be available throughout the entire Congress for speakers. The room is located on the 1st Level (Maximilian).

If using a PowerPoint presentation (or any other PC based application, such as PDF), please note you need to bring it on USB Memory stick and load it on one of the Congress computers in the Speakers' Ready Room at least 1 hour before the start of the session.

The recommended format for PPT presentations is 16:9.

Please make sure to prepare your presentation accordingly.

Please note that the Congress computers in the session halls are being supplied with Office 2010 (at least).

If combining video films with PowerPoint, please make sure to check it in the session hall where your lecture is taking place during the break prior to your session, at least 30 minutes before the start of the session - **even after checking it in the Speakers' Ready Room.**

Alternatively you may supply your own laptop computer. In such a case please confirm that it has a VGA socket for external signal and come to check it first in the Speakers' Ready Room as soon as you arrive and later on in the session hall where your lecture is taking place during the break prior to your session, at least 30 minutes before the start of the session.

Important note for Apple Mac users:

In order to use MAC presentations on a PC compatible computer please note that you need to prepare it according to the instructions below, before bringing it to the Speakers' Ready Room:

1. Use a common font, such as Arial, Times New Roman, Verdana etc. (special fonts might be changed to a default font on a PowerPoint based PC).
2. Insert pictures as JPG files (and not TIF, PNG or PICT - these images will not be visible on a PowerPoint based PC).

Alternatively you may use your own Macintosh laptop computer. In such a case please confirm you provide it with a **VGA adaptor** for external signal, advise the operators in the Speakers' Ready Room about it as soon as you arrive and later on test it in the session hall where your lecture is taking place during the break prior to your session, at least 30 minutes before the start of the session

SCIENCE AT A GLANCE PRESENTATIONS

EAS is proud to have Science at a Glance E-Poster sessions that will be located in the Exhibition area, providing the unique opportunity for convivial scientific discussions and exchange. For further details please refer to the Overview of these Sessions.

OVERVIEW OF SCIENCE AT A GLANCE E-POSTER SESSIONS

SESSION I, MONDAY, MAY 30, 2016 13:00-14:00

Session Topic	Session Chair	E-Poster Station	Poster #
Lipids and Lipoproteins	Jörg Heeren, Germany	Station A	SaG001-SaG008
Vascular Biology I	Guido de Meyer, Belgium	Station B	SaG009-SaG016
Genetic, Omics and in silico Approaches	Neville Sanjana, USA	Station C	SaG017-SaG024
CV Risk Factors and Atherosclerosis I	Yuji Matsuzawa, Japan	Station D	SaG25-SaG032

SESSION II, MONDAY, MAY 30, 2016 14:00-15:00

Session Topic	Session Chair	E-Poster Station	Poster #
Experimental Cardiovascular Medicine I	Paolo Parini, Sweden	Station A	SaG033-SaG040
Nutrition, Nutraceuticals and Cardiovascular Disease	Alice H. Lichtenstein, USA	Station B	SaG041-SaG048
Pharmacology of Dyslipidemia	Maurizio Averna, Italy	Station C	SaG049-SaG056
Imaging in Vascular Dysfunction and Myocardial Infarction	Wolfgang Koenig, Germany	Station D	SaG057-SaG064

SESSION III, TUESDAY, MAY 31, 2016 13:00-14:00

Session Topic	Session Chair	E-Poster Station	Poster #
CV risk factors and Atherosclerosis II	Winfried März, Germany	Station A	SaG065-SaG072
Vascular Biology II	Herbert Stangl, Austria	Station B	SaG073-SaG080
Insulin Resistance, Diabetes, Metabolic Syndrome and Obesity	Gerald Watts, Australia	Station C	SaG081-SaG088
Hypertension, Liver and Chronic Renal Disease	TBA	Station D	SaG089-SaG096

SESSION IV, TUESDAY, MAY 31, 2016 14:00-15:00

Session Topic	Session Chair	E-Poster Station	Poster #
Experimental Cardiovascular Medicine II	Matti Jauhiainen, Finland	Station A	SaG097-SaG104
Immunity and Atherosclerosis	Giuseppina Caligiuri, France	Station B	SaG105-SaG112
Emerging Aspects in Pharmacological Treatment of Primary and Secondary Dyslipidemia	Benjamin Dieplinger, Austria	Station C	SaG113-SaG120
Vascular Biology III	Joachim Herz, USA	Station D	SaG121-SaG128

POSTER PRESENTATIONS

Posters will be on display in 2 shifts. Please check the Scientific Programme to see the exact poster board number, date, and time of the poster discussion groups.

The organisers are not responsible for any posters that have not been removed by the end of sessions on Wednesday, June 1.

POSTER SHIFT I

Posters may be mounted from 17:30 on Sunday, May 29, 2016 and should remain on display until Monday, May 30, 2016 at 18:30.


POSTER SHIFT II

Posters may be mounted from 08:30 on Tuesday, May 31, 2016 and should remain on display until Wednesday, June 1, 2016 at 12:30.

Authors are asked to actively participate in both the poster sessions on the day in which their poster was allocated to.

Poster sessions will take place on Monday, May 30 from 13:00-14:00, 17:00-18:00 and Tuesday, May 31 from 13:00-14:00, 17:00-18:00.

POSTER AREA MAP



POSTER OVERVIEW

Please note that posters of Abstract presenters that were not registered to the congress by the deadline were not allocated poster boards. Such abstract presenters are requested to approach the poster help desk to be allocated an available poster board on-site.

POSTER SHIFT I – MONDAY, MAY 30, 2016

Session Time	Topic	Poster Board
13:00-14:00	Vascular Biology: Endothelium and Smooth Muscle Cells	001 – 044
	Vascular Biology: Macrophages, Inflammation, Immunity	045 - 088
	Vascular Biology: Myocardial Infarction, Stroke, Peripheral Vascular Disease	089 - 134
	Vascular Biology: Immune Disease and Cardiovascular Pathologies	135 - 142
	Lipoproteins and Lipid Metabolism: ApoB Containing Lipoproteins	143 - 163
	Lipoproteins and Lipid Metabolism: Lipoprotein Metabolism	164 - 187
17:00-18:00	Lipoproteins and Lipid Metabolism: Lp(a)	188 - 210
	Lipoproteins and Lipid Metabolism: HDL	211 - 245
	CVD Risk Factors	246 - 320

POSTER SHIFT II – TUESDAY, MAY 31, 2016

Session Time	Topic	Poster Board
13:00-14:00	Metabolic Abnormalities and Atherosclerosis: Diabetes	001 - 056
	Metabolic Abnormalities and Atherosclerosis: Adipose Tissue	057 - 066
	Metabolic Abnormalities and Atherosclerosis: Kidney	067 - 081
	Metabolic Abnormalities and Atherosclerosis: NASH and Liver Abnormalities	082 - 090
	Dyslipidemias: Dyslipidemias, Screening and Treatment	091 - 167
	17:00-18:00	Dyslipidemias: Treatment
Dyslipidemias: Coagulation		200 - 210
Dyslipidemias: Endothelial Dysfunction		211 – 220
Genetics, Nutrition, Biomarkers: Genetics, Gene Regulation		221 - 259
Genetics, Nutrition, Biomarkers: Nutrition		260 - 298
Genetics, Nutrition, Biomarkers: Biomarkers		299 - 333
Genetics, Nutrition, Biomarkers: Guidelines and Miscellaneous		334 - 344

Please note that posters of abstract presenters that were not registered to the Congress by the deadline were not allocated poster boards. Such abstract presenters are requested to approach the poster help desk to be allocated an available poster board on-site.

PROGRAMME AT A GLANCE

Plenary Session	Workshop	Science at a Glance Session	Young Investigators Session	Oral Communication Session
Company Sponsored Session	EBAC Accredited Session	Poster Walk Session	Other	Social Event

SUNDAY, MAY 29, 2016

	Exhibition & Posters Area	Nikolai N. Anitschkow (Tirol)	Karl Landsteiner (Innsbruck)	Carl von Rokitansky (Brussel)	Wilhelm Auerswald (Strassburg)
12:00-13:30				12:30-13:30 Meet the Expert Supported Session Not included in the CME/CPD programme	
13:30-14:00	Break				
14:00-15:30				EBAC Accredited Educational Programme Diet and Prevention of Cardiovascular Disease	14:00-15:00 EBAC Accredited Educational Programme Gene Therapy and Lipoprotein Lipase Deficiency
15:30-16:00	Break				
16:00-17:30		Educational Symposium Supported Session Not included in the CME/CPD programme			
17:30-18:00	Break				
18:00-19:45		Opening Ceremony, including the Anitschkow Lecture			
19:45- 20:45	Welcome Reception				

MONDAY, MAY 30, 2016

	Exhibition & Posters Area	Nikolai N. Anitschkow (Tirol)	Karl Landsteiner (Innsbruck)	Carl von Rokitansky (Brussel)	Wilhelm Auerswald (Strassburg)
08:30-10:30		Plenary Session: Integrative Approach in Atherosclerosis			
10:30-11:00	Coffee Break, Exhibition and Poster Viewing				
11:00-12:30		Workshop 1.1 Novel Aspects of Pathogenesis in Atherosclerosis	Workshop 2.1 Lipoproteins and Extracellular Matrix	11:00-11:45 Advanced Clinical Seminar Debate on Statin Associated Muscle Symptoms (SAMS) - A Problem for Clinicians or a Problem with Clinicians? 11:45-12:30 Advanced Clinical Seminar Role of Nutrition in Disease Pathology	Workshop 3.1 Novel Therapies
12:30-15:00	Break, Exhibition and Poster Viewing				
		13:00-14:00 Science at a Glance Session I	13:00 – 14:30 Educational Symposium Supported Session Not included in the CME/CPD programme	13:00 – 14:00 EBAC Accredited Educational Programme Nutraceuticals with Lipid Lowering: Who Can Benefit?	
		13:00-14:00 Poster Walk Session I			
		14:00-15:00 Science at a Glance Session II	13:00 – 14:30 Educational Symposium Supported Session Not included in the CME/CPD programme		
15:00-16:30		EAS- ESC Joint Workshop Sex differences in Cardiovascular Diseases	Workshop 1.2 Therapeutic and Diagnostic Targeting of the Arterial Wall	Workshop 2.2 Adipose Tissue – Liver Axis	15:00-15:45 Late Breaking: Basic Science 15:45-16:30 Young Investigator Award Session
16:30-17:00	Coffee break, Exhibition and Poster Viewing				
17:00-18:30	17:00-18:00 Poster Walk Session II	Young Investigator Session Vascular Biology and Inflammation	Young Investigator Session Lipids and Lipoproteins Metabolism	Young Investigator Session Clinical Epidemiology and Pharmacology	Oral Communication Session Vascular Biology
18:40-19:40		Keynote Lecture			

TUESDAY, MAY 31, 2016

	Exhibition & Posters Area	Nikolai N. Anitschkow (Tirol)	Karl Landsteiner (Innsbruck)	Carl von Rokitansky (Bruszel)	Wilhelm Auerswald (Strassburg)
08:30-10:30		Plenary Lecture: Lipid Biology, New Insights			
10:30-11:00	Coffee Break, Exhibition and Poster Viewing				
11:00-12:30		Workshop 1.3 Cellular Stress Response in Atherosclerosis	Workshop 2.3 Gut- Liver Axis	ICCR-EAS Joint Session Management of Cardiometabolic Risk; Where Do We Stand?	Workshop 3.2 Vascular Aging and Athero-thrombosis
12:30-15:00	Break, Exhibition and Poster Viewing				
	13:00-14:00 Science at a Glance Session III		13:00-14:30 Educational Symposium Supported Session Not included in the CME/CPD programme	13:00-14:00 EBAC Accredited Educational Programme Low HDL High Triglyceride, Diabetic Dyslipidaemia	13:00-14:00 EBAC Accredited Educational Programme Lysosomal Acid Lipase Deficiency
	13:00-14:00 Poster Walk Session III	14:00-14:45 Supported Session		14:10-14:55 Supported Session Not included in the CME/CPD programme	14:10-14:55 Supported Session Meet the Expert Not included in the CME/CPD programme
	14:00-15:00 Science at a Glance Session IV	Special Lecture Not included in the CME/CPD programme			
15:00-16:30		Workshop 3.3 Genetics in Risk Factor Prevention and Treatment	Late Breaking: Clinical Science	15:00-16:30 EAS Initiatives Update Session (open to all)	Advanced Clinical Seminar Economics and Guidelines/ Technology of the Future
				16:30-16:50 EAS General Assembly	
16:30-17:00	Coffee Break, Exhibition and Poster Viewing				
17:00-18:30	17:00-18:00 Poster Walk Session IV	Workshop 3.5 Epigenetics and Gene Regulation	Oral Communication Session Imaging, Biomarkers	Oral Communication Session Intracellular Lipid	Young Investigator Session Novel pathways in

WEDNESDAY, JUNE 1, 2016

	Exhibition & Posters Area	Karl Landsteiner (Innsbruck)	Carl von Rokitansky (Bruszel)	Wilhelm Auerswald (Strassburg)	Fritz Pregl (Freiburg)
08:30-10:30		Plenary Session: Future Therapeutic Challenges			
10:30-11:00	Coffee Break, Exhibition and Poster Viewing				
11:00-12:30		Workshop 1.4 Inflammation Immunity and Atherosclerosis	Workshop 3.4 Biology of CVD Risk	Workshop 4.4 New Guidelines on Prevention of Cardiovascular Disease in Clinical Practice	Workshop 2.4 Novel Role of Lipoprotein Receptors

CONGRESS FLOOR PLAN

LEVEL 0



LEVEL 2



LEVEL 1



LEVEL 3



HALL NAME EULOGY OF DISTINGUISHED SCIENTISTS

NIKOLAI N. ANITSCHKOW (1885-1964)

Professor of the Department of Pathological Physiology of the Military Medical Academy St. Petersburg, Russia. In 1913, experimental pathologist Dr. Nikolai N. Anitschkow showed that simply feeding to rabbits purified cholesterol dissolved in sunflower oil induced vascular lesions closely resembling those of human atherosclerosis, both grossly and microscopically. Controls fed with only the sunflower oil showed no lesions. It is fair to say that this paper marked the beginning of the modern era of atherosclerosis research. Dr. Anitschkow was not only a keen-eyed structural pathologist and a careful experimentalist; he thought in terms of function and time-related pathogenesis.

However, the landmark studies by Dr. Anitschkow were largely rejected at the time. An important reason for this was that the findings were inconsistent with the prevailing view of atherosclerosis. It was generally accepted to be an inevitable accompaniment of aging (the "senescence hypothesis"). If the full significance of his findings had been appreciated at the time, we might have saved more than 30 years in the long struggle to settle the cholesterol controversy.

In honor of Dr. Nikolai N. Anitschkow, the "Anitschkow Prize in Atherosclerosis Research" awarded annually by the EAS recognizes outstanding research in the field of atherosclerosis and linked metabolic disturbances.



K. Landsteiner

KARL LANDSTEINER (1868-1943)

Karl Landsteiner, Austrian pathologist, studied medicine at the University of Vienna. In 1896 he became an assistant in the Hygiene Institute at Vienna where he was interested in the mechanisms of immunity and in the nature of antibodies. From 1898 till 1908 he held the post of assistant in the

University Department of Pathological Anatomy in Vienna, in 1911 he became Professor of Pathological Anatomy in the University of Vienna. He showed that the cause of poliomyelitis could be transmitted to monkeys by injecting into them material prepared by grinding up the spinal cords of children who had died from this disease. His work laid the foundations of our knowledge of the cause and immunology of poliomyelitis.

Landsteiner made numerous contributions to both pathological anatomy, histology and immunology, all of which showed, not only his meticulous care in observation and description, but also his biological understanding. But his name will no doubt always be honoured for his discovery in 1901 of the blood groups, for which he was given the Nobel Prize for Physiology or Medicine in 1930. In 1875 Landois had reported that, when man is given transfusions of the blood of other animals, these foreign blood corpuscles are clumped and broken up in the blood vessels of man with the liberation of haemoglobin. In 1901-1903 Landsteiner pointed out that a similar reaction may occur when the blood of one human individual is transfused, not with the blood of another animal, but with that of another human being, and that this might be the cause of shock, jaundice, and haemoglobinuria that had followed some earlier attempts at blood transfusions.

His suggestions, however, received little attention until, in 1909, he classified human blood into the now well-known A, B, AB, and O groups and showed that transfusions between individuals of groups A or B do not result in the destruction of new blood cells and that this catastrophe occurs only when a person is transfused with the blood of a person belonging to a different group. Earlier, in 1901-1903, Landsteiner had suggested that, because the characteristics which determine the blood groups are inherited, the blood groups may be used to decide instances of doubtful paternity. In 1922, he accepted a post in the Rockefeller Institute for Medical Research in New York. It was here that he did further work on the blood groups which greatly extended the number of these groups, and studied bleeding in the new-born, leading to the discovery of the Rh-factor in blood, which relates the human blood to the blood of the rhesus monkey.



KARL BARON VON ROKITANSKY (1804-1878)

Austrian pathologist whose endeavours to establish a systematic picture of the sick organism from nearly 100,000 autopsies—30,000 of which he himself performed—helped make the study of pathological anatomy a cornerstone of modern

medical practice and established the New Vienna School as a world medical centre during the latter half of the 19th century.

A professor of pathological anatomy at the Vienna General Hospital, he inspired the Bohemian student Ignaz Semmelweis, later a martyr to the cause of antiseptic medical practice, to take up the study of medicine and afterward supported him in his struggle to eliminate childbed fever by cleaning up Europe's maternity wards.

First to detect bacteria in lesions of malignant endocarditis, an often rapidly fatal inflammation of the membrane lining the inner walls of the heart, Rokitansky created the basis for a differentiation of lobar pneumonia (originating in the lower lobe of the lung) and lobular pneumonia, or bronchopneumonia (originating in the finer subdivisions of the branched bronchial tree). He made a fundamental study of acute yellow atrophy of the liver (now known as Rokitansky's disease), established the micropathology of pulmonary emphysema (a condition of the lung characterized by enlarged air spaces separated from the terminals of the bronchial tree), and first described spondylolisthesis, the forward displacement of one vertebra over another.



WILHELM AUERSWALD (1917-1981)

Wilhelm Auerswald, Austrian physiologist, graduated from medical school at the University of Vienna in 1940. Auerswald became assistant at the Physiological Institute of the University of Vienna in 1944. Under the later-appointed Director Carl Schwarz-Wendl Auerswald could finish his habilitation in Physiology in 1950 and was established in 1968 as the successor to Gustav Schubert.

His scientific work includes 370 publications in the fields of physiology and pathology of blood proteins, nutrition, thrombosis, atherosclerosis, aerospace- and work physiology. It was Auerswald's concern to make his research results available for practical medicine; he provided valuable pioneering work in the fields of plasma replacement, productions of vaccines (first Poliomyelitis vaccine in Austria) and immunoglobulins (first intravenous application). His blood coagulation studies gained high international reputation.

In his teaching Auerswald was anxious to consider physiology as medical basic science with strong and immediate reference to the bedside; he also succeeded in renaming his workplace into the Department of Medical Physiology. Its translation and adaptation of the "Textbook of Physiology"



FRITZ PREGL (1869-1930)

Fritz Pregl, Austrian physiologist and chemist, studied medicine at the University of Graz and received his M.D. In 1894, he became assistant lecturer for physiology and histology under Alexander Rollett, taking over the chair when Rollett died in 1903.

During this time Pregl also acquired a thorough

knowledge of all branches of chemistry under the guidance of Professor Skraup. He started investigating the components of albuminous bodies and the analysis of bile acids. His work, however, was handicapped by the lack of sufficient starting materials and this fact impelled him to look for methods requiring smaller amounts when making quantitative analyses of elements in compounds.


The years 1910-1913, whilst professor at the University of Innsbruck, were almost entirely devoted to developing the method of quantitative organic micro-analysis. Pregl continued this work when he was recalled to Graz in 1913.

Initially Pregl's scientific work had been mainly in the fields of physiology and physiological chemistry; later he turned to the study of the constitution of chemical compounds, in particular the investigation of bile acids. By 1912 he was able, by using his own methods of quantitative micro-analysis, to make measurements of carbon, hydrogen, nitrogen, sulphur, and halogen, using only 5-13 mg of starting materials with results as accurate as those obtained by macro-analysis. Later he perfected his techniques so that as little as 3-5 mg were adequate. Pregl also contributed a number of micromethods for measuring atomic groups and developed a series of apparatus, including a sensitive microbalance, necessary for his work. The greatest honour was the award of the Nobel Prize for Chemistry by the Swedish Academy of Sciences in 1923. The Nobel Committee pointed out that it was not for a discovery, but for modifying and improving existing methods that Pregl was awarded the prize. Following the Nobel Prize for Chemistry in 1923, chemists from all over the world came to the Medico-Chemical Institute in Graz to study Pregl's techniques of quantitative organic micro-analysis under his guidance.



84th EAS CONGRESS

May 29 - June 1, 2016
Innsbruck, Austria



Scientific Programme
SUNDAY, MAY 29, 2016

www.eas2016.kenes.com

SUNDAY, MAY 29, 2016

12:30 - 13:30

C. von Rokitansky Hall

Industry Symposium: Meet the Expert

Supported Session. Not included in the CME/CPD Programme.

For programme details please refer to the Recognition, Acknowledgements & Commercial Support section in the final Programme.

13:30 - 14:00

Exhibition & Poster Area

Break

14:00 - 15:30

C. von Rokitansky Hall

EBAC Accredited Session: Diet and Prevention of Cardiovascular Disease

EBAC®

This educational programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s); Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

EAS have independently organised all matters related to this 90-minute Programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from BASF, Raisio and Unilever in support of the Programme.

	Chair: E. Bruckert (France)	1
14:00	SHOULD SATURATED FAT BE TARGETED FOR THE PREVENTION OF CARDIOVASCULAR DISEASE? A.H. Lichtenstein (USA)	2
14:20	SUGAR INTAKE AND CARDIOVASCULAR DISEASE - SHOULD IT BE THE NEXT FIGHT TO DECREASE CVD? J.P. Després (Canada)	3
14:40	PLANT STEROL AND STANOLS AND CARDIOVASCULAR DISEASE. IMPACT OF ENRICHED FOODS AND CHOLESTEROL-LOWERING DRUGS J. Chapman (France)	4
15:00	ROLE OF MICROBIOTA ON CARDIOVASCULAR DISEASE J. Fu (Netherlands)	5
15:20	PANEL DISCUSSION A.H. Lichtenstein (USA) J.P. Després (Canada) J. Chapman (France) J. Fu (Netherlands)	6 7 8 9

14:00 - 15:00

W. Auerswald Hall

EBAC Accredited Session: Gene Therapy and Lipoprotein Lipase Deficiency

EBAC®

This educational programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s); Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

EAS have independently organised all matters related to this 60-minute Programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from Chiesi in support of the Programme.

	Chair: J. Borén (Sweden)	10
	Chair: M. Averna (Italy)	11
14:00	GENETIC SEVERE HYPERTRIGLYCERIDEMIA A. Zambon (Italy)	12
14:15	GENETIC THERAPY FOR LIPOPROTEIN LIPASE DEFICIENCY E. Stroes (Netherlands)	13
14:45	CASE REPORT E.S. Thiessen (Germany)	14
14:45	CONCLUSION AND DISCUSSION	15

15:30 - 16:00

Exhibition & Poster Area

Break

16:00 - 17:30

N. Anitschkow Hall

Industry Symposium: Company Sponsored Session

Supported Session. Not included in the CME/CPD Programme.

For programme details please refer to the Recognition, Acknowledgements & Commercial Support section in the final Programme.

17:30 - 18:00

Exhibition & Poster Area

Break

18:00 - 19:45

N. Anitschkow Hall

Plenary: Opening Ceremony, including the Anitschkow Lecture

Chair: A. Catapano (Italy)	16
Chair: H. Dieplinger (Austria)	17
Chair: F. Kronenberg (Austria)	18
18:00 WELCOME FROM EAS PRESIDENT A. Catapano (Italy)	19
18:03 WELCOME FROM IAS PRESIDENT Y. Matsuzawa (Japan)	20
18:06 WELCOME FROM MAYOR OF INNSBRUCK C. Oppitz-Plörer (Austria)	21
18:09 WELCOME FROM PRESIDENT OF THE MEDICAL UNIVERSITY OF INNSBRUCK H. Fritsch (Austria)	22
18:12 WELCOME FROM AUSTRIAN ATHEROSCLEROSIS SOCIETY & CONGRESS CHAIR H. Dieplinger (Austria)	23
18:15 ACKNOWLEDGEMENT OF JOURNAL EDITOR-IN-CHIEF, PROFESSOR STEVE HUMPHRIES A. Catapano (Italy)	24
18:20 MUSICAL INTERLUDE	25
18:30 INTRODUCTION TO ANITSCHKOW PRIZE WINNER A. Catapano (Italy)	26
18:35 ANITSCHKOW LECTURE: ENDOTHELIAL CELL METABOLISM: A NOVEL PLAYER IN ATHEROSCLEROSIS? BASIC PRINCIPLES AND THERAPEUTIC OPPORTUNITIES P. Carmeliet (Belgium)	27
19:25 CLOSING REMARKS AND INVITATION TO WELCOME RECEPTION F. Kronenberg (Austria)	28
19:30 MUSICAL INTERLUDE	29

19:45 - 20:45


Exhibition Area

Welcome Reception



84th EAS CONGRESS

May 29 - June 1, 2016
Innsbruck, Austria



Scientific Programme
MONDAY, MAY 30, 2016

www.eas2016.kenes.com

Key journals in Cardiology



Editor-in-Chief
J.S. Borer (New York, N.Y.)

An invaluable aid in understanding and treating heart disease

Cardiology features:

- First reports on original clinical, preclinical and fundamental research
- 'Turning Basic Research into Clinical Success'
- 'Clinical Trial Design'
- Topical comprehensive reviews in selected areas of cardiovascular disease
- 'Editorial Comments'



www.karger.com/crd



Editor-in-Chief
U. Pohl (Munich)

A source of current research

The *Journal of Vascular Research* publishes original articles and reviews of scientific excellence in vascular and microvascular biology, physiology and pathophysiology. The scope of the journal covers a broad spectrum of vascular and lymphatic research, including vascular structure, vascular function, haemodynamics, mechanics, cell signalling, intercellular communication, growth and differentiation.



www.karger.com/jvr

KARGER

KIT6241

MONDAY, MAY 30, 2016

8:30 - 10:30

N. Anitschkow Hall

Plenary: Integrative Approach in Atherosclerosis

	Chair: A. Catapano (Italy)	30
	Chair: H. Dieplinger (Austria)	31
8:30	GENETIC PROTECTION FROM CORONARY ARTERY DISEASE: THE ROLE OF ABCG5 AND ABCG8 H. Hobbs (USA)	32
9:00	GWAS FOR CORONARY ARTERY DISEASE H. Schunkert (Germany)	33
9:30	LEADING THE WAY TO GENETICS AND PHARMACOGENOMICS IN THE CLINIC T. Manolio (USA)	34
10:00	EPIGENETICS IN ATHEROSCLEROSIS A. El-Osta (Australia)	35

10:30 - 11:00

Exhibition & Poster Area

Coffee Break, Exhibition & Poster Viewing

11:00 - 12:30

N. Anitschkow Hall

Workshop 1.1: Novel Aspects of Pathogenesis in Atherosclerosis

Chair: C.J. Binder (Austria)	36
Chair: S. Ylä-Herttuala (Finland)	37
11:00 BEYOND VASCULAR INFLAMMATION: RECENT ADVANCES IN UNDERSTANDING ATHEROSCLEROSIS K. Ley (USA)	38
11:25 B-CELLS AND ATHEROSCLEROSIS C.J. Binder (Austria)	39
11:50 REGULATORY T CELLS FROM PATIENTS WITH ATHEROSCLEROSIS HAVE ENHANCED SUPPRESSION FUNCTION DUE TO INCREASED EFFECTOR/ RESTING RATIO AND PRO-INFLAMMATORY SKEWING I.E. Dumitriu , P. Baruah, J.C. Kaski (United Kingdom)	40
12:03 CONTROL OF ATHEROSCLEROSIS BY AN APOE RECEPTOR-DEPENDENT NEUROMODULATOR J. Herz (USA)	41
12:16 DYNAMIN-RELATED PROTEIN 1 INHIBITION REDUCES OSTEOGENIC DIFFERENTIATION INDUCED TYPE 1 COLLAGEN SECRETION AND PREVENTS HUMAN VASCULAR CELL CALCIFICATION M. Rogers , N. Maldonado, J. Hutcheson, C. Goettsch, M. Aikawa, E. Aikawa (USA)	42

11:00 - 12:30

K. Landsteiner Hall

Workshop 2.1: Lipoproteins and Extracellular Matrix

Chair: J. Borén (Sweden)	43
Chair: P. Gordts (USA)	44
11:00 POSTPRANDIAL HYPERLIPIDEMIA, ENDOTHELIAL DYSFUNCTION AND CARDIOVASCULAR RISK: FOCUS ON INCRETINS P.D. Reaven (USA)	45
11:30 THE ROLE OF PROTEOGLYCANS IN HEPATIC TRIGLYCERIDE-RICH LIPOPROTEIN METABOLISM: ROLE OF ACOCIII AND APOAV P. Gordts (USA)	46
12:00 INCREASED LIPOPROTEIN BINDING TO ARTERIAL PROTEOGLYCANS AND NORMAL MACROPHAGE CHOLESTEROL EFFLUX CAPACITY DEFINE THE PRO-ATHEROGENIC FEATURE OF CKD DYSLIPIDEMIA M. Pedrelli , P. Stenvinkel, M.E. Minniti, K. Emma, A. Dikkers, S. Ebtehaj, M. Gomaraschi, P. Barany, A.R. Qureshi, G. Camejo, B. Lindholm, K. Oörni, U. Tietge, L. Calabresi, E. Hurt-Camejo, P. Parini (Sweden)	47
12:15 BROWN AND BEIGE ADIPOCYTE ACTIVITY CONTROLS METABOLIC FLUX THROUGH THE HDL COMPARTMENT N. Schaltenberg , A. Bartelt, J. Clara, A. Worthmann, C. Lisa M., R. Franz, H. Markus, N. Stefan K., S. Ludger, J. Heeren (Germany)	48

11:00 - 11:45

C. von Rokitsky Hall

Advanced Clinical Seminar 4.1: Debate on Statin Associated Muscle Symptoms (SAMS) - A Problem for Clinicians or a Problem with Clinicians?

Chair: C. Packard (United Kingdom)	49
11:00 LESSONS FROM CLINICAL EXPERIENCE U. Laufs (Germany)	50
11:20 LESSONS FROM CLINICAL TRIALS J.M. Armitage (United Kingdom)	51
11:40 DISCUSSION	52

11:45 - 12:30

C. von Rokitansky Hall

Workshop 4.2: Role of Nutrition in Disease Pathology

Chair: E. Bruckert (France)	53
Chair: J.M. Titze (Germany)	54
11:45 ROLE OF SODIUM IN ATHEROSCLEROSIS J.M. Titze (Germany)	55
12:05 SATURATED FAT IN THE DIET: GOOD OR BAD? I. Brouwer (Netherlands)	56
12:25 DISCUSSION	57

11:00 - 12:30

W. Auerswald Hall

Workshop 3.1: Novel Therapies

Chair: F. Mach (Switzerland)	58
Chair: D. Gaudet (Canada)	59
11:00 ANTI-INFLAMMATORY INTERVENTIONS VERSUS INTENSIVE LDL LOWERING F. Mach (Switzerland)	60
11:25 COMPARATIVE EFFECTS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITION, STATIN AND EZETIMIBE THERAPY ON ATHEROGENIC AND PROTECTIVE LIPID FACTORS: THE ACCENTUATE TRIAL S. Nicholls , K. Ray, C. Ballantyne, L. Beacham, D. Miller, G. Ruotolo, J. Riesmeyer (Australia)	61
11:50 A NOVEL COMBINATORIAL NON-VIRAL VECTOR TO TREAT FAMILIAL HYPERCHOLESTEROLAEMIA (FH) A. Kerr , L. Tam, M. Cioroch, A. Hale, G. Douglas, K. Channon, R. Wade-Martins (United Kingdom)	62
12:03 CURRENT STATUS-PHASE I TRIAL OF CELL-TRANSPLANTATION THERAPY WITH ALLOGENEIC ADIPOSE TISSUE-DERIVED MULTILINEAGE PROGENITOR CELLS IN SEVERE FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS UNDERGOING LDL-APHERESIS M. Koseki , S. Ayami, T. Okada, T. Kobayashi, M. Asaji, R. Kawase, M. Nishida, Y. Sakata, S. Yamashita (Japan)	63
12:16 NOVEL INTRANASAL ANTI-CETP VACCINE AGAINST THE DEVELOPMENT OF ATHEROSCLEROSIS AND FATTY LIVER DISEASE J. Mas-Oliva , B. Delgado-Coello, K. Méndez-Acevedo (Mexico)	64

12:30 - 15:00

Exhibition & Poster Area

Break, Exhibition & Poster Viewing

13:00 - 14:00

Exhibition Area

Science at a Glance Session I

13:00 - 14:00

Kristall Foyer

Poster Walk Session I

13:00 - 14:30 **N. Anitschkow Hall**

Industry Symposium: Company Sponsored Session

Supported Session. Not included in the CME/CPD Programme.

For programme details please refer to the Recognition, Acknowledgements & Commercial Support section in the final Programme.

13:00 - 14:30 **K. Landsteiner Hall**

Industry Symposium: Company Sponsored Session

Supported Session. Not included in the CME/CPD Programme.

For programme details please refer to the Recognition, Acknowledgements & Commercial Support section in the final Programme.

13:00 - 14:00 **C. von Rokitansky Hall**

EBAC Accredited Session: Nutraceuticals with Lipid Lowering Activity: Who Can Benefit?



This educational programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s); Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

EBAC* EAS have independently organised all matters related to this 60-minute Programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from Meda (Rottapharm) in support of the Programme.

	Chair: P. Kovanen (Finland)	65
	Chair: G. Assmann (Germany)	66
13:00	GUIDELINES IN PRIMARY PREVENTION E. Farinaro (Italy)	67
13:15	TO BRIDGE THE GAP BETWEEN LIFESTYLE AND PHARMACOLOGICAL TREATMENT: DO WE HAVE AN UNMET NEED? B. Paulweber (Austria)	68
13:30	PLANT NUTRACEUTICALS FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA: THE AVAILABLE CLINICAL DATA E. Bruckert (France)	69
13:45	DISCUSSION AND CONCLUSION	70

14:00 - 15:00 **Exhibition Area**

Science at a Glance Session II

15:00 - 16:30 **N. Anitschkow Hall**

EAS-ESC Joint Workshop: Sex Differences in Cardiovascular Diseases

	Chair: I. Hoefer (Netherlands)	71
	Chair: L. Tokgözoğlu (Turkey)	72
15:00	PUBLIC HEALTH PERSPECTIVES ON CARDIOVASCULAR CARE FOR MEN AND WOMEN K. Kotseva (United Kingdom)	73
15:22	SEX DIFFERENCES IN HEART DISEASE IN CLINICAL PRACTICE E. Bossano Prescott (Denmark)	74
15:45	SEX-SPECIFIC BIOMARKERS FOR CARDIOVASCULAR DISEASES B. Nordestgaard (Denmark)	75
16:07	SEX-SPECIFIC GENOMIC AND PROTEOMIC REGULATION IN CARDIOVASCULAR DISEASE G. Kararigas (Germany)	76

15:00 - 16:30

K. Landsteiner Hall

Workshop 1.2: Therapeutic and Diagnostic Targeting of the Arterial Wall

Chair: E. Stroes (Netherlands)	77
Chair: A. Tawakol (USA)	78
15:00 NANOMEDICINE AS DIAGNOSTIC TOOL FOR CARDIOVASCULAR DISEASE D. Letourneur (France)	79
15:25 NON-INVASIVE IMAGING OF ATHEROSCLEROTIC BURDEN AND INFLAMMATION A. Tawakol (USA)	80
15:50 INCREASED ARTERIAL WALL INFLAMMATION IN PATIENTS WITH FAMILIAL DYSBETALIPROTEINEMIA S. Verweij , S. Bernelot Moens, J. Kroon, J. Schnitzler, E. Stroes (Netherlands)	81
16:03 GENE THERAPY REDUCES ANGIOPLASTY INDUCED CORONARY RESTENOSIS IN A HIGH CHOLESTEROL SWINE MODEL D. Agrawal , P. Gunasekar, C. Boosani, V. Swier, M. Radwan, M. Del Core, W. Hunter (USA)	82
16:16 SPOTTY CALCIFICATION AS A MARKER OF VULNERABLE PLAQUE: NOVEL FINDINGS FROM IN-VIVO STUDY IN SURVIVORS OF CARDIAC ARREST AND IN-VITRO STUDY IN AUTOPTIC SCD PATIENTS J. Pu , P. Zhang, G.S. Mintz, X. Ma, B. He (China)	83

15:00 - 16:30

C. von Rokitansky Hall

Workshop 2.2: Adipose Tissue – Liver Axis

Chair: M. Taskinen (Finland)	84
Chair: F. Karpe (United Kingdom)	85
15:00 BIOLOGY OF ADIPOSE TISSUE PHENOTYPE AND ITS LINK TO DISEASE F. Karpe (United Kingdom)	86
15:25 APO AV, BEYOND TRIGLYCERIDES R.O. Ryan (USA)	87
15:50 FGF21 LOWERS PLASMA TRIGLYCERIDES BY ACCELERATING LIPOPROTEIN CATABOLISM IN WHITE AND BROWN ADIPOSE TISSUES C. Schlein , S. Talukdar, M. Heine, A.W. Fischer, L.M. Krott, S.K. Nilsson, M.B. Brenner, J. Heeren, L. Scheja (Germany)	88
16:03 OAT2 DEPLETION IMPROVES INSULIN SENSITIVITY AND HEPATIC STEATOSIS P. Parini , C. Pramfalk, O. Ahmed, L. Larsson, F. Karpe, M. Neville, M. Eriksson (Sweden)	89
16:16 SHORT-TERM COLD EXPOSURE MODULATES HUMAN VLDL AND HDL METABOLISM K. Nahon , G. Hoeke, L. Bakker, D. Drettwan, P. Pagel, I. Jazet, J. Berbée, M. Boon, P. Rensen (Netherlands)	90

15:00 - 15:45

W. Auerswald Hall

Late Breaking: Basic Science

Chair: J. Herz (USA)	91
Chair: R. Zechner (Austria)	92
15:00 FLOW PERTURBATION MEDIATES NEUTROPHIL RECRUITMENT AND POTENTIATES ENDOTHELIAL INJURY VIA TLR2 IN MICE. A NOVEL IN VIVO APPROACH FOR PROBING THE PATHOPHYSIOLOGY OF SUPERFICIAL EROSION	93
G. Franck , G. Sausen, T. Mawson, M. Salinas, G. Masson, A. Cole, M. Beltrami-Moreira, Y. Chatzizisis, Y. Tesmenitsky, E. Swartz, G. Sukhova, F. Swirski, M. Nahrendorf, E. Aikawa, K. Croce, P. Libby (USA)	
15:15 THE ATYPICAL CADHERIN FAT1 SUPPRESSES MITOCHONDRIAL RESPIRATION TO LIMIT SMOOTH MUSCLE CELL RESPONSE TO VASCULAR INJURY	94
N. Sibinga , L.L. Cao, D. Riascos-Bernal, P. Chinnasamy, C. Dunaway, M. Pujato, A. Fiser (USA)	
15:30 THE CORONARY ARTERY DISEASE RISK ASSOCIATED GENE PLPP3/PPAP2B SUPPRESSES ATHEROSCLEROSIS IN MICE	95
A. Morris , P. Mueller, J. Brandon, L. Yang, S. Smyth (USA)	

15:45 - 16:30

W. Auerswald Hall

Young Investigator Award Session

Chair: P. Kovanen (Finland)	96
Chair: G. Dallinga-Thie (Netherlands)	97
15:45 GRP94 REGULATES CIRCULATING CHOLESTEROL LEVELS THROUGH BLOCKADE OF PCSK9-INDUCED LDLR DEGRADATION	98
S. Poirier (Canada)	
16:05 ASSOCIATION BETWEEN FAMILIAL HYPERCHOLESTEROLEMIA AND PREVALENCE OF TYPE 2 DIABETES MELLITUS	99
J. Besseling (Netherlands)	

16:30 - 17:00

Exhibition & Poster Area

Coffee Break, Exhibition & Poster Viewing

17:00 - 18:00

Kristall Foyer

Poster Walk Session II

17:00 - 18:30

N. Anitschkow Hall

Young Investigator Session: Vascular Biology and Inflammation

Chair: K. Öörni (Finland)	100
Chair: L.O. Martinez (France)	101
17:00 IRON ACCELERATES CARDIOVASCULAR DISEASE: THE IMPORTANCE OF MAINTAINING IRON BALANCE	102
F. Vinchi , A. Simmelbauer, S. Altamura, B. Galy, M.W. Hentze, M. Muckenthaler (Germany)	
17:15 INCREASED APOA-I TRANSCRIPTION BY BET INHIBITOR JQ1(+) ACTS INDEPENDENTLY FROM PPAR-ALPHA ACTIVATION AND IS LINKED TO ER-STRESS INHIBITION	103
S.E. Van der Krieken , H.E. Popeijus, R.P. Mensink, J. Plat (Netherlands)	
17:30 PHOSPHATIDYLSERINE IMPROVES ANTI-INFLAMMATORY FUNCTION OF RECONSTITUTED HDL IN MACROPHAGES VIA SR-BI-, AKT- AND P38 MAPK-DEPENDENT PATHWAYS	104
M. Darabi , E. Tubeuf, M. Lhomme, I. Guillas-Baudouin, C. Dauteuille, M. Patel, T. Huby, E.L. Gautier, K.A. Rye, P. Lesnik, W. Le Goff, A. Kontush (France)	
17:45 CCAAT/ENHANCER BINDING PROTEIN DELTA CONTRIBUTES TO LIPID ACCUMULATION IN M1 MACROPHAGES OF BLOOD VESSEL LESIONS	105
H.Y. Lai , L.W. Hsu, P.Y. Liu, J.M. Wang (Taiwan)	
18:00 INHIBITION OF THE CHOLESTEROL SYNTHESIS PATHWAY PREVENTS TRAINED INNATE IMMUNITY	106
S. Bekkering , S. Bernelot Moens, S. Verweij, J. Roeters van Lennep, J. Van Tuijl, L. Joosten, E. Stroes, M. Netea, N. Riksen (Netherlands)	
18:15 SELECTIVE DONOR ENDOTHELIAL HEPARAN SULFATE MODIFYING ENZYME NDST1 DELETION SIGNIFICANTLY BLOCKS REJECTION AFTER RENAL TRANSPLANT	107
S. Ambadapadi , H. Chen, D. Wakefield, S. Morshed, W. Clapp, A. Lucas (USA)	

17:00 - 18:30

K. Landsteiner Hall

Young Investigator Session: Lipids and Lipoprotein Metabolism

- Chair: **L. Scheja** (Germany) 108
 Chair: **A. Ritsch** (Austria) 109
- 17:00 PARAOXONASE 1 (PON1) MAINTAINS CELLULAR CHOLESTEROL HOMEOSTASIS VIA THE REGULATION OF CHOLESTEROL EFFLUX 110
 S. Ikhlef, H. Berrougui, **A. Khalil** (Canada)
- 17:15 A UBIQUITOUS TRANSCRIPTION FACTOR INFLUENCES DIET-INDUCED THERMOGENESIS AND SENSITIZES BAT TO NORADRENERGIC STIMULI IMPROVING CARDIOMETABOLIC HEALTH 111
P.P. Laurila, J. Soronen, S. Kooijman, M. Boon, M.R. Taskinen, V. Olkkonen, S. Ripatti, P. Kovanen, P. Rensen, M. Jauhiainen (Finland)
- 17:30 CALCIUM DEPENDENT ENDOCYTOSIS AND RECYCLING OF LIPOPROTEIN(A) IN HEPG2 CELLS 112
M. SHARMA, G. Redpath, S. McCormick (New Zealand)
- 17:45 PLASMA CETP IS DERIVED FROM HEPATIC KUPFFER CELLS RATHER THAN ADIPOSE TISSUE 113
L. Blauw, R. De Mutsert, Y. Wang, H. Lamb, A. De Roos, F. Rosendaal, W. Jukema, S. Van der Tuin, S. Rensen, R. Shiri-Sverdlov, B. Atanasovska, J. Fu, W. Buurman, J.W. Greve, M. Hofker, K. Willems van Dijk, P. Rensen (Netherlands)
- 18:00 IN VIVO INHIBITION OF NUCLEAR FACTOR OF ACTIVATED T CELLS (NFAT) RESTORES MICROVASCULAR ENDOTHELIAL FUNCTION IN DIABETIC MICE 114
E. Garcia-Vaz, A. Mc Neilly, J. Gallagher, R. Mc Crimmon, F. Khan, M.F. Gomez (Sweden)
- 18:15 OXYSTEROLS, 24S-HYDROXYCHOLESTEROL AND 27-HYDROXYCHOLESTEROL, IN SUBJECTS WITH GENETIC HYPERCHOLESTEROLEMIA NEGATIVE FOR LDLR/APOB/PCSK9/APOE MUTATIONS. ASSOCIATION WITH LIPIDS AND CAROTID ATHEROSCLEROSIS 115
L. Baila-Rueda, A. Cenarro, I. Lamiquiz-Moneo, R. Mateo-Gallego, A.M. Bea-Sanz, S. Perez-Calahorra, V. Marco-Benedi, F. Civeira (Spain)

17:00 - 18:30

C. von Rokitansky Hall

Young Investigator Session: Clinical Epidemiology and Pharmacology

- Chair: **K. Kotseva** (United Kingdom) 116
 Chair: **P.D. Reaven** (USA) 117
- 17:00 APABETALONE (RVX-208) DECREASES ATHEROGENIC, THROMBOTIC AND INFLAMMATORY MEDIATORS IN VITRO AND IN PLASMA OF PATIENTS WITH CARDIOVASCULAR DISEASE (CVD). 118
N. Wong, E. Kulikowski, S. Wasiak, D. Gilham, C. Calosing, T. Laura, C. Halliday, J. Johansson, M. Sweeney (Canada)
- 17:15 IMPACT OF DIABETES, INSULIN RESISTANCE AND CETP INHIBITION ON CIRCULATING PCSK9 LEVELS IN PATIENTS AT HIGH CARDIOVASCULAR RISK: THE ILLUMINATE STUDY 119
B. Arsenault, F. Tabet, W. Bao, F. Petrides, G.K. Hovingh, S.M. Boekholdt, D. DeMicco, K.A. Rye, D. Waters, J. Kastelein, P. Barter, G. Lambert (Canada)
- 17:30 CLINICAL CHARACTERISTICS AND LONG-TERM CLINICAL OUTCOMES OF PATIENTS WITH TYPICAL RESTING CHEST PAIN ACCORDING TO THE TYPES OF VASOMOTOR RESPONSE TO AN ACETYLCHOLINE PROVOCATION TEST 120
E.M. Lee, H.S. Seo, M.H. Choi, H.K. Kim, S.Y. Lee, N.H. Kim, D.O. Kang, C.U. Choi, J.W. Kim, E.J. Kim, S.W. Rha, C.G. Park, D.J. Oh (Republic of Korea)
- 17:45 RESPONSE TO TREATMENT AND OCCURRENCE OF CARDIOVASCULAR (CV) COMPLICATIONS IN PATIENTS WITH AUTOSOMAL RECESSIVE HYPERCHOLESTEROLEMIA (ARH): A RETROSPECTIVE ANALYSIS 121
L. D'Erasmus, I. Minicocci, L. Masana, J. Roeters van Lennep, M. Harada-Shiba, S. Muntoni, P. Pintus, S. Bertolini, C. Sirtori, L. Calabresi, C. Pavanello, M. Averna, A.B. Cefalù, D. Noto, A. Pacifico, G. Pes, R. Fellin, E. Manzato, S. Zambon, M. Arca (Italy)
- 18:00 ASSOCIATION OF PERIPHERAL BLOOD MONONUCLEAR CELLS ADENYLATE CYCLASE-ASSOCIATED PROTEIN 1 MRNA WITH CORONARY ARTERY DISEASE 122
M. Sopic, J. Joksić, V. Spasojević Kalimanovska, D. Kalminaovska Oštrić, K. Anđelković, Z. Jelić Ivanović (Serbia)
- 18:15 FILAGGRIN MUTATIONS AS RISK FACTORS FOR ISCHEMIC STROKE IN THE GENERAL POPULATION 123
 A. Varbo, B.G. Nordestgaard, **M. Benn** (Denmark)

17:00 - 18:30

W. Auerswald Hall

Oral Communication Session: Vascular Biology

- Chair: **L. Yvant-Charvet** (France) 124
Chair: **K. Ley** (USA) 125
- 17:00 SELECTIVE HDL-RAISING GENE TRANSFER COUNTERACTS THE DEVELOPMENT OF PRESSURE OVERLOAD-INDUCED CARDIOMYOPATHY IN MICE 126
R. Amin, I. Muthuramu, F. Jacobs, **B. De Geest** (Belgium)
- 17:15 BONE MARROW-SPECIFIC SIRT6 DELETION INCREASES ATHEROGENESIS BY INCREASING MACROPHAGE SCAVENGER RECEPTOR 1 127
T. Arsiwala, L. J. van Tits, M. Miranda, K. Nussbaum, J. Weber, S. Stivala, J. H. Beer, M. Greter, B. Becher, M. O. Hottiger, R. Mostoslavsky, J. Auwerx, T. F. Lüscher, C. M. Matter (Switzerland)
- 17:30 T CELL-SPECIFIC CD40L CONTRIBUTES TO ATHEROSCLEROSIS 128
C. Bürger, H. Winkels, C. Spitz, S. Meiler, S. Reim, C. Weber, E. Lutgens, N. Gerdes (Germany)
- 17:45 STRUCTURAL REMODELING AND GLUCOSE METABOLISM IMPAIRMENT AT EARLY ATHEROSCLEROSIS: IN-SITU AORTA ALTERATIONS AND PLASMA TRANSLATION. 129
M. Martin-Lorenzo, L. Gonzalez-Calero, A.S. Maroto, P.J. Martinez, A. Heredero, G. Aldamiz-Echevarria, F. Vivanco, G. Alvarez-Llamas (Spain)
- 18:00 LIVER-SPECIFIC ABLATION OF HNF-4 α IN MICE IS ASSOCIATED WITH CHANGES IN PLASMA LIPOPROTEIN PROFILES AND THE EXPRESSION OF GENES INVOLVED IN LIPOPROTEIN METABOLISM 130
E. Thymiakou, D. Kardassis (Greece)
- 18:15 HEPATOCYTE-SPECIFIC PPAP2B ABLATION INCREASES PLASMA LEVELS OF SEVERAL MINOR PRO-ATHEROGENIC LIPID SPECIES AND WORSENS ATHEROSCLEROSIS IN APOE-/- MICE 131
M. Busnelli, S. Manzini, M. Hilvo, C. Parolini, G.S. Ganzetti, F. Dellera, K. Ekroos, M. Jänis, C.R. Sirtori, R. Laaksonen, G. Chiesa (Italy)

18:40 - 19:40

N. Anitschkow Hall


Plenary: Keynote Lecture

- Chair: **A. Catapano** (Italy) 132
Chair: **W.J. Schneider** (Austria) 133
- 18:40 HOW GENES CONTROL CHOLESTEROL 134
M.S. Brown (USA)



84th EAS CONGRESS

May 29 - June 1, 2016
Innsbruck, Austria



Scientific Programme
TUESDAY, MAY 31, 2016

www.eas2016.kenes.com

TUESDAY, MAY 31, 2016

8:30 - 10:30

N. Anitschkow Hall

Plenary: Lipid Biology, New Insights

Chair: **G. Kostner** (Austria) 135

Chair: **O. Wiklund** (Sweden) 136

8:30 PATHOPHYSIOLOGY OF INTERCELLULAR AND INTRAVASCULAR LIPOLYSIS 137

R. Zechner (Austria)

9:00 ADIPOSE TISSUE BROWNING AND METABOLIC HEALTH 138

J. Heeren (Germany)

9:30 NUCLEAR RECEPTORS IN LIPID METABOLISM 139

D. Mangelsdorf (USA)

10:00 ANGIOGENESIS AND ENDOTHELIAL CELL DYSFUNCTION
IN ATHEROSCLEROSIS: A NOVEL TARGET FOR TREATMENT 140

P. Carmeliet (Belgium)

10:30 - 11:00

Exhibition & Poster Areater Area

Coffee Break, Exhibition & Poster Viewing

11:00 - 12:30

N. Anitschkow Hall

Workshop 1.3: Cellular Stress Response in Atherosclerosis

Chair: G.R.Y. De Meyer (Belgium)	198
Chair: R. Prassl (Austria)	199
11:00 MICTOPARTICLES IN ATHEROSCLEROSIS C.M. Boulanger (France)	200
11:25 ROLE OF AUTOPHAGY IN VASCULAR DISORDERS G.R.Y. De Meyer (Belgium)	201
11:50 HYPERCHOLESTEROLEMIA ALTERS THE MICRORNA PROFILE OF VASCULAR SMOOTH MUSCLE CELL-DERIVED MICTOPARTICLES D. De Gonzalo Calvo , A. Cenarro, F. Civeira, V. Llorente-Cortés (Spain)	202
12:03 A FUNCTIONAL GENETIC VARIANT IN THE LIPID DROPLET-ASSOCIATED PROTEIN PERILIPIN 2 (PLIN2) AFFECTS CHOLESTEROL CONTENT AND AUTOPHAGY IN HUMAN PRIMARY MACROPHAGES TREATED WITH OXLDL E. Ehrenborg , P. Gustafsson, O. Werngren, M. Pedrelli, P. Parini, J. Magné (Sweden)	203
12:16 EXTRACELLULAR LIPID PARTICLES ACCUMULATING IN HUMAN CAROTID ARTERY INTIMA INDUCE STERILE INFLAMMATION IN MACROPHAGES S. Lehti, I. Belevich, S.D. Nguyen, P. Lindsberg, E. Jokitalo, P.T. Kovanen, K. Oörni (Finland)	204

11:00 - 12:30

K. Landsteiner Hall

Workshop 2.3: Gut - Liver Axis

Chair: A. Moschetta (Italy)	205
Chair: D. Kardassis (Greece)	206
11:00 THE GUT MICROBIOME ENDOCRINE ORGAN: BACTERIALLY SIGNALS DRIVING CARDIO-METABOLIC DISEASES M.J. Brown (USA)	207
11:25 INTESTINAL NUCLEAR RECEPTORS IN LIPID REGULATION A. Moschetta (Italy)	208
11:50 A MARCH6 AND IDOL E3 UBIQUITIN LIGASE CIRCUIT UNCOUPLES CHOLESTEROL SYNTHESIS FROM LIPOPROTEIN UPTAKE IN HEPATOCYTES A. Loregger , E. Cook, J. Nelson, M. Moeton, L. Sharpe, S. Engberg, M. Karimova, G. Lambert, N. Zelcer (Netherlands)	209
12:03 BUTYRATE VIA THE GUT-BRAIN CIRCUIT REDUCES APPETITE AND ACTIVATES BROWN ADIPOSE TISSUE Y. Wang , L. Zhuang, C. Yi, C.K. Chuang, S. Kooijman, K. Willems van Dijk, A.K. Groen, P.C.N. Rensen	210
12:16 NON-ALCOHOLIC FATTY LIVER DISEASE AS A CAUSE OF ISCHEMIC HEART DISEASE: A MENDELIAN RANDOMIZATION STUDY AND META-ANALYSIS OF 170,998 INDIVIDUALS B. Lauridsen , S. Stender, T. Kristensen, K. Kofoed, B. Nordestgaard, A. Tybjærg-Hansen (Denmark)	211

11:00 - 12:30**C. von Rokitansky Hall****Workshop: ICCR-EAS Joint Session: Management of Cardiometabolic Risk; Where Do We Stand?**

	Chair: J.P. Després (Canada)	212
	Chair: J. Chapman (France)	213
11:00	MANAGEMENT OF SUBJECTS AT HIGH CARDIOMETABOLIC RISK - WHERE DO WE FALL? J.P. Després (Canada)	214
11:22	DOES THE HEALTHY METABOLICALLY OBESE PHENOTYPE EXIST? L. Van Gaal (Belgium)	215
11:45	TRANSLATING NUTRITIONAL SCIENCE INTO CLINICAL PRACTICE V. Malik (USA)	216
12:07	NAFLD - THE NOVEL TREAT FOR VASCULAR DISEASE M. Taskinen (Finland)	217

11:00 - 12:30**W. Auerswald Hall****Workshop 3.2: Vascular Aging and Atherothrombosis**

	Chair: C. Gaetano (Germany)	218
	Chair: B. Föger (Austria)	219
11:00	VASCULAR PROGENITOR CELLS, LYMPHATICS, ANGIOGENESIS AND ATHEROSCLEROSIS A. Kari (Finland)	220
11:25	SIRTUINS IN CARDIOVASCULAR DISEASE C. Gaetano (Germany)	221
11:50	PENTRAXIN 3 DEFICIENCY IS ASSOCIATED WITH INCREASED ARTERIAL THROMBOSIS IN ANIMAL MODELS F. Bonacina , S. Barbieri, L. Cutuli, P. Amadio, A. Doni, M. Sironi, S. Tartari, B. Bottazzi, C. Garlanda, E. Tremoli, A. Mantovani, A.L. Catapano, G.D. Norata (Italy)	222
12:03	HDL MODULATES CARDIAC GLUCOSE METABOLISM AND INFLAMMATION AND IMPROVES CARDIAC FUNCTION AFTER MYOCARDIAL ISCHEMIA-REPERFUSION INJURY B. Kingwell , S. Heywood, A. Richart, D. Henstridge, K. Alt, H. Kiriazis, A. Carey, H. Kammoun, H. Begum, L. Delbridge, P. Meikle, C. Hagemeyer, M. Febbraio, X.J. Du, A. Siebel (Australia)	223
12:16	DIET-INDUCED OBESITY REQUIRES SIGNALLING THROUGH TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED FACTOR 1 (TRAF-1) IN ADIPOCYTES D. Wolf , N. Anto Michel, I. Hilgendorf, Bode, A. Zirlik (Germany)	224

12:30 - 15:00**Exhibition & Poster Area****Break, Exhibition & Poster Viewing****13:00 - 14:00****Exhibition Area****Science at a Glance Session III****13:00 - 14:00****Kristall Foyer****Poster Walk Session III**

13:00 - 14:30

K. Landsteiner Hall

Industry Symposium: Company Sponsored Session

Supported Session. Not included in the CME/CPD Programme.

For programme details please refer to the Recognition, Acknowledgements & Commercial Support section in the final Programme.

13:00 - 14:00

C. von Rokitansky Hall

EBAC Accredited Session: Low HDL High Triglyceride, Diabetic Dyslipidaemia



This educational programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s); Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

EBAC®

EAS have independently organised all matters related to this 60-minute Programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from Mylan in support of the Programme.

Chair: O. Wiklund (Sweden)	225
13:00 DIABETIC DYSLIPIDEMIA A. Zambon (Italy)	226
13:20 TRIGLYCERIDE, REMNANTS AND ATHEROSCLEROSIS B. Nordestgaard (Denmark)	227
13:40 CONCLUSION AND DISCUSSION	228

13:00 - 14:00

W. Auerswald Hall

EBAC Accredited Session: Lysosomal Acid Lipase Deficiency



EBAC®

This educational programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s); Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS). EAS have independently organised all matters related to this 60-minute Programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from Alexion in support of the Programme.

Chair: E. Bruckert (France)	229
Chair: P. Kovanen (Finland)	230
13:00 LIPID METABOLISM ABNORMALITIES IN GENERAL WITH DIFFERENTIAL DIAGNOSIS INCLUDING ALSO LAL-D T. Stulnig (Austria)	231
13:20 LIPID METABOLISM ABNORMALITIES IN LAL-D AS A LYSOSOMAL STORAGE DISEASE WITH A FOCUS ON SPECIFIC SIGNS AND SYMPTOMS M. Averna (Italy)	232
13:40 CONCLUSION AND DISCUSSION	233

14:00 - 15:00

Exhibition Area

Science at a Glance Session IV

14:00 - 14:45

N. Anitschkow Hall

Industry Symposium: Special Lecture

Supported Session. Not included in the CME/CPD Programme.

For programme details please refer to the Recognition, Acknowledgements & Commercial Support section in the final Programme.

14:10 - 14:55

C. von Rokitansky Hall

Industry Symposium: Company Sponsored Session

Supported Session. Not included in the CME/CPD Programme.

For programme details please refer to the Recognition, Acknowledgements & Commercial Support section in the final Programme.

14:05 - 14:50

W. Auerswald Hall

Industry Symposium: Meet the Expert

Supported Session. Not included in the CME/CPD Programme.

For programme details please refer to the Recognition, Acknowledgements & Commercial Support section in the final Programme.

15:00 - 16:30

N. Anitschkow Hall

Workshop 3.3: Genetics in Risk Factor Prevention and Treatment

- Chair: **G. Utermann** (Austria) 234
 Chair: **S. Ripatti** (Finland) 235
- 15:00 GENETIC DISCOVERIES FOR LIPID GENETIC TRAITS. LESSON LEARNED FROM FAMILIES AND THE GENERAL POPULATION 236
S. Ripatti (Finland)
- 15:20 LOSS-OF-FUNCTION MUTATIONS IN *APOC3*, REMNANT CHOLESTEROL, LDL CHOLESTEROL, AND RISK OF ISCHEMIC VASCULAR DISEASE 237
 A.B. Jørgensen, R. Frikke-Schmidt, B. Nordestgaard, **A. Tybjaerg-Hansen** (Denmark)
- 15:34 LEUKOCYTE TELOMERE LENGTH, GENETICALLY DETERMINED, IS CAUSALLY ASSOCIATED WITH THE PROGRESSION OF CAROTID INTIMA-MEDIA THICKNESS AND INCIDENCE OF CARDIOVASCULAR EVENTS 238
A. Baragetti, J. Palmen, K. Garlaschelli, L. Grigore, S. Humphries, A.L. Catapano, P.J. Talmud, N. Giuseppe Danilo (Italy)
- 15:48 DEEP SEQUENCING IDENTIFIES DNA METHYLATION DEPENDENT GENES IMPLICATED IN DIABETIC COMPLICATIONS 239
I. Khurana, A. El-Osta (Australia)
- 16:02 PLEIOTROPIC MOLECULAR TARGETS OF COXIBS REVEALS NOVEL GENOMIC LOCI CONFERRING CORONARY ARTERY DISEASE RISK 240
I. Brønne, C. Willenborg, B. Reiz, L. Zeng, V. Tragante do Ó, T. Meitinger, N.J. Samani, T. Kessler, F.W. Asselbergs, J. Erdmann, H. Schunkert (Germany)
- 16:16 INVESTIGATION OF MULTIPLE DYSLIPIDEMIAS IN A LARGE AUSTRIAN PEDIGREE BY GENETIC RISK SCORES AND EXOME SEQUENCING 241
E. Nikkola, A. Ko, R.M. Cantor, R. Muxel, N. Matikainen, S. Söderlund, M.M. Motazacker, J.A. Kuivenhoven, J. Boren, F. Kronenberg, W. Schneider, A. Palotie, M. Laakso, M.R. Taskinen, P. Pajukanta (USA)

15:00 - 16:30

K. Landsteiner Hall

Late Breaking: Clinical ScienceChair: **P. Moulin** (France) 242Chair: **M. Vrablik** (Czech Republic) 243

- 15:00 A PILOT STUDY OF MBX-8025 IN THE TREATMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH) 244
 D. Gaudet, S. Saheb, E. Bruckert, J. De Graaf, G. Langslet, J.C. Tardif, S. Bergheanu, A. Steinberg, Y.J. Choi, R. Martin, C. McWherter, J. Kastelein, **P. Boudes** (USA)
- 15:15 AFFITOPE-BASED ANTI-PCSK9 (PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9) VACCINE (AT04A) REDUCES ATHEROSCLEROSIS IN APOE*3LEIDEN.CETP MICE 245
 G. Galabova, C. Juno, J.W.A. Van der Hoorn, E.J. Pieterman, M. Pouwer, C. Landlinger, J.W. Jukema, H.M.G. Princen, **G. Staffler** (Austria)
- 15:30 TREATMENT ADHERENCE TO THE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 INHIBITOR ALIROCUMAB IN SIX ODYSSEY PHASE 3 CLINICAL STUDIES WITH TREATMENT DURATION OF 52 - 104 WEEKS 246
M. Farnier, H.M. Colhoun, W.J. Sasiela, J. Edelberg, G. Asset, J.G. Robinson (France)
- 15:45 SAFETY AND EFFICACY OF EVINACUMAB, A MONOCLONAL ANTIBODY TO ANGPTL3, IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: A SINGLE-ARM, OPEN-LABEL, PROOF-OF-CONCEPT STUDY 247
D. Gaudet, D.A. Gipe, E. Khoury, R. Pordy, W. Sasiela, K.C. Chan
- 16:00 DYNAMIC CHANGES IN MR SIGNALS OF INTRAPLAQUE HEMORRHAGE ARE STRONGLY CORRELATED WITH PLAQUE PROGRESSION: A SERIAL IMAGING STUDY ON CAROTID ATHEROSCLEROSIS 248
 J. Sun, J. Liu, N. Balu, D. Hippe, K. William, A. Wang, G. Canton, T. Hatsukami, **C. Yuan** (USA)
- 16:15 MORTALITY IN RELATION TO GLYCAEMIC STATUS IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE 249
I.D. Hjellestad, E. Søfteland, R.M. Nilsen, E.S. Husebye, T. Jonung (Norway)

15:00 - 16:30 C. von Rokitansky Hall**EAS Initiatives Update Session (open to all)**

Chair: A. Catapano (Italy)	250
Chair: O. Wiklund (Sweden)	251
15:00 WELCOME AND OVERVIEW OF EAS ACTIVITIES A. Catapano (Italy)	252
15:15 FHSC UPDATE K.K. Ray (United Kingdom)	253
15:30 CONSENSUS ACTIVITIES HIGHLIGHT- CONSENSUS ON FASTING/ NONFASTING LIPID ANALYSES (WITH EFLM) B. Nordestgaard (Denmark)	254
15:45 EDUCATIONAL ACTIVITIES HIGHLIGHT- ADVANCED COURSES & EAS ACADEMY ACCREDITED PROGRAMMES L. Tokgözoğlu (Turkey)	255
15:55 OTHER ACTIVITIES: GUIDELINES & CONSENSUS UPDATE A. Catapano (Italy)	256
16:05 OTHER ACTIVITIES: JOURNAL A. von Eckardstein (Switzerland)	257
16:15 Q&A A. Catapano (Italy)	258

15:00 - 16:30 W. Auerswald Hall**Advanced Clinical Seminar: Economics and Guidelines/
Technology of the Future**

Chair: M. Banach (Poland)	259
Chair: G. Dallinga-Thie (Netherlands)	260
15:00 PHARMACO-ECONOMICS - HOW TO EXPLORE IT G. Corrao (Italy)	261
15:30 CRISPRCAS9 TECHNOLOGY AS A NEW STRATEGY FOR TARGET DISCOVERY N. Sanjana (USA)	262
16:00 WHAT DID WE LEARN FROM Lp(a)? SUMMARY OF THE SATELLITE MEETING G. Kostner (Austria)	263

16:30 - 16:50 C. von Rokitansky Hall**EAS General Assembly (Members Only)****16:30 - 17:00 Exhibition & Poster Area****Coffee Break, Exhibition & Poster Viewing****17:00 - 18:00 Kristall Foyer****Poster Walk Session IV****17:00 - 18:30 N. Anitschkow Hall****Workshop 3.5: Epigenetics and Gene Regulation**

Chair: L. Maegdefessel (Sweden)	264
Chair: A. El-Osta (Australia)	265
17:00 THE EMERGING ROLE OF MICRORNAS IN CARDIOVASCULAR DISEASE L. Maegdefessel (Sweden)	266
17:25 IDENTIFICATION OF HISTONE DEACETYLASE 3 AS A MOLECULAR BRAKE OF WHITE ADIPOSE TISSUE BROWNING M. Crestani , A. Ferrari, E. Fiorino, R. Long, N. Mitro, G. Cermenati, A. Mai, D. Caruso, E. De Fabiani, S.W. Hiebert (Italy)	267
17:38 HYPERCHOLESTEROLEMIA TRANSFORMS HIGH-DENSITY LIPOPROTEINS- MEDIATED TRNA-DERIVED SMALL RNA INTERCELLULAR COMMUNICATION R. Allen, D. Michell, W. Zhu, S. Zhao, Q. Sheng, L. MacRae, K. Vickers (USA)	268
17:51 QUAKING POST-TRANSCRIPTIONALLY PROMOTES DIFFERENTIATION OF MONOCYTES INTO PRO-ATHEROGENIC MACROPHAGES BY CONTROLLING PRE-MRNA SPLICING AND GENE EXPRESSION R.G. De Bruin, L. Shiue, J. Prins, A. Djaramshi, H. De Boer, W.S. Fagg, J. Van Gils, J. Duijs, C. Van Kooten, J.W. Jukema, H. Van Esch, T.J. Rabelink, H. Kazan, E.A.L. Biessen, M. Ares Jr., A.J. Van Zonneveld , E. Van der Veer (Netherlands)	269
18:09 INNATE IMMUNE CELL ACTIVATION IN SYMPTOMATIC AND ASYMPTOMATIC ATHEROSCLEROSIS IN HUMANS IN VIVO S. Bekkering , I. Van den Munckhof, T. Nielen, J. Rutten, J. De Graaf, L. Joosten, M. Netea, M. Gomes, N. Riksen (Netherlands)	270

17:00 - 18:30

K. Landsteiner Hall

Oral Communication Session: Imaging, Biomarkers and Clinical Epidemiology

- Chair: **D. Letourneur** (France) 271
 Chair: **B. Paulweber** (Austria) 272
- 17:00 ULTRA-SMALL POSITIVE AND NEGATIVE DUAL CONTRAST IRON OXIDE NANOPARTICLES FOR MOLECULAR IMAGING OF CARDIOVASCULAR DISEASE 273
H. Ta, Z. Li, K. Peter, C. Hagemeyer, A. Whittaker (Australia)
- 17:15 COMPUTED TOMOGRAPHY ANGIOGRAPHY DERIVED COMPARED TO INVASIVE FRACTIONAL FLOW RESERVE ASSESSMENT. A META-ANALYSIS. 274
S. Baumann, M. Renker, S. Hetjens, T. Becher, D. Loßnitzer, I. Akin, M. Borggreffe, U.J. Schoepf (Germany)
- 17:30 PLASMA CERAMIDES IDENTIFY RESIDUAL CARDIOVASCULAR RISK IN STATIN TREATED CORONARY ARTERY DISEASE PATIENTS 275
R. Laaksonen, K. Ekroos, M. Sysi-Aho, T. Vihervaara, D. Kauhanen, M. Hilvo, R. Hurme, E. Ringdal Pedersen, G. Tell, O. Nygård (Finland)
- 17:45 IN TYPE 2 DIABETES MELLITUS THE GLP-1 EFFECTS ON PLATELETS ARE IMPAIRED 276
 C. Barale, C. Frascaroli, F. Cavalot, A. Guerrasio, **I. Russo** (Italy)
- 18:00 INCREASED F2-ISOPROSTANE OXIDATIVE STRESS IN CORONARY ARTERY DISEASE (CAD) PATIENTS WITH POOR ASPIRIN-INDUCED THROMBOXANE B2 INHIBITION 277
L.R. Lopez, T. Bottiglieri, A. Vasudevan, C. Swift, R. Schiffmann, P.A. McCullough (USA)
- 18:15 ASYMMETRIC DIMETHYLARGININE DIRECTLY PROMOTES CHRONIC KIDNEY DISEASE PROGRESSION: EVIDENCE FROM A MENDELIAN RANDOMIZATION APPROACH IN THE GCKD STUDY 278
M. Schneider, M. Mieth, S. Titze, F. Kronenberg, Y. Li, R. Maas, K.U. Eckardt (Germany)

17:00 - 18:30

C. von Rokitansky Hall

Oral Communication Session: Intracellular Lipid Metabolism

- Chair: **D. Kratky** (Austria) 279
 Chair: **J. Heeren** (Germany) 280
- 17:00 AN UNEXPECTED ROLE OF AUTOPHAGY IN TARGETING FUNCTIONAL MITOCHONDRIAL ATP SYNTHASE TO THE PLASMA MEMBRANE: ITS ROLE IN HDL ENDOCYTOSIS 281
L.O. Martinez, G. Cardouat, S. Fried, S. Najib (France)
- 17:15 α/β HYDROLASE DOMAIN-CONTAINING 6 (ABHD6) DEGRADES THE LATE ENDOSOMAL/LYSOSOMAL LIPID BIS(MONOACYLGLYCERO)PHOSPHATE 282
R. Zimmermann (Austria)
- 17:30 CONVERGENT SIGNALING PATHWAYS CONTROLLED BY LRP1 CYTOPLASMIC AND EXTRACELLULAR DOMAINS LIMIT CELLULAR CHOLESTEROL ACCUMULATION 283
P. Boucher, Z. El Asmar, J. Terrand, M. Jenty, L. Host, M. Mlih, A. Zerr, H. Justiniano, R. Matz L., C. Boudier, E. Scholler, J.M. Garnier, D. Bertaccini, D. Thiersé, C. Schaeffer, V.D. Alain, J. Herz (France)
- 17:45 MONOGLYCERIDE LIPASE REGULATES ENDOCANNABINOID TONE AND ATHEROSCLEROTIC PLAQUE STRUCTURE IN APOLIPOPROTEIN E-DEFICIENT MICE 284
N. Vujic, S. Schlager, T.O. Eichmann, M. Goeritzer, C.T. Madreiter-Sokolowski, S. Schauer, A. Lass, R. Zimmermann, G. Hoefler, W.F. Graier, B. Radovic, D. Kratky (Austria)
- 18:00 LACK OF ADIPOSE TISSUE LIPOLYSIS PROTECTS AGAINST PRESSURE OVERLOAD-INDUCED HEART FAILURE 285
A. Foryst-Ludwig, J. Salatzki, S. Brix, Z. Ban, J. Grune, R. Klopffleisch, M. Rothe, E. Kershaw, U. Kintscher (Germany)
- 18:15 A LOSS-OF-FUNCTION VARIANT IN OSBPL1A PREDISPOSES TO LOW PLASMA HDL CHOLESTEROL LEVELS AND IMPAIRED CHOLESTEROL EFFLUX CAPACITY 286
J. Van Capelleveen, J. Pirhonen, M.M. Motazacker, M. Weber-Boyyat, M. Jauhiainen, G.K. Hovingh, G.M. Dallinga-Thie, V. Olkkonen (Netherlands)

17:00 - 18:30

W. Auerswald Hall


Young Investigator Session: Novel Pathways in Atherosclerosis

Chair: J.A. Kuivenhoven (Netherlands)	287
Chair: R.O. Ryan (USA)	288
17:00 REDUCING AMYLOID PROCESSING PREVENTS DIABETES INDUCED VASCULAR DYSFUNCTION. P. Meakin , F. Khan, M. Ashford (United Kingdom)	289
17:15 A LIPID METABOLITE PROFILE IN ATHEROSCLEROTIC PLAQUES ASSOCIATED WITH INCREASED INFLAMMATION AND CARDIOVASCULAR RISK L. Tomas , H. Björkbacka, A. Edsfeldt, A. Danielsson, M. Wigren, H. Grufman, A. Persson, C. Prehn, J. Adamski, J. Nilsson, I. Gonçalves (Sweden)	290
17:30 A COMPLEX ATHEROSCLEROTIC PHENOTYPE OF MIF GENE-DEFICIENT MICE IN AN ATHEROGENIC APOE-/- BACKGROUND UNCOVERS A NOVEL CONNECTION BETWEEN MIF AND B CELLS C. Schmitz , E. Straußfeld, O. El Bounkari, H. Noels, J. Bernhagen (Germany)	291
17:45 MARKERS OF VULNERABLE PLAQUES IN NON-HUMAN PRIMATES UNDER ATHEROGENIC DIET V. Di Cataldo , J. Piraquive Agudelo, A. Geloën, M. Verset, A. Paturet, A. Serusclat, F. Lambertson, D. Ibarolla, F. Lavenne, D. Le Bars, H. Contamin, E. Canet-Soulas (France)	292
18:00 THE ROLE OF INFLAMMATION IN THE ASSOCIATION BETWEEN ADIPOSITY AND SUBCLINICAL ATHEROSCLEROSIS T. Christen , S. Trompet, K.B. Gast, P.C.N. Rensen, J.A.P. Willems van Dijk, H.J. Lamb, A. De Roos, J.W. Jukema, F.R. Rosendaal, S. Le Cessie, R. De Mutsert (Netherlands)	293
18:15 THE RELATIONSHIP OF NETRIN- 1 EXPRESSION WITH MACROPHAGE INFILTRATION AND POLARIZATION IN HUMAN EPICARDIAL ADIPOSE TISSUE AND SEVERITY OF CORONARY ARTERY DISEASE K.M. Gurses , F. Ozmen, D. Kocyigit, N. Yersal, E. Bilgic, E. Kaya, C. Kopru, T. Soyal, S. Doganci, L. Tokgozoglu, P. Korkusuz (Turkey)	294



84th EAS CONGRESS

May 29 - June 1, 2016
Innsbruck, Austria



Scientific Programme
WEDNESDAY, JUNE 1, 2016

www.eas2016.kenes.com

www.eas2017.com



85TH EAS CONGRESS



April
23-26
2017
PRAGUE
CZECH REPUBLIC

SAVE
THE
DATE

WEDNESDAY, JUNE 1, 2016

8:30 - 10:30

K. Landsteiner Hall

Plenary: Future Therapeutic Challenges

Chair: F. Kronenberg (Austria)	295
Chair: L. Tokgözoğlu (Turkey)	296
8:30 IN INTEGRATIVE OMICS APPROACH IN HUMAN DISEASE RESEARCH K. Suhre (Qatar)	297
9:00 DRUGS FOR METABOLIC DISORDERS AND OBESITY M. Tschöp (Germany)	298
9:30 THE USE OF NOVEL THERAPIES IN ATHEROSCLEROSIS: FROM ANTIBODIES TO NANOTECHNOLOGY E. Stroes (Netherlands)	299
10:00 LESSONS LEARNED FROM EMERGING THERAPIES FOR SEVERE HYPERTRIGLYCERIDEMIA D. Gaudet (Canada)	300

10:30 - 11:00

Exhibition & Poster Area

Coffee Break, Exhibition & Poster Viewing

11:00 - 12:30

K. Landsteiner Hall

Workshop 1.4: Inflammation, Immunity and Atherosclerosis

	Chair: G.D. Norata (Italy)	301
	Chair: E. Lutgens (Netherlands)	302
11:00	TARGETING THE ADAPTIVE IMMUNE SYSTEM: A NEW STRATEGY IN ATHEROSCLEROSIS E. Lutgens (Netherlands)	303
11:25	CHOLESTEROL, INFLAMMATION AND IMMUNITY L. Yvant-Charvet (France)	304
11:50	CD27 CO-STIMULATION FOSTERS REGULATORY T CELL SURVIVAL AND AMELIORATED PROGRESSION OF ATHEROSCLEROSIS. H. Winkels , S. Meiler, C. Spitz, C. Buerger, A. Faussner, J. Borst, C. Weber, E. Lutgens, N. Gerdes	305
12:03	EARLY ATHEROPROTECTION BY SYK INHIBITION FAILS IN ESTABLISHED DISEASE WHEN LOCAL MACROPHAGE PROLIFERATION DOMINATES LESION PROGRESSION A. Lindau, C. Haerdtnr, F.K. Swirski, P. Libby, L. Hein, C. Bode, A. Zirlik, I. Hilgendorf (Germany)	306
12:16	DEFICIENCY OF SECRETED IGM ANTIBODIES CAUSES INCREASED PLASMA IGE LEVELS THAT PROMOTE ATHEROSCLEROSIS D. Tsiantoulas , I. Bot, M. Kiss, B. Bartolini-Gritti, L. Göderle, M. Ozsvar-Kozma, T. Perkmann, K. Hartvigsen, A. Bergthaler, D.H. Conrad, J. Kuiper, Z. Mallat, H. Jumaa, C.J. Binder (Austria)	307

11:00 - 12:30

C. von Rokitansky Hall

Workshop 3.4: Biology of CVD Risk

	Chair: H. Colhoun (United Kingdom)	308
	Chair: F. Kronenberg (Austria)	309
11:00	NOVEL BIOMARKERS FOR CVD IN METABOLIC DISORDERS H. Colhoun (United Kingdom)	310
11:25	CIRCULATING CELLS AND CVD RISK G. Pasterkamp (Netherlands)	311
11:50	CIRCULATING MICRORNA-122 IS ASSOCIATED WITH INCIDENT METABOLIC SYNDROME AND TYPE-2 DIABETES P. Willeit , X. Yin, D. Kaudewitz, P. Skroblin, A. Zampetaki, A.R. Moschen, C.M. Ramirez, L. Goedeke, N. Rotllan, E. Bonora, A.D. Hughes, P. Santer, C. Fernandez-Hernando, H. Tilg, J. Willeit, S. Kiechl, M. Mayr (United Kingdom)	312
12:03	ASSOCIATIONS BETWEEN LIPOPROTEIN SUBFRACTIONS AND GENOME-WIDE DNA METHYLATION IN KORA F4 L. Pfeiffer , R. Wilson, H. Grallert, E. Reischl, A. Peters, C. Gieger, S. Wahl, M. Waldenberger (Germany)	313
12:16	PLASMA LIPIDOMIC PROFILES IMPROVE UPON CONVENTIONAL RISK FACTORS TO PREDICT CARDIOVASCULAR EVENTS P. Munda, C. Barlow, N. Mellett, K. Huynh, Z. Alshehry, G. Wong, B. Kingwell, P. Nestel, P. Thompson, D. Sullivan, E. Barnes, J. Simes, A. Tonkin, P. Meikle (Australia)	314

11:00 - 12:30

W. Auerswald Hall

Workshop: New Guidelines on Prevention of Cardiovascular Disease in Clinical Practice

Chair: A. Catapano (Italy)	315
Chair: M. Piepoli (Italy)	316
11:00 INTRODUCTION: WHAT IS NEW IN THESE GUIDELINES? M. Piepoli (Italy)	318
11:05 HOW CAN WE IDENTIFY HIGH RISK? I. Graham (Ireland)	319
11:20 WHAT ARE THE RISK FACTOR TARGETS? TBA	320
11:35 LIPIDS: WHAT IS NEW? A. Catapano (Italy)	321
11:50 POPULATION APPROACH TO PREVENT CVD E. Bossano Prescott (Denmark)	322
12:05 PANEL DISCUSSION	323
12:25 CONCLUSIONS A. Catapano (Italy) M. Piepoli (Italy)	324 325

11:00 - 12:30

F. Pregl Hall


Workshop 2.4: Novel Role of Lipoprotein Receptors

Chair: A. von Eckardstein (Switzerland)	327
Chair: E. Steyrer (Austria)	328
11:00 NOVEL ROLE OF ENDOTHELIAL RECEPTORS IN ATHEROSCLEROSIS A. von Eckardstein (Switzerland)	329
11:25 SOLUBLE LR11, A CIRCULATING MARKER FOR ATHEROSCLEROSIS H. Bujo (Japan)	330
11:50 REGULATION OF HDL-C LEVELS VIA ABCA1: A ROLE FOR <i>LRP1</i> F. Oldoni , J. Van Capelleveen, M.M. Motazacker, J. Heeren, R. Sinke, G. Dallinga-Thie, D. Hui, K. Hovingh, J.A. Kuivenhoven (Netherlands)	331
12:03 SORLA IS A NOVEL HIGH AFFINITY PCSK9 RECEPTOR THAT INHIBITS ITS INACTIVATION BY FURIN C. Gustafsen , S. Skeldal, S.L. Jensen, O.M. Andersen, C.M. Petersen, P. Madsen, S. Glerup (Denmark)	332
12:16 UNRAVELLING THE MECHANISM AND IMPORTANCE OF BROWN ADIPOSE TISSUE WHOLE LIPOPROTEIN UPTAKE A. Fischer , K. Gottschling, N. Mangels, M. Heine, J. Heeren (Germany)	333



84th EAS CONGRESS

May 29 - June 1, 2016
Innsbruck, Austria



**SCIENCE AT A GLANCE
E-POSTER PRESENTATIONS**

www.eas2016.kenes.com



CALL FOR PAPERS

Atherosclerosis

Official Journal of the European Atherosclerosis Society

Atherosclerosis publishes original papers and review articles reporting research findings and investigations into all aspects of atherosclerosis, its complications and related diseases. Encompassing: lipoprotein metabolism, disorders of lipid transport, arterial and vascular biology, including vascular imaging and flow studies, cardiovascular stem cell biology, thrombosis and inflammation. Papers covering genetics, meta-analysis and epidemiology of atherosclerosis are of interest, as are dietary studies and investigations into diabetes and hypertension as related to atherosclerosis and cardiovascular risk factors.

Publisher, Koos Admiraal, k.admiraal@elsevier.com

Editor-in-Chief: **A. von Eckardstein**

If you have a specific question please contact our Editorial Assistant, S. Negrini, Simona.Negrini@usz.ch



BENEFITS OF PUBLISHING IN ATHEROSCLEROSIS

- Seamless electronic editorial system, from online submission to article publication, with clear instructions and online tracking.
- Improved presentation and the option to enrich your article with graphical abstracts, video, 3D images and linkage of content to relevant databases.
- Rapid editorial processing and availability of accepted articles (2-3 weeks after acceptance) as "articles in press"
- Advance notification of article publication via ScienceDirect's alerting service
- High visibility, with articles appearing in Scopus and PubMed shortly after publication
- Unparalleled international readership via ScienceDirect, with **10 million active users** monthly from over **120 countries**. Over **80,000 Atherosclerosis** articles are downloaded every month.
- *Atherosclerosis* available via mobile Apps for increased accessibility
- Authors receive quarterly updates of the number of downloads of their article
- Open access publishing available

BENEFITS OF PUBLISHING IN ATHEROSCLEROSIS

Easy online submission at: <http://ees.elsevier.com/ath>

More information on the types of papers we publish and further instructions for authors can be found at: www.atherosclerosis-journal.com

Poster #

MONDAY, MAY 30, 2016

13:00 - 14:00

Exhibition Area

Lipids and Lipoproteins

	Chair: J. Heeren (Germany)	334
SAG001	CONSEQUENCES OF DEFECTIVE LIPOLYSIS IN THE SMALL INTESTINE ON LIPID METABOLISM M. Korbelius , S. Obrowsky, S. Rainer, N. Vujic, D. Kratky (Austria)	335
SAG002	POSTTRANSCRIPTIONAL REGULATION OF THE LDLR BY ACTH TREATMENT - IMPORTANCE OF PCSK9 IN LIVER WHILE IDOL TAKES THE SCENE IN THE ADRENALS M. Ghosh Laskar, B. Angelin, M. Rudling (Sweden)	336
SAG003	TNF-ALPHA INDUCES PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9) EXPRESSION IN HEPATIC HEPG2 CELL LINE IN A SOCS-3-DEPENDENT MANNER M. Ruscica , Ricci, C. Macchi, P. Magni, L. Jingwen, A. Corsini, N. Ferri (Italy)	337
SAG004	A POTENTIAL ROLE OF CHOLESTEROL UPTAKE CAPACITY, A NEW MEASURE FOR HIGH-DENSITY LIPOPROTEIN FUNCTIONALITY, IN CORONARY RISK STRATIFICATION A. Harada , R. Toh, K. Murakami, M. Kiriya, K. Yoshikawa, T. Kubo, K. Miwa, Y. Irino, K. Mori, N. Tanaka, T. Ishida, K. Hirata (Japan)	338
SAG005	LOW-DENSITY LIPOPROTEIN UPREGULATE SR-BI THROUGH SP1 SER702 PHOSPHORYLATION IN HEPATIC CELLS L. Wang , F. Yang, Y. Du, J. Zhang, B. Hong (China)	339
SAG006	SNPS LOCATED IN ABCA1, CETP AND APOA5/A4/C3/A1 ARE ASSOCIATED WITH PLASMA CHOLESTEROL EFFLUX C. Talbot , J. Plat, H. Popeijus, A. Ritsch, R. Mensink	340
SAG007	IDENTIFICATION OF A NOVEL APOLIPOPROTEIN THAT FACILITATES MTP-MEDIATED LIPID TRANSPORT H. Peng , C.S. Liu, T.Y. Chiu, H.T. Chen, J.J.Y. Yen, H.F. Yang-Yen (Taiwan)	341
SAG008	BETA CELL-SPECIFIC DELETION OF ABCA1 AND ABCG1 REGULATES THE INCREASE OF SMALL NUCLEOLAR RNAs IN ADIPOCYTES F. Tabet , L. Hou, B. Cochran, L.F. Cuesta Torres, P.J. Barter, K.A. Rye (Australia)	342

Poster #

13:00 - 14:00

Exhibition Area

Vascular Biology I

- Chair: **G.R.Y. De Meyer** (Belgium) 343
- SAG009 HIGH-DENSITY LIPOPROTEIN PHOSPHOLIPID CONTENT AND APOLIPOPROTEIN A-I LEVEL ARE DETERMINANTS OF CHOLESTEROL EFFLUX CAPACITY IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA 344
M. Ogura, M. Harada-Shiba (Japan)
- SAG010 A HIGH-THROUGHPUT SCREENING OF KINASE INHIBITORS IDENTIFIES A REGULATORY ROLE OF VEGF SIGNALING FOR TRANSENDOTHELIAL TRANSPORT OF HIGH-DENSITY LIPOPROTEINS 345
S. Velagapudi, L. Rohrer, A. Von Eckardstein (Switzerland)
- SAG011 MITOPHAGY ACTS AS A SAFEGUARD MECHANISM AGAINST HUMAN VASCULAR SMOOTH MUSCLE CELL APOPTOSIS INDUCED BY ATHEROGENIC LIPIDS 346
H. Nahapetyan, A. Swiader, J. Faccini, R. D'Angelo, E. Mucher, M. Elbaz, P. Boya, C. Vindis (France)
- SAG012 SMOOTH MUSCLE CELLS PCSK9 KNOCK-OUT EXHIBIT AN IMPAIRED RESPONSE TO PDGF STIMULATION 347
S. Marchianò, G. Tibolla, A. Corsini, A.L. Catapano, N. Ferri (Italy)
- SAG013 5-METHOXYTRYPTOPHAN REDUCES NEOINTIMA FORMATION FOLLOWING ARTERIAL INJURY 348
C.H. Chen, Y.C. Ho, H.H. Ho, C.H. Su, S.F. Yet (Taiwan)
- SAG014 IMPACT OF FIBRE ORIENTATION IN FIBROUS CAP ON THE MECHANICAL LOADING IN HUMAN CORONARY ATHEROSCLEROTIC PLAQUES 349
Z. Teng, G. Douglas, A. Brown, M. Sutcliffe, J. Gillard (United Kingdom)
- SAG015 MDM2 E3 LIGASE-MEDIATED UBIQUITINATION AND DEGRADATION OF HDAC1 IN VASCULAR CALCIFICATION 350
H. Kook, D.H. Kwon, G.H. Eom, S. Shin, E.M. Kim, Y.U. Lee, N. Choe (Republic of Korea)
- SAG016 IN VITRO MIGRATION OF PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS) INTO HUMAN HEALTHY AND DISEASED ARTERIES 351
B. Jakic, C. Krapf, M. Buszko, G. Cappellano, M. Grimm, G. Wick (Austria)

Poster #

13:00 - 14:00

Exhibition Area

Genetic, Omics and in silico Approaches

- Chair: **N. Sanjana** (USA) 352
- SAG017 GENE EXPRESSION PROFILES OF RECURRENT ACUTE PANCREATITIS RISK IN SEVERE HYPERTRIGLYCERIDEMIA 353
K. Tremblay, D. Gaudet (Canada)
- SAG018 EVIDENCE FOR ENHANCED DE NOVO LIPOGENESIS AND UNCOUPLING OF OBESITY FROM TYPE 2 DIABETES RISK IN THE LOW-EXPRESSION VARIANT CARRIERS OF FATTY ACID-BINDING PROTEIN 4 354
J. Saksi, P. Ijäs, A. Jula, H. Heikkilä, J. Tuimala, O. Dwivedi, T.M. Tuomi, L. Groop, M. Jauhiainen, P. Kovanen, P. Lindsberg (Finland)
- SAG019 THE PREVALENCE OF FAMILIAL HYPERLIPIDAEMIA AND HYPER-LIPOPROTEIN(A) IN MUTATION-NEGATIVE FAMILIAL HYPERCHOLESTEROLAEMIA AND ASSOCIATIONS WITH CARDIOVASCULAR EVENTS 355
K. Ellis, J. Pang, D. Chan, A. Hooper, D. Bell, J. Burnett, G. Watts (Australia)
- SAG020 THE RS16900627 POLYMORPHISM OF THE RECEPTOR-INTERACTING PROTEIN 2 (*RIP2*) GENE IS ASSOCIATED WITH SUBCLINICAL ATHEROSCLEROSIS. THE GENETICS OF ATHEROSCLEROTIC DISEASE (GEA) MEXICAN STUDY 356
G. Vargas-Alarcon, R. Posadas-Sánchez, J. Angeles-Martínez, E. Alvarez-León, N. Pérez-Hernández, J.M. Rodríguez-Pérez, J.M. Fragoso, G. Cardoso, T. Villarreal-Molina, C. Posadas-Romero (Mexico)
- SAG021 RARE VARIANTS IN ABCG2 IDENTIFIED BY SEQUENCING MAY INFLUENCE THE LIPID RESPONSE TO ROSUVASTATIN TREATMENT 357
M. Hu, J. Chan, B. Tomlinson (Hong Kong- China)
- SAG022 CHARACTERISTICS OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN SPAIN 358
R.M. Sánchez-Hernández, M. Stef, S. Perez-Calahorra, F. Almagro, P. Sáenz-Aranzúbia, N. Plana, J.T. Real, F. Blanco-Vaca, J.F. Ascaso, F. Civeira, M. Pocovi (Spain)
- SAG023 CLINICAL CHARACTERISTICS AND PREVALENCE OF CARDIOVASCULAR DISEASE RISK FACTORS IN SUBJECTS SCREENED FOR FAMILIAL HYPERCHOLESTEROLEMIA - A CROSS SECTIONAL STUDY IN THE NETHERLANDS 359
M.L. Hartgers, J. Besseling, B. Lucius, L. Kutikova, G.K. Hovingh (Netherlands)
- SAG024 LOOKS LIKE FH BUT IT'S NOT FH - EXTENDED LIPID PROFILE OF PAEDIATRIC CLINICAL FH PATIENTS REVEALS A DIFFERENT LIPID PROFILE IN FH NEGATIVE PATIENTS 360
A.M. Medeiros, **M. Bourbon**, P. Aguiar (Portugal)

Poster #

13:00 - 14:00

Exhibition Area

CV Risk Factors and Atherosclerosis I

- Chair: **Y. Matsuzawa** (Japan) 361
- SAG025 SERUM PHOSPHATIDYLCHOLINE PLASMALOGEN AND ALKYL-PHOSPHATIDYLCHOLINE CONCENTRATIONS ARE INVERSELY ASSOCIATED WITH MYOCARDIAL INFARCTION INCIDENCE IN PATIENTS WITH PERIPHERAL ARTERY DISEASE 362
J. Moxon, R. Jones, G. Wong, D. Liu, J. Weir, R. Behl-Gilhotra, B. Kingwell, P. Meikle, J. Golledge (Australia)
- SAG026 SERUM ACYLCARNITINES AND RISK OF INCIDENT TYPE 2 DIABETES IN PATIENTS WITH SUSPECTED STABLE ANGINA PECTORIS - A PROSPECTIVE COHORT STUDY 363
E.W. Rebnord, E. Strand, G.F.T. Svingen, P.R. Njølstad, G. Mellgren, G.S. Tell, R.K. Berge, A. Svardal, O.K. Nygård, E.R. Pedersen (Norway)
- SAG027 ANTI-APOLIPOPROTEIN A-1 ANTIBODIES AS A NOVEL CARDIOVASCULAR RISK FACTOR: RESULTS FROM THE COLAUS STUDY 364
N. Vuilleumier (Switzerland)
- SAG028 REDUCTION IN PLASMA CHOLESTEROL EFFLUX CAPACITY FROM HUMAN MACROPHAGES IS ASSOCIATED WITH THE APPEARANCE OF CLINICAL FEATURES OF METABOLIC SYNDROME 365
J. Gall, E. Frisdal, R. Bittar, W. Le Goff, E. Bruckert, P. Lesnik, M. Guerin, P. Giral (France)
- SAG029 REMNANT CHOLESTEROL PREDICTS CARDIOVASCULAR EVENT RISK IN PATIENTS WITH TYPE 2 DIABETES INDEPENDENTLY FROM THE BASELINE CORONARY ARTERY DISEASE STATE 366
C. Saely, D. Zanolin, P. Rein, A. Vonbank, **A. Leihnerer**, A. Muendlein, H. Drexel (Austria)
- SAG030 THE PROSPECTIVE RELATIONSHIPS OF CIRCULATING AND URINARY CHOLINE METABOLITES WITH INCIDENT TYPE 2 DIABETES AMONG PATIENTS WITH SUSPECTED STABLE ANGINA PECTORIS 367
G.F.T. Svingen, H. Schartum-Hansen, E.R. Pedersen, P.M. Ueland, G.S. Tell, G. Mellgren, P.R. Njølstad, R. Seifert, E. Strand, T. Karlsson, O.K. Nygård (Norway)
- SAG031 ASSOCIATIONS OF TRIGLYCERIDES WITH PERCENT BODY FAT IN ADOLESCENTS: THE PEP FAMILY HEART STUDY 368
T. Bertsch, G.M. Haas, E. Liepold, P. Schwandt (Germany)
- SAG032 HEPATITIS C VIRUS (HCV) AND ATHEROSCLEROSIS RISK: A ROLE FOR LOW-DENSITY IMMUNE COMPLEXES? 369
M. Bassendine, S. Nielsen, D. Neely (United Kingdom)

Poster #

14:00 - 15:00

Exhibition Area

Experimental Cardiovascular Medicine I

- Chair: **P. Parini** (Sweden) 370
- SAG033 THE ROLE OF MICRO RNAS AND THEIR TARGETS IN A CAROTID ARTERY INTIMAL HYPERPLASIA 371
Y.U. Lee, N. Choe, E.M. Kim, S. Shin, D.H. Kwon, T. Kook, H. Kook (Republic of Korea)
- SAG034 HEPATIC MIRNA EXPRESSION PROFILING IN GENETICALLY MODIFIED MOUSE MODELS OF DIFFERENT ATHEROSCLEROSIS SUSCEPTIBILITY 372
S. Manzini, M. Busnelli, M. Chiara, C. Parolini, F. Dellera, G.S. Ganzetti, D.S. Horner, G. Chiesa (Italy)
- SAG035 ESTRADIOL PROTECTS OVARECTOMIZED FEMALE RATS AGAINST FRUCTOSE RICH DIET INDUCED CARDIAC INFLAMMATION 373
M. Bundalo, M. Zivkovic, G. Koricanac, A. Stankovic (Serbia)
- SAG036 IMPACT OF ENDOTHELIAL LIPASE OVEREXPRESSION ON CHOLESTEROL EFFLUX CAPACITY OF SERUM, APOLIPOPROTEIN B-DEPLETED SERUM AND HDL 374
I. Schilcher, A. Hrzenjak, T. Eichmann, T. Stojakovic, H. Scharnagl, G. Marsche, S. Frank (Austria)
- SAG037 SR-BI INVOLVED ON PLASMA HDL2-APOA-I RECIRCULATION TO PRE β -HDL IN MICE 375
M. Tsujita, T. Yokota, N. Akita, F.J. Gonzalez, S. Yokoyama (Japan)
- SAG038 MICE ABUNDANT IN MURICHOIC BILE ACIDS SHOW RESISTANCE TO DIETARY INDUCED STEATOSIS, WEIGHT GAIN, AND TO IMPAIRED GLUCOSE METABOLISM 376
Y. Bonde, G. Eggertsen, M. Rudling (Sweden)
- SAG039 IMPACT OF *LITOMOSOIDES SIGMODONTIS* ANTIGEN ON T CELL DIFFERENTIATION AND ON THE DEVELOPMENT OF INITIAL ATHEROSCLEROTIC LESIONS IN APOE-KNOCKOUT MICE 377
C. Kühn, M. Tauchi-Brück, J. Ajendra, A. Hörauf, C. Stumpf, S. Achenbach, M. Hübner, B. Dietel (Germany)
- SAG040 UNSTABLE LDL - NOVEL MECHANISM OF ATHEROGENESIS AND LINK TO CARDIOVASCULAR DEATHS 378
M. Ruuth, S.D. Nguyen, T. Vihervaara, T.D. Laajala, M. Uusitupa, U. Schwab, M. Savolainen, J. Sinisalo, T. Aittokallio, R. Käkelä, M. Jauhiainen, P. Kovanen, K. Oörni (Finland)

Poster #

14:00 - 15:00

Exhibition Area

Nutrition, Nutraceuticals and Cardiovascular Disease

- Chair: **A.H. Lichtenstein** (USA) 379
- SAG041 MIDDLE-TERM DIETARY SUPPLEMENTATION WITH RED YEAST RICE PLUS COENZYME Q10 IMPROVES LIPID PATTERN, ENDOTHELIAL REACTIVITY AND ARTERIAL STIFFNESS IN MODERATELY HYPERCHOLESTEROLEMIC SUBJECTS 380
A. Cicero, M. Morbini, M. Rosticci, S. D'Addato, E. Grandi, C. Borghi (Italy)
- SAG042 INCREASED OXIDATIVE STRESS AND IMPAIRED MITOCHONDRIAL BIOGENESIS AND DYNAMICS ARE IMPROVED BY RICE BRAN ENZYMOLOGICAL EXTRACT DIET SUPPLEMENTATION 381
C. Perez Ternero, C. Werner, M. Alvarez de Sotomayor, M.D. Herrera, U. Laufs (Spain)
- SAG043 INVESTIGATION OF THE IMPACT OF CROCUS SATIVUS ON THE METABOLIC PROFILE OF DIABETIC RATS 382
P. Konstantopoulos, L.M. Korou, I. Vlachos, I. Doulamis, A. Tzani, S. Fragouli, G. Mastorakos, N. Katsilambros, D. Perrea (Greece)
- SAG044 LONG-CHAIN METABOLITES OF A-TOCOPHEROL EMERGE FROM THE SHADOW OF THEIR PRECURSORS: A-13'-OH AND A-13'-COOH AS A NEW CLASS OF REGULATORY METABOLITES 383
L. Schmölz, M. Wallert, S. Cifollilli, S. Kluge, G. Cruciani, M. Gleib, O. Werz, F. Galli, M. Birringer, S. Lorkowski (Germany)
- SAG045 CONSUMPTION OF POLYUNSATURATED FAT IMPROVES THE SATURATED FATTY ACID-MEDIATED IMPAIRMENT OF HDL ANTIOXIDANT POTENTIAL 384
A. García León, L. Cedó, J. Metso, D. Santos, J.L. Sánchez-Quesada, J. Julve, J. Mora-Brugués, M. Jauhiainen, F. Blanco-Vaca, J.C. Escolà-Gil (Spain)
- SAG046 PLASMA LEVELS OF THE PRO-ATHEROGENIC NUTRIENT BIOMARKER TMAO IS INCREASED BY EXPOSURE TO DIOXIN-LIKE POLLUTANTS THROUGH UPREGULATION OF FMO3 385
M. Petriello, J. Hoffman, M. Sunkara, A. Morris, B. Hennig (USA)
- SAG047 SOYA-ENRICHED MIXED DIET SIGNIFICANTLY IMPROVES CARDIOVASCULAR AND METABOLIC RISK FACTORS: A RANDOMIZED CONTROLLED TRIAL 386
M. Ruscica, C. Pavanello, B. Morlotti, M. Gomaschi, C. Vitali, R. Bosio, C.R. Sirtori, A. Arnoldi, P. Magni (Italy)
- SAG048 PREVALENCE AND 2010-15 SECULAR TRENDS IN SUGAR-SWEETENED BEVERAGES SALES IN EUROPE AND THE MIDDLE EAST 387
B. Arsenaull, M.R. Taskinen, J.P. Després (Canada)

Poster #

14:00 - 15:00

Exhibition Area

Pharmacology of Dyslipidemia

- Chair: **M. Averna** (Italy) 388
- SAG049 ATTAINMENT OF ACC/AHA RECOMMENDED LDL-C LOWERING WITH STATIN AND EZETIMIBE STATIN THERAPIES 389
P. Toth, H. Bays, M. Farnier, E. Jensen, J. Tomassini, A. Polis, J. Foody, A. Tershakovec (USA)
- SAG050 EFFICACY AND SAFETY OF PITAVASTATIN IN PAEDIATRIC FH COMPARED WITH OTHER STATINS FROM COCHRANE DATABASE 390
M. Harada-Shiba, T. Ohta, A. Ohtake, T. Okada, O. Arisaka, J. Kastelein, I. Luirink (Japan)
- SAG051 HOW TO IMPROVE THE CHOLESTEROL-LOWERING EFFICACY OF EZETIMIBE IN STATIN-INTOLERANT PATIENTS IN CLINICAL PRACTICE: A RETROSPECTIVE STUDY 391
A. Cicero, M. Morbini, S. D'Addato, F. Fogacci, M. Rosticci, C. Borghi (Italy)
- SAG052 IDENTIFICATION AND MANAGEMENT OF CANADIAN PATIENTS WITH SYMPTOMS OF STATIN INTOLERANCE: RESULTS FROM A REAL-WORLD CLINICAL PRACTICE SURVEY 392
P. Oh, G.K. Hovingh, S.R. Gandra, J. McKendrick, **R. Dent**, H.M. Wieffer, A.L. Catapano, R.S. Rosenson, E.S.G. Stroes (Switzerland)
- SAG053 PCSK9 CIRCULATING LEVELS AND CETP PLASMA ACTIVITY ARE ASSOCIATED INDEPENDENTLY OF LIPID LOWERING THERAPIES 393
J. Girona, D. Ibarretxe, N. Plana, S. Guaita, N. Amigó, M. Heras, **L. Masana** (Spain)
- SAG054 UNDERSTANDING LIPOPROTEIN(A) METABOLISM: REBOUND ANALYSES OF LIPOPROTEIN(A) AND PCSK9 CONCENTRATIONS FOLLOWING REGULAR LIPOPROTEIN APHERESIS TREATMENT (THE LIPARE-STUDY) 394
E. Waldmann, E.M. Ooi, P.H.R. Barrett, D.C. Chan, S.M. Marcovina, G.F. Watts, K.G. Parhofer (Germany)
- SAG055 DPP4 INHIBITOR, ANAGLIPTIN, AMELIORATES FASTING AND POSTPRANDIAL HYPERTRIGLYCERIDEMIA 395
M. Sairyo, D. Masuda, T. Kobayashi, H. Matsuda, T. Okada, R. Kawase, K. Nakatani, M. Koseki, T. Ohama, M. Nishida, Y. Sakata, S. Yamashita (Japan)
- SAG056 FAMILIAL HYPERCHOLESTEROLEMIA IN PRIMARY CARE IN GERMANY - DIABETES AND CARDIOVASCULAR RISK EVALUATION: TARGETS AND ESSENTIAL DATA FOR COMMITMENT OF TREATMENT (DETECT) STUDY 396
N. Schmidt, B. Schmidt, A. Dressel, U. Fraass, I. Gergei, J. Klotsche, L. Pieper, H. Scharnagel, M.E. Kleber, W. März, H.U. Wittchen, T. Grammer (Germany)

Poster #

14:00 - 15:00

Exhibition Area

Imaging in Vascular Dysfunction and Myocardial Infarction

- Chair: **W. Koenig** (Germany) 397
- SAG057 A NOVEL TC-99M AND FLUORESCENCE LABELED PEPTIDE AS A MULTIMODAL IMAGING AGENT FOR TARGETING ANGIOGENESIS IN A MURINE HINDLIMB ISCHEMIA MODEL 398
D.W. Kim, S.G. Kim, M.H. Kim, C.G. Kim (Republic of Korea)
- SAG058 REPRODUCIBILITY OF ENDOTHELIAL SHEAR STRESS AND LOW DENSITY LIPOPROTEIN TRANSPORT MODELING IN COMPUTED TOMOGRAPHY ANGIOGRAPHIC IMAGING DATA 399
A. Sakellarios, C.V. Bourantas, S.L. Papadopoulou, T. De Vries, P.H. Kitslaar, C. Gyrisis, K.K. Naka, S. Veldhof, G.W. Stone, J.H.C. Reiber, L.K. Michalis, P.W. Serruys, P.J. De Feyter, H.M. Garcia Garcia, D.I. Fotiadis (Greece)
- SAG059 USAGE OF NOVEL HYBRID PIXEL DETECTORS FOR NATIVE ATHEROSCLEROTIC PLAQUE IMAGING BY HIGH RESOLUTION X-RAY COMPUTED TOMOGRAPHY 400
A. Zhemchugov, A. Svetlikov, D. Kozhevnikov, G. Shelkov, S. Urazgildeeva, **V. Gurevich** (Russia)
- SAG060 COMPOSITION OF CORONARY PLAQUES BY CT ANGIOGRAPHY: VALIDATION BY NEAR-INFRARED SPECTROSCOPY 401
J.A. Goldstein, R.D. Madder, S. Dixon (USA)
- SAG061 ACTIVATED-PLATELET TARGETED FIBRINOLYTIC DRUGS: NOVEL TARGETED-THERANOSTIC MICROBUBBLES FOR SIMULTANEOUS DIAGNOSIS, TREATMENT AND MONITORING USING MOLECULAR ULTRASOUND TECHNOLOGY 402
X. Wang, K. Peter (Australia)
- SAG062 CARDIOVASCULAR EVENTS IN PATIENTS TREATED BY LIPOPROTEIN APHERESIS (LA) - ANALYSIS OF POSSIBLE REASONS 403
S. Tselmin, S. Fischer, F. Pistrosch, G. Müller, U. Julius (Germany)
- SAG063 THE RELATIONSHIP BETWEEN INSULIN LIKE GROWTH FACTOR-1 AND CORONARY ARTERY CALCIUM SCORE IN CARDIOVASCULAR ASYMPTOMATIC ADULT MEN 404
K.C. Park, M.J. Kim, K.C. Kim, B.H. Choi, K.H. Park, H.C. Cho (Republic of Korea)
- SAG064 2013 ACC/AHA VERSUS 2004 NCEP ATP III GUIDELINES IN THE PREDICTION OF CORONARY ARTERY CALCIFICATION PROGRESSION IN A KOREAN POPULATION 405
C.H. Jung, S. Kim, W.J. Lee, J.Y. Park, C.Y. Park (Republic of Korea)

Poster #

TUESDAY, MAY 31, 2016

13:00 - 14:00

Exhibition Area

CV Risk Factors and Atherosclerosis II

- Chair: **W. März** (Germany) 406
- SAG065 SERUM LEVELS OF ANTI-APOLIPOPROTEIN A-1 IGG ARE ASSOCIATED WITH LONG-TERM DISABILITY AND CEREBRAL LESION VOLUME IN ACUTE ISCHEMIC STROKE PATIENTS 407
N. Satta, F. Carbone, F. Montecucco, J. Virzi, F. Burger, A. Roth, G. Roversi, C. Tamborino, I. Casetta, S. Seraceni, A. Trentini, M. Padroni, F. Dallegri, P. Lalive, F. Mach, E. Fainardi, N. Vuilleumier (Switzerland)
- SAG066 GLYCATION OF APOA-I LINKS DIABETES AND CVD 408
J. Domingo-Espin, O. Nilsson-Wolanin, J. Dalla-Riva, K. Bernfur, M. Lindahl, J. Lagerstedt (Sweden)
- SAG067 APOLIPOPROTEIN CII AND CIII: PROGNOSTIC MARKERS OF CARDIOVASCULAR RISK? 409
H. Schrnagl, M.E. Kleber, T.B. Grammer, T. Stojakovic, M.M. Hoffmann, W. März (Austria)
- SAG068 SERUM MMP-8 AND TIMP-1 ASSOCIATE WITH INCIDENT CVD EVENTS AND ALL-CAUSE MORTALITY IN A POPULATION-BASED COHORT 410
I. Kormi, A.S. Havulinna, V. Salomaa, T. Tervahartiala, T. Sorsa, P.J. Pussinen (Finland)
- SAG069 PLASMA CONCENTRATIONS OF AFAMIN ARE ASSOCIATED WITH THE PREVALENCE AND INCIDENCE OF TYPE 2 DIABETES MELLITUS 411
B. Kollerits, C. Huth, S. Kiechl, C. Lamina, C. Meisinger, C. Herder, L. Kedenko, J. Willeit, B. Thorand, D. Dähnhardt, D. Stöckl, M. Roden, W. Rathmann, B. Paulweber, A. Peters, H. Dieplinger, F. Kronenberg (Austria)
- SAG070 OMENTIN-1 AND RISK OF STROKE: RESULTS FROM THE EPIC-POTSDAM COHORT STUDY 412
J. Menzel, R. Di Giuseppe, R. Biemann, C. Wittenbecher, K. Aleksandrova, T. Pischon, A. Fritsche, M.B. Schulze, H. Boeing, B. Isermann, C. Weikert (Germany)
- SAG071 AGE, GENDER AND BLOOD LIPID LEVELS: A CHANCE TO IMPROVE CARDIOVASCULAR RISK ASSESSMENT 413
W. Balder, J.K. De Vries, I.M. Nolte, J.A. Kuivenhoven, P.W. Kamphuisen (Netherlands)
- SAG072 THE ADDED VALUE OF AORTIC PWV BEYOND TRADITIONAL RISK FACTORS IN CARDIOVASCULAR RISK STRATIFICATION 414
B. Benczur, R. Bocskei, A. Cziraki, M. Illyes (Hungary)

Poster #

13:00 - 14:00

Exhibition Area

Vascular Biology II

- Chair: **H. Stangl** (Austria) 415
- SAG073 ENDOTHELIAL DYNAMIC CHANGES IN CHONDROITIN SULFATE AND DERMATAN SULFATE PROTEOGLYCANS INDUCED BY VERY LOW DENSITY LIPOPROTEINS 416
R.E. Oberkersch, Y. Rasente, S. Yuschak, N. Volpi, G. Calabrese (Argentina)
- SAG074 PRO-ATHEROGENIC OXIDIZED-LDL/B2-GLYCOPROTEIN I COMPLEXES IN CORONARY ARTERY DISEASE PATIENTS ARE ASSOCIATED WITH DISEASE SEVERITY 417
L.R. Lopez, K.P. Bliden, R. Chaudhary, R. Damrongwatanasuk, K.E. Guyer, M.G. Gesheff, C.J. Franzese, U.S. Tantry, P.A. Gurbel (USA)
- SAG075 PAI-1 EXPRESSION RENDERS M2 POLARIZED MACROPHAGES PROTEOLYTICALLY QUIESCENT 418
P. Hohensinner, J. Baumgartner, B. Ebenbauer, B. Thaler, D. Konstantin, C. Kaun, S. Stojkovic, M. Fischer, G. Maurer, K. Huber, J. Wojta (Austria)
- SAG076 IN VITRO EVIDENCE OF A PRO-INFLAMMATORY ACTION OF PCSK9 IN THP-1-DERIVED MACROPHAGES 419
C. Ricci, A. Corsini, N. Ferri (Italy)
- SAG077 INCREASED MITOCHONDRIAL ROS ACCELERATE ATHEROSCLEROSIS IN MITOCHONDRIAL CATALYTIC ENZYME 3 DEFICIENT MICE 420
S.H. Park, S.K. Hur, J.Y. Yoo, S.J. Jeong, G.T. Oh (Republic of Korea)
- SAG078 COMPARATIVE EFFECT OF SILYMARIN AND SILYBIN TREATMENT ON INFLAMMATION AND OXIDATIVE STRESS IN TRANSGENIC SPONTANEOUSLY HYPERTENSIVE RATS OVEREXPRESSING HUMAN C-REACTIVE PROTEIN 421
O. Oliyarnyk, H. Malinska, I. Markova, J. Trnovska, V. Skop, L. Kazdova, R. Vecera, M. Pravenec (Czech Republic)
- SAG079 PONATINIB AUGMENTS VASOCONSTRICTION AND ATTENUATES VASORELAXATION IN MOUSE AORTIC RINGS 422
A. Kirsch, R. Kirchmair, S. Frank (Austria)
- SAG080 CARDIOVASCULAR RISK FACTORS DIFFER IN INFLAMMATION PATHOLOGY IN PATIENTS WITH CLINICALLY SYMPTOMATIC LOWER LIMB ATHEROSCLEROSIS 423
J. Jalkanen, M. Maksimow, S. Jalkanen, H. Hakovirta (Finland)

Poster #

13:00 - 14:00

Exhibition Area

Insulin Resistance, Diabetes, Metabolic Syndrome and Obesity

- Chair: **G. Watts** (Australia) 424
- SAG081 BARIATRIC SURGERY-INDUCED WEIGHT LOSS IN MORBIDLY OBESE PATIENTS PROMOTES A FAVORABLE DECREASE IN THE GENE EXPRESSION OF MARKERS OF SUBCUTANEOUS ADIPOSE TISSUE HOMEOSTASIS 425
J. Julve, E. Pardina, R. Ferrer, J. Rossell, J.A. Baena-Fustegueras, J.M. Fort, A. Lecube, J. Peinado-Onsurbe (Spain)
- SAG082 EFFECTS OF OBESITY AND BARIATRIC SURGERY ON HDL FUNCTIONALITY AND MICROVASCULAR COMPLICATIONS OF OBESITY 426
Y. Liu, T. Siahmansur, J.D. Schofield, S. Hama, R. Yadav, S. Adam, M. France, S. Kwok, R. Donn, A. Stevens, J. Ho, B.J. Ammori, A. Syed, P.N. Durrington, H. Soran (United Kingdom)
- SAG083 BODY MASS INDEX AND MORTALITY OVER 3 DECADES 427
S. Afzal, A. Tybjærg-Hansen, G.B. Jensen, B.G. Nordestgaard (Denmark)
- SAG084 WAIST CIRCUMFERENCE AND BODY MASS INDEX CORRELATE WITH CEREBRAL GLUCOSE METABOLISM IN THE TEMPORAL LOBE IN DIABETIC PATIENTS 428
N. García-Casares, J. García-Arnés, A. Gutiérrez-Cardo, J. Rioja, M.J. Ariza, F. Alfaro, A. Nabrozidis, P. González-Santos (Spain)
- SAG085 COMPONENTS OF THE METABOLIC SYNDROME AND RISK OF TYPE 2 DIABETES 429
S. Marott, B. Nordestgaard, A. Tybjærg-Hansen, **M. Benn** (Denmark)
- SAG086 THE PLASMA PROTEOME OF TANGIER DISEASE PATIENTS REVEALS PERTURBATIONS OF DIABETIC AND INFLAMMATORY PATHWAYS 430
J. McParland, E. Pashos, D. Rader, **M. Cuchel** (USA)
- SAG087 ROLE OF PCSK9 (PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9) IN OBESITY AND METABOLIC SYNDROME: BEYOND LDLR TARGETING 431
G. Balzarotti, G. Tibolla, M. Ruscica, M. Stramba-Badiale, A.L. Catapano, D.G. Norata (Italy)
- SAG088 DIPEPTIDYL PEPTIDASE-4 INHIBITORS AND PROTECTION AGAINST STROKE: A SYSTEMATIC REVIEW AND META-ANALYSIS 432
F. Barkas, M. Elisaf, V. Tsimihodimos, H. Milionis (Greece)

Poster #

13:00 - 14:00

Exhibition Area

Hypertension, Liver and Chronic Renal Disease

- Chair: **A. Zambon** (Italy) 433
- SAG089 PRO-ATHEROGENIC LIPOPROTEIN PROFILE ASSOCIATED WITH WHITE MATTER LESIONS IN CHRONIC KIDNEY DISEASE PATIENTS: A 1H-NMR METABOLOMIC APPROACH 434
N. Amigó, R. Fuertes, C. Cabré, M. Vinaixa, M. Romeu, M. Muñoz, M. Giralt, J. Soler, J. Aquilera, M.T. Compte, X. Correig, A. Martínez-Vea (Spain)
- SAG090 ALTERED INFLAMMATORY PARAMETERS AND CHEMERIN LEVELS AFTER RENAL TRANSPLANTATION 435
R. Szentimrei, M. Harangi, H. Lőrincz, E.V. Varga, A. Szentpéteri, P. Fülöp, I. Seres, **G. Paragh** (Hungary)
- SAG091 RENAL DISEASE IS ASSOCIATED WITH MODIFIED PON1 DISTRIBUTION AT HDL SUBCLASSES 436
M. Miljkovic, J. Kotur-Stevuljevic, A. Stefanovic, J. Vekic, A. Zeljkovic, T. Gojkovic, S. Simic-Ogrizovic, V. Spasojevic-Kalimanovska, Z. Jelic-Ivanovic (Serbia)
- SAG092 HEPATIC TRANSCRIPTOMIC SIGNATURES IN A MOUSE MODEL OF THE METABOLIC SYNDROME 437
D. Nasias, I. Evangelakos, D. Kardassis (Greece)
- SAG093 STRONGLY INCREASING PREVALENCE OF HYPERTENSION BY INCREASING OVERWEIGHT IN CHILDREN AND ADOLESCENTS 438
G.M. Haas, E. Liepold, T. Bertsch, P. Schwandt (Germany)
- SAG094 ASSOCIATION OF CORONARY ARTERY CALCIFICATION AND ARTERIAL MICRO-CALCIFICATION OF THE VASCULAR ACCESS IN INCIDENT HEMODIALYSIS PATIENTS 439
B.M. Choi, Y.O. Kim, H.C. Song, Y.B. Lee (Republic of Korea)
- SAG095 LIVER DISEASE ALTERS HIGH-DENSITY LIPOPROTEIN COMPOSITION, METABOLISM AND FUNCTION 440
M. Trieb, V. Stadlbauer, R. Birner-Gruenberger, **G. Marsche** (Austria)
- SAG096 ENHANCED STATUS OF PROTHROMBOGENESIS AND ITS ASSOCIATION WITH SERUM LDL-C LEVELS IN SUBJECTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA 441
N.A. Mohd Kasim, R. Rahmat, S. Abdul Razak, S. Muid, T. Rahman, **H. Nawawi** (Malaysia)

Poster #

14:00 - 15:00

Exhibition Area

Experimental Cardiovascular Medicine II

- Chair: **M. Jauhiainen** (Finland) 442
- SAG097 CONSEQUENCES OF LYSOSOMAL ACID LIPASE DEFICIENCY IN MACROPHAGES 443
M.C. Duta-Mare, B. Radovic, S. Schlager, M. Wegscheider, D. Kolb-Lenz, T. Madl, S. Stryeck, D. Kratky (Austria)
- SAG098 PEROXIREDOXIN 1 HAVE PROTECTIVE ROLE IN THE VASCULAR DISEASE BY REGULATING MACROPHAGES 444
S. Kim, S.J. Jeong, G.T. Oh (Republic of Korea)
- SAG099 THE ATHEROPROTECTIVE ACTIVITY OF *GANODERMA* AND ITS ACTION MECHANISM IN MICE 445
F.E. Mo, P.L. Hsu, Y.C. Lin (Taiwan)
- SAG100 THE APOE*3LEIDEN.GK+/- MOUSE AS NOVEL TRANSLATIONAL MODEL FOR DYSLIPIDEMIA, TYPE 2 DIABETES AND MACROVASCULAR COMPLICATIONS 446
M. Pouwer, S. Heinonen, M. Behrendt, A.C. Andréasson, E. Pieterman, A. Van den Hoek, W. Jukema, B. Leighton, A.C. Jönsson-Rylander, H. Princen (Netherlands)
- SAG101 PPAR γ ACTIVATION ATTENUATES OXIDATIVE STRESS AND IMPROVES CEREBRAL ARTERIES ENDOTHELIAL DYSFUNCTION IN AGING RAT THROUGH UP-REGULATING UCP2 447
P. Wang, G. Cai, F. Wang, P. Zhou, Q. Wang (China)
- SAG102 EFFECTS OF CHRONIC INFLAMMATION ON MEGAKARYOCYTE AND PLATELET FUNCTION IN A CONDITIONAL MOUSE MODEL 448
M. Salzmann, M. Haase, C. Arzt, M. Mussbacher, A. Assinger, J.A. Schmid (Austria)
- SAG103 GENETIC CORRELATIONS BETWEEN CIRCULATING MIRNAS AND LIPID PROFILES REVEAL NOVEL BIOMARKERS OF CVD RISK 449
L. Michael, S. McAhren, S. Kumar, J. Peralta, H. Kulkarni, W. Gerard, J. Weir, C. Barlow, M. Kowala, P. Meikle, J. Blangero, J. Curran (USA)
- SAG104 ELEVATED LDL AND OXIDATIVE STRESS CONTRIBUTE TO ARRHYTHMOGENIC CARDIOMYOPATHY PHENOTYPIC MANIFESTATION 450
L. Arnaboldi, I. Stadiotti, S. Brambilla, G. Milano, A. Scopece, F. Cattaneo, A. Granata, C. Tondo, A. Corsini, G. Pompilio, E. Sommariva (Italy)

Poster #

14:00 - 15:00

Exhibition Area

Immunity and Atherosclerosis

- Chair: **G. Caligiuri** (France) 451
- SAG105 A NOVEL MECHANISM OF STATINS IN ATHEROSCLEROTIC AND IN HIGH-RISK SUBJECTS: MODULATION OF THE ADIPONECTIN RECEPTOR PATHWAY IN CIRCULATING MONOCYTES 452
K. Gasbarrino, H. Zheng, S.S. Daskalopoulou (Canada)
- SAG106 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AND THE RISK OF STROKE IN PATIENTS WITH RHEUMATOID ARTHRITIS 453
Y.R. Chen, H. Fang-I, W. Hsin-Chiao, C. Hung-Yi (Taiwan)
- SAG107 THE PROTEIN COMPOSITION OF INTIMA AND MEDIA THORACIC AORTA LAYERS IN ATHEROSCLEROSIS WITH AUTOANTIGENS DETECTION AND IDENTIFICATION USING PROTEOMIC TECHNOLOGIES 454
R. Zhetisheva, V. Naumov, L. Kovalyov, M. Kovalyova, I. Kamenihina, L. Novikova, M. Shogenova, A. Karpov (Russia)
- SAG108 EXPRESSION OF E06, A NATURAL MONOCLONAL ANTIBODY TARGETED TO OXIDIZED PHOSPHOLIPIDS (OXPL), ATTENUATES THE PROGRESSION OF AORTIC SCLEROSIS IN AGED HYPERLIPIDEMIC MICE 455
C. Yeang, M.Y. Hung, J. Pattison, K. Bowden, N. Dalton, K.L. Peterson, J.L. Witztum, S. Tsimikas, X. Que (USA)
- SAG109 CCL22/ MACROPHAGE-DERIVED CHEMOKINE EXPRESSION VIA HISTAMINE IN THE ATHEROSCLEROSIS 456
S. Kimura, S. Yamada, H. Noguchi, K.Y. Wang, T. Nakayama (Japan)
- SAG110 SOLUBLE URIC ACID PROMOTES DEVELOPMENT OF ATHEROSCLEROSIS LESIONS VIA ENHANCEMENT OF INNATE INFLAMMATION IN MICE 457
Y. Kimura, T. Yanagida, A. Onda, K. Asako, H. Kikuchi, H. Kono (Japan)
- SAG111 PENTRAXIN 3 PLAYS A KEY ROLE IN THE IMMUNOMODULATION OF DIET INDUCED-OBESITY IN MICE 458
A. Moregola, F. Bonacina, U. Guerrini, E. Bonavita, C. Garlanda, A. Mantovani, A.L. Catapano, G.D. Norata (Italy)
- SAG112 REGULATORY CD19+CD24^{HI}CD38^{HI} B CELLS ARE DECREASED IN PATIENTS WITH CORONARY ATHEROSCLEROSIS AND HAVE IMPAIRED INTERLEUKIN-10 PRODUCTION IN RESPONSE TO CPG 459
I.E. Dumitriu, P. Baruah, J.C. Kaski (United Kingdom)

Poster #

14:00 - 15:00

Exhibition Area

Emerging Aspects in Pharmacological Treatment of Primary and Secondary Dyslipidemia

- Chair: **B. Dieplinger** (Austria) 460
- SAG113 EFFICACY AND SAFETY OF LONG-TERM COADMINISTRATION OF FENOFIBRATE AND EZETIMIBE IN PATIENTS WITH COMBINED HYPERLIPIDEMIA: RESULTS OF THE EFECTL TRIAL 461
S. Oikawa, S. Yamashita, N. Nakaya, J. Sasaki, S. Kono, G. EFECTL Study Investigators (Japan)
- SAG114 EFFICACY AND SAFETY OF EVOLOCUMAB IN PATIENTS ON HIGH- VS MODERATE-INTENSITY BACKGROUND STATIN THERAPY 462
H. Soran, A. Lira, R. Dent, I. Bridges, R. Somaratne, M. Koren (United Kingdom)
- SAG115 PHARMACODYNAMIC RELATIONSHIP BETWEEN PCSK9, ALIROCUMAB, AND LDL-C LOWERING IN FOUR PHASE 3 ODYSSEY TRIALS WITH/ WITHOUT STATIN BACKGROUND 463
J.G. Robinson, M. Farnier, J.J. Kastelein, E.M. Roth, M.R. Taskinen, H.M. Colhoun, A. Brunet, A.T. DiCioccio, G. Lecorps, R. Pordey, M.T. Baccara-Dinet, C.P. Cannon (USA)
- SAG116 OMEGA-3 CARBOXYLIC ACIDS IN SEVERE HYPERTRIGLYCERIDEMIA: EVOLVE II STUDY RESULTS 464
E. Stroes, T. De Bruin, M. Davidson, H. Yang, M. Kvarnstrom, T. Lundstrom (Netherlands)
- SAG117 CARDIOVASCULAR EVENT RATES IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH): TRIAL ASSESSING LONG-TERM USE OF PCSK9 INHIBITION IN SUBJECTS WITH GENETIC LDL DISORDERS (TAUSSIG) STUDY INTERIM RESULTS 465
F. Raal, C. Kurtz, N. Honarpour, L. Tang, E.A. Stein (South Africa)
- SAG118 TRANSITION FROM LDL APHERESIS TO EVOLOCUMAB IN HETEROZYGOUS FH IS EQUALLY EFFECTIVE IN LOWERING LDL- BUT WITHOUT LOWERING HDL CHOLESTEROL 466
A. Hovland, K.T. Lappegård (Norway)
- SAG119 THE IMPACT OF SELECTIVE LDL APHERESIS ON SERUM ADIPOKINE LEVELS IN PATIENTS WITH HYPERCHOLESTEROLEMIA 467
V.E. Varga, H. Lőrincz, N. Zsíros, P. Fülöp, I. Seres, G. Paragh, J. Balla, M. Harangi (Hungary)
- SAG120 THE MECHANISM OF STATIN-INDUCED MODULATION OF VITAMIN D METABOLISM 468
J. Beltowski (Poland)

14:00 - 15:00

Exhibition Area

Vascular Biology III

Chair: **J. Herz** (USA)

- SAG121 ACUTE EXPOSURE TO AIR POLLUTION AGGRAVATES ACUTE MYOCARDIAL INFARCTION AND SUBSEQUENT ISCHEMIC HEART FAILURE IN MICE 469
D. Wolf, T. Marchini, N. Anto Michel, D. Dürschmied, I. Hilgendorf, C. Bode, A. Zirlik (Germany) 470
- SAG122 EFFECT OF OMEGA-3 FATTY ACID SUPPLEMENTATION ON ARTERIAL ELASTICITY IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA ON STATIN THERAPY 471
D. Chan, **J. Pang**, P.H.R. Barrett, D.R. Sullivan, T.A. Mori, J.R. Burnett, F.M. Van Bockxmeer, G.F. Watts (Australia)
- SAG123 THE ABSENCE OF PCSK9 DETERMINES A LOWER NEOINTIMAL FORMATION IN RESPONSE TO PERIVASCULAR CAROTID COLLAR PLACEMENT 472
N. Ferri, G. Tibolla, A. Dhyani, R. Baetta, A. Catapano, A. Corsini (Italy)
- SAG124 BLOOD LEVEL OF CD45+ PLATELETS AND DEVELOPMENT OF RESTENOSIS AFTER DRUG-ELUTING STENT IMPLANTATION IN PATIENTS WITH CORONARY ARTERY DISEASE 473
Z. Gabbasov, S. Kozlov, I. Melnikov, **S. Byazrova**, O. Saburova (Russia)
- SAG125 PLASMA FROM PATIENTS WITH CALCIFIED AORTIC DISEASE TRIGGERS AN OSTEOBLAST-LIKE PHENOTYPE SWITCH IN HUMAN AORTIC VALVE INTERSTITIAL CELLS 474
L. Cattan-Lévy, M.P. Jacob-Lenet, M. Dehoux, C. Deschildre, I. Codogno, M. Morvan, A.T. Gaston, G. Even, J.B. Michel, D. Messika-Zeitoun, A. Nicoletti, G. Caligiuri, **J. Khallou-Laschet** (France)
- SAG126 A NOVEL PLAYER IN VASCULAR CALCIFICATION: HYPOXIA INDUCES OSTEOGENIC DIFFERENTIATION AND EXTRACELLULAR MATRIX MINERALIZATION OF VASCULAR SMOOTH MUSCLE CELLS 475
V. Jeney, B. Enikő, T. Emese, T. Andrea (Hungary)
- SAG127 HH RESPONSIVE CELLS CONTRIBUTE TO VSMC ACCUMULATION FOLLOWING VASCULAR INJURY 476
P. Cahill, **E. Fitzpatrick**, H. Jay-Christian, S. Diana, R. Hakimjavadi, E. Redmond (Ireland)
- SAG128 METABOLOMIC PROFILING OF ASCENDING THORACIC AORTIC ANEURYSMS AND DISSECTIONS - IMPLICATIONS FOR PATHOPHYSIOLOGY AND BIOMARKER DISCOVERY 477
C. Doppler, K. Arnhard, J. Dumfarth, K. Heinz, K. Danzl, B. Messner, C. Stern, D. Bernhard (Austria)

84th EAS CONGRESSMay 29 - June 1, 2016
Innsbruck, Austria

Poster Presentation - Shift I
SUNDAY, MAY 29 -
MONDAY, MAY 30

Board #

MONDAY, MAY 30, 2016

Vascular Biology: Endothelium and Smooth Muscle Cells

- | | | |
|-----|--|-----|
| 001 | SIGMA-1 RECEPTOR INVOLVEMENT IN RHOA/ROCK ACTIVATION AND ENDOTHELIAL DYSFUNCTION INDUCED BY COCAINE
C.G. Saez , M.P. Hernández, K. Pereira-Flores, M. Palominos, A. Leguina-Ruzzi, D. Mezzano, J. Pereira (Chile) | 478 |
| 002 | P38 MITOGEN-ACTIVATED PROTEIN KINASE IS INVOLVED IN ARGINASE-II-MEDIATED ENOS-UNCOUPLING IN AGING AND OBESITY
Y. Yu , J.P. Montani, X. Ming, Z. Yang (Switzerland) | 479 |
| 003 | SOLUBLE ENDOGLIN EFFECTS ON ENDOTHELIAL CELLS IN VITRO
M. Varejckova , I. Nemeckova, P. Fikrova, E. Dolezelova, B. Vitverova, P. Nachtigal (Czech Republic) | 480 |
| 004 | THE RHOGEF TRIO REGULATES ANGIOGENIC SPROUTING THROUGH VE-CADHERIN
J. Kroon , I. Timmerman, M. Hoogenboezem, S.A. Van de Pavert, E.M. Weijers, P. Koolwijk, J.D. Van Buul (Netherlands) | 481 |
| 005 | IDENTIFICATION OF FLOW-SENSITIVE GENES DURING EMBRYOTIC VASCULAR DEVELOPMENT
C.W. Ni , N. Lawson (United Arab Emirates) | 482 |
| 006 | THE NEURONAL GUIDANCE CUE SEMAPHORIN 3F IS HIGHLY EXPRESSED BY ENDOTHELIAL CELLS UPON LAMINAR FLOW AND INHIBIT MONOCYTE MIGRATION
H. Zhang , R.G. De Bruin, W.M.P.J. Sol, E.P. Van der Veer, B.M. Van den Berg, T.J. Rabelink, A.J. Van Zonneveld, J.M. Van Gils (Netherlands) | 483 |
| 007 | SUPPLEMENTATION WITH A COMBINATION OF L-CITRULLINE AND L-ARGININE RESTORES THE PLASMA L-ARGININE CONCENTRATION AND RETARDS ENDOTHELIAL SENESENCE
T. Hayashi , K. Ina, M. Kuzuya (Japan) | 484 |
| 008 | FICUS DELTOIDEA ENHANCES EXPRESSION OF ENDOTHELIAL NITRIC OXIDE SYNTHASE AND REDUCES ENDOTHELIN-1 ON STIMULATED HUMAN CORONARY ARTERY ENDOTHELIAL CELLS
R. Ahmad , T. Rahman, N.A. Mohd Kasim, G.A. Froemming, S. Muid, N.H. Ismail, A.M. Ali, H. Nawawi (Malaysia) | 485 |
| 009 | ANTI-OXIDANT PROPERTIES OF FENUGREEK AND SAPONINS, AND THEIR EFFECTS ON ENOS EXPRESSION ON HUMAN CORONARY ARTERY ENDOTHELIAL CELLS.
R. Ahmad , T. Rahman, G.A. Froemming, H. Nawawi (Malaysia) | 486 |

Board #		
010	ANTIOXIDANT PROPERTIES OF SAFFRON AND CROCIN AND THEIR EFFECTS ON ENDOTHELIAL NITRIC OXIDE SYNTHASE EXPRESSION IN STIMULATED HUMAN CORONARY ARTERY ENDOTHELIAL CELLS R. Ahmad , N.A. Mohd Kasim, T. Rahman, G.A. Froemming, H. Nawawi (Malaysia)	487
011	GLYCATED LDL INDUCE ENDOPLASMIC RETICULUM STRESS ALONG WITH THE STIMULATION OF VCAM-1 EXPRESSION IN HUMAN ENDOTHELIAL CELLS, AND THE ENSUING MONOCYTE ADHESION L. Toma , G.M. Sanda, M. Deleanu, C.S. Stancu, A.V. Sima (Romania)	488
012	ENDOTHELIAL CELL DEATH AND DISASSEMBLY IN ATHEROSCLEROSIS S. Paone , G. Atkin-Smith, R. Tixeira, S. Caruso, L. Jiang, I. Poon, M. Hulett (Australia)	489
013	LEVOROTATORY-AMLODIPINE PLUS FLUVASTATIN CONFER ADDITIVE EFFECTS ON RETARDING ENDOTHELIUM-MESENCHYMAL TRANSITION THROUGH SUPPRESSING ROCK1 EXPRESSION A. Cai , L. Liwen, Z. Yingling, C. Jiyang, L. Xida (China)	490
014	STUDIES ON THE MECHANISM OF ACTION OF THE ANTIPROLIFERATIVE EFFECT OF NO-DONORS FUOXANS IN SMOOTH MUSCLE CELLS L. Arnaboldi , M. Lombardi, M. Sinelli, B. Rolando, L. Lazzarato, R. Fruttero, A. Gasco, A. Corsini (Italy)	491
015	THE DIACYLGLYCEROL ACETYLTRANSFERASE INHIBITORS XANTHOLHUMOL AND AMIDEPSINE D REVEAL LIPID SYNTHESIS AS A PROMOTER OF ANGIOGENESIS K. Astanina, J. Spang, R.T. Hahn, D. Oster, J. Hoppstaedter, A.K. Kierner (Germany)	492
016	PROLIFERATION OF ENDOTHELIAL PROGENITOR CELLS BY 11,12-EPOXYEICOSATRIENOIC ACID IN I/R INJURED RAT S. Kim , J.K. Chae, J.L. Young, Y.S. Kim, S.H. Lee, S.R. Lee, K.S. Rhee, W.H. Kim, J. Ko (Republic of Korea)	493
017	HIGH LEVELS OF SOLUBLE ENDOGLIN INDUCE INFLAMMATION AND OXIDATIVE STRESS IN AORTA COMPENSATED WITH PRESERVED NO-DEPENDENT VASODILATATION MICE FED HIGH FAT DIET K. Jezkova , J. Rathouska, I. Nemeckova, P. Fikrova, E. Dolezelova, M. Varejckova, B. Vitverova, C. Bernabeu, J.M. Novoa, S. Chlopicki, P. Nachtigal (Czech Republic)	494
018	MEMBRANE CONTACT SITES IN ENDOTHELIAL CELLS A. Kivelä , V. Olkkonen (Finland)	495
019	ENDOTHELIAL PROGENITOR CELLS BEFORE AND AFTER TREATMENT WITH METFORMIN IN PATIENTS WITH FAMILIAL COMBINED HYPERLIPIDEMIA AND INSULIN RESISTANCE C.O. Aragona , E. Imbalzano, V. Cairo, C. Conte, F. Mamone, A. Lo Gullo, M.A. Sardo, A. Saitta, G. Mandraffino (Italy)	496

Board #		
020	ENDOTHELIAL DYSFUNCTION, BLOOD LIPID SPECTRUM, LEVEL OF LEPTIN AND MASS OF BODY IN PATIENT WITH CORONARY HEART DISEASE IN COMBINATION WITH HEPATIC STEATOSIS. N. Grechanyk , A. Filippova, A. Kuryata (Ukraine)	497
021	UNDERSTANDING THE INTERACTIVE EFFECTS OF DOXORUBICIN AND RADIOTHERAPY ON ENDOTHELIAL CELL FUNCTION - THE ROLE OF JNK G. Hargrave , M. Boyd, R. Plevin (United Kingdom)	498
022	THE CAPACITY OF EL MODIFIED SERUM / APO B DEPLETED SERUM TO PROTECT VASCULAR ENDOTHELIAL FUNCTION S. Radulović , A. Kirsch, I. Schilcher, M. Lechleitner, C. Nussold, S. Hallström, S. Frank (Austria)	499
023	ULTRASTRUCTURAL STUDY OF ENDOTHELIUM IN ADVANCED CAROTID ARTERY ATHEROSCLEROSIS A. Evdokimenko , T. Gulevskaya, T. Gulevskaya, S. Scrylev, V. Shchipakin, M. Tanashyan (Russia)	500
024	THE ASSESSMENT OF VARIANT DOUBLE FILTRATION PLASMAPHERESIS (DFPP) IMPACT ON THE ADHESION MOLECULES CONTENT IN STABLE CORONARY ARTERY DISEASE (CAD) PATIENTS AFTER CORONARY STENTING M. Pyatchenkov , V. Tishko, A. Sokolov (Russia)	501
025	THE EFFECTS OF HIV-INFECTION AND ANTI-RETROVIRAL TREATMENT ON ENDOTHELIAL FUNCTION IN A SOUTH AFRICAN COHORT N. Mashele , S. Charania, F. Essop, I. Webster, C. Westcott, N. Goswami, P. De Boever, T. Nawrot, H. Strijdom (South Africa)	502
026	THE ROLE OF INHIBITORS OF WNT SIGNALING IN CARDIOVASCULAR EVENTS C. Röss , A. Kirschner, M. Paulweber, K. Willeit, L. Kedenko, G. Goebel, K. Rufinatscha, K. Salzmann, G. Staudacher, H. Tilg, B. Igelseder, B. Paulweber, S. Kaser (Austria)	503
027	THE GOOD? THE BAD? THE UGLY! RETINOIC ACID IN MYOCARDIAL INFARCTION K. Danzl (Austria)	504
028	ARTERIAL STIFFNESS CORRELATES WITH EXTRACELLULAR MATRIX TURNOVER IN HEART FAILURE WITH PRESERVED EJECTION FRACTION PATIENTS M. Martínez-Marin , J. Perez-Calvo, C. Josa-Laorden, I. Lacambra-Blasco, I. Gimenez-Lopez, J. Rubio-Gracia, V. Garces-Horna, M. Sanchez-Marteles, F. Ruiz-Laiglesia, P. Samperiz-Legarre, I. Torres-Courchoud, B. Amores-Arriaga, R. Martinez-Marin, C. Sanz-Bescos, F. Roncales-Garcia Blanco (Spain)	505
029	BYGLICAN EXPRESSION, ARTERIAL STIFFNESS AND PROATHEROGENIC PROFILE IN FORMER SMOKERS AFTER 1-YEAR SMOKE CESSATION G. Mandraffino , C.O. Aragona, V. Cairo, F. Mamone, A. Lo Gullo, M.A. Sardo, A. Saitta, E. Imbalzano (Italy)	506

Board #		
030	HIGH, NOT LOW LEVELS OF ENDOGENOUS ENDOSTATIN SERUM LEVELS PREDICT EVENT-FREE SURVIVAL IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE B. Zierfuss , C. Herz, C. Höbaus, R. Koppensteiner, G.H. Schernthaner (Austria)	507
031	HIGH FRUCTOSE CONSUMPTION IMPAIRS AORTIC FUNCTION AND METABOLIC PARAMETERS COMPARED TO GLUCOSE IN FEMALE RATS G. Sanguesa , M.D.M. Cascales, S. Shaligram, F. Akther, M. Baena, R. Rahimian, J.C. Laguna, M. Alegret, N. Roglans (Spain)	508
032	MECHANICAL CONDITIONS AROUND NEOVESSELS IN POPLITEAL ATHEROSCLEROTIC PLAQUES - AN ANALYSIS USING FINITE ELEMENT METHOD M. Mocan , M. Bogdan, B. Sorin Nicu (Romania)	509
033	LASER CONFOCAL MICROSCOPY OF ARTERIAL WALL: ROLE OF SIGNALING MOLECULES IN MECHANISMS OF RESTENOSIS I. Kvetnoi , K. Kozlov, E. Sedova, I. Bolotov, V. Polyakova (Russia)	510
034	HOMOARGININE: A NEW POTENTIAL AVENUE IN THE MANAGEMENT OF NEOINTIMAL HYPERPLASIA? F. Dellera , G.S. Ganzetti, A. Froio, S. Manzini, M. Busnelli, A. Meinitzer, G. Chiesa, C. Parolini (Italy)	511
035	SOLUBLE ST2 IS A NOVEL MARKER OF AORTIC STIFFNESS AND ARTERIOSCLEROSIS MEASURED BY INVASIVE HEMODYNAMIC STUDY S.H. Kim , H.L. Kim, W.H. Lim, J.B. Seo, W.Y. Chung, J.H. Zo, H.L. Lee, M.A. Kim, D.G. Park, G.J. An (Republic of Korea)	512
036	VASCULAR RESPONSES TO INSULIN ARE IMPAIRED AFTER DIET-INDUCED OBESITY WHEREAS RESPONSES TO IGF-1 ARE MAINTAINED G.K. Povlsen , I. Buza, H. Boonen, J. Worm (Denmark)	513
037	CARDIOMETABOLIC AND VASCULAR EFFECTS OF TREATMENT WITH A FIXED-DOSE COMBINATION ANTI-RETROVIRAL DRUG CONTAINING NUCLEOSIDE AND NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIS AND NNRTIS) IN ADULT RATS H. Strijdom , N. Goswami, P. De Boever, C. Westcott, T. Ogundipe, F. Everson, A. Genis (South Africa)	514
038	SHORT-TERM AEROBIC EXERCISE IMPROVES AORTIC STIFFNESS IN WOMEN AFTER MENOPAUSE P. Wohlfahrt , J. Pitha, I. Kralova Lesna, O. Auzky, P. Suchanek, P. Stavek (Czech Republic)	515
039	EFFECTS OF ADIPONECTIN ON VASCULAR PROPERTIES OF CAROTID ARTERY ASSOCIATED WITH MATRIX REMODELING W.C. Tsai , Y.T. Sun (Taiwan)	516

Board #		
040	THE LABILE IRON POOL AND PARAMETERS OF ARTERIAL WALL ELASTICITY P. Risko , J. Pláteník, R. Buchal, J. Potočková, P. Kraml (Czech Republic)	517
041	THE EFFECT OF HIGH-FAT DIET ON THE BARRIER FUNCTIONS AND INFLAMMATORY STATUS OF HUMAN VASCULAR ENDOTHELIAL CELLS P. Gorzelak-Pabis, E. Luczak, K. Wojdan, M. Broncel , M. Chalubinski (Poland)	518
042	MODIFYING THE GUT MICROBIOME WITH POLYPHENOLS AND A LECTIN LIMITED DIET IMPROVES ENDOTHELIAL FUNCTION S. Gundry (USA)	519
043	GENOMIC REARRANGEMENTS IN HUMAN ATHEROSCLEROTIC VASCULAR TISSUES A. Sleptcov , M. Nazarenko, I. Lebedev, N. Skryabin, O. Barbarash, V. Puzyrev (Russia)	520
044	INTIMA-MEDIA THICKNESS OF THE DESCENDING AORTA IS INFLUENCED BY AORTIC VALVE DISEASE J. Petrini , M. Ring, P. Eriksson, A. Franco-Cereceda, K. Caidahl, M.J. Eriksson (Sweden)	521

Vascular Biology: Macrophages, Inflammation, Immunity

045	EFFECTS OF OXIDIZED LDL IN M2 MACROPHAGES. IMPLICATIONS IN ATHEROSCLEROSIS F. Goncalves , K. Alcantara, V. Moura, P. Nolasco, J. Kalil, M. Hernandez (Brazil)	522
046	HUMAN MACROPHAGES EXPOSED TO OXIDIZED LDL OR TUNICAMYCIN EXHIBIT INCREASED MMP-9 EXPRESSION, SECRETION AND ACTIVITY BY A MECHANISM INVOLVING ENDOPLASMIC RETICULUM STRESS G.M. Sanda , M. Deleanu, C.S. Stancu, M. Simionescu, A.V. Sima (Romania)	523
047	RECOMBINANT DOMAIN V OF BETA(2)-GLYCOPROTEIN I INHIBITS OXLDL-INDUCED TF EXPRESSION IN MACROPHAGES Y. Chi , T. Yu, Q. Liu, J. Qin, J. Li, Y. Chen, M. Li (China)	524
048	REDUCED DIETARY INTAKE OF TLR2 AND TLR4 STIMULANTS FAVOURABLY MODIFIES LIPID AND INFLAMMATORY MARKERS OF CARDIOMETABOLIC RISK IN HEALTHY MEN T. Faraj , C. Erridge (United Kingdom)	525
049	THE ROLE OF OXIDIZED LOW-DENSITY LIPOPROTEINS AND AUTOANTIBODIES TO THEM IN ATHEROGENESIS IN PATIENTS WITH CORONARY ATHEROSCLEROSIS M. Shogenova , A. Karpov, R. Zhetisheva, V. Masenko, V. Naumov (Russia)	526

Board #		
050	CELL-SPECIFIC UPREGULATION OF APOLIPOPROTEIN E GENE EXPRESSION IN MACROPHAGES BY GLUCOCORTICOIDS V.G. Trusca , E.V. Fuior, I.M. Fenyo, I.F. Tudorache, D. Kardassis, M. Simionescu, A.V. Gafencu (Romania)	527
051	INTERLEUKIN-27 POLYMORPHISMS ARE ASSOCIATED WITH PREMATURE CORONARY ARTERY DISEASE AND INSULIN RESISTANCE. THE GENETICS OF ATHEROSCLEROTIC DISEASE (GEA) MEXICAN STUDY R. Posadas-Sánchez , N. Pérez-Hernández, J.M. Rodríguez-Pérez, J. Angeles-Martínez, C. Posadas-Romero, G. Cardoso-Saldaña, T. Villarreal-Molina, G. Vargas-Alarcón (Mexico)	528
052	ENZYMATIC DEGRADATION OF 7-KETOCHOLESTEROL (7-KC), A NEW STRATEGY FOR THE TREATMENT OF ATHEROSCLEROSIS I. Perveen , S. Ahmed (Pakistan)	529
053	HUMAN MONOCYTE-DERIVED MACROPHAGES FROM CORONARY ARTERY DISEASE PATIENTS SHOW AN IMPAIRED PHENOTYPE S. Eligini , S. Fiorelli, N. Cosentino, V. Cavalca, S. Colli, G. Marenzi, E. Tremoli (Italy)	530
054	AGE-ALBUMIN REDUCES ABCA-1 CONTENT IN MACROPHAGES BY INDUCING ITS MODIFICATION BY AGE AND DEGRADATION BY THE UBIQUITIN-PROTEASOME AND LYSOSOMAL SYSTEM. R. Tallada Iborra , A. Machado-Lima, U. Fabres Machado, L. Rui, E.R. Nakandakare, S. Yokoyama, M. Passarelli (Brazil)	531
055	MONOCYTE ACTIVATION CORRELATES WITH ATHEROGENIC MITOCHONDRIAL MUTATIONS A. Orekhov , N. Nikiforov, N. Elizova, M. Sazonova, A. Zhelankin, I. Sobenin (Russia)	532
056	FOXO1 AND NF- κ B REGULATE CYCLOOXYGENASE-2 EXPRESSION UNDER LYSOPHOSPHATIDYLCHOLINE TREATMENT IN HUMAN CARDIAC FIBROBLAST H.C. Tseng , C.M. Yang (Taiwan)	533
057	DIVERGENT EFFECTS OF SODIUM SALICYLATE ON GLUCOSE METABOLISM AND REVERSE CHOLESTEROL TRANSPORT IN OBESITY S. Kajani , M. O'Reilly, W. Guo, F. McGillicuddy (Ireland)	534
058	PRO-INFLAMMATORY GENE EXPRESSION IN ADIPOSE TISSUE IN PATIENTS WITH ATHEROSCLEROSIS S. Cejková , I. Králová Lesná, J. Froněk, A. Králová, R. Poledne (Czech Republic)	535
059	RESPONSE GENE TO COMPLEMENT-32 REGULATES TGF- β EXTRACELLULAR MATRIX EXPRESSION IN HUMAN AORTIC ATHEROSCLEROTIC WALL S.I. Vlaicu , A. Tatmir, D. Boodhoo, A.P. Mekala, C.A. Tegla, V. Rus, H. Rus (Romania)	536

Board #		
060	THE ASSOCIATION BETWEEN PLASMA INTERLEUKIN-27 (IL-27) LEVELS AND THE SEVERITY OR INSTABILITY OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CAD K. Miura , E. Saita, N. Suzuki, K. Miyata, N. Ikemura, R. Ohmori, Y. Ikegami, Y. Kishimoto, K. Kondo, Y. Momiyama (Japan)	537
061	FEATURES OF CELLULAR AND VASCULAR INFLAMMATORY RESPONSE IN PATIENTS WITH UNSTABLE ANGINA AND MYOCARDIAL INFARCTION N. Musikhina , T. Petelina, L. Gapon, O. Irina, V. Kuznetsov (Russia)	538
062	EVALUATION OF MMP-7 AND TIMP-1 IN PATIENTS WITH CORONARY ATHEROSCLEROSIS C.R. Revnic , C. PENA, S. VOINEA, F. REVNIC, B. PALTINEANU (Romania)	539
063	RELATIONSHIP BETWEEN MMP-9, TIMP-1, HS CRP AND THE SEVERITY OF ATHEROSCLEROTIC CORONARY ARTERY DISEASE C.R. Revnic , C. PENA, S. PRADA, F. REVNIC, G. PRADA (Romania)	540
064	INTERMEDIATE DENSITY LIPOPROTEIN IS ASSOCIATED WITH MONOCYTE SUBSET DISTRIBUTION IN PATIENTS WITH STABLE ATHEROSCLEROSIS K. Krychtiuk , S. Kastl, T. Pongratz, G. Goliash, L. Gaspar, G. Maurer, K. Huber, E. Dostal, S. Pfaffenberger, S. Oravec, J. Wojta, W. Speidl (Austria)	541
065	THE ROLE OF MYELOID DENDRITIC CELLS, CHEMOKINE CCL17 AND T-CELL RECEPTOR CCR4 IN ATHEROGENESIS A. Karpov , A. Rvatcheva, M. Shogenova, R. Zhetisheva, V. Masenko, V. Naumov (Russia)	542
066	THE INFLAMMATORY PROCESS AS A RISK FACTOR OF DEVELOPING ATHEROSCLEROSIS IN PATIENTS WITH RHEUMATOID ARTHRITIS I. Starodubtseva (Russia)	543
067	MMP-12 AND TIMPS BEHAVIOUR IN STROKE RELATED TO CAROTID ARTERY STENOSIS N. Cifani, F. Del Porto, L. Ferri , M. Proietta, D. Toni, R. Dito, M. De Michele, A. Falcou, M. Taurino (Italy)	544
068	ATHEROSCLEROTIC PATIENTS HAVE M1-SKEWED MONOCYTES: COMORBIDITIES AND RISK FACTORS CONTRIBUTE H. Williams, V. Patel, G. Cassorla, N. Pertsoulis, S. Li , J. Fletcher, H. Medbury (Australia)	545
069	INCREASED GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) IS ASSOCIATED WITH INFLAMMATION IN OBESE SUBJECTS M. Malczewska-Malec, M. Malczewska-Malec , A. Polus, J. Goralska, U. Razny, A. Dembinska-Kiec, B. Solnica (Poland)	546

Board #		
070	INCREASING B1A LYMPHOCYTES THROUGH APRIL OVEREXPRESSION IN APOLIPOPROTEIN E-DEFICIENT MICE STABILIZES ADVANCED ATHEROSCLEROTIC LESIONS BY DECREASING NECROTIC AREA AND INCREASING SMOOTH MUSCLE CELL CONTENT	547
	K.H. Zheng , S. Bernelot Moens, S.I. Van Leuven, S. Havik, D. Baeten, E. Stroes (Netherlands)	
071	CYTOMEGALOVIRUS DNA LOAD AND T-LYMPHOCYTES ACTIVATION IN ATHEROSCLEROTIC PLAQUES	548
	A. Lebedeva , E. Nikitskaya, O. Ivanova, J.C. Grivel, E. Maryukhnich, A. Shpektor, E. Vasilieva, L. Margolis (Russia)	
072	INTERLEUKIN-17-RELATED PATHWAYS ARE INVOLVED IN CAROTID ATHEROSCLEROSIS, BUT NOT IN STANFORD-A ACUTE AORTIC DISSECTION	549
	F. Del Porto, N. Cifani, L. Ferri , S. Perrotta, R. Dito, M. Iaconi, R. Carletti, M. Proietta, L. Tritapepe, C. Di Gioia, M. Taurino (Italy)	
073	ROLE OF T HELPER 17 LYMPHOCYTE SUBPOPULATIONS IN CRITICAL CAROTID ARTERY STENOSIS	550
	M. Proietta, N. Cifani, F. Del Porto, L. Ferri , G. Orgera, S. Perrotta, R. Dito, L. Tritapepe, M. Iaconi, M. Taurino (Italy)	
074	INCREASED FREQUENCIES OF CIRCULATING T-HELPERS 17 AND DIMINISHED REGULATORY T-CELLS TO T-HELPERS 17 RATIO PREDICT CAROTID ATHEROSCLEROSIS PROGRESSION	551
	A. Filatova, A. Shchinova , E. Pylaeva, A. Potekhina, A. Osokina, M. Tripoten, O. Pogorelova, T. Balakhonova, E. Noeva, E. Klesareva, O. Afanasieva, T. Arefieva (Russia)	
075	DECREASED BONE MARROW ACTIVITY MEASURED BY USING 18F-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY AMONG PATIENTS WITH CEREBRAL ARTERY ATHEROSCLEROSIS	552
	J.M. Kim , L. Eun Seoung, P. Kwang-Yeol, S. Ju Won, J. Keun-Hwa (Republic of Korea)	
076	PSORIASIS AND CORONARY ARTERY DISEASE: THE ROLE OF INFLAMMATION	553
	P. Altieri , H.L. Banchs, J. Nieves (Puerto Rico)	
077	ABSENCE OF FIBRONECTIN-EDA CONTRIBUTES TO SEPSIS OUTCOMES IN A MURINE MODEL	554
	A. Dhyani , V.K. Pulakazhi Venu, P. Uboldi, A.F. Muro, A.L. Catapano, D.G. Norata (Italy)	
078	HUMAN HERPESVIRUS ACTIVATION IN PATIENTS WITH ACUTE CORONARY SYNDROME	555
	E. Nikitskaya , O. Ivanova, M. Elena, G. Jean-Charles, A. Lebedeva, A. Shpektor, L. Margolis, E. Vasilieva (Russia)	

Board #		
079	BACILLE-CALMETTE-GUÉRIN LOWERS PLASMA CHOLESTEROL AND DELAYS ATHEROSCLEROTIC LESION PROGRESSION IN MICE	556
	A. Van Dam , S. Bekkering, M. Crasborn, L. Van Beek, S. Van den Berg, F. Vrieling, S. Joosten, V. Van Harmelen, M. De Winther, E. Lutgens, M. Boon, N. Riksen, P. Rensen, J. Berbée (Netherlands)	
080	IDENTIFYING FEATURES OF VASCULAR INFLAMMATORY RESPONSE IN PATIENTS WITH MYOCARDIAL INFARCTION USING THE SYNTAX SCORE	557
	T. Petelina , N. Musikhina, L. Gapon, I. Osipova, V. Kuznetsov (Russia)	
081	REDOX-ACTIVE IRON IN MONOCYTES ISOLATED FROM PATIENTS WITH CHRONIC CARDIOVASCULAR DISEASE	558
	P. Kraml , P. Riško, J. Pláteník, J. Potočková (Czech Republic)	
082	PATIENTS WITH RHEUMATOID ARTHRITIS SHOWED ALTERED LIPOPROTEIN PROFILE WITH DYSFUNCTIONAL HIGH-DENSITY LIPOPROTEINS TO EXACERBATES INFLAMMATION AND ATHEROSCLEROTIC PROCESS	559
	J.Y. Kim , E.Y. Lee, K.H. Cho (Republic of Korea)	
083	THE LEVEL OF NITRIC OXIDE REGULATES LIPOCALIN-2 EXPRESSION UNDER INFLAMMATORY CONDITION IN RINM5F BETA-CELLS	560
	S.Y. Chang , Y.H. Jo, M.J. Kim (Republic of Korea)	
084	DIFFERENTIAL WHITE BLOOD CELL COUNT AND METABOLIC SYNDROME IN JAPANESE MEN	561
	Y. Ikeda , N. Hisakawa, T. Ohguro, J. Nishiuchi, Y. Kumon (Japan)	
085	NON-HDL CHOLESTEROL RELATES TO PRO-INFLAMMATORY STATUS OF HUMAN VISCERAL ADIPOSE TISSUE	562
	R. Poledne , I. Kralova Lesna, A. Kralova, A. Sekerkova, J. Fronek (Czech Republic)	
086	EFFECT OF FAT COMPOSITION OF A MEAL ON THE ACUTE POSTPRANDIAL INFLAMMATORY RESPONSE	563
	I. Shapira , O. Raz, S. Berliner (Israel)	
087	THE RELATIONSHIP BETWEEN <i>HELICOBACTER PYLORI</i> INFECTION AND ARTERIAL STIFFNESS IN ADULTS WITH ABNORMAL GASTRIC ENDOSCOPIC FINDINGS	564
	K.C. Park , M.J. Kim, K.S. Park, Y.S. Kim, H.C. Cho, H.R. Sung, K.H. Park, B.H. Choi, K.C. Kim (Republic of Korea)	
088	PROTECTIVE EFFECT OF CAROTENOIDS ON CX40 AD CX43 EXPRESSION IN THE LEFT VENTRICLE OF NORMOTENSIVE WISTAR RATS AFTER ADMINISTRATION OF LPS	565
	K. Frimmel , J. Krizak, B. Liptak, J. Navarova, V. Knezl, E. Breierova, I. Bernatova, L. Okruhlicova (Slovakia)	

Board #

Vascular Biology: Myocardial Infarction, Stroke, Peripheral Vascular Disease

089	EFFECT OF THROMBOLYTIC THERAPY AND PERCUTANEOUS CORONARY INTERVENTION (PCI) ON INFLAMMATORY MEDIATORS B. Bagheri , A. Garjani, B. Taherkhanchi, B. Sohrabi, F. Mousavi (Iran)	566
090	EFFECT OF ENDOVASCULAR TREATMENT AT PATIENTS WITH EARLY POSTINFARCTION STENOCARDIA S. Salakhitdinov , M. Kenjaev, S. Abdijalilova, A. Nizomov (Uzbekistan)	567
091	TERMS OF SUCCESS OF REHABILITATION IN PATIENTS WITH MULTIFOCAL ATHEROSCLEROSIS P. Bondarenko , A. Novikova, M. Ivanov, M. Ermina, M. Chvostova, A. Yadernaya, R. Al-Banna (Russia)	568
092	INTERSECTED GENES IN HYPERLIPIDEMIA AND CORONARY BYPASS PATIENTS: FEASIBLE BIOMARKERS FOR CORONARY HEART DISEASE Y. Maneerat , K. Prasongsukarn, S. Benjathummarak, W. Dechkhajorn, U. Chaisri (Thailand)	569
093	MYOCARDIAL STANNING AFTER THROMBOLYTIC THERAPY FOR ACUTE MYOCARDIAL INFARCTION. M. Kenjaev , S. Kenjaev, S. Abdijalilova, A. Nizomov (Uzbekistan)	570
094	EARLIEST OUTCOMES OF ACUTE CORONARY SYNDROME IN PATIENTS WITH TYPE 2 DIABETES S. Abdijalilova , M. Kenjaev, L. Botirova, U. Ganiyev, A. Nizomov (Uzbekistan)	571
095	N-ACETYLCYSTEINE IN A COMBINATION THERAPY REDUCES MYOCARDIAL DAMAGE IN PATIENTS WITH ACUTE CORONARY SYNDROME AND IMPROVES LEFT VENTRICULAR FUNCTION AFTER PERCUTANEOUS CORONARY INTERVENTION. A. Nizomov , B. Toshev, M. Mukhamedova, J. Berdiqulov (Uzbekistan)	572
096	RELATIONSHIP BETWEEN LIPID DISORDERS AND SEVERITY AND NATURE OF CORONARY ARTERY LESIONS IN MALE PATIENTS WITH CORONARY ARTERY DISEASE V. Kashtalap , O. Barbarash, O. Hryachkova, A. Novitskaya (Russia)	573
097	PHYSIOLOGICAL AND BIOCHEMICAL PARAMETERS OF HYPERTHYROID RAT HEART DURING ISCHEMIA REPERFUSION C.R. Revnic , C. PENA, F. REVNIC, A.S. NICA, S. PRADA, G. PRADA (Romania)	574
098	ACUTE ARTERIAL OCCLUSION OF APPARENTLY HEALTHY ARTERIES - A CONCLUSIVE EXPLANATION USING FRACTAL PHYSICS D. Tesloianu , M. Agop, I. Nedelciuc (Romania)	575

Board #

099	AUTOLYSIS IN CAD STEMI ANTEROSEPTOAPICOLATERAL WALL PATIENT, A CASE REPORT P. Sudjana , F. Nugraha, C. Achmad, A. Purnomowati, T. Aprami (Indonesia)	576
100	VENOUS THROMBOEMBOLISM AND CORONARY SYNDROME A. Babets , A. KURIATA (Ukraine)	577
101	ASSOCIATION OF BASELINE APOLIPOPROTEIN B AND FRIEDEWALD LDLC WITH LONG-TERM RE-INFARCTION IN HYPERTRIGLYCERIDEMIC PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION M. Hermans , A. Van der Laarse, M. Schalij, F. Romijn, N. Smit, Y. Van der Burgt, W. Jukema, C. Cobbaert (Netherlands)	578
102	CORRELATION OF HIGH-SENSITIVE CRP, CAROTID INTIMA-MEDIA THICKNESS, AND THE CHRONIC KIDNEY DISEASE OF HEALTHY RESIDENTS: RESULTS FROM THE KYUSHU AND OKINAWA POPULATION STUDY (KOPS) Y. Tanaka , M. Shimizu, N. Furusyo, Y. Kato, J. Hayashi (Japan)	579
103	ATHEROSCLEROTIC SOFT PLAQUE REGRESSION USING TRANSCUTANEOUS LOW-LEVEL COMBINED DUAL-FREQUENCY SONICATION ACCOMPANIED BY HIGH-DOSE ATORVASTATIN AND PESDA MICROBUBBLES ADMINISTRATION H. Mehrad , M. Mokhtari-Dizaji, H. Ghanaati (Iran)	580
104	INDIVIDUAL ATORVASTATIN DOSES TITRATION TO TREATMENT OF CAROTID PLAQUES IN PATIENTS WITH ARTERIAL HYPERTENSION I-II DEGREE N. Balashenka , V. Podpalov (Belarus)	581
105	EFFECT OF SHORT-TERM INTENSIVE ROSUVASTATIN THERAPY ON CAROTID ATHEROSCLEROTIC PLAQUE VOLUME IN VERY HIGH CARDIOVASCULAR RISK PATIENTS USING THE THREE-DIMENSIONAL ULTRASOUND Z. Luginova , M. Koshurnikova, E. Solovieva, T. Balakhonova, A. Susekov (Russia)	582
106	PLEIOTROPIC EFFECTS OF ANTI-ATHEROSCLEROTIC CILOSTAZOL ON BRAIN OF STROKE-PRONE SPONTANEOUSLY HYPERTENSIVE RATS (SHR-SP) K. Abe , Y. Omote, T. Yamashita, R. Morihara, Y. Nakano, Y. Ohta (Japan)	583
107	ASSOCIATION BETWEEN VO ₂ PEAK AND CLAUDICATION WALKING TIME MEASURED DURING WALKING ON A TREADMILL AND IN COMMUNITY SETTINGS OUTDOOR WALK - PILOT STUDY E. Rostonic , A. Kulik, J. Trzeciak, P. Mika (Poland)	584
108	EFFECTS OF NORDIC POLE WALKING ON OXIDATIVE STRESS AND WALKING ABILITIES IN PATIENTS WITH INTERMITTENT CLAUDICATION E. Rostonic , M. Więcek, M. Bawelski, M. Maciejczyk, J. Głodzik, P. Mika (Poland)	585

Board #		
109	LOW NUMBER OF CIRCULATING CD34 POSITIVE CELL IS ASSOCIATED WITH GREATER PROGRESSION OF CORONARY CALCIUM DETERMINED BY MDCT T. Miyoshi , M. Doi, K. Nakamura, H. Ito (Japan)	586
110	A GIANT LEFT ATRIUM Y. Saleh , A. Almaghraby, B. Hammad, M. Elbahey, A. Samoka, A. Ghoneem, M. Seleem (Egypt)	587
111	ARTERIAL STIFFNESS AS A PREDICTOR OF RECOVERY OF LEFT VENTRICULAR SYSTOLIC FUNCTION AFTER ACUTE MYOCARDIAL INFARCTION TREATED WITH PRIMARY PERCUTANEOUS CORONARY INTERVENTION G. Mandraffino , C.O. Aragona, S. Quartuccio, G. Trapani, A. Saitta, M. Vatrano, E. Imbalzano (Italy)	588
112	EVALUATION OF CHANGES OF GLOBAL LONGITUDINAL STRAIN IN PATIENTS WITH STEMI AFTER MYOCARDIAL REVASCULARIZATION V. Oleynikov , V. Galimskaya, E. Romanovskaya (Russia)	589
113	ASSESSMENT OF EFFICIENT REVASCULARIZATION ON DYNAMICS OF VELOCITY PARAMETERS IN PATIENTS WITH STEMI V. Oleynikov , V. Galimskaya, E. Romanovskaya, I. Avdeeva (Russia)	590
114	STRUCTURAL AND FUNCTIONAL PROPERTIES OF THE MAJOR ARTERIES IN PATIENTS WITH CORONARY HEART DISEASE AND HEALTHY SUBJECTS V. Oleynikov , A. Khromova, L. Salyamova (Russia)	591
115	LIVER DYSFUNCTION AND 18F-NAF ATHEROSCLEROTIC PLAQUE UPTAKE - ANALYSIS IN HIGH-CARDIOVASCULAR RISK INDIVIDUALS M. Santos , M. Castelo-Branco, R. Silva, A. Gomes, P. Donato, J. Ferreira, C. Domingues, M. Pego, L. Gonçalves, M.J. Ferreira (Portugal)	592
116	THE RELATIONSHIP BETWEEN CALCIFIED PLAQUES AND RESTENOSIS AFTER CAROTID ENDARTERECTOMY H. Katano , K. Yamada, M. Mase (Japan)	593
117	ASSOCIATION BETWEEN SERUM ZINC LEVEL AND CAROTID ATHEROSCLEROSIS WITHOUT PLAQUE M. Park (Republic of Korea)	594
118	PLAQUE CHARACTERISATION AND ANALYSIS IN THE RISK STRATIFYING PATIENTS WITH SYMPTOMATIC CAROTIS STENOSIS D. Vanoli , P. Lindqvist (Sweden)	595
119	AREA MEASUREMENT OF CAROTID PLAQUE COMPARING B-MODE, DOPPLER COLOR AND CONTRAST-ENHANCED ULTRASOUND IMAGING E. Nyman , D. Vanoli, C. Grönlund, U. Näslund, P. Lindqvist (Sweden)	596

Board #		
120	DO STROKE PATIENTS WITH NORMAL CAROTID ARTERIES REQUIRE TEE FOR EXCLUSION OF RELEVANT AORTIC PLAQUE? B. Muinjonov, E. Giyazitdinova (Uzbekistan)	597
121	QUANTIFICATION OF MICROVESSELS DENSITY IN CAROTID PLAQUE BY CONTRAST-ENHANCED ULTRASOUND WITH HISTOPATHOLOGIC VALIDATION A. Evdokimenko , L. Druina, A. Chechetkin, S. Scrylev, T. Gulevskaya, M. Tanashyan (Russia)	598
122	REFERENCE VALUES FOR LOCAL ONE-POINT CAROTID STIFFNESS BY ECHO-TRACKING IN A LARGE POPULATION OF HEALTHY SUBJECTS S. Favretto , S. Carerj, J. Jaroch, K. Łoboz-Grudzień, F. Antonini-Canterin, C. Zito, E. Bossone, M. Plrisi, O. Vriz (Italy)	599
123	INVESTIGATION OF PROTOPORPHYRIN IX-MEDIATED SONODYNAMIC THERAPY ON INTERMEDIATE STAGE ATHEROSCLEROSIS USING A NEW COMPUTERIZED B- MODE ULTRASOUND ANALYZING METHOD H. Mehrad , M. Farhodi (Iran)	600
124	NON-INVASIVE HIGH-FREQUENCY ULTRASOUND USING INTIMA AND INTIMA/MEDIA THICKNESS RATIO (BUT NOT CIMT), CORRECTLY MONITORED EXPECTED BENEFICIAL VASCULAR EFFECTS OF MENOPAUSAL HORMONE THERAPY T. Naessen , M. Larsson (Sweden)	601
125	LIMITATIONS OF CONTRAST-ENHANCED ULTRASOUND WITH EVALUATION OF NEOVASCULARISATION IN THE ATHEROSCLEROTIC PLAQUE A. Evdokimenko , L. Druina, A. Chechetkin, M. Tanashyan, T. Gulevskaya, S. Scrylev (Russia)	602
126	COMPARISON OF THE RESULTS OF CORONARY ANGIOGRAPHY AND PARAMETERS OF LOCAL RIGIDITY OF COMMON CAROTID ARTERY IN PATIENTS WITH CORONARY HEART DISEASE V. Oleynikov, L. Salyamova, A. Khromova, N. Burko (Russia)	603
127	EFFICACY OF SCREENING OF SUBCLINICAL AORTAL ATHEROSCLEROSIS IN WORKING-AGE POPULATION DEPENDING ON INVESTIGATIONAL METHODS. N. Koziolova , A. Chernyavina (Russia)	604
128	SUBCLINICAL CAROTID AND CEREBRAL ATHEROSCLEROSIS SCREENING IN WORKING-AGE POPULATION: EFFICACY OF DIFFERENT INVESTIGATIONAL METHODS. N. Koziolova , A. Chernyavina (Russia)	605
129	RETINAL VASCULAR CALIBER, OCULAR BLOOD FLOW AND ENDOTHELIN-1 LEVEL IN BLOOD SERUM IN PATIENTS WITH SUBCLINICAL ATHEROSCLEROSIS N. Adzhemian , V. Neroev, T. Kiseleva, M. Ezhov, N. Balatskaya, N. Ilina, V. Tankovskiy (Russia)	606

Board #		
130	INVESTIGATING THE FEASIBILITY OF B-MODE ULTRASONOGRAPHY ACCOMPANIED BY PESDA MICROBUBBLES ADMINISTRATION FOR ACCURATE VISUALIZATION OF INTRAPLAQUE NEOVASCULARIZATION	607
	H. Mehrad , M. Mokhtari-Dizaji, H. Ghanaati (Iran)	
131	SUBCLINICAL ATHEROSCLEROSIS AND COGNITIVE IMPAIRMENT IN UZBEKISTAN	608
	D. Akramova , A. Umarov (Uzbekistan)	
132	THE RELATIONSHIP BETWEEN NONALCOHOLIC HEPATIC STEATOSIS AND CAROTID ATHEROSCLEROSIS AT THE ELDERLY	609
	A. Capisizu , A. Zamfirescu, R. Dascalescu, O. Stanciu, S.M. Aurelian (Romania)	
133	RELATIONSHIP BETWEEN THE CHOLESTEROL AND TRIGLYCERIDE CONTENT OF LIPOPROTEIN SUBCLASSES AND CAROTID INTIMA MEDIA THICKNESS: RESULTS FROM THE KYUSHU AND OKINAWA POPULATION STUDY	610
	N. Furusyo , M. Shimizu, Y. Kato, Y. Tanaka, J. Hayashi (Japan)	
134	CONFOCAL DUAL-PULSED ELECTROHYDRAULIC SHOCK WAVE THERAPY ACCOMPANIED BY PESDA MICROBUBBLES AND ATORVASTATIN ADMINISTRATION REDUCE THE ATHEROSCLEROTIC INTRAPLAQUE NEOVESSELS IN THE RABBIT CAROTID ARTERY	611
	H. Mehrad , S.A. Seyedikhosroshahi (Iran)	

Vascular Biology: Immune Disease and Cardiovascular Pathologies

135	EVALUATION OF SERUM CHEMERIN LEVEL IN PATIENTS WITH HASHIMOTO'S THYROIDITIS	612
	E. Berta, M. Harangi , V.E. Varga, H. Lőrincz, I. Seres, E.V. Nagy, G. Paragh, M. Bodor (Hungary)	
136	RISK FACTORS OF ATHEROSCLEROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS WITH THYROID GLAND LESION	613
	R. Sayfutdinov, O. Bugrova , K. Nagornova, M. Dobrolubov, N. Artemova (Russia)	
137	CARDIOVASCULAR MORTALITY AND MORBIDITY IN A GROUP OF PATIENTS WITH HIV DIAGNOSIS	614
	E. Sifuentes Diaz , M. Monsalvo Hernando, C. Palomar Muñoz, N. Caro Gomez, E. Lopez Tinoco, R. Toro (Spain)	
138	ARE CARDIOVASCULAR RISK FACTORS THE NEW THREAT TO HIV PATIENTS?	615
	M. Monsalvo , E. Sifuentes Diaz, A. Caceres Gestoso, P. Perez Guerrero, I. Tinoco Racero, A. De los Santos Moreno (Spain)	

Board #		
139	SYSTEMIC LUPUS ERYTHEMATOSUS FLARE-UP IS ASSOCIATED WITH INCREASED 5-YEARS CAROTID INTIMA-MEDIA THICKNESS PROGRESSION	616
	A. Baragetti , M. Magnoni, K. Garlaschelli, L. Grigore, M. Berteotti, I. Scotti, E. Bozzolo, A. Berti, A.A. Manfredi, E. Ammirati, A.L. Catapano, G.D. Norata (Italy)	
140	PREVALENCE OF INCREASED ARTERIAL STIFFNESS AND PERIPHERAL ARTERIAL DISEASE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS	617
	K. Tziomalos , I. Gkougkourelas, A. Sarantopoulos, E. Bekiari, E. Makri, N. Raptis, K. Tselios, M. Pantoura, A. Hatzitolios, P. Boura (Greece)	
141	PREVALENCE OF INCREASED ARTERIAL STIFFNESS AND PERIPHERAL ARTERIAL DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS	618
	K. Tziomalos , I. Gkougkourelas, A. Sarantopoulos, E. Bekiari, N. Raptis, E. Makri, K. Tselios, M. Pantoura, A. Hatzitolios, P. Boura (Greece)	
142	ARTERIAL STIFFNESS IN A BLACK SOUTH AFRICAN COHORT INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS (HIV)	619
	C.M. Fourie , J.M. Van Rooyen, H.W. Huisman, C.M. Mels, W. Smith, R. Kruger, S. Botha, L. Lammertyn, L. Gafane, A.E. Schutte (South Africa)	

Lipoproteins and Lipid Metabolism: ApoB Containing Lipoproteins

143	DEVELOPMENT OF A NOVEL HOMOGENEOUS ASSAY FOR REMNANT LIPOPROTEINS	620
	N. Satoh , M. Ikaida, Y. Ito (Japan)	
144	MOST OF THE HEPATIC TRIGLYCERIDE LIPASE (HTGL) IS BOUND TO APOE-RICH HDL IN POST-HEPARIN PLASMA	621
	K. Nakajima , S. Usui, R. Shinohata, K. Miyashita, S. Imamura, J. Kobayashi, T. Machida, H. Sumino, M. Murakami (Japan)	
145	NOVEL ROLE OF A TRIGLYCERIDE-SYNTHESIZING ENZYME: DGAT1 AT THE CROSSROAD BETWEEN TRIGLYCERIDE AND CHOLESTEROL METABOLISM	622
	V. Sachdev , C. Leopold, R. Bauer, J.V. Patankar, J. Iqbal, S. Obrowsky, M. Doktorova, M. Goeritzer, B. Scheicher, D. Kolb, G. Hoefler, A.V. Turnbull, A. Zimmer, M.M. Hussain, A.K. Groen, D. Kratky (Austria)	
146	THE ROLE OF ANGPTL3 IN HUMAN LIPOPROTEIN METABOLISM	623
	A. Tikka , J. Metso, M. Jauhiainen (Finland)	
147	ASSOCIATION OF THE POSTPRANDIAL CHYLOMICRON TRIGLYCERIDE/APOB INDEX AND CARDIOVASCULAR EVENTS	624
	H. Schrnagl , C. Werner, T. Stojakovic, W. März, U. Laufs (Austria)	

Board #		
148	SYSTEMATIC ASSAY OF LIPOPROTEIN LIPASE ACTIVITY AND MASS IN COHORT OF PATIENTS WITH HISTORY OF TYPE V HYPERLIPIDEMIA	625
	O. Marmontel , M. Di Filippo, S. Nony, C. Marcais, C. Caussy, S. Charriere, A. Sassolas, P. Moulin (France)	
149	APOLIPOPROTEIN C-III GLYCOFORMS CORRELATE HETEROGENEOUSLY WITH PLASMA LIPID PROFILE IN SUBJECTS WITH CORONARY ARTERY DISEASE	626
	C. Chiariello , A. Castagna, N. Martinelli, P. Guarini, M. Manfredi, E. Ranzato, S. Martinotti, E. Marengo, D. Cecconi, O. Olivieri (Italy)	
150	PLASMA APOLIPOPROTEIN CIII LEVELS AND INCIDENT CORONARY ARTERY DISEASE RISK: THE EPIC-NORFOLK PROSPECTIVE POPULATION STUDY.	627
	J. Van Capelleveen , S.J. Bernelot Moens, X. Yang, N.T. Wareham, K.T. Khaw, E.S.G. Stroes, J.L. Witztum, G.K. Hovingh, S.M. Boekholdt, S. Tsimikas (Netherlands)	
151	14C MIRISTIC ACID AND 3H CHOLESTEROL UPTAKE STUDIES IN AGING RABBIT AORTA AND HEART MUSCLE.THE IMPACT OF SERUM FACTORS FROM PATIENTS WITH LIPID METABOLIC DISORDERS	628
	C.R. Revnic , C. Pena, F. Revnic, S. Voinea, B. Paltineanu (Romania)	
152	LDL SUBFRACTIONAL ANALYSIS: A LABORATORY DIAGNOSTIC ASSAY IN PATIENTS WITH CAROTID AND CORONARY ATHEROSCLEROSIS	629
	N. Gavrilova , V. Metelskaya, I. Ozerova, E. Yarovaya, S. Boytsov (Russia)	
153	THERMAL STABILITY OF HUMAN PLASMA LDL(-): A PARADOXICAL BEHAVIOR OF LDL AGGREGATION	630
	A. Rull, S. Jayaraman, A. Rivas, M. Pérez Cuellar, J. Ordóñez Llanos, J.L. Sánchez Quesada , O. Gursky (Spain)	
154	LIPOPROTEINS FROM CORD BLOOD OF SMALL BABY FOR GESTATIONAL AGE SHOWED ELEVATED TRIGLYCERIDE AND DIMINISHED APOA-I CONTENT WITH MORE PRO-ATHEROSCLEROTIC AND PRO-INFLAMMATORY ACTIVITY	631
	S.M. Kim , C. Kyung-Hyun (Republic of Korea)	
155	POLOXAMERS INHIBIT ASSOCIATION OF MULTIPLY MODIFIED LDL, BUT DO NOT REDUCE THEIR ATHEROGENIC POTENTIAL	632
	A. Melnichenko, N. Elizova, A. Orekhov (Russia)	
156	MULTIPLE MODIFICATION OF LDL CIRCULATING IN BLOOD OF ATHEROSCLEROTIC PATIENTS	633
	A. Orekhov , I. Sobenin, A. Melnichenko (Russia)	
157	COMPARABILITY STUDY OF CANDIDATE REFERENCE METHODS FOR LDL-P MEASUREMENTS	634
	N. Clouet Foraison , S. Vaslin-Reimann, C. Cobbaert, P. Gillery, V. Delatour (France)	

Board #		
158	THE DETERMINATION OF APOLIPOPROTEIN B BY CALCULATION AND BY MEASUREMENT ON SET OF DYSLIPIDEMIC PATIENTS	635
	L. Cibickova , R. Gasko, H. Vaverkova, D. Karasek (Czech Republic)	
159	ADIPONECTIN AS A BLOCKER OF OXIDIZED LDL	636
	A. Kakino , Y. Fujita, T. Sawamura (Japan)	
160	STRUCTURAL CHANGES INDUCED BY ACIDIC PH IN HUMAN APOLIPOPROTEIN B-100	637
	A. Benito-Vicente , J.A. Fernández-Higuero, J.C.G. Milicua, A. Etxebarria, H. Ostolaza, J.L.R. Arrondo, C. Martin (Spain)	
161	OXIDIZED LOW-DENSITY LIPOPROTEINS AND LECTIN-LIKE OXIDIZED LDL RECEPTOR-1 ARE POSITIVELY ASSOCIATED TO PCSK9 IN TYPE 2 DIABETES MELLITUS	638
	Y. Nekaies, B. Baudin , S. Kalbousi, M. Sakly, N. Attia (France)	
162	LIPIDOMICS OF PLASMA, LIVER AND AORTA OF PCSK9-KO MICE	639
	G. Chiesa , M. Busnelli, C. Parolini, S. Manzini, G.S. Ganzetti, F. Dellerà, M. Suoniemi, M. Hilvo, R. Hurme, K. Ekroos, C.R. Sirtori, R. Laaksonen (Italy)	
163	SUBFRACTIONAL DISTRIBUTION OF APO B-CONTAINING LIPOPROTEINS: A NEW MARKER FOR DETECTION OF INDIVIDUAL CARDIOVASCULAR RISK	640
	V. Metelskaya , I. Ozerova, N. Gavrilova, E. Yarovaya, S. Boytsov (Russia)	

Lipoproteins and Lipid Metabolism: Lipoprotein Metabolism

164	NOVEL CHIMERAS PROVIDE INSIGHT INTO STRUCTURE/FUNCTION ACTIVITY IN APOLIPOPROTEIN E3 AND APOLIPOPROTEIN AI	641
	V. Narayanaswami , M. Lek, N. Ibe, W. Beck, J. Bielicki, P. Weers (USA)	
165	EFFECTS OF TUMOR BEARING ON SERUM AND LIVER LIPID LEVELS IN SATO LUNG CARCINOMA (SLC)-IMPLANTED RATS: EFFECT OF A DIFFERENCE IN IMPLANTED CELL NUMBERS	642
	M. Kawasaki (Japan)	
166	EFFECTS OF ROSUVASTATIN ON GENE EXPRESSION OF LIVER LDL-R, PCSK9, SREBP-2, AND LRP1 IN OVARIETOMIZED RATS SUBMITTED OR NOT TO VOLUNTARY EXERCISE	643
	J.M. Lavoie, E.T. Ngo Sock , G. Mayer (Canada)	
167	BLOOD LEVELS OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) IN MEN OF DIFFERENT POPULATION SUBGROUPS AND ITS RELATIONSHIP WITH UNFAVORABLE LONG-TERM PROGNOSIS	644
	K. Astrakova , Y. Ragino, E. Shakhtshneider, S. Astrakov, M. Voevoda (Russia)	

Board #		
168	LDL RECEPTOR (LDLR) EXPRESSION AND FUNCTION IN HUMAN PANCREATIC BETA CELLS A. Thedrez , R. Scharfmann, P. Parnet, E. Nobécourt, G. Lambert (France)	645
169	HIGH INTAKE OF SODIUM CHLORIDE EXACERBATES DEGRADATION OF HUMAN LIPOPROTEINS AND IMPAIRMENT OF REPRODUCTIVE CAPACITY VIA TESTICULAR TOXICITY IN ZEBRAFISH E.Y. Lee , K.H. Cho (Republic of Korea)	646
170	MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN IN THE ISCHEMIC HEART M. Klevstig , M. Scharin Täng, M. Ståhlman, M. Levin, J. Borén (Sweden)	647
171	STABLE ISOTOPE KINETIC STUDY OF APOLIPOPROTEIN M IN HEALTHY SUBJECTS M. Croyal , M. Chétiveaux, K. Ouguerram, S. Billon-Crossouard, E. Nobécourt, M. Krempf (France)	648
172	HEPATOSTEATOSIS AND ESTROGEN INCREASE APOLIPOPROTEIN O PRODUCTION IN THE CHICKEN B. Schmidinger , A. Weijler, W.J. Schneider, M. Hermann (Austria)	649
173	NORMALIZATION OF LIPOPROTEIN PROFILE DURING PREGNANCY IN LCAT DEFICIENCY A. Ossoli , E. Hanna, S. Simonelli, R. Mullan, S. Chamney, J. Chestnutt, F. Stewart, G. Franceschini, L. Calabresi (Italy)	650
174	CHARGED RESIDUES IN THE C-TERMINAL DOMAIN OF APOLIPOPROTEIN A-I MEDIATE OLIGOMERIZATION P. Weers , V. Narayanaswami, L. Fuentes, J. Horn, R. Ellena, K. Cong (USA)	651
175	EFFECTS OF APOE VARIANTS ON PLTP INTERACTION AND ACTIVATION OF LOW AND HIGH ACTIVITY FORMS OF PLTP M. Jauhiainen , I. Dafnis, J. Metso, V. Zannis, A. Chroni (Finland)	652
176	HIGH-PERFORMANCE GEL PERMEATION CHROMATOGRAPHY ANALYSIS DEMONSTRATES ATHEROGENIC PROPERTIES OF LIPOPROTEINS IN PATIENTS WITH CHOLESTERYL ESTER TRANSFER PROTEIN DEFICIENCY T. Okada , T. Ohama, M. Okazaki, H. Matsuda, M. Sairoy, Y. Zhu, R. Kawase, D. Masuda, M. Koseki, M. Nishida, Y. Sakata, S. Yamashita (Japan)	653
177	COMPARISON OF FATTY ACID COMPOSITION OF SUBCUTANEOUS, PERICARDIAL AND EPICARDIAL ADIPOSE TISSUE AND ATRIAL TISSUE IN PATIENTS WITH HEART DISEASE R. Bülow Eschen , J. Gu, J.J. Andreasen, A. Andreasen, S. Lundbye-Christensen, E. Berg Schmidt (Denmark)	654
178	DIETARY SATURATED FATTY ACIDS AGGRAVATE PRESSURE OVERLOAD-INDUCED CARDIOMYOPATHY IN MICE IN THE ABSENCE OF CARDIAC STEATOSIS I. Muthuramu, R. Amin, N. Singh, A. Postnov, O. Gheysens, P. Van Veldhoven, B. De Geest (Belgium)	655

Board #		
179	MYRISTIC ACID PLASMA LEVELS ARE STRONGLY CORRELATED WITH TRIGLYCERIDE AND APOLIPOPROTEIN C-III PLASMA CONCENTRATION IN A COHORT OF SUBJECTS WITH OR WITHOUT CORONARY ARTERY DISEASE G. Speziali , D. Cecconi, N. Martinelli, O. Olivieri, A. Castagna, P. Guarini (Italy)	656
180	SPHINGOMYELIN CONTENT OF ERYTHROCYTE MEMBRANES IS IN LINEAR ASSOCIATION WITH MEMBRANES' LOADING WITH CHOLESTEROL IN CORONARY ARTERY DISEASE PATIENTS. G. Chalikias, P. Kikas , I. Drosos, M. Pavlaki, A. Thomaidis, S. Konstantinides, D. Tziakas (Greece)	657
181	COMPLEX PHOSPHOLIPIDS ASSOCIATE WITH ARTERIAL NOREPINEPHRINE, NON-ESTERIFIED FATTY ACIDS AND HEART RATE, MARKERS OF SYMPATHETIC NERVE SYSTEM IN METABOLIC SYNDROME SUBJECTS INDEPENDENTLY OF INSULIN RESISTANCE P. Nestel , N. Straznicky, A. Anwar, M. Pyush, P. Meikle (Australia)	658
182	ATHEROGENIC INDEX OF PLASMA FOR PREDICTION OF FUTURE CARDIOVASCULAR DISEASE IN PREDIABETES AND DIABETES POPULATION P. Regmi , B. Baral, M. Raut, M.P. Khanal (Nepal)	659
183	INVESTIGATION OF LPL INDEPENDENT PATHWAYS OF TG-RICH LIPOPROTEIN METABOLISM IN LPL DEFICIENCY D. Gaudet , D. Brisson, K. Tremblay (Canada)	660
184	EFFECT OF SALSALATE ON METABOLIC SYNDROME-RELATED PARAMETERS AND ACTIVITY OF BROWN ADIPOSE TISSUE IN WISTAR AND HEREDITARY HYPERTRIGLYCERIDEMIC RATS V. Skop , J. Trnovska, M. Huttli, H. Malinska, I. Markova, O. Oliyarnyk, L. Kazdova (Czech Republic)	661
185	SPECIFIC CIRCULATING PHOSPHOLIPIDS, ACYLCARNITINES, AMINO ACIDS AND BIOGENIC AMINES ARE AEROBIC EXERCISE MARKERS T. Felder , S. Ring-Dimitriou, S. Auer, S. Soyak, L. Kedenko, M. Rinnerthaler, J. Cadamuro, E. Haschke-Becher, E. Aigner, B. Paulweber, W. Patsch (Austria)	662
186	HETEROGENEITY OF PLASMA LOW DENSITY LIPOPROTEINS AND HIGH DENSITY LIPOPROTEINS: SOME GENDER PECULIARITIES IN SUBFRACTIONAL DISTRIBUTION V. Metelskaya , I. Ozerova, N. Gavrilova, S. Boytsov (Russia)	663
187	IDENTIFICATION OF A NOVEL LXR TARGET E.C.L. Cook , J.K. Nelson, V. Sorrentino, N. Zelcer (The Netherlands)	664

Board #

Lipoproteins and Lipid Metabolism: Lp(a)

- 188 PROGNOSTIC VALUE OF COMBINED LIPOPROTEIN(A) AND HOMOCYSTEINE IN ANGIOGRAPHICALLY PROVEN PATIENTS WITH CORONARY ARTERY DISEASE 665
S.W. Kwon, H.M. Kwon (Republic of Korea)
- 189 LIPOPROTEIN(A) MEASUREMENT AND ASSOCIATION WITH MEDICAL HISTORY IN SECONDARY CARE LIPID CLINICS 666
K.E. Shipman, A.J. Lawson, W. Alkaaby, A.F. Jones, R. Cramb (United Kingdom)
- 190 ELEVATED LIPOPROTEIN(A) AND ISCHEMIC STROKES- A CASE REPORT 667
P. Moriarty, N. Sehar, L. Denney, F. Perez-Marques, A. Panchal, P. Luna (USA)
- 191 RATIONALE AND DESIGN OF A CLINICAL TRIAL TO ASSESS LP(A) LOWERING WITH IONIS-APO(A)-LRX IN PATIENTS UNDERGOING APHERESIS FOR ELEVATED LP(A) AND RECURRENT CARDIOVASCULAR EVENTS 668
P.M. Moriarty, E.S. Thiessen, J.L. Witztum, N.J. Viney, S. Tsimikas (USA)
- 192 PREVALENCE OF LPA SINGLE NUCLEOTIDE POLYMORPHISMS AND ISOFORMS IN PATIENTS ENROLLED IN A PHASE 2 IONIS-APO(A)RX CLINICAL TRIAL 669
E.S. Stroes, F.M. Van der Valk, D. Gaudet, I. Gouni-Berthold, N.P. Riksen, E. Steinhagen-Thiessen, B. Isermann, B. Nordestgaard, N.J. Viney, S. Marcovina, S.G. Hughes, J. Tami, S. Xia, J.L. Witztum, S. Tsimikas (Netherlands)
- 193 NATURAL TEMPORAL VARIABILITY IN LP(A) LEVELS IN PATIENTS ENROLLED IN THE PLACEBO ARMS OF IONIS-APO(A)RX ANTISENSE OLIGONUCLEOTIDE CLINICAL TRIALS 670
N.J. Viney, S. Marcovina, J. Tami, S. Xia, J.L. Witztum, **S. Tsimikas** (USA)
- 194 PROGNOSTIC VALUE OF SERUM LIPOPROTEIN(A) LEVELS ON LONG-TERM MORTALITY IN A LARGE SAMPLE OF SUBJECTS IN PRIMARY CARDIOVASCULAR PREVENTION: DATA FROM THE BRISIGHELLA HEART STUDY 671
F. Fogacci, **S. D'Addato**, A.F.G. Cicero, E. Bertagnin, S. Palmisano, L. D'Agostini, E. Grandi, M. Giovannini, C. Borghi (Italy)
- 195 A SYSTEMATIC REVIEW AND META-ANALYSIS COMPARING THE EFFECTS OF STATINS AND FIBRATES ON PLASMA LIPOPROTEIN(A) LEVELS 672
A. Sahebkar, L.E. Simental-Mendía, M. Banach, M.C. Serban, G.F. Watts (Iran)
- 196 DEFINING THE MECHANISM OF LIPOPROTEIN(A) [LP(A)] LOWERING BY ALIROCUMAB IN TRANSGENIC MOUSE MODELS 673
C. Yeang, P. Miu, S. Green, X. Yang, M.Y. Hung, J.L. Witztum, S. Tsimikas (USA)

Board #

- 197 LIPOPROTEIN(A)-CHOLESTEROL (LP(A)-C) LEVELS DETERMINED BY VERTICAL AUTO PROFILE (VAP) CORRELATES WEAKLY WITH LP(A) MASS BUT MODESTLY WITH HDL-C: IMPLICATIONS FOR APPROPRIATE INTERPRETATION OF CLINICAL DATA 674
C. Yeang, S. Tsimikas (USA)
- 198 LIPOPROTEIN(A) AND INSULIN RESISTANCE: A POSSIBLE INVERSE RELATIONSHIP BETWEEN TWO WELL-KNOWN CARDIOVASCULAR RISK FACTORS 675
C.O. Aragona, E. Imbalzano, V. Cairo, F. Mamone, A. Lo Gullo, M.A. Sardo, A. Saitta, G. Mandraffino (Italy)
- 199 A NOVEL MODIFIED LIPID TETRAD INDEX AS PREDICTOR OF PREMATURE CORONARY ARTERY DISEASE IN INDIANS 676
S. Das (India)
- 200 CIRCULATING LIPOPROTEIN (A) [LP(A)] LEVELS AND RISK OF CARDIOVASCULAR DISEASE: THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY 677
R. Hoogeveen, W. Sun, V. Salim, B. Christie (USA)
- 201 THE ROLE OF LP(A) LEVELS AND APOPROTEIN(A) PHENOTYPE IN THE DEVELOPMENT OF ATHEROSCLEROSIS IN PATIENTS WITH CORONARY ARTERY DISEASE 678
D. Labudovic, K. Toseska-Trajkovska, S. Alabakovska, J. Bogdanska, S. Jovanova (FYR Macedonia)
- 202 LIPOPROTEIN(A) AND T-HELPER CELLS AS INDEPENDENT PREDICTORS OF RAPID PROGRESSION OF CAROTID ATHEROSCLEROSIS 679
O. Afanasieva, E. Pylaeva, T. Arefieva, E. Klesareva, M. Afanasieva, A. Potekhina, A. Shchinova, T. Balakhonova, O. Pogorelova, M. Tripoten, S. Pokrovsky (Russia)
- 203 POPULATION AND ASSAY THRESHOLDS FOR THE PREDICTIVE VALUE OF LIPOPROTEIN(A) FOR RISK OF CORONARY ARTERY DISEASE: THE EPIC-NORFOLK PROSPECTIVE POPULATION STUDY 680
R. Verbeek, S.M. Boekholdt, R.M. Stoekenbroek, G.K. Hovingh, J.L. Witztum, N.J. Wareham, M.S. Sandhu, K.T. Khaw, S. Tsimikas (Netherlands)
- 204 STATUS OF INFLAMMATION, ENDOTHELIAL ACTIVATION AND PROTHROMBOGENESIS AMONG NEGRO AND MALAYS WITH METABOLIC SYNDROME 681
S.S. Mokhtar, N.A. Mohd Mokhsin, F. Mohd Nor, S.A. Shaari, H. Nawawi, B.P. Hoh, T. Rahman (Malaysia)
- 205 ELEVATED LIPOPROTEIN(A) LEVELS RESULT IN A HIGH CARDIOVASCULAR RISK – A PROSPECTIVE ANALYSIS OF A LIPIDOLOGY OUTPATIENTS UNIT 682
U. Schatz, S. Fischer, U. Julius, S.R. Bornstein, S. Tselmin (Germany)

Board #		
206	PROFILE OF CIRCULATING MIRNAS IN PATIENT WITH HIGH LP(A) TREATED BY LDL/LP(A) APHERESIS D. Dlouha , J. Pitha, Z. Eretova, O. Viklicky, A. Parikova (Czech Republic)	683
207	FAMILIAL HYPERCHOLESTEROLEMIA (FH) WITH ELEVATED LIPOPROTEIN(A) (LP(A)) LEVELS AND AGGRESSIVE CORONARY HEART DISEASE: A CASUISTIC APPROACH A. Dybvig , A. Græsdal (Norway)	684
208	LIPOPROTEIN(A) IS A PREDICTOR OF ONE-YEAR VEIN GRAFT OCCLUSIONS IN STABLE ANGINA PATIENTS RECEIVED LIPOPROTEIN APHERESIS FOR REFRACTORY HYPERCHOLESTEROLEMIA AFTER CORONARY ARTERY BYPASS GRAFTING R. Adzhiev , M. Ezhov, O. Afanasieva, S. Pokrovsky (Russia)	685
209	LIPOPROTEIN(A) LEVEL AS A PREDICTOR OF LONG-TERM CARDIOVASCULAR OUTCOMES AFTER PERCUTANEOUS CORONARY INTERVENTIONS M. Mitroshkin , M. Ezhov, M. Safarova, O. Afanasieva, Y. Matchin, S. Pokrovsky (Russia)	686
210	EFFECT OF NIACIN ON LIPOPROTEIN SUBFRACTIONS CONCENTRATION IN PATIENTS WITH ELEVATED LIPOPROTEIN(A) E. Utkina , O. Afanasieva, N. Artemieva, M. Ezhov, I. Adamova, Y. Berestetskaya, S. Pokrovsky (Russia)	687

Lipoproteins and Lipid Metabolism: HDL

211	FUNCTIONAL DIFFERENCES BETWEEN APOLIPOPROTEIN E- AND APOLIPOPROTEIN A-I- CONTAINING HDL PARTICLES S. Filou , E. Karavia, C. Constantinou, E. Zvintzou, K. Kypreos (Greece)	688
212	APOA-I DEPLETION IN CHOW-FED APOEKO MICE SEVERELY WORSENS CORONARY ATHEROSCLEROSIS DEVELOPMENT G.S. Ganzetti , M. Busnelli, C. Parolini, S. Manzini, F. Delleria, C.R. Sirtori, G. Chiesa (Italy)	689
213	EVALUATION OF NOVEL APOA-I TWO-SITE IMMUNOASSAYS J. Lövgren , P. Negi, T. Heikkilä, T. Tallgren, K. Pettersson, M. Jauhiainen, U. Lamminmäki (Finland)	690
214	EICOSAPENTAENOIC ACID (EPA) MEMBRANE INCORPORATION REDUCES ABCA1-DEPENDENT CHOLESTEROL EFFLUX IN UNLOADED AS WELL AS IN CHOLESTEROL-LOADED PRIMARY HUMAN MACROPHAGES THROUGH DIFFERENT MECHANISMS N. Fournier , S. Tardivel, B. Vedie, J.F. Benoist, F. Allaoui, J.L. Paul (France)	691

Board #		
215	EFFECTS OF MODERATE AND EXCESS ALCOHOL CONSUMPTION ON THE REVERSE CHOLESTEROL TRANSPORT IN VIVO D. Greco , L. Mele, A. Piemontese, S. Battista, A. Poli, F. Bernini, I. Zanotti (Italy)	692
216	PROBUCOL OXIDIZED PRODUCTS, SPIROQUINONE AND DIPHENOQUINONE, PROMOTE REVERSE CHOLESTEROL TRANSPORT IN MICE K. Shiotani , E. Yakushiji, M. Ayaori, T. Nishida, S. Takiguchi, H. Uto-Kondo, M. Sasaki, M. Yogo, T. Komatsu, R. Lu, S. Yokoyama, K. Ikewaki (Japan)	693
217	INFLAMMATION POTENTLY SUPPRESSES ABCA1-MEDIATED CHOLESTEROL EFFLUX FROM MACROPHAGES, AND NOT ADIPOCYTES, VIA ACTIVATION OF JAK/STAT PATHWAY M. O'Reilly , M. Goodwin, O. Ansmidte, H. Roche, F. McGillicuddy (Ireland)	694
218	IDENTIFICATION OF A NOVEL UPREGULATOR OF ABCA1 AND SRB1 EXPRESSION WITH THE ACTION OF REGULATING CHOLESTEROL METABOLISM IN VITRO AND IN VIVO S. Si , Y. Xu, C. Liu, P. Liu, X. Wang, B. Hong (China)	695
219	ELEVATED LEVELS OF LECITHIN:CHOLESTEROL ACYLTRANSFERASE (LCAT) ARE ASSOCIATED WITH REDUCED ATHEROMA BURDEN – AN IVUS STUDY D. Rhainds , C. Gebhard, M. Cossette, M.C. Guertin, E. Rhéaume, J.C. Tardif (Canada)	696
220	EVALUATION OF HDL CHOLESTEROL EFFLUX CAPACITY (CEC) AFTER CONSUMPTION OF AN INNOVATIVE PASTA ENRICHED WITH BIOACTIVE COMPONENTS AND FUNCTIONAL PROBIOTICS E. Cipollari , F. Zimetti, M.P. Adorni, N. Ronda, D. Angelino, N. Pellegrini, F. Bernini, E. Favari (Italy)	697
221	AEROBIC EXERCISE TRAINING DOES NOT SYSTEMATICALLY AFFECT MACROPHAGE GENE EXPRESSION INVOLVED IN REVERSE CHOLESTEROL TRANSPORT AND CHOLESTEROL EFFLUX IN CETP TRANSGENIC MICE P.R. Pinto , K.S. Silva, D.J. Gomes, A. Machado-Lima, R.T. Iborra, G.S. Ferreira, E.C.R. Quintao, E.R. Nakandakare, U.F. Machado, M.L.C. Corrêa-Giannella, S. Catanozi, M. Passarelli (Brazil)	698
222	HDL CHOLESTEROL EFFLUX IS NOT PREDICTIVE OF CARDIOVASCULAR RISK IN DIABETIC PATIENTS ON HEMODIALYSIS C. Kopecky , S. Ebtehaj, B. Genser, C. Wanner, M.D. Saemann, U. Tietge (Austria)	699
223	XANTHOHUMOL, A PRENYLATED FLAVONOID IN HOPS, PROMOTES MACROPHAGE REVERSE CHOLESTEROL TRANSPORT IN HAMSTER H. Hirata , H. Uto-Kondo, M. Ogura, M. Ayaori, K. Ikewaki (Japan)	700

Board #		
224	FAT-ACTIVATED ER STRESS INDUCES THE REDUCTION OF ABCG5/8 EXPRESSION IN THE SMALL INTESTINE AND LIVER OF HYPERLIPIDEMIC HAMSTERS AND THE APPEARANCE OF DYSFUNCTIONAL HDL C.S. Stancu , M.G. Carnuta, G.M. Sanda, L. Toma, M. Deleanu, L.S. Niculescu, M. Simionescu, A.V. Sima (Romania)	701
225	ASSOCIATIONS BETWEEN LIPID SUBFRACTIONS AND SERUM MYELOPEROXIDASE LEVELS IN UNTREATED HYPERLIPIDEMIC PATIENTS A. Szentpéteri , H. Lőrincz, N. Zsíros, V.E. Varga, I. Seres, M. Katkó, P. Fülöp, G. Paragh, M. Harangi (Hungary)	702
226	ASSOCIATION OF HIGH-DENSITY LIPOPROTEIN SUBCLASSES WITH CAROTID INTIMA-MEDIA THICKNESS SHIMANE COHRE STUDY Y. Notsu , T. Nabika, S. Yano, A. Nagai (Japan)	703
227	HIGH DENSITY LIPOPROTEINS EXERT PRO-INFLAMMATORY EFFECTS ON MACROPHAGES VIA PASSIVE CHOLESTEROL DEPLETION AND PKC-NF-KB/STAT1-IRF1 SIGNALING E. Van der Vorst , K. Theodorou, Y. Wu, M. Hoeksema, P. Goossens, C. Bursill, L. Huitema, S. Tas, M. Gijbels, K. McDaniels, C.C. Wang, M. Leitges, T. Lawrence, L. Touqui, J. Plat, M. Van Eck, K.A. Rye, M. De Winther, E. Biessen, M. Donners (Germany)	704
228	RELATIONSHIP BETWEEN FRAMINGHAM SCORE, HDL-CHOLESTEROL AND C-REACTIVE PROTEIN AT ELDERLY PATIENTS S. Opris , G. Constantin, M. Grigorie (Romania)	705
229	THE LIPID FRACTIONS AS RISK FACTORS FOR ATHEROSCLEROSIS IN DIFFERENT AGE GROUPS IN BOSNIAN POPULATION B. Pojskic , E. Stimjanin, L. Pojskic, H. Selimovic, A. Macic-Dzankovic, S. Palo, I. Sisic (Bosnia and Herzegovina)	706
230	METRICS OF HIGH-DENSITY LIPOPROTEIN FUNCTION AND HOSPITAL MORTALITY IN ACUTE HEART FAILURE PATIENTS I. Potočnjak, V. Degoricija, M. Trbušić, S. Dokoza Terešak, B. Radulović, G. Pregartner, B. Andrea, B. Tiran, G. Marsche, S. Frank (Austria)	707
231	CAUSAL LINK BETWEEN SERUM AMYLOID A AND OXIDATIVE DAMAGES TO HIGH-DENSITY LIPOPROTEIN S. Jayaraman , C. Haupt, O. Gursky (USA)	708
232	INFLUENCE OF HDL-CHOLESTEROL LEVELS ON HDL PARTICLES LIPID COMPOSITION IN HEALTHY INDIVIDUALS. AN NMR-BASED LIPIDOMIC STUDY C. Kostara, V. Tsimihodimos, E. Bairaktari, M. Elisaf (Greece)	709
233	HIGH-DENSITY LIPOPROTEIN (HDL) FUNCTION AND SUBCLASS DISTRIBUTION IN OBESE AND NORMAL-WEIGHT BLACK AND WHITE AFRICAN WOMEN. N. Woudberg , J. Goedecke, D. Blackhurst, M. Frias, R. James, L. Opie, S. Lecour (South Africa)	710

Board #		
234	SMALL, DENSE HDL DISPLAY POTENT VASORELAXING ACTIVITY, REFLECTING THEIR ELEVATED CONTENT OF S1P L. Persègol, M. Darabi , C. Dauteuille, M. Lhomme, R. Salvayre, A. Nègre-Salvayre, S. Monier, A. Kontush (France)	711
235	ESTIMATION OF HDL ANTIOXIDATIVE ACTIVITY IN SUBJECTS WITH ACUTE CORONARY SYNDROME H. Thakkar , V. Vincent, A. Roy, S. Singh, L. Ramakrishnan, A. Singh (India)	712
236	HDL-SPHINGOMYELIN REDUCTION AFTER WEIGHT LOSS BY AN ENERGY-RESTRICTED DIET IS ASSOCIATED WITH THE IMPROVEMENT OF METABOLIC SYNDROME COMPONENTS IN OVERWEIGHT PATIENTS O. Pérez-Méndez , M. Martínez-Ramírez, M. Madero (Mexico)	713
237	A PHASE III MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (TANGO) TO EVALUATE CER-001 ON CAROTID ATHEROSCLEROSIS (VESSEL WALL AREA) IN PATIENTS WITH FAMILIAL PRIMARY HYPOALPHALIPOPROTEINAEMIA E. Stroes , R. Benghozi, J.L. Dasseux, J. Genest, H. Ginsberg, C. Keyserling, E. Leitersdorf, P. Raggi, A. Von Eckardstein (Netherlands)	714
238	VITAMIN D STATUS AND HDL FUNCTIONALITY IN HEALTHY PRE-MENOPAUSAL WOMEN F. Zimetti , D. Kocyigit, D. Greco, M.P. Adorni, N. Ronda, K.M. Gurses, S.H. Oguz, A. Gurlek, L. Tokgozoglu (Italy)	715
239	STATUS OF INFLAMMATION AND ENDOTHELIAL ACTIVATION IN SUBJECTS WITH LOW HIGH DENSITY LIPOPROTEIN CHOLESTEROL AMONG ABORIGINES IN MALAYSIA N.A. Mohd Mokhsin , W.N.H. Wan Ahmad, F.H. Sakri, N.A. Mohd Kasim, N. Mohd Nasir, S. Abdul Razak, M. Md Yasin, A. Mohd Ismail, T. Rahman, H. Nawawi (Malaysia)	716
240	EFFECT OF STATINS ON HDL IN FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS M. Licona-Rashid , R. Yahya, D. Wattimena, J. Roeters van Lennep, C. Christoffersen, E. Sijbrands, A. Verhoeven, M. Mulder (Netherlands)	717
241	HDL AS A CRUCIAL INDICATOR OF AN EARLY CLINICAL MANIFESTATION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA S. Urazgildeeva , M.V. Muzalevskaya, A.V. Tregubov, T.V. Nekrasova, V.S. Gurevich (Russia)	718
242	ENDOTHELIAL PROTECTIVE PROPERTIES OF HDL IMPROVE EARLY AFTER ROUX-EN-Y GASTRIC BYPASS BUT NOT AFTER DIET-INDUCED WEIGHT LOSS: THE SUPERIOR CARDIOMETABOLIC BENEFITS OF RYGB E. Osto, E. McLoughlin, P. Doytcheva , M. Charakida, L. Van Gaal, J. Deanfield, T. Lüscher (Switzerland)	719

Board #		
243	EFFECTS OF BARIATRIC SURGERY ON HIGH-DENSITY LIPOPROTEIN SUBTYPES	720
	G. Rega-Kaun , C. Kaun, E. Dostal, S. Oravec, M. Prager, J. Wojta, W. Speidl (Austria)	
244	INTERLEUKIN-6 REDUCES PARAOXONASE-1 ACTIVITY IN A DOSE-DEPENDENT MANNER; EVIDENCE FOR A POTENTIAL NOVEL LIPOPROTEIN-BASED MODULATORY MECHANISM	721
	A. Abedpour Dehkordi, H. Nayeri , G.A. Naderi, N. Jafari Dinani, M. Boshtam (Iran)	
245	TERMINALIA ARJUNA MODULATES LIPID EFFLUX AND INFLAMMATION IN HYPERCHOLESTEROLEMIC RABBITS	722
	V. Dhawan , R. Rather, D. Trikha (India)	

CVD Risk Factors

246	ELEVATED NEUTROPHILS, MONOCYTES AND WHITE CELL COUNTS IN PATIENTS WITH MYOCARDIAL INFARCTION COMPARED WITH STABLE CORONARY ARTERY DISEASE	723
	I. Trakarnwijitr , B. Li, H. Adams, J. Layland, J. Garlick, A. Wilson (Australia)	
247	THE RISK FACTORS OF ATHEROSCLEROSIS IN ROMA POPULATION IN SOUTH BOHEMIA	724
	V. Adamkova , J. Hubacek, D. Novakova, V. Adamek, V. Lanska, V. Tothova (Czech Republic)	
248	LIPOPROTEIN PHENOTYPE IN NAÏVE PATIENTS WITH KLINEFELTER SYNDROME	725
	A. Antonucci , A. Bonaldo, P. Scarinzi, M. Barichello, P. Bigolin, N. Caretta, M. Ghezzi, R. Selice, M. Terrin, D. Vianello, R. Marin, A. Ferlin, C. Foresta, E. Manzato, F. Fabris, S. Bertocco, S. Zambon, A. Zambon (Italy)	
249	RISK OF DEMENTIA HOSPITALISATION ASSOCIATED WITH CARDIOVASCULAR RISK FACTORS IN MIDLIFE AND OLDER AGE: THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY	726
	B. Muinjonov, E. Giyazitdinova (Uzbekistan)	
250	PULSE WAVE VELOCITY IS CORRELATED WITH THE SERUM N-TERMINAL FRAGMENT OF BRAIN NATRIURETIC PEPTIDE LEVEL INDEPENDENTLY OF CENTRAL BLOOD PRESSURE AND THE AUGMENTATION INDEX	727
	M. Shimizu , N. Furusyo, Y. Kato, Y. Tanaka, J. Hayashi (Japan)	
251	ATHEROSCLEROTIC LESIONS OF AORTO-ILIAC SEGMENT AND LONG-TERM CONSEQUENCES OF RECONSTRUCTIVE OPERATIONS	728
	A. Kozireva , M. Ivanov, P. Bondarenko, M. Ermina, D. Kozhevnikov, P. Puzdriak, A. Yadernaya, A. Kebryakov (Russia)	
252	COMBINED EFFECTS OF ADIPONECTIN AND VISCERAL FAT ON THE RISK OF METABOLIC SYNDROME	729
	K.H. Ha , D.J. Kim, H.C. Kim (Republic of Korea)	

Board #		
253	THE NEED TO CREATE AWARENESS TOWARDS CHOLESTEROL	730
	J. Frutuoso , M. Bourbon (Portugal)	
254	CORONARY ARTERY DISEASE AS A RISK FOR DEVELOPING TYPE 2 DIABETES MELLITUS	731
	C. Saely, A. Vonbank, P. Rein, D. Zanolin, A. Leiberer , A. Muendlein, H. Drexel (Austria)	
255	C-REACTIVE PROTEIN SIGNIFICANTLY PREDICTS CARDIOVASCULAR EVENTS BOTH IN PERIPHERAL ARTERIAL DISEASE PATIENTS WITH AND IN PERIPHERAL ARTERIAL DISEASE PATIENTS WITHOUT THE METABOLIC SYNDROME	732
	A. Vonbank, C. Saely, P. Rein, D. Zanolin, A. Leiberer , H. Drexel (Austria)	
256	PRO B-TYPE NATRIURETIC PEPTIDE SIGNIFICANTLY PREDICTS FUTURE VASCULAR EVENTS IN PERIPHERAL ARTERIAL DISEASE PATIENTS WITH TYPE 2 DIABETES	733
	A. Vonbank, C. Saely, P. Rein, D. Zanolin, A. Leiberer , H. Drexel (Austria)	
257	OVERWEIGHT IN CHILDREN OF PATIENTS WITH EARLY CORONARY HEART DISEASE: RELATION TO OWN AND PARENTAL CHARACTERISTICS	734
	M. Konnov, A. Deev (Russia)	
258	AGE-DEPENDENCE OF THE MAGNITUDE OF LIPID PROFILE VARIABLES RESEMBLANCE BETWEEN FIRST DEGREE RELATIVES IN FAMILIES OF PATIENTS WITH EARLY CORONARY HEART DISEASE	735
	M. Konnov, A. Deev , N. Gratsiansky (Russia)	
259	THE EFFECT OF MOXONIDINE ON LIPID PROFILE OF PATIENTS WITH ARTERIAL HYPERTENSION, GRADE 1 AND 2	736
	E. Karlafti , A. Hatzitolios, T. Didangelos, M. Baltatzi, G. Koliakos, A. Kalkavouri, E. Liorda, V. Chasiotis, C. Savopoulos (Greece)	
260	RISK OF INCIDENT HYPERTENSION ACCORDING TO METABOLIC HEALTH AND OBESITY: DEFINITION OF METABOLIC HEALTH DOES NOT MATTER	737
	C.H. Jung , W.J. Lee, J.Y. Park, C.Y. Park, S. Kim (Republic of Korea)	
261	BRACHIAL-ANKLE PULSE WAVE VELOCITY IS ASSOCIATED WITH COMPOSITE CAROTID AND CORONARY ATHEROSCLEROSIS IN A MIDDLE-AGED ASYMPTOMATIC POPULATION	738
	H.J. Joo , S.A. Cho, J.Y. Cho, S. Lee, J.H. Park, S.H. Hwang, S.J. Hong, C.W. Yu, D.S. Lim (Republic of Korea)	
262	SUSTAINED METABOLIC SYNDROME AFTER LIFESTYLE COUNSELING WAS ASSOCIATED WITH HIGHER RISK OF SUBCLINICAL CORONARY ATHEROSCLEROSIS	739
	H.J. Joo , S.A. Cho, J.Y. Cho, S. Lee, J.H. Park, S.H. Hwang, S.J. Hong, C.W. Yu, K.J. An, D.S. Lim (Republic of Korea)	

Board #		
263	ASSOCIATION OF PRO12ALA PPAR γ AND -308G/A TNF α WITH PPAR γ AND TNF α MRNA LEVELS IN VISCERAL ABDOMINAL TISSUE IN FERTILE WOMEN IN RUSSIA	740
	A. Kopytova , T. Usenko, V. Miroshnikova, E. Bazhenova, M. Nikolaev, A. Panteleeva, I. Semenova, A. Neimark, E. Baranova, S. Pchelina (Russia)	
264	CAN NON-CHOLESTEROL STEROLS AND LIPOPROTEIN SUBCLASSES DISTRIBUTION PREDICT DIFFERENT PATTERNS OF CHOLESTEROL METABOLISM AND STATIN THERAPY RESPONSE?	741
	T. Gojković , S. Vladimirov, V. Spasojević-Kalimanovska, A. Zeljković, J. Vekić, D. Kalimanovska-Oštrić, Z. Jelić-Ivanović (Serbia)	
265	SERUM LIPID PROFILE ON ADMISSION FOR ISCHEMIC STROKE/ TRANSIENT ISCHEMIC ATTACK	742
	T. Vassalo, F. Faria, T. Duarte, I. Colaço, D. Cruz , J.L. Ducla Soares (Portugal)	
266	DETERMINATION OF FACTORS CONTRIBUTING TO ATHEROSCLEROTIC DISEASE PROGRESSION IN PATIENTS WITH SYMPTOMATIC PERIPHERAL ARTERIAL DISEASE (PAD)	743
	L.P. Zielinski, M.M. Chowdhury , B.P. Worsfold, S.C. Harrison, J.R. Boyle, P.D. Hayes, P.A. Coughlin (United Kingdom)	
267	COMPLIANCE INITIATIVES IN MANAGEMENT OF PATIENTS WITH CORONARY ARTERY DISEASE AND PARKINSONISM SYNDROME	744
	A. Shalaeva , N. Dadabaeva, M. Bozorboev, G. Kasimdjanova (Uzbekistan)	
268	HEART RATE TURBULENCE AS A MORTALITY PREDICTOR IN 5 YEARS STUDY IN PATIENTS WITH CRORONARY HEART DISEASE	745
	N. Zagidullin , D. Gareeva, I. Lackman, I. Sagitov, S. Zagidullin (Russia)	
269	EFFECTS OF ASTHMA SEVERITY ON CHANGE OF PRESSURE OF PULMONARY ARTERY IN PATIENTS WITH ARTERIAL HYPERTENSION	746
	A. Odegova, E. Tarlovskaya (Russia)	
270	CLINICAL CHARACTERISTICS OF PATIENTS ON HEMODIALYSIS WITH PERIPHERAL ARTERIAL DISEASE	747
	N. Aoyama (Japan)	
271	ASSOCIATIONS BETWEEN OSTEOPOROSIS AND SIGNIFICANT CORONARY ARTERY DISEASE IN ASYMPTOMATIC POSTMENOPAUSAL WOMEN	748
	S.N. Lee (Republic of Korea)	
272	ADJUSTED NECK CIRCUMFERENCE AND METABOLIC SYNDROME: RESULTS FROM THE BRISIGHELLA HEART STUDY	749
	E. Bertagnin, S. D'Addato , F. Fogacci, S. Palmisano, L. D'Agostini, A.F.G. Cicero, M. Giovannini, M. Rosticci, C. Borghi (Italy)	
273	NON-CORONARY ATHEROSCLEROSIS PREVALENCE ACCORDING TO THE DATA OF THE ADULT POPULATION SCREENING	750
	R. Khokhlov , L. Tribuntseva, V. Burlachuk, L. Khokhlov (Russia)	

Board #		
274	EPICARDIAL FAT THICKNESS IS ASSOCIATED WITH HIGHER VAGAL TONE	751
	S. Lee , Y.S. Lee, B. Kim (Republic of Korea)	
275	PREVALENCE OF RISK FACTORS AND CARDIOVASCULAR DISEASES IN EMPLOYEES OF A SINGLE PLANT IN DIFFERENT AGE GROUPS	752
	R. Allanov , R. Rakhimov, E. Shalaeva, N. Dadabaeva (Uzbekistan)	
276	CHADS2 AND CHA2DS2-VASC SCORES PREDICT CARDIOVASCULAR DISEASE IN STATIN-TREATED INDIVIDUALS WITHOUT ATRIAL FIBRILLATION	753
	F. Barkas , E. Klouras, G. Liamis, M. Elisaf, E. Liberopoulos (Greece)	
277	ACCURATE CARDIOVASCULAR EVENT RISK ESTIMATION CAN BE OBTAINED USING CORONARY ARTERY SCAN	754
	M. Gracia , D. Craiem, A. Simon (Spain)	
278	THE ASSOCIATION OF AN ELEVATED SERUM ENDOSTATIN LEVEL AND CAROTID ATHEROSCLEROSIS: RESULTS FROM THE KYUSHU AND OKINAWA POPULATION STUDY (KOPS)	755
	Y. Kato , M. Shimizu, N. Furusyo, Y. Tanaka, J. Hayashi (Japan)	
279	SERUM ENDOSTATIN IS CORRELATED TO RENAL FUNCTION INDEPENDENTLY OF CAROTID ATHEROSCLEROSIS: RESULTS FROM THE KYUSHU AND OKINAWA POPULATION STUDY (KOPS)	756
	Y. Kato , M. Shimizu, N. Furusyo, Y. Tanaka, J. Hayashi (Japan)	
280	SYSTEMATIC REVIEW OF HERPES ZOSTER AND ITS ASSOCIATION WITH CARDIOVASCULAR EVENTS	757
	N. Erskine , H. Tran, L. Levin, C. Ulbricht, R. Goldberg (USA)	
281	EXPOSURE TO CARDIOVASCULAR DISEASE RISK FACTORS IN CHILDHOOD IS ASSOCIATED WITH INCREASED CAROTID EXTRA MEDIAL THICKNESS IN ADULTHOOD: THE CHILDHOOD DETERMINANTS OF ADULT HEALTH STUDY	758
	H. West , M. Skilton, B. Fraser, T. Dwyer, A. Venn, C. Magnussen (Australia)	
282	CANDIDATE GENE POLYMORPHISMS RELATED TO LIPID AND CARBOHYDRATE METABOLISM SHOW AN ASSOCIATION WITH RISK FACTOR COMPONENTS OF THE METABOLIC SYNDROME IN ASIAN INDIANS.	759
	T. Maistry (South Africa)	
283	CLINICAL CHARACTERISTICS AND LDL-CHOLESTEROL MANAGEMENT IN PATIENTS WITH CARDIOVASCULAR EVENT AND/OR DIABETES IN THE NETHERLANDS	760
	E. Heintjes, J. Kuiper, B. Lucius, F. Penning-van Beest, L. Kutikova , A. Liem, R. Herings (Switzerland)	
284	WAIST-HIP-RATIO AND 1-YEAR CLINICAL OUTCOME IN PATIENTS WITH NON-ST-ELEVATION ACUTE CORONARY SYNDROME	761
	H.W. Lee, T.J. Hong , J.H. Choi, B.W. Kim (Republic of Korea)	

Board #		
285	<p>GLOMERULAR FILTRATION RATE (GFR) MODERATES THE PROTECTIVE EFFECT OF MEDITERRANEAN DIET AGAINST CARDIOVASCULAR INCIDENCE: 10-YEAR FOLLOW-UP (2002-12) OF THE ATTICA STUDY</p> <p>E. Georgousopoulou, C. Pitsavos, D. Panagiotakos, C. Chrysoshoou, I. Skoumas, M. Chatzigeorgiou, D. Tousoulis, C. Stefanadis (Greece)</p>	762
286	<p>PLAQUE CHARACTERIZATION AND REMODELING BY CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY AND CORONARY EVENTS</p> <p>S.U. Kwon (Republic of Korea)</p>	763
287	<p>DURATION OF DIABETES IS AN INDEPENDENT DETERMINANT AND INTERACTED WITH GENDER FOR ACUTE MYOCARDIAL INFARCTION</p> <p>Y.D. Jiang (Taiwan)</p>	764
288	<p>PRESENCE OF CAROTID PLAQUES AND CARDIOVASCULAR DISEASE EVENTS: A PROSPECTIVE STUDY</p> <p>A. Bea, E. Jarauta, R. Mateo-Gallego, S. Perez-Calahorra, V. Marco-Benedi, I. Lamiquiz-Moneo, L. Baila-Rueda, A. Cenarro, F. Civeira (Spain)</p>	765
289	<p>TWO-GENERATION CARDIOVASCULAR DISEASE PREVALENCE IN FAMILIAL HYPERCHOLESTEROLEMIA</p> <p>R. Mateo-Gallego, S. Perez-Calahorra, M. Laclaustra, N. Plana, C. Lahoz, J. Pedro-Botet, J.F. Ascaso, A. Vila Belmonte, P. Valdivielso, A. Brea, F. Civeira (Spain)</p>	766
290	<p>RAPID RISE IN PREVALENCE OF HYPERTENSION IN YOUNG IN NATIONAL CAPITAL REGION (NCR) OF DELHI, INDIA</p> <p>A. Roy, P.A. Praveen, R. Amarchand, D. Prabhakaran, A. Krishnan, K.S. Reddy (India)</p>	767
291	<p>VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL, BLOOD PRESSURE, AND HEART RATE: THE GAIN IN CONTEXT OF CIRCUMSTANCES</p> <p>E. Pello, T. Kouznetsova, Y. Nikitin, J. Staessen (Russia)</p>	768
292	<p>IMPROVING CARDIOVASCULAR PREVENTION IN PATIENTS WITH HIGH CARDIOVASCULAR RISK THROUGH AN INNOVATIVE APPROACH: "THE COACHING" CARE MODEL</p> <p>S. Mosteoru, K. Kotseva, O.C. Cosor, L. Gaita, R. Pleava, A. Dumitrescu, G. Mut-Vitcu, D. Gaita, S. Mancas, D. Wood (Romania)</p>	769
293	<p>OVERWEIGHT/OBESITY AND CORONARY HEART DISEASE: AGE DEPENDENCIES IN METABOLIC MEDIATION</p> <p>J. Fritz, S. Strohmaier, G. Nagel, H. Concin, H. Ulmer (Austria)</p>	770
294	<p>DECREASED SERUM LEVELS OF SOLUBLE DIPEPTIDYL PEPTIDASE IV ARE ASSOCIATED WITH ALL-CAUSE DEATH IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE</p> <p>M.T. Howanietz, C.T. Herz, C. Höbaus, R. Koppensteiner, G.H. Schernthaner (Austria)</p>	771

Board #		
295	<p>FACTORS PREDICTING SURVIVAL OVER TWO DECADES OF OBSERVATION AFTER PERIPHERAL PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY: A RETROSPECTIVE STUDY</p> <p>M. Schneider, C. Herz, C. Höbaus, R. Koppensteiner, G.H. Schernthaner (Austria)</p>	772
296	<p>ANALYSIS OF THE DIRECT CAUSES OF DEATH IN PATIENTS WITH ACUTE STEMI TREATED WITH PRIMARY PCI FROM 2005 TO 2014</p> <p>Y.H. Li, P.T. Lee, T.H. Chao, W.C. Tsai (Taiwan)</p>	773
297	<p>KLOTHO GENE POLYMORPHISMS ARE ASSOCIATED WITH PROGRESSION OF ATHEROMATOSIS IN PATIENTS WITH CKD. RESULTS OF TWO YEARS FOLLOW-UP OF THE NEFRONA COHORT</p> <p>M. Gracia, A. Betriu, M. Martínez, D. Arroyo, M. Abajo, E. Fernández, J.M. Valdivielso (Spain)</p>	774
298	<p>RHEUMATOID ARTHRITIS AND ATHEROSCLEROSIS: WHY IS IMPORTANT TO EVALUATE THIS?</p> <p>M. Parvu, S. Coman, S. Voidazan (Romania)</p>	775
299	<p>COMPARISON OF COMBINED THERAPY OF CAD ACCOMPANIED BY GASTRODUODENAL PATHOLOGY</p> <p>Y. Balandina, Z. Simonova, Y. Tarlovskaya (Russia)</p>	776
300	<p>INCREASED VISCERAL FAT AND LOWER MUSCLE STRENGTH ASSOCIATED WITH ACUTE MYOCARDIAL INFARCTION</p> <p>E. Okuyan, B. Ayca, S. Varol (Turkey)</p>	777
301	<p>HIGH PREVALENCE OF CVD RISK FACTORS AND UNSATISFACTORY CONTROL OF LDL-C LEVELS IN 40-YEARS-OLD MEN AND 50-YEARS-OLD WOMEN IN THE CZECH REPUBLIC</p> <p>Z. Chmelik, M. Vrablík (Czech Republic)</p>	778
302	<p>PLASMA METHIONINE IS NOT ASSOCIATED WITH RISK OF ACUTE MYOCARDIAL INFARCTION IN PATIENTS WITH SUSPECTED STABLE ANGINA PECTORIS</p> <p>I. Dhar, V. Lysne, P. Ueland, A. McCann, O. Nygård (Norway)</p>	779
303	<p>THE DIFFERENCE IN BLOOD PRESSURE READINGS BETWEEN ARMS AND CARDIOVASCULAR RISK: AN URBANITE INDIAN STUDY</p> <p>P. Bhasin, S. Kapoor (India)</p>	780
304	<p>ASSOCIATION BETWEEN PREPROCEDURAL NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS WITH THE INFLAMMATORY RESPONSE FOLLOWING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION</p> <p>F. Rached, F. Brito Jr, C. Garzillo, T. Nascimento, M.A. Perin, C.V. Serrano Jr (Brazil)</p>	781

Board #		
305	THE INCIDENCE AND SEVERITY OF ANGINA PECTORIS IN PATIENTS AFTER ELECTIVE PERCUTANEOUS CORONARY INTERVENTION (OPTIMA II) N. Logunova , Y. Karpov, V. Buza, D. Tomilova (Russia)	782
306	HYBRID INTERVENTION ON FEMOROPOPLITEAL ARTERIAL SEGMENT IN COMPARISON WITH CONVENTIONAL SURGICAL TECHNIQUE P. Puzdriak, V. Shlomin, Y. Didenko, Y. Yurtaev, M. Ivanov, P. Bondarenko , R. Magomedov (Russia)	783
307	PREVALENCE OF CARDIOVASCULAR RISK FACTORS IN MIDDLE-AGED SUBJECTS OF HIGH RISK LITHUANIAN POPULATION S. Kutkiene , M. Petrylaite, Z. Petrulioniene (Lithuania)	784
308	MULTIPLE CORONARY FISTULAE INTO LEFT VENTRICLE AS A RARE CAUSE OF MYOCARDIAL ISCHEMIA A. Averkova , K. Savostyanov, D. Zateyshchikov (Russia)	785
309	SUBCLINICAL MANIFESTATIONS OF ATHEROSCLEROSIS IN HYPERTENSIVE FEMALES WITH RHEUMATOID ARTHRITIS AND ITS RELATIONSHIP WITH THE ADIPONECTIN LEVEL, INSULIN RESISTANCE, ENDOTHELIAL FUNCTION O. Sirenko , O. Kuryata, T. Lysunets (Ukraine)	786
310	THE PREVALENCE OF CEREBRAL AUTOSOMAL DOMINANT ARTERIOPATHY WITH SUBCORTICAL INFARCTS AND LEUCOENCEPHALOPATHY (CADASIL) IN UZBEKISTAN B. Muinjonov , E. Giyazitdinova (Uzbekistan)	787
311	7 T MRI REVEALS DIFFUSE IRON DEPOSITION IN PUTAMEN AND CAUDATE NUCLEUS IN CADASIL B. Muinjonov , E. Giyazitdinova (Uzbekistan)	788
312	TENASCIN-C DEFICIENCY ATTENUATES ABDOMINAL AORTIC ANEURYSM FORMATION A.K. Schaefer , F. Nagel, P. Kaiser, D. Santer, K. Trescher, A. Kiss, B.K. Podesser (Austria)	789
313	A CASE OF FATAL OBSTRUCTIVE SHOCK A. Almaghraby , Y. Saleh, B. Hammad, A. Samoka, M. Elbahey, M. Seleem (Egypt)	790
314	CARDIOVASCULAR RISK FACTORS IN WOMEN AND MEN A. Nikolova , M. Milanova (Bulgaria)	791
315	CAROTID INTIMA-MEDIA THICKNESS AS A PROGNOSTIC RISK MARKER OF DEMENTIA AT THE ELDERLY R. Dascalescu , A. Zamfirescu, S.M. Aurelian, O. Stanciu, A. Capisizu (Romania)	792

Board #		
316	PATHOPHYSIOLOGICAL MECHANISMS FOR PRESERVING GRAFT PATENCY IN PATIENTS WITH COMPROMISED OUTFLOW TRACT AFTER DISTAL RECONSTRUCTION A. Zotikov, Z. Adyrkhaev, V. Mitish, N. Ascerov, A. Kozhanova, A. Ivandaev , M. Abdulgamidov, A. Pokrovsky (Russia)	793
317	OUTDOOR AIR POLLUTION AND ISCHEMIC STROKE SEVERITY: AN ECOLOGICAL STUDY IN THESSALONIKI N. Kakaletsis , K. Tziomalos, C. Savopoulos, M. Riga, S. Bouziana, M. Spanou, S. Kostaki, S. Angelopoulou, K. Karatzas, I.A. Hatzitolios (Greece)	794
318	GENDER FEATURES OF MYOCARDIAL INFARCTION AND STROKE RISK IN GENERAL POPULATION WITH VITAL EXHAUSTION IN RUSSIA / SIBERIA: WHO PROGRAM MONICA-PSYCHOSOCIAL V. Gafarov, E. Gromova, I. Gagulin, D. Panov, A. Gafarova, M. Voevoda (Russia)	795
319	RELATIONSHIP OF STRESS WITH METABOLIC SYNDROME AND CORONARY HEART DISEASE IN MIDDLE-AGED POLICE OFFICERS M. Janczura , J. Dropinski, A. Stanisz, K. Kotula-Horowitz, R. Rosa, T. Domagala (Poland)	796
320	PRELIMINARY RESULTS OF THE EGYPTIAN CARDIOVASCULAR RISK FACTORS PROJECT: MULTICENTER OBSERVATIONAL STUDY OF THE PATTERN OF RISK FACTOR PROFILE IN EGYPTIAN PATIENTS WITH ACUTE CORONARY SYNDROME W. Hamed , A. Reda, A. El-Kersh, A. Shalaby, M. Beshay (Egypt)	797

Abstract not Registered

400 THE ZINC-SUPPLEMENTED TO RABBITS FED A HIGH CHOLESTROL DIET DELAYS THE PROGRESSION OF ATHEROSCLEROSIS 798
Y. Al mohy (Kingdom of Saudi Arabia)

401 EVALUATION OF THE SAFETY AND EFFICACY OF STATIN IN ELDERLY PATIENTS 799
R. Alves, C. Gonçalves, N. Borges Jr (Brazil)

402 CD34+ BONE MARROW DERIVED CELLS INHIBIT INTIMAL HYPERPLASIA IN MOUSE MODEL OF VASCULAR INJURY 800
S. Ananthasheshan, E. Kurzejamska, M. Lazarczyk, P. Religa (Sweden)

403 ESCHERICHIA COLI LIPOPOLYSACCHARIDE AND CPG MAY AFFECT ATHEROGENESIS THROUGH THE MODULATION OF ENDOTHELIAL BARRIER AND TOLEROGENIC PHENOTYPE OF APOLIPOPROTEIN B100-PULSED DENDRITIC CELLS 801
M. Chalubinski, K. Wojdan, E. Luczak, P. Gorzelak, G. Katarzyna, B. Maciej, G. Adrian, R. Karolina, C. Magdalena, B. Marlena (Poland)

404 MODIFICATIONS OF LOW DENSITY LIPOPROTEIN IN ATHEROSCLEROSIS 802
G.I. Constantin, S. Opris (Romania)

405 ISCHEMIC HEART DISEASE AND EARLY DIAGNOSIS. STUDY ON THE PREDICTIVE VALUE OF 2D STRAIN 803
G. Dattilo, A. Lamari, M. Casale, E. Imbalzano, P. Busacca, C. De Gregorio, G. Di Bella (Italy)

406 REDUCED AVAILABILITY OF DIETARY CHOLESTEROL IN INFANCY PROGRAMS THE INTESTINAL CHOLESTEROL ABSORPTION DURING ADULTHOOD IN MICE 804
L.G. Dimova, J.F. De Boer, T. Plösch, H.J. Verkade, U.J.F. Tietge (Netherlands)

407 CARDIOVASCULAR RISK AND PROINFLAMMATORY CYTOKINES IN PATIENTS WITH METABOLIC SYNDROME 805
R. Dragut, E. Rusu, R. Nan, H. Popescu, F. Rusu, M. Jinga, A. Cursaru, L. Grosu, G. Radulian (Romania)

408 IS HIGH-DENSITY LIPOPROTEIN SUITABLE PREDICTOR FOR DEVELOPMENT OF METABOLIC SYNDROME: A 10-YEAR FOLLOW-UP IN ADULTS 806
M. Gharipour, M. Sadeghi, N. Sarrafzadegan (Iran)

409 VIOLATIONS IN THE LEVEL OF SERUM LIPIDS APPEAR AT ALL PATIENTS WITH PROSTATITIS THAT IS ASSOCIATED WITH DECREASE IN THE LEVEL OF THE FREE TESTOSTERONE 807
A. Govorin, **D. Zaytsev** (Russia)

410 ON THE DEVELOPMENT OF ANTI-ATHEROSCLEROTIC DRUGS ON THE BASIS OF NATURAL PRODUCTS USING CELL CULTURES 808
S. Jargin (Russia)

411 POSSIBLE ASSOCIATION BETWEEN COMMON CAROTID ARTERY LUMEN DIAMETER AND VASCULAR FUNCTION IN NATURAL POPULATIONS OF SHE MINORITY FROM FUJIAN PROVINCE IN CHINA 809
H. Liu, H. Yongqiang, W. Hongyu, L. Jinbo (China)

412 IDENTIFICATION OF COFILIN-1 INDUCES G0/G1 ARREST AND AUTOPHAGY IN ANGIOTENSIN-(1-7)-TREATED HUMAN AORTIC ENDOTHELIAL CELLS FROM ITRAQ QUANTITATIVE PROTEOMICS 810
W.Y. Lo, H.J. Wang (Taiwan)

413 HYPOTHYROIDISM IS THE INDEPENDENT FACTOR OF ATHEROSCLEROSIS 811
O. Kupchynskaya, N. Tsyrlutneva, O. Gulkevych, V. Bezrodnyi, M. Mospan, **A. Logvinenko** (Ukraine)

414 DYSLIPIDEMIA IN PATIENTS WITH HEART FAILURE AND HYPOTHYROIDISM 812
A. Logvinenko (Ukraine)

415 THE ROLE OF OXIDATIVE STRESS ON AMYLOID-LIKE PROTEIN FORMATION AND AORTIC VALVE CALCIFICATION 813
I. Mamarelis, E. Koutoulakis, C. Kotoulas, V. Mamareli, V. Dritsa, J. Anastassopoulou (Greece)

416 IMPACT OF THE LIPID AND ANTHROPOMETRIC PARAMETERS ON THE LDL(-) AND AUTOANTIBODIES ANTI-LDL(-) 814
A.P.Q. Mello, I.T. Silva, N.R.T. Damasceno (Brazil)

417 LIFESTYLE - THE SILENT KILLER, LEADING TO CARDIOVASCULAR EVENTS ACROSS CONTINENTS IN YOUNG APPARENTLY HEALTHY INDIANS 815
R. Narain, A. Pulikal, S. Sharma (United Kingdom)

418 BURDEN OF CARDIOVASCULAR RISK IN YOUNG, APPARENTLY HEALTHY INDIANS IN UK & INDIA. TIME FOR INTERVENTION? 816
R. Narain, S. Sharma (United Kingdom)

419 RELATIONSHIP OF CAROTID AND FEMORAL ARTERY INTIMA-MEDIA THICKNESS WITH HISTOPATHOLOGIC ARTERIAL ATHEROSCLEROSIS IN CHRONIC KIDNEY DISEASE 817
N. Nezami, K. Ghabili, B. Shokouhi, M. Mirchi, M. Gojazadeh, S. Ghorashi, M.K. Tarzamni (USA)

420 IN VIVO/EX VIVO INTEGRATED IMAGING MODEL FOR CORONARY AND CAROTID PLAQUE RISK ASSESSMENT: A PROOF OF CONCEPT STUDY 818
G. Pelosi, D. Panetta, A. Sakellarios, N. Filipovic, T. Exarchos, V. Federico, C. Fiorentini, A. Gennaro, S. Rocchiccioli, P.A. Salvadori, M.G. Trivella, D. Fotiadis, O. Parodi (Italy)

421 SYNTAX SCORE AS A MARKER OF PLURIDISTRICTUAL ATHEROSCLEROSIS 819
G. Polizzi, S. Evola, S. Novo, V. Evola (Italy)

- 422 PERCUTANEOUS TRANSVENOUS MITRAL COMMISSUROTOMY IN PATIENTS WITH CALCIFIC MITRAL STENOSIS : IMMEDIATE AND IN-HOSPITAL CLINICAL, ECHOCARDIOGRAPHIC AND HEMODYNAMIC OUTCOME 820
T. Rahman, A.A.S. Majumder, M.Z. Ali (Bangladesh)
- 423 THE EFFECT OF PINACIDIL ON HUMAN SAPHENOUS VEINS OBTAINED FROM THE PATIENTS WITH AND WITHOUT DIABETES MELLITUS TYPE 2 821
J. Rajkovic, M. Peric, R. Novakovic, D. Nezic, V. Djokic, V. Zivanovic, V. Kanjuh, H. Heinle, L. Gojkovic-Bukarica (Serbia)
- 424 SR-BI ANTAGONISES THE S1P/S1PR2-MEDIATED PRO-INFLAMMATORY EFFECTS INDUCED BY OX-LDL IN HUVECS 822
K. Ren, Y.J. Lu, X. Liu, Q.H. Zhang, Z.C. Mo, Z.L. Tang, Y. Jiang, X.S. Peng, G.H. Yi (China)
- 425 APOA-I INDUCES S1P RELEASE FROM ENDOTHELIAL CELLS THROUGH ABCA1 AND SR-BI IN A POSITIVE FEEDBACK MANNER. 823
K. Ren, X. Liu, R. Suo, S.L. Xiong, Q.H. Zhang, Z.C. Mo, Z.L. Tang, J. Yue, X.S. Peng, G.H. Yi (China)
- 426 TGF- β DOWN-REGULATES APOLIPOPROTEIN M EXPRESSION VIA THE TAK1-JNK-C-JUN PATHWAY IN HEPG2 CELLS 824
K. Ren, X. Liu, Z.C. Mo, Q.H. Zhang, Z.L. Tang, Y. Jiang, X.S. Peng, G.H. Yi (China)
- 427 THE HYPERCHOLESTEROLEMIC SWINE MODEL OF ATHEROGENESIS: STATISTICAL APPROACHES TO MOLECULAR MARKERS AND PLAQUE MORPHOLOGY ASSOCIATION 825
S. Rocchiccioli, G. Pelosi, A. Cecchetti, E. Capobianco, M.G. Trivella (Italy)
- 428 A NEW MARKER FOR ST ELEVATION MYOCARDIAL INFARCTION: PRESEPSIN? 826
F.N. Turhan caglar, N. Isikssacan, I. Biyik, F. Akturk, S. Opan, H. Cebe, I. Ungan, O. Karakaya (Turkey)
- 429 THE ROLE OF CHOLESTERYL ESTER TRANSFER PROTEIN EXPRESSION ON ENDOTHELIAL CELLS: OXIDATIVE STRESS AND VASCULAR DYSFUNCTION. 827
A. Wanschel, E. Lorza, A. Paiva, J. Stravinsky, D. Gabriel, T. Rentz, D. Guizoni, A. Davel, A. Salerno, H. Oliveira (Brazil)
- 430 THE EFFECT OF OXIDIZED CHOLESTEROL ON BARRIER FUNCTIONS AND IL-10 MRNA EXPRESSION IN HUMAN INTESTINAL EPITHELIUM CO-CULTURED WITH DENDRITIC CELLS IN THE TRANSWELL SYSTEM 828
K. Wojdan, M. Chalubinski, P. Gorzelak, M. Borowiec, M. Broncel (Poland)
- 431 IMPROVEMENT OF HIGH-DENSITY LIPOPROTEIN FUNCTIONALITY BY CO-CONSUMPTION OF HIGH DOSAGE VITAMIN C AND CLOVE VIA CETP INHIBITION 829
J.A. Yoo, K.H. Cho
- 432 IMPACT OF AN ABDOMINAL AORTIC CALCIFICATION ON THE MORPHOLOGY OF LOW LIMB ARTERY ATHEROSCLEROSIS 830
V. Zelinskiy, M. Melnikov, V. Andreev, S. Alexandra (Russia)

84th EAS CONGRESS

May 29 - June 1, 2016
Innsbruck, Austria



Poster Presentation - Shift II
TUESDAY, MAY 31 -
WEDNESDAY, JUNE 1

Board #

TUESDAY, MAY 31, 2016

Metabolic Abnormalities and Atherosclerosis: Diabetes

001	<p>MODY TYPE DIABETES MELLITUS AND COGNITIVE IMPAIRMENT</p> <p>B. Muinjonov, E. Giyazitdinova (Uzbekistan)</p>	831
002	<p>POLYMORPHISM IN GENES INVOLVED IN LIPID METABOLISM IN MODY PATIENTS</p> <p>E. Shakhtshneider, A. Ovsyannikova, A. Kurilshikov, D. Ivanoshchuk, O. Rymar, Y. Ragino, M. Voevoda (Russia)</p>	832
003	<p>METABOLIC CONTROL IN TYPE 2 DIABETIC PATIENTS</p> <p>B. Orhan (Turkey)</p>	833
004	<p>ONE-YEAR RESULTS OF A MULTIDISCIPLINARY SCREENING PROGRAM FOR DIABETES, CARDIOVASCULAR AND PULMONARY DISEASES AMONG 67-YEARS OLD CITIZENS IN VIBORG MUNICIPAL, DENMARK</p> <p>A. Høgh, M. Dahl, J. S. Lindholt (Denmark)</p>	834
005	<p>DIFFERENCES IN LIPID PROFILE CONTROL AMONG DIABETIC PATIENTS AT VERY HIGH CARDIOVASCULAR RISK ACCORDING TO THEIR CLINICAL FEATURES</p> <p>D. García Fuertes, E. Villanueva Fernández, M. Crespín Crespín, F.J. Castillo Bernal, I. Guerado Espinosa, M.C. Castro Jiménez, A. Rodríguez Cubero (Spain)</p>	835
006	<p>FACTORS RELATED TO THE APPEARANCE OF MAJOR EVENTS DURING FOLLOW-UP OF DIABETIC PATIENTS AT VERY HIGH CARDIOVASCULAR RISK</p> <p>M. Crespín Crespín, D. García Fuertes, E. Villanueva Fernández, F.J. Castillo Bernal, A. Rodríguez Cubero, I. Guerado Espinosa, M.C. Castro Jiménez (Spain)</p>	836
007	<p>CONTROL OF CARDIOVASCULAR RISK FACTORS IN A NON-SELECTED COHORT OF DIABETIC PATIENTS AT VERY HIGH CARDIOVASCULAR RISK</p> <p>E. Villanueva Fernández, D. García Fuertes, M. Crespín Crespín, F.J. Castillo Bernal, M.C. Castro Jiménez, A. Rodríguez Cubero, I. Guerado Espinosa (Spain)</p>	837
008	<p>THE IMPORTANCE OF HDL CHOLESTEROL LEVELS IN DIABETIC INDIVIDUALS : 9.2-YEAR SURVEY OF CARDIOVASCULAR EVENTS</p> <p>K. Ina, T. Hayashi, M. Kuzuya (Japan)</p>	838
009	<p>CONCORDANCE OF GLUCOSE BASED AND OF HBA1C BASED DIAGNOSES OF DIABETES IN PATIENTS WITH ESTABLISHED CORONARY ATHEROSCLEROSIS - A COMPARISON BETWEEN MEN AND WOMEN</p> <p>C. Saely, D. Zanolin, P. Rein, A. Vonbank, A. Leiberer, A. Muendlein, H. Drexel (Austria)</p>	839

Board #		
010	ASSOCIATION OF INSULIN RESISTANCE WITH CAROTID INTIMA-MEDIA THICKNESS AND BRACHIAL FLOW-MEDIATED DILATION IN THE SUBJECTS WITH METABOLIC SYNDROME	840
	T. Domagala , M. Janczura, K. Kotula-Horowitz, J. Dropinski, T. Iwaniec, J. Zagajewski, A. Stanisz (Poland)	
011	ASSOCIATION OF INSULIN RESISTANCE, AS DETERMINED BY HOMEOSTASIS MODEL ASSESSMENT (HOMA), WITH METABOLIC SYNDROME AMONG MIDDLE-AGED SUBJECTS	841
	M. Janczura , K. Kotula-Horowitz, T. Iwaniec, A. Stanisz, J. Dropinski, T. Domagala (Poland)	
012	DYSLIPIDEMIA WITH AND WITHOUT INSULIN RESISTANCE: SIMILARITIES AND DIFFERENCES	842
	I. Pchelin , N. Hudiakova, A. Shishkin, O. Vasilkova (Russia)	
013	DYSLIPIDEMIA CONTROL IN TYPE 2 DIABETES: EXPERIENCE OF A PORTUGUESE CENTRE IN THE LAST DECADE	843
	J. Sequeira Duarte , C. Tavares Bello, R. Fonseca, R. Ferreira, M. Oliveira, C. Saraiva, C. Gouveia, F. Santos, J. Azinheira, C. Vasconcelos (Portugal)	
014	CORRELATION BETWEEN HOMOCYSTEINE AND TYPE-2 DIABETES MELLITUS COMPLICATIONS CORRELATION BETWEEN HOMOCYSTEINE AND TYPE-2 DIABETES MELLITUS COMPLICATIONS	844
	M. Akhvediani , M. Emukhvari, N. Zabakhidze, T. Kvantaliani (Georgia)	
015	SERUM APOLIPOPROTEIN B48 CONCENTRATION IS HIGH IN PATIENTS WITH IMPAIRED GLUCOSE TOLERANCE AND INCREASES AFTER ORAL GLUCOSE INGESTION IN PATIENTS WITH DIABETES MELLITUS	845
	D. Masuda (Japan)	
016	FASTING INSULIN LEVELS PREDICT FATAL CARDIOVASCULAR (CVD) EVENTS MORE ACCURATELY THAN ANY OTHER MARKER OF GLUCOSE METABOLISM. THE 10-YEAR FOLLOW-UP OF THE ATTICA STUDY (2002-2012)	846
	E. Georgousopoulou, D. Panagiotakos, C. Chrysohoou, I. Skoumas, A. Laskaris, C. Stefanadis, C. Pitsavos (Greece)	
017	ALTERATIONS OF METABOLIC PARAMETERS AND ANTIOXIDANT ENZYMES IN DIABETIC AGING FEMALE RAT BRAIN: NEUROPROTECTIVE ROLE OF METFORMIN	847
	P. Kumar , N. Baquer (India)	
018	CARDIO- AND NEPHROPROTECTIVE EFFECTS OF EZETIMIBE/SIMVASTATIN COMBINATION IN TYPE 2 DIABETES MELLITUS	848
	R. Sayfutdinov , O. Bugrova, O. Boeva (Russia)	
019	ROLE OF NEW ADIPOKINES IN THE PATHOGENESIS OF ATHEROSCLEROSIS IN MORBIDLY OBESE SUBJECTS	849
	A. Gentili , P. Trayhurn, S.Y. Alomar, M.S. Zaibi, S. De Vuono, M.A. Ricci, A. Alaeddin, D. Siepi, M. Boni, G. Vaudo, G. Lupattelli (Italy)	

Board #		
020	DOES TYPE 2 DIABETES ASSOCIATE ATHEROSCLEROTIC PROCESS?	850
	D. Gabrielyan , L. Gabrielyan, A. Artemova, D. Zhokhov, M. Ivanov, P. Bondarenko, M. Ermina, A. Yadernaya (Russia)	
021	SEVERITY OF ATHEROSCLEROTIC LESIONS AND FOOT SYNOVIAL TENDON COMPLEX INJURY AS FACTORS OF SEPSIS DEVELOPMENT IN PATIENTS WITH DIABETIC FOOT	851
	E. Shalaeva , B. Janabaev, Q. Matmurotov, U. Kasimov, U. Pulatov, A. Bobabekov (Uzbekistan)	
022	RELATIONSHIP BETWEEN CAROTID ARTERY INTIMA-MEDIA THICKNESS AND CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH DIABETES	852
	V. Vasilkova , T. Mokhort, E. Naumenko (Belarus)	
023	SERUM LEVELS OF SOLUBLE RECEPTOR FOR ADVANCED END PRODUCTS ARE ASSOCIATED WITH RESTENOSIS OCCURRENCE IN PATIENTS WITH DIABETES MELLITUS AFTER DRUG-ELUTING STENT IMPLANTATION	853
	S. Kozlov, Z. Gabbasov, S. Byazrova , O. Saburova, V. Masenko (Russia)	
024	EFFECT OF THE EDUCATION IN HOSPITALIZATION OF DIABETIC INDIVIDUALS FOR DIABETES CONTROL AND PREVENTION OF COMPLICATIONS AS A TOOL OF HOSPITAL AND CLINIC COOPERATION	854
	T. Hayashi , K. Ina, M. Kuzuya (Japan)	
025	BMI IS NOT AN IMPORTANT FACTOR FOR THE DEVELOPMENT OF SUBCLINICAL ATHEROSCLEROSIS IN ELDERLY DIABETIC SUBJECTS WITH METABOLIC SYNDROME	855
	G. Yoshino , H. Yoshino, T. Ann, K. Kawakami, T. Akiyama, Y. Inoue (Japan)	
026	RESVERATROL AND QUERCETIN PROTECT ISOLATED MOUSE CORPORA CAVERNOSA FROM IN VITRO-INDUCED DIABETIC ERECTILE DYSFUNCTION	856
	C. Boydens, B. Pauwels, L. Vandendaele, J. Van de Voorde (Belgium)	
027	DIABETIC VASCULAR DISEASE AND MATURITY-ONSET DIABETES OF THE YOUNG	857
	J.M. Mafra , G. Gaspar, M. Bourbon (Portugal)	
028	RELATIONSHIP BETWEEN 25 HYDROXY-VITAMIN D AND ANKLE BRACHIAL INDEX IN TYPE 2 DIABETIC PATIENTS	858
	S. Lahiani , I. Oueslati, K. Bouzid, K. Khiari, S. Ghezaiel, H. Ben Ahmed, H. Belhadj Hassen, H. Baccar, J. Abdelmoula, N. Ben Abdallah (Tunisia)	
029	ANKLE BRACHIAL INDEX IN THE PREDICTION OF CORONARY HEART DISEASE IN TYPE 2 DIABETIC PATIENTS	859
	K. Bouzid , H. Ben Ahmed, I. Oueslati, S. Lahiani, K. Khiari, N. Khessairi, J. Belagha, S. Ghezaiel, N. Ben Abdallah, H. Baccar, J. Abdelmoula (Tunisia)	
030	CARDIOVASCULAR EFFECTS OF INCRETINS IN PATIENTS WITH TYPE 1 DIABETES	860
	M. Arutyunova , A. Glazunova, S. Martynov, I. Klephortova, A. Ilyin, O. Manchenko, I. Ulianova, M. Shamkhalova, M. Shestakova (Russia)	

Board #		Board #	
031	SEVERITY OF CORONARY ARTERY STENOSIS IN PATIENTS WITH CRITICAL PERIPHERAL ARTERY DISEASE UNDERGOING HIGH AMPUTATION E. Shalaeva , B. Janabaev, B. Babadjanov, Q. Matmurotov, U. Kasimov, U. Pulatov, A. Bobabekov (Uzbekistan)	861	041 GENE FOR CONNEXIN 37 IS ASSOCIATED WITH ATHEROSCLEROTIC CHANGES IN WOMEN WITH DIABETES MELLITUS TYPE 2. J. Pitha , P. Pithova, P. Stavek, J.A. Hubacek, O. Auzky, T. Neskudla, T. Pelikanova, M. Kvapil (Czech Republic)
032	HIGH PREVALENCE OF NON DIPPERS HYPERTENSIVE DIABETIC PATIENTS: THE ROLE OF AMBULATORY BLOOD PRESSURE MONITORING IN EFFECTIVE TREATMENT V. Manea , C. Pop, L. Pop (Romania)	862	042 LPPLA2 IN GESTATIONAL DIABETES MELLITUS - A PROTECTIVE SYSTEM FOR PLACENTA AND FETUS? C. Wadsack (Austria)
033	THE IMPACT OF BARIATRIC SURGERY ON CARDIOMETABOLIC PROFILE AND ADIPOKINE LEVELS F. Reis de Azevedo Rabello , S. Santoro dos Santos Pereira, M.L. Corrêa-Giannella, D. Giannella Neto, E. Sant'Anna Melo, B. Caramelli (Brazil)	863	043 CINNAMALDEHYDE ATTENUATES HIGH GLUCOSE-INDUCED OXIDATIVE STRESS AND ENDOTHELIAL DYSFUNCTION AS AN NRF2 ACTIVATOR F. Wang , P. Wang, J. Wan, J. Hou, P. Zhou (China)
034	BARIATRIC SURGERY IMPROVES LIPID PROFILE IN MORBIDLY OBESE PATIENTS BY LOWERING LDL-C AND INCREASING HDL-C AND THE LARGE HDL-PARTICLES C.A. Kjellmo , T. Nestvold, K.T. Lappegård, A. Hovland, M. Mathisen (Norway)	864	044 ASSOCIATION OF DIFFERENT CHOLESTEROL HOMEOSTASIS PATTERNS WITH ABDOMINAL OBESITY IN PATIENTS WITH CORONARY ARTERY DISEASE S. Vladimirov , T. Gojković, V. Spasojević-Kalimanovska, A. Zeljković, J. Vekić, D. Kalimanovska-Oštrić, Z. Jelić-Ivanović (Serbia)
035	EFFECTS OF BARIATRIC SURGERY ON MICROVASCULAR DYSFUNCTION AND METABOLIC PROFILE IN MORBID OBESITY M. Naeimi Kararoudi , G. Lupattelli, S. Ministrini, V. Bianconi, M.A. Ricci, S. De Vuono, P. Mariani, A. Moriconi, M. Boni, E. Mannarino, L. Pasqualini (Italy)	865	045 ASSOCIATION BETWEEN NT-PROBNP AND VISCERAL ADIPOSITY J. Suwa (Japan)
036	FACTORS DETERMINING AND STRATEGIES FOR IMPROVING TREATMENT ADHERENCE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: DOCTOR, COMMUNITY PHARMACIST AND PATIENT PERSPECTIVES. ADHERI2 STUDY. E. Labrador-Barba, A. Hernández-Mijares, M. Rodríguez-de Miguel, M.J. Faus-Dader, M.L. Orera-Peña , F.J. Alonso Moreno (Spain)	866	046 INCREASED INFLAMMATORY EFFECT ON MONOCYTES OF ELECTRONEGATIVE LDL AND DECREASED PROTECTION BY HDL FROM POORLY CONTROLLED TYPE 2 DIABETIC PATIENTS M. Estruch-Alrich , I. Miñambres, J.L. Sánchez-Quesada, A. Pérez-Pérez, J. Ordóñez-Llanos, S. Benítez (Spain)
037	PREVALENCE OF 25 HYDROXY-VITAMIN D DEFICIENCY AND ITS CORRELATION WITH GLYCEMIC CONTROL IN DIABETIC PATIENTS S. Lahiani , K. Bouzid, I. Oueslati, K. Khiari, N. Bchir, A. Melki, A. Bartkiz, H. Ben Ahmed, H. Baccar, J. Abdelmoula, N. Ben Abdallah (Tunisia)	867	047 TRANSGENIC OVEREXPRESSION OF THE NRF2 AMELIORATES INSULIN RESISTANCE AND CHANGES FATTY ACIDS IN MEMBRANE PHOSPHOLIPIDS IN SPONTANEOUSLY HYPERTENSIVE RATS I. Markova , H. Malinska, O. Oliyarnyk, L. Kazdova, M. Pravenec (Czech Republic)
038	COMBINED DEVELOPMENT OF MACROVASCULAR AND CHRONIC KIDNEY DISEASE IN TYPE 2 DIABETES ASSOCIATED WITH POLYMORPHISM OF TNF- α GENE O. Vikulova, N. Lebedeva , A. Zheleznyakova, A. Nikitin, M. Shamkhalova, M. Shestakova (Russia)	868	048 HYPOLIPIDEMIC THERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: ANALYSIS TYPICAL APPROACHES I. Sapozhnikova, E. Tarlovskaya (Russia)
039	FEATURES OF VASCULAR REMODELING AND METABOLIC DISORDERS IN PATIENTS WITH ESSENTIAL HYPERTENSION AND CONCOMITANT TYPE 2 DIABETES DEPENDING ON GENETIC POLYMORPHISM PPAR γ 2 A. Shalimova , A. Belovol, L. Bobronnikova, M. Kochueva (Ukraine)	869	049 DIABETES AWARENESS AMONG CORONARY DISEASE PATIENTS DIFFERS SIGNIFICANTLY BETWEEN MEN AND WOMEN C. Saely, D. Zanolin, A. Vonbank, A. Leiberer , H. Drexel (Austria)
040	NEUTROPHIL/LYMPHOCYTE RATIO AND VASCULAR INFLAMMATION IN OBESE WOMEN B. Ilincic , M. Djeric, E. Stokic, R. Mijovic, S. Nikolic, Z. Stosic (Serbia)	870	050 INDIAN DIABETES RISK SCORE (IDRS) FOR TYPE 2 DIABETES MELLITUS SCREENING IN YOUNG ADULTS: EFFECT OF YOGA AND MEDITATION V. Sharma (India)
			051 ASSOCIATION OF RED CELL DISTRIBUTION WIDTH WITH CORONARY ARTERY DISEASE IN PATIENTS WITH DIABETES IN MULTI-ETHNIC SINGAPORE C. Chiong , Y.J. Chee, X. Gao, R. Dalan (Singapore)
			871
			872
			873
			874
			875
			876
			877
			878
			879
			880
			881

Board #		
052	PREDICTORS OF 10-YEAR MORTALITY ARE DIFFERENT IN DIABETIC AND NON-DIABETIC PATIENTS WITH CHRONIC LOWER EXTREMITY PERIPHERAL ARTERIAL DISEASE	882
	T. Mueller , F. Hinterreiter, W. Poelz, M. Haltmayer, B. Dieplinger (Austria)	
053	HAND GRIP STRENGTH SIGNIFICANTLY PREDICTS CARDIOVASCULAR EVENT RISK IN PATIENTS WITH TYPE 2 DIABETES MELLITUS	883
	P. Rein, C. Saely, A. Vonbank, D. Zanolin, A. Leiherer , H. Drexel (Austria)	
054	TELMISARTAN ATTENUATES HYPERGLYCEMIA-AGGRAVATED VCAM-1 EXPRESSION AND MONOCYTES ADHESION IN TNF α -STIMULATED ENDOTHELIAL CELLS BY INCREASING GSK3 β -SER9 PHOSPHORYLATION	884
	D.H. Cho , J.E. Lee, K.H. Song (Republic of Korea)	
055	GENETIC VARIANTS AND LIPID TRAITS IN THE HONG KONG CHINESE PATIENTS WITH TYPE 2 DIABETES	885
	M. Hu, C. Tam, W.Y. So, J. Chan, B. Tomlinson , R. Ma (Hong Kong- China)	
056	ANTIATHEROGENIC EFFECT OF METFORMIN IN TWO MOUSE LINES WITH DIFFERENT SUSCEPTIBILITY TO GLUCOSE INTOLERANCE	886
	A. Asai , Y. Shuto, M. Nagao, T. Miyazawa, H. Sugihara, S. Oikawa (Japan)	

Metabolic Abnormalities and Atherosclerosis: Adipose Tissue

057	EPICARDIAL FAT ,CARDIAC CHAMBERS AND CORONARY CALCIFICATION IN HYPERTENSIVE PATIENTS	887
	A. Almusawi, H. Nafakhi, H. Alnafakh , A. Albasri (Iraq)	
058	ADIPOKINES AND CYTOKINES SERUM LEVELS IN CHILDREN AND ADOLESCENTS AND ITS RELATIONSHIP WITH OBESITY	888
	C. Rodriguez-Leal, M. Monsalvo-Hernando, I. Tinoco-Racero, E. Segura, N. Caro, M. Lagares Carballo, A. Perez, C. Perez, M. Rodriguez -Rosety, T. Pery, A. Mangas, T. Rocio (Spain)	
059	INDUCIBILITY OF TRIGLYCERIDE TURNOVER IN WHITE FAT – A MARKER OF LEAN PHENOTYPE	889
	K. Adamcova , P. Flachs, P. Zouhar, K. Bardova, M. Svobodova, P. Janovska, A. Keenan, L. Madsen, J. Jones, K. Kristiansen, J. Kopecky (Czech Republic)	
060	RELATIONSHIP OF ORPHAN RECEPTOR RORA AND CHOLESTEROL TRANSPORTERS ABCA1 AND ABCG1 EXPRESSION IN VISCERAL ADIPOSE TISSUE	890
	V. Miroshnikova , A. Panteleeva, E. Demina, T. Usenko, E. Bazhenova, I. Semenova, O. Berkovich, E. Baranova, S. Pchelina (Russia)	

Board #		
061	EPICARDIAL FAT AND BMI RELATIONSHIPS WITH CORONARY ATHEROSCLEROTIC MARKERS IN PATIENTS WITH CORONARY CALCIUM SCORE >0: THE EFFECT OF AGE AND GENDER	891
	A. Albasri, H. Nafakhi, A. Almusawi, H. Alnafakh (Iraq)	
062	COLD-INDUCED CHANGES IN WHITE ADIPOSE TISSUE OF A/J AND C57BL/6J MICE	892
	K. Bardova , P. Flachs, K. Adamcova, M. Svobodova, J. Kopecky (Czech Republic)	
063	RELATION BETWEEN EPICARDIAL FAT TISSUE AND INFLAMMATORY MARKERS IN PREGNANTS WITH PREECLAMPSIA	893
	H.A. Cakmak , B. Dincgez Cakmak, C. Yayla Abide, E. Inci Coskun, M. Erturk (Turkey)	
064	LIPOSOMES FOR MICRORNA DELIVERY TO HUMAN ADIPOCYTES	894
	G. Schratler , M. Karbiener, G. Almer, H. Mangge, M. Scheideler, R. Prassl (Austria)	
065	OVARECTOMY AFFECTS SUBSTRATE UTILIZATION IN BROWN ADIPOSE TISSUE AND INDUCES LIVER DICARBONYL STRESS IN RATS	895
	J. Trnovska , H. Malinska, V. Skop, L. Kazdova (Czech Republic)	
066	EFFECT OF BMI ON EPICARDIAL FAT ,CARDIAC CHAMBERS AND CORONARY CALCIFICATION CORRELATIONS	896
	H. Alnafakh , H. Nafakhi, A. Albasri, A. Almusawi (Iraq)	

Metabolic Abnormalities and Atherosclerosis: Kidney

067	ARE WE FOLLOWING THE GUIDELINES TO PREVENT CONTRAST INDUCED ACUTE KIDNEY INJURY? A CLINICAL AUDIT ON PATIENTS WITH CHRONIC KIDNEY DISEASE(CKD) UNDERGOING CORONARY ANGIOGRAM	897
	V. Kanthasamy , S. Gill (United Kingdom)	
068	EFFECT OF RECOMMENDED DIETARY PROTEIN RESTRICTION ON THE PROGRESSION OF KIDNEY DISEASE	898
	C. Visinoni , A. Baragetti, I. Baragetti, C. Biazzi, K. Garlaschelli, L. Grigore, C. Pozzi, N. Giuseppe Danilo, C. Alberico L (Italy)	
069	VERY MILD RENAL ENDOTHELIAL DAMAGE AND GLOMERULAR HYPERFILTRATION MAY PRECEDE INCIDENT HYPERTENSION IN THE JAPANESE GENERAL POPULATION: THE WATARI STUDY	899
	M. Munakata , T. Hattori, S. Konno (Japan)	
070	EARLY BIOMARKERS OF CHRONIC KIDNEY DISEASE IN DIABETIC PATIENTS	900
	Z. Zuraeva , O. Mikhaleva, O. Vikulova, A. Ilyin, M. Shamkhalova, M. Shestakova (Russia)	

Board #		
071	CHOLESTEROL LEVELS AND GLOMERULAR FILTRATION RATE - IS THERE ANY ASSOCIATION? J. Frutuoso , M. Bourbon (Portugal)	901
072	HIGH-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS AND CONTRAST-INDUCED ACUTE KIDNEY DISEASE IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION Y. Liu , L. Hua-Long, W. Dengxuan, Z. Jianbin, C. Shiqun, D. Chong-Yang, C. Ping-Yan, T. Ning, C. Ji-Yan (China)	902
073	EVALUATION OF THE ASSOCIATION OF PLASMA PENTRAXIN 3 LEVELS WITH TYPE 2 DIABETES AND DIABETIC NEPHROPATHY IN PATIENTS WITH RENAL FAILURE. P. Miarka, M. Walus-Miarka , D. Fedak, M. Kuzniewski, A. Pietrzycka, E. Wieczorek-Surdacka, P. Jasik, B. Przepiorkowska-Hoyer, M. Kapusta, B. Idzior-Walus, W. Sulowicz (Poland)	903
074	CARDIOMETABOLIC RISK IN PATIENTS WITH CHRONIC RENAL DISEASE RELATED TO HYPERTRIGLYCERIDEMIA-LOW HDL -CHOLESTEROL ASSOCIATION R. Toro , I. Tinoco, B. Ruiz-Estevez, C. Rodriguez-Leal, E. Segura, N. Caro, C. Perez, I. Garcia, D. Gomez -Villarejo, M. Rodriguez-Rosety, M. Lagares, A. Mangas (Spain)	904
075	CORRELATION OF THYROID STIMULATING HORMONE TO KIDNEY FUNCTION OF HEALTHY RESIDENTS: RESULTS FROM THE KYUSHU AND OKINAWA POPULATION STUDY (KOPS) Y. Tanaka , M. Shimizu, N. Furusyo, Y. Kato, J. Hayashi (Japan)	905
076	EX VIVO ORGAN-PRESERVING SURGERY ON KIDNEYS FOR RENAL CELL CARCINOMA AND RENAL ARTERY ANEURYSMS A. Teplov, A. Zotikov, A. Gritskevich, Z. Adyrkhaev, S. Pyanikin, I. Timina, I. Pyatkova, A. Kozhanova, A. Ivandaev , A. Pokrovsky (Russia)	906
077	ISHCEMIC PRECONDITIONING IN CONTRAST-INDUCED NEPHROPATHY PROPHYLACTICS IN PATIENTS WITH MILD CHRONIC KIDNEY FAILUTE N. Zagidullin , A. Dunaeva, E. Sherbakova, S. Zagidullin (Russia)	907
078	CHARACTERISTICS OF LONG-TERM SURVIVORS IN A DIABETIC DIALYSIS PATIENT COLLECTIVE (4D STUDY) S. Triebswetter (Germany)	908
079	EVALUATION OF CARDIOVASCULAR RISK IN PATIENTS WITH CHRONIC KIDNEY DISEASE I. Oueslati , S. Lahiani, K. Bouzid, K. Khiari, H. Kaaroud, E. Elfaleh, A. Bartkiz, N. Ben Abdallah, J. Abdelmoula (Tunisia)	909
080	ADULT RELAPSING FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) MAINTAINED IN PARTIAL REMISSION FOLLOWING LIPOPROTEIN APHERESIS: CASE STUDY A. Haikal , N. Sehar, L. Denney, P. Moriarty (USA)	910

Board #		
081	SURGICAL TREATMENT OF ANEURYSM AND ARTERIOVENOUS FISTULA OF RENAL ARTERIES A. Zotikov, A. Gritskevich, Z. Adyrkhaev, I. Timina, I. Pyatkova, V. Cigankov, A. Varava, A. Kozhanova, A. Ivandaev , M. Demina, A. Pokrovsky (Russia)	911

Metabolic Abnormalities and Atherosclerosis: NASH and Liver Abnormalities

082	APO-B48 IN PATIENTS WITH TYPE 2 DIABETES AND NON-ALCOHOLIC FATTY LIVER DISEASE B. Idzior-Waluś , M. Walus-Miarka, A. Trojak, P. Miarka, M. Kapusta (Poland)	912
083	ASSOCIATION BETWEEN SERUM MONOCYTE CHEMOATTRACTANT PROTEIN-1(MCP-1) LEVELS, INSULIN RESISTANCE AND SUBCLINICAL ATHEROSCLEROSIS IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS N. Leach , S.C. Vesa, T. Alexescu, E. Dronca, V. Negrean, S. Dorel P. (Romania)	913
084	CARDIOMETABOLIC RISK FACTORS IN YOUNG V/S MIDDLE-AGED PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE R. Ivanova , C. Marinova, A. Alexiev, L. Mateva (Bulgaria)	914
085	CONTINUOUS GRADING OF EARLY FIBROSIS IN NAFLD USING LABEL-FREE IMAGING J. Pirhonen , J. Arola, S. Sädevirta, P. Luukkonen, S.M. Karppinen, T. Pihlajaniemi, A. Isomäki, M. Hukkanen, H. Yki-Järvinen, E. Ikonen (Finland)	915
086	THE ROLE OF VITAMIN D3 IN HIGH FAT DIET INDUCED FATTY LIVER DISEASE AND OBESITY. R. Kheder , J. Hobkir, M. Browning, C. Stover (United Kingdom)	916
087	COMPARATIVE ANALYSIS OF SERUM LIPIDS IN PATIENTS WITH CHRONIC HEPATITIS C, NONALCOHOLIC FATTY LIVER DISEASE, AND HEALTHY CONTROLS R. Ivanova , I. Valkov, C. Marinova, A. Alexiev, K. Antonov, D. Jeleu, L. Mateva (Bulgaria)	917
088	LIPID-MODIFYING EFFECTS OF CURCUMIN IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE Y. Panahi, P. Kianpour, R. Mohtashami, R. Jafari, A. Sahebkar (Iran)	918
089	EFFECTS OF BODY WEIGHT ON HEPATIC STEATOSIS IN ESSENTIAL HYPERTENSION C.H. Chou , W.C. Tsai (Taiwan)	919
090	HEPATIC STEATOSIS IS INDEPENDENTLY ASSOCIATED WITH ERECTILE DYSFUNCTION: ONE MORE LINK BETWEEN THE LIVER AND CARDIOVASCULAR RISK? F. Rached , A. Laurinavicius, R. Conceição, R. Santos (Brazil)	920

Board #

Dyslipidemias: Dyslipidemias, Screening and Treatment

091	PREVALENCE OF DIABETES MELLITUS IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA S. Perez-Calahorra , R. Mateo-Gallego, N. Plana, J.P. Botet-Montoya, J.F. Ascaso, C. Lahoz, F. Almagro, R.M. Sánchez-Hernández, I. Lamiquiz-Moneo, F. Civeira (Spain)	921
092	FAMILIAL HYPERCHOLESTEROLEMIA (FH) IN CHILDREN AND ADOLESCENTS: OPTIMIZATION OF DETECTION FOR EARLY TREATMENT E. De Faria (Brazil)	922
093	DIAGNOSTIC PERFORMANCE OF VARIOUS FAMILIAL HYPERCHOLESTEROLAEMIA CRITERIA COMPARED TO THE DUTCH LIPID CLINIC CRITERIA IN AN ASIAN POPULATION S. Abdul Razak, R. Rahmat, N.A. Mohd Kasim, T. Abdul Rahman, S. Muid, N. Mohd Nasir, Z. Ibrahim, S. Kasim, H. Nawawi (Malaysia)	923
094	DUTCH SCORE AND "CASCADE SCREENING" FOR THE IDENTIFICATION OF PATIENTS AFFECTED BY HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA S. Sperlongano , C. Garaffa, F. Natale, F. Fimiani, E. Garaffa, L. D'Acerno, M. Laringe, G. Limongelli, G. Piccinocchi, P. Calabrò (Italy)	924
095	RETROSPECTIVE OBSERVATIONAL STUDY ON THE DIAGNOSIS AND THERAPY OF THE FH ON A SAMPLE OF REAL WORLD POPULATION C. Garaffa , F. Natale, S. Sperlongano, F. Fimiani, M. Laringe, L. D'Acerno, E. Garaffa, G. Limongelli, G. Piccinocchi, P. Calabrò (Italy)	925
096	INTERNATIONAL COMPARISON OF PRIMARY CARE KNOWLEDGE AND PRACTICES OF FAMILIAL HYPERCHOLESTEROLAEMIA (FH) G.F. Watts (Australia)	926
097	INTERNATIONAL COMPARISON OF SERVICES AND FACILITIES FOR THE CARE OF FAMILIAL HYPERCHOLESTEROLAEMIA (FH) G.F. Watts (Australia)	927
098	SWITCH TO ROSUVASTATIN VERSUS ADDITION OF EZETIMIBE IN PATIENTS RECEIVING ATORVASTATIN: EFFECT ON URINE 8-ISOPROSTANE LEVELS E. Klouras , C. Tellis, F. Barkas, E. Liberopoulos, M. Elisaf, A. Tselepis (Greece)	928
099	CASCADE GENETIC SCREENING FOR FAMILIAL HYPERCHOLESTEROLEMIA IN WEST SIBERIA E. Shakhtshneider, K. Makarenkova, D. Ivanoshchuk, P. Orlov, Y. Ragino, M. Voevoda (Russia)	929
100	LIPID CLINIC EXPERIENCE OF GENOTYPING FOR FAMILIAL HYPERCHOLESTEROLAEMIA K. Shipman , R. Cramb (United Kingdom)	930

Board #

101	CAROTID PLAQUES AND INTIMA-MEDIA THICKNESS - ARE THE SAME RISK FACTORS IN MEN AND WOMEN WITH FAMILIAL HYPERCHOLESTEROLEMIA? M. Walus-Miarka , B. Idzior-Walus, D. Czarnecka, M. Kloch-Badetek, W. Wojciechowska, M. Kapusta (Poland)	931
102	SEVERE FAMILIAL HYPERCHOLESTEROLEMIA: PREVALENCE AND CHARACTERIZATION OF PATIENTS PRESENTING FOR CARDIAC CATHETERIZATION B. Zafrir , C. Shapira, G. Lavie, D.A. Halon, M.Y. Flugelman (Israel)	932
103	THE CT CORONARY CALCIUM SCORE IN FAMILIAL HYPERCHOLESTEROLAEMIA: COMPARISON BETWEEN PATIENTS WITH FH MUTATIONS AND THOSE WITH NO IDENTIFIED MUTATION S. Chaudhuri , M. Labib, A. Abeysekera (United Kingdom)	933
104	THE UK PAEDIATRIC FAMILIAL HYPERCHOLESTEROLAEMIA (FH) REGISTER: PRELIMINARY DATA S. Humphries , J. Cooper, U. Ramaswami (United Kingdom)	934
105	CASE REPORT: HYPERCHOLESTEROLEMIC PATIENT WITH NEW HOMOZYGOUS LDLR MUTATION AND SEVERE EARLY CORONARY HEART DISEASE T. Grenkowitz, U. Kassner , N. Buchmann, N. El-Zidy-Ibrahim, D. Spira, I. Demuth, E. Steinhagen-Thiessen (Germany)	935
106	FAMILIAL HYPERCHOLESTEROLAEMIA - GEOMAPPING OF THE BASELINE LDL LEVELS AND CHARACTERISATION OF LDL RECEPTOR MUTATIONS FOR PATIENTS DIAGNOSED IN THE NORTH WALES SCREENING PROGRAMME 2010-2015 M. De Soysa , R. Gingell, Y.P. Teoh (United Kingdom)	936
107	ESTABLISHMENT OF A NATIONWIDE CASCADE SCREENING PROGRAM AND REGISTER FOR FAMILIAL HYPERCHOLESTOLEMIA IN GERMANY - CARE HIGH N. Schmidt , W. März, T. Grammer (Germany)	937
108	EPISODIC MEMORY PERFORMANCE IN YOUNG ADULTS WITH FAMILIAL HYPERCHOLESTEROLEMIA M. Mauri , N. Cuenca, R.M. Borrallo, E. Romero, J. Ottino, I. García-García, M.A. Jurado, M. Garolera (Spain)	938
109	CARRIERS OF THE LDL RECEPTOR MUTATIONS WITHIN THE EXON 12 IN GENERAL POPULATION J. Hubacek , A. Fellnerova, D. Dlouha, L. Schwarzova, V. Adamkova (Czech Republic)	939
110	TARGETED NEXT-GENERATION SEQUENCING OF THE LDLRAP1 GENE IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA D. Ivanoshchuk , E. Shakhtshneider, K. Makarenkova, P. Orlov, Y. Ragino, M. Voevoda (Russia)	940

Board #		
111	FH CLINICS - TWO SHORT YEARS OF EXPERIENCE I. Colaço, T. Vassalo, F. Faria, D. Cruz , J.L. Ducla Soares (Portugal)	941
112	ACHIEVEMENT OF EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS) TARGETS WITH LOMITAPIDE, A MICROSOMAL TRANSFER PROTEIN INHIBITOR IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA (HOFH) H. Phillips , M. Ager, A. Hutchings (United Kingdom)	942
113	USING PERCENTILES TO DIAGNOSE FAMILIAL HYPERCHOLESTEROLEMIA IN PORTUGAL A. Pereira , A.C. Alves, A.M. Medeiros, C. Mariano, M. Bourbon (Portugal)	943
114	LOW-DENSITY LIPOPROTEIN GENE SCORE TO IDENTIFY POLYGENIC FORMS OF FAMILIAL HYPERCHOLESTEROLEMIA IN A SPANISH POPULATION J.M. Martín-Campos, J. Julve, N. Plana, R. Figueras, E. Esteve, M. Mauri, M. Bueno, A. Caixàs, E. Llargués, A. Vila, C. Morales, C. Soler, J. Argimón, J. Mayos, J. Grau, A. Zamora, L. Matas, L. Vila, L. Masana, F. Blanco-Vaca (Spain)	944
115	GENETIC ANALYSIS OF FAMILIAL HYPERCHOLESTEROLAEMIA IN IBEROAMERICAN COUNTRIES J. Chora, P. Mata, R. Santos, A. Cárdenas Vázquez, M. Stoll, L. Schreier, A. Cuevas, A.C. Alves, A.M. Medeiros, L. Perez Isla, C. Jannes, A. Pereira, N. Dell'Oca, X. Reyes, P. Corral, V. Bañares, T. Magaña-Torres, C. Aguilar-Salinas, R. Alonso, M. Bourbon (Argentina)	945
116	IDENTIFICATION OF A NEW MUTATION IN THE N-TERMINAL REGION OF THE APOLIPOPROTEIN B GENE IN FAMILIAL HYPERCHOLESTEROLEMIA M. Abifadel , S. Elbitar, Y. Ghaleb, G. Peloso, N. Stitzel, P. El Khoury, J.P. Rabes, V. Carreau, E. Bruckert, S. Kathiresan, M. Varret, C. Boileau (France)	946
117	PRELIMINARY RESULTS OF RUSSIAN FAMILIAL HYPERCHOLESTEROLEMIA REGISTRY I.V. Sergienko, A.A. Ansheles, A.B. Popova, M.I. Voevoda, V.S. Gurevich, V.V. Henkel, V.V. Kukharchuk, M.V. Ezhov (Russia)	947
118	CLINICAL CHARACTERISTICS OF COMMON PCSK9 GAIN-OF-FUNCTION E32K VARIANT WITH HIGHER TG ELEVATION, AND DOUBLE HETEROZYGOUES WITH COMMON PCSK9 VARIANTS AND LDLR MUTATIONS A. Nohara , M.A. Kawashiri, H. Tada, M. Yoshida, M. Mori, C. Nakanishi, K. Yagi, A. Inazu, M. Yamagishi, H. Mabuchi (Japan)	948
119	PROPROTEIN CONVERTASE SUBTILISIN/KEXIN 9 (PCSK9) V4I VARIANT WITH LDLR MUTATIONS MODIFIES THE PHENOTYPE OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA M. Hori , N. Ohta, A. Takahashi, M. Ogura, H. Makino, T. Tamanaha, Y. Miyamoto, M. Harada-Shiba (Japan)	949
120	HEREDITARY DEFECT OF APOLIPOPROTEIN B 100 - ANALYSIS OF GROUP OF PATIENTS TREATED WITH STANDARD PERORAL LIPID-LOWERING THERAPY IN ST. ANNE'S UNIVERSITY HOSPITAL BRNO O. Kyselak , V. Soska (Czech Republic)	950

Board #		
121	D374Y MUTATION IN THE PCSK-9 GENE IN TURKISH PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA: LONG TERM FOLLOW-UP WITH GOOD CLINICAL COURSE M. Kayikcioglu , E.K. Kocabas, A.T. VARDARLI, Z. EROGLU, H. DOKMEN, N. SALMAN, S. PAYZIN, L.H. CAN (Turkey)	951
122	ATHEROSCLEROSIS IN MONOGENIC FAMILIAL HYPERCHOLESTEROLEMIA VERSUS POLYGENIC HYPERCHOLESTEROLEMIA M. Sharifi , A. Gallivan, D. Harvey, L. Ka Wah, J. Cooper, M. Futema, S.E. Humphries, D. Nair (United Kingdom)	952
123	FIRST PCSK-9 MUTANT PATIENT IN TURKEY E. Kaya Kocabas , M. Kayikcioglu, A. Tetik Vardarli, Z. Eroglu (Turkey)	953
124	GENETIC EPIDEMIOLOGY OF ARH IN SICILY R. Spina , V. Valenti, V. Ingrassia, M.P. La Spada, C. Scrimali, G. Misiano, D. Noto, O. Palesano, G.I. Altieri, V. Licata, F. Fayer, C.M. Barbagallo, A.B. Cefalù, M. Averna (Italy)	954
125	CONSTRUCTION OF A NEW FAMILIAL HYPERCHOLESTEROLAEMIA VARIANT DATA BASE: A SYSTEMATIC REVIEW FOR A 2015 UPDATE S. Azevedo, J.R. Chora, A.C. Alves, A.M. Medeiros, M. Bourbon (Portugal)	955
126	MOLECULAR BASIS OF FAMILIAL HYPERCHOLESTEROLEMIA IN POLAND – UPDATE FROM THE POLISH NATIONAL CENTRE OF DIAGNOSTICS AND TREATMENT OF FAMILIAL HYPERCHOLESTEROLEMIA M. Chmara , M. Zuk, A. Mickiewicz, A. Brandt, K. Chlebus, J. Kubalska, J. Bautembach-Minkowska, M. Stroniawska-Woźniak, M. Bednarska-Makaruk, L. Kłosiewicz-Latoszek, A. Rynkiewicz, M. Mysliwiec, M. Gruchala, J. Limon, B. Wasag (Poland)	956
127	MORTALITY OF CARDIOVASCULAR DISEASE IN PATIENTS WITH GENETICALLY VERIFIED FAMILIAL HYPERCHOLESTEROLEMIA K. Retterstøl , J. Igland, L. Ose, K.B. Holven, T.P. Leren, M.B. Veierød, L. Mundal (Norway)	957
128	HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH) IN CHILDREN: AN ITALIAN EXPERIENCE F. Guaraldi , M.D. Di Taranto, C. Giacobbe, G. Fortunato, O. Guardamagna (Italy)	958
129	GENETIC ANALYSIS OF FAMILIAL HYPERCHOLESTEROLEMIA IN MEXICO A. Vazquez Cardenas , M.T. Magaña Torres, Y. Sanchez Lopez, T. Hernandez Flores, A.G. Colima Fausto, J.R. González Garcia, F. Escalante, D. Gonzalez Marines, C. Aguilar Salinas, M. Bourbon (Mexico)	959
130	35 YEARS OF EXPERIENCE WITH CHILDREN AFFECTED WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH): A CASE SERIES OF NINE PATIENTS K. Widhalm , K. Derfler, G. Kostner, O. Helk (Austria)	960

Board #		
131	PROGRAM STRATEGIES FOR FAMILIAL HYPERCHOLESTEROLEMIA IN URUGUAY	961
	M. Stoll , X. Reyes, N. Dell'Oca, F. Machado, A. Ressia, G. Fernandez, Zelarayán M(1) (Uruguay)	
132	EFFECT OF APOE GENOTYPE ON LDL CHOLESTEROL LEVELS IN FH AND FDB PATIENTS: IS THERE SEX-SPECIFICALLY PROTECTIVE GENOTYPE?	962
	L. Schwarzova , A. Horinek, J. Hubacek, M. Vrablik, T. Freiburger, L. Tichy, H. Vaverkova, R. Ceska (Czech Republic)	
133	GENETIC AND PHENOTYPIC CHARACTERIZATION OF LDL-RECEPTOR IN PATIENTS WITH A CLINICAL DIAGNOSIS OF FAMILIAL HYPERCHOLESTEROLEMIA: TWO NOVEL MUTATIONS	963
	C. Pavanello , C. Tarlarini, S. Penco, L. Calabresi, S. Castelnuovo, G. Mombelli, C. Sirtori (Italy)	
134	THE R46L POLYMORPHISM OF PCSK9 GENE AND LIPID PROFILE IN CAUCASIAN POPULATION OF RUSSIA	964
	K. Astrakova , E. Shakhtshneider, D. Ivanoshchuk, Y. Ragino, S. Astrakov, M. Voevoda (Russia)	
135	FAMILIAL HYPERCHOLESTEROLAEMIA IN PRIMARY CARE: AWARENESS, KNOWLEDGE AND PRACTICES AMONG PRIMARY CARE DOCTORS IN MALAYSIA	965
	A.S. Ramli, N.A. Mohd Mokhsin , S. Abdul Razak, M. Md Yasin, Z. Ismail, N.A. Mohd Kasim, T. Rahman, H. Nawawi (Malaysia)	
136	PERCEPTIONS ON HEALTH COMMUNICATION, SYMPTOMS AND CAUSES IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA TREATED IN SPECIALIST CLINICS	966
	N.A. Mohd Mokhsin , S. Abdul Razak, A.S. Ramli, M. Md Yasin, N.A. Mohd Kasim, S.S. Kasim, T. Rahman, H. Nawawi (Malaysia)	
137	CARDIOVASCULAR DISEASE RESEARCH BY USING DATA FROM ELECTRONIC HEALTH RECORDS	967
	L. Majnaric , S. Sabanovic (Croatia)	
138	LDL APHERESIS IN CHILDREN WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: A CASE SERIES	968
	I. Luirink , A. Wiegman, B. Hutten, J. Groothoff (Netherlands)	
139	EVALUATION OF PLASMA-FED LIPID APHERESIS IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA.	969
	P. Downie , G. Bayly, L. Hart, S. Douglas, J. Griffin (United Kingdom)	
140	LOMITAPIDE IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA - FIRST EXPERIENCES IN CLINICAL PRACTICE	970
	A. Vogt (Germany)	

Board #		
141	ANALYSIS OF CANDIDATE SINGLE NUCLEOTIDE VARIATIONS ASSOCIATED WITH POLYGENIC HYPERCHOLESTEROLEMIA IN FAMILIES WITH THE CLINICAL DIAGNOSIS OF FAMILIAL HYPERCHOLESTEROLEMIA	971
	I. Lamiquiz Moneo , M.R. Perez-Ruiz, E. Jarauta, M.T. Tejedor, L. Baila-Rueda, A.M. Bea, R. Mateo-Gallego, A. Cenarro, F. Civeira (Spain)	
142	STUDY OF APOB MUTATIONS AND FAMILIAL HYPERCHOLESTEROLEMIA PHENOTYPES	972
	J. Bassani Borges, G. Medeiros Bastos, T.K. Almendros Afonso, E. Da Silva Rodrigues, H. Strelow Thurow, T. Dominguez Crespo Hirata, A. Arpad Faludi , R. Marques Gonçalves, R. Dominguez Crespo Hirata, M. Hiroyuki Hirata (Brazil)	
143	FUNCTIONAL ANALYSIS OF MUTATIONS LOCATED IN THE LDL RECEPTOR SIGNAL SEQUENCE CODING REGION	973
	T. Freiburger , J. Pavlouskova, K. Reblova, L. Tichy, L. Fajkusova (Czech Republic)	
144	ATTAINMENT OF LDL-C TREATMENT TARGET IN FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS: A THEORETICAL MODEL EXPLORING EFFICACY OF CURRENT AND NOVEL LIPID LOWERING THERAPIES	974
	M.L. Hartgers , J. Besseling, G.K. Hovingh (Netherlands)	
145	CARDIOVASCULAR DISEASE IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA SUBJECTS ON STATIN TREATMENT	975
	V. Marco-Benedi , S. Perez-Calahorra, N. Plana, J.C. Pedro-Botet, J. Ascaso, C. Lahoz, F. Almagro, E. Ros, A. Brea, M. Suarez-Tembra, R.M. Sanchez-Hernández, A. Vila Belmonte, F. Civeira (Spain)	
146	LONG-TERM TREATMENT WITH EVOLOCUMAB HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS: RESULTS FROM THE TRIAL ASSESSING LONG-TERM USE OF PCSK9 INHIBITION IN SUBJECTS WITH GENETIC LDL DISORDERS (TAUSSIG)	976
	E.A. Stein, T. Sampietro, R. Santos, M. Harada-Shiba, E. Bruckert, D. Blom, G.K. Hovingh, P. Couture, V. Blaha, M. Farnier, O. Descamps, H. Soran, S. Kasichayanula, J. Gibbs, C. Kurtz, L. Tang, N. Honarpour, S.M. Wasserman, F.J. Raal (South Africa)	
147	LIPID-LOWERING THERAPY AND TARGET ATTAINMENT AMONG HYPELIPIDEMIC INDIVIDUALS WITH OR WITHOUT FAMILIAL HYPERCHOLESTEROLEMIA: EVIDENCE FROM A LIPID CLINIC	977
	F. Barkas , E. Klouras, T. Dimitriou, G. Liamis, E. Liberopoulos, M. Elisaf (Greece)	
148	INCIDENCE OF CARDIOVASCULAR DISEASE AMONG INDIVIDUALS WITH AND WITHOUT FAMILIAL HYPERCHOLESTEROLEMIA ATTENDING A LIPID CLINIC	978
	F. Barkas , E. Klouras, T. Dimitriou, G. Liamis, M. Elisaf, E. Liberopoulos (Greece)	

Board #		
149	CHANGES IN PLASMA LIPOPROTEIN SUBFRACTIONS IN PATIENTS WITH POLYGENIC HYPERCHOLESTEROLEMIA, FAMILIAL COMBINED HYPERLIPOPROTEINEMIA, AND FAMILIAL HYPERCHOLESTEROLEMIA AFTER ATORVASTATIN	979
	B. Muinjonov , E. Giyazitdinova (Uzbekistan)	
150	PREVALENCE OF DYSLIPIDAEMIA AMONG ADULTS AGED 50-64 YEARS IN IRELAND: THE IRISH LONGITUDINAL STUDY ON AGEING (TILDA)	980
	C. Murphy , E. Shelley, T. Fahey, R.A. Kenny (Ireland)	
151	IMPACT OF SOCIAL AND CLINICAL PARAMETERS ON NON-HDL CHOLESTEROL IN SCHOOL CHILDREN	981
	A. Pereira , F. Guarnieri, A.P.Q. Mello, R. Santos Filho, T.L.R. Martinez (Brazil)	
152	STATIN PRESCRIPTION PATTERNS, ADHERENCE, AND ATTAINMENT OF CHOLESTEROL TREATMENT GOALS IN CLINICAL CARE IN ELDERLY WITH HYPERLIPIDEMIA AND CORONARY HEART DISEASE: A RUSSIAN OBSERVATION STUDY	982
	M. Bubnova , D. Aronov (Russia)	
153	STUDY OF THE PREVALENCE OF DYSLIPIDEMIAS IN CHILDREN AND ADOLESCENTS ATTENDED BY THE NATIONAL HEALTH SYSTEM IN CAMPINAS - SÃO PAULO - BRAZIL	983
	E. De Faria , E.I. Gomes, V.H. Zago, E.S. Parra, N.B. Panzoldo, G. Redezuk (Brazil)	
154	CLINICAL MANAGEMENT AND QUALITY OF LIFE IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA UNDERGOING LIPID-APHERESIS IN TURKEY: FIRST RESULTS OF A NATION-WIDE SURVEY (A-HIT REGISTRY)	984
	M. Kayıkcıoğlu , L. Tokgozoglu, S. Pirildar, M. Yilmaz, L. Kaynar, M. Aktan, R. Durmus, A. Temizhan, O. Ozcebe, T. Akyol, H. Okutan, S. Sag, B. Altunkeser, M. Yenercag, E. Kurtoglu, S. Demircioglu, O. Salcioglu, M. Demir, H. Yilmaz, O. (Turkey)	
155	FUNCTIONALLY CHARACTERIZATION OF LDLR MISSENSE ALTERATIONS FOUND IN CLINICAL FH PATIENTS	985
	A.C. Alves , S. Azevedo, A. Benito-Vicente, A. Etxebarria, P. Barros, A.M. Medeiros, C. Martin, M. Bourbon (Portugal)	
156	GENETIC VARIANTS OF PCSK9 GENE IN CORONARY ARTERY DISEASE AMONG SOUTH INDIAN PATIENTS	986
	M. Ganesan (India)	
157	FAMILIAL COMBINED HYPERLIPIDEMIA IN CHILDREN: BIOCHEMICAL CHARACTERIZATION IN PEDIATRIC AGE	987
	F. Abello , E. Barabesi, A. Bosusco, O. Guardamagna, D. Vianello, A. Zambon (Italy)	

Board #		
158	VALIDATION OF SERUM APOB/CHOLESTEROL AND APOB/NON-HDL CHOLESTEROL RATIOS AS SCREENING TESTS FOR TYPE III HYPERLIPIDAEMIA	988
	C. Boot, E. Holmes , D. Neely, F. Jenkinson, H. Datta, L. Hughes (United Kingdom)	
159	TREATMENT OF THERAPY-REFRACTORY HYPERCHOLESTEROLEMIA WITH PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 ANTIBODIES (PCSK9-I) IN CARDIOVASCULAR HIGH RISK PATIENTS - EFFECTIVITY AND SAFETY IN CLINICAL ROUTINE	989
	T. Hollstein , D. Spira, N. Buchmann, N. El-Zidy Ibrahim, T. Bobbert, E. Steinhagen-Thiessen, U. Kassner (Germany)	
160	SEARCHING FOR THE <i>ELUSIVE</i> FAMILIAL HYPERCHOLESTEROLAEMIA GENE MUTATIONS FOR INDEX PATIENTS - USING HISTORICAL LABORATORY LDL-C RESULTS IN PRIMARY CARE. A NORTH WALES EXPERIENCE.	990
	Y.P. Teoh , R. Gingell (United Kingdom)	
161	HIGH TRIGLYCERIDES, LOW HDL CHOLESTEROL AND A LOW LDL CHOLESTEROL PER APOLIPOPROTEIN B RATIO PREDICT INCIDENT DIABETES IN PATIENTS WITH ESTABLISHED CORONARY ARTERY DISEASE	991
	C. Saely, P. Rein, A. Vonbank, D. Zanolin, A. Leiberer , A. Muendlein, H. Drexel (Austria)	
162	CARDIOVASCULAR COMORBIDITIES LINKED TO OBESITY IN FORMER ATHLETES FROM TRANSYLVANIA	992
	V. Negrean , O. Orășan, T. Alexescu, N. Leach, I. Para, M. Milaciu (Romania)	
163	E_LIPID: CHARACTERIZATION OF THE LIPID PROFILE IN THE PORTUGUESE POPULATION	993
	C. Mariano, M. Antunes, Q. Rato, M. Bourbon (Portugal)	
164	SEVERE HYPERCHOLESTEROLEMIA IN HOSPITAL PRACTICE-SINGLE CENTRE EXPERIENCE IN SINGAPORE	994
	S. Dissanayake , S.P. Li Tin, J.F. Choi Wan, M.S. Wong, S. Tavintharan (Singapore)	
165	HIGH PREVALENCE OF FAMILIAL HYPERCHOLESTEROLEMIA IN ARGENTINA: RESULTS OF THE FIRST DETECTION PROGRAM.	995
	P. Corral , G.I. López, A. Cristaldi, J.C. Tuseddo, L. Cacciagiú, G. Berg, L. Schreier (Argentina)	
166	NETWORK ANALYSIS APPROACH TO FIND NEW CANDIDATE GENES AND PATHWAYS INVOLVED IN THE PATHOPHYSIOLOGY OF FAMILIAL HYPERCHOLESTEROLEMIA	996
	N. Rossi, M. Bourbon , F. Enguita (Portugal)	
167	PARAMETRES OF ARTERIAL REMODELING IN FAMILAL HYPERCHOLESTEROLEMIA PATIENTS	997
	V. Korneva , T. Kuznetsova (Russia)	

Board #

Dyslipidemias: Treatment

- 168 EFFECTS OF DIFFERENT DOSES OF ATORVASTATIN ON PLATELET AGGREGATION, ENDOTHELIAL FUNCTION, LEVELS OF SEROTONIN, ANGIOTENSIN II, BLOOD PRESSURE, CEREBRAL BLOOD FLOW IN HYPERTENSIVE PATIENTS WITH HYPERLIPIDEMIA 998
M. Bubnova, D. Aronov, E. Semenova (Russia)
- 169 EFFECT OF STATIN ON FASTING BLOOD SUGAR LEVEL; COMPARISONS OF KINDS OF STATINS AND ASSOCIATED PARAMETERS 999
C.J. Kim, M.A. Kim (Republic of Korea)
- 170 DIFFERENT ROLE OF ACHIEVED LDL-CHOLESTEROL AND HS-CRP LEVEL IN FUTURE CARDIOVASCULAR DISEASE OUTCOMES IN NON-PERCUTANEOUS CORONARY INTERVENTION PATIENTS WITH ONGOING STATIN THERAPY OF MODERATE INTENSITY 1000
M.H. Hyun, E. Lee, B.G. Choi, H.S. Seo, J.O. Na, C.U. Choi, H.E. Lim, J.W. Kim, S.W. Rha, E.J. Kim, C.G. Park, D.J. Oh (Republic of Korea)
- 171 COMPARISON THE EFFECT ON FASTING BLOOD SUGAR BETWEEN ATORVASTATIN, ROUSUVASTATIN AND PITAVASTATIN IN KOREAN POPULATION 1001
Y.S. Lee, Y.W. Park, S.P. Hong, J.B. Lee, J.K. Ryu, J.Y. Choi, K.S. Kim (Republic of Korea)
- 172 COMPARISON OF LIPID MANAGEMENT BETWEEN ELDERLY AND NON-ELDERLY PATIENTS WITH AND WITHOUT CORONARY HEART DISEASE (CHD) 1002
N. Kume, R. Shimizu, H. Torii, D. Yasuda, Y. Hiraoka, T. Hashida (Japan)
- 173 STATIN ESCAPE PHENOMENON: DOES IT REALLY EXIST? EVIDENCE FROM A LIPID CLINIC 1003
F. Barkas, E. Klouras, T. Dimitriou, M. Elisaf, E. Liberopoulos (Greece)
- 174 EFFECTS OF LOW-DOSE VS. MODERATE-DOSE PITAVASTATIN ON LONG-TERM CARDIOVASCULAR EVENTS IN KOREAN PATIENTS WITH CORONARY ARTERY DISEASE REQUIRING STENT IMPLANTATION: PROSPECTIVE, 3-YEAR FOLLOW-UP TRIAL 1004
D.S. Lim, H.J. Kim, Y.C. Kim, B.G. Kang, S.M. Jeon, **S.J. Hong**, J.Y. Cho, S.H. Lee, H.J. Joo, J.H. Park, C.W. Yu (Republic of Korea)
- 175 GENE VARIANTS ASSOCIATED WITH STATIN-INDUCED MYOPATHY: DETERMINATION IN A CZECH POPULATION 1005
J. Petrková, L. Kocourkova, V. Zizkova, M. Taborsky, M. Petrek (Czech Republic)
- 176 THE SAFETY OF STATINS IN PATIENTS WITH CHRONIC KIDNEY DISEASE 1006
Y.K. Cho (Republic of Korea)
- 177 ONE YEAR PERSISTENCE OF ATORVASTATIN AND AMLODIPINE FIXED DOSE COMBINATION VERSUS ATORVASTATIN THERAPY 1007
G. Simonyi, F. Tamás (Hungary)

Board #

- 178 IMPACT OF FENOFIBRATE THERAPY ON ENDOTHELIAL FUNCTION IN THE SUBJECTS WITH METABOLIC SYNDROME 1008
K. Kotula-Horowitz, M. Janczura, T. Iwaniec, R. Rosa, J. Zagjewski, **T. Domagala** (Poland)
- 179 THE EFFICACY OF EVOLOCUMAB AND OTHER LIPID-LOWERING THERAPIES (LLT) FOR THE MANAGEMENT OF LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C): A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS (NMA) 1009
G. Worthy, S.R. Gandra, I. Bridges, G. Worth, R. Dent, L.I. Cheng, C. Forbes, S. Deshpande, J. Ross, J. Kleijnen, **E.S.G. Stroes** (Netherlands)
- 180 EFFICACY AND SAFETY OF FIXED-DOSE COMBINATION OF OLMESARTAN MEDOXOMIL AND ROSUVASTATIN IN KOREAN PATIENTS WITH HYPERTENSION AND DYSLIPIDEMIA 1010
S.H. Kim, H.L. Lee, W.H. Lim, H.L. Kim, J.B. Seo, W.Y. Chung, J.H. Zo, M.A. Kim, H.S. Kim (Republic of Korea)
- 181 THE EFFECTS OF ALIROCUMAB ON LDL CHOLESTEROL LEVELS IN PATIENTS RECEIVING STATINS 1011
H. Habibinejad (Iran)
- 182 TESTOSTERONE UNDECANOATE IMPROVES LIPID PROFILE IN PATIENTS WITH TYPE 1 DIABETES AND HYPOGONADOTROPHIC HYPOGONADISM. RESULTS FROM TEST-T1D RANDOMIZED CLINICAL TRIAL. 1012
J.J. Chillarón, **J. Pedro-Botet**, M. Fernández-Miró, M. Albareda, L. Vila, D. Benaiges, J.A. Flores Le-Roux (Spain)
- 183 EFFECT OF TOCILIZUMAB ON CARDIAC BIOMARKERS HIGH-SENSITIVITY TROPONIN T AND NT-PROBNP IN RHEUMATOID ARTHRITIS: POST HOC ANALYSIS OF A RANDOMISED CONTROLLED TRIAL 1013
P. Welsh, K. Tuckwell, N. Sattar (United Kingdom)
- 184 CCAAT/ENHANCER BINDING PROTEIN DELTA CONTRIBUTES TO AN EARLIER PHASE OF PRO-INFLAMMATORY RESPONSE IN DOXORUBICIN RELATED CARDIOMYOPATHY 1014
J.T. Wen, **L.W. Hsu**, P.Y. Liu (Taiwan)
- 185 EFFECT OF ENDOTOXIN AND NATURAL CAROTENOIDS ON AORTIC ENDOTHELIAL TIGHT JUNCTIONS' OCCLUDIN EXPRESSION 1015
J. Krizak, K. Frimmel, E. Breierova, R. Sotnikova, J. Navarova, I. Bernatova, L. Okruhlicova (Slovakia)
- 186 EFFECT OF DHA/EPA SUPPLEMENTATION ON ENDOTHELIAL DAMAGE MARKERS. THE BIOCLAIMS STUDY 1016
J. Góralaska, M. Malczewska-Malec, U. Razny, A. Zdzienicka, A. Gruca, A. Chabowski, M. Sanak, A. Dembinska-Kiec, B. Solnica (Poland)

Board #		
187	IN VITRO PHARMACOLOGICAL EVALUATION OF MULTITARGET THROMBOXANE PROSTANOID RECEPTOR/ COX-2 AGENTS: A POSSIBLE STRATEGY TO SOLVE THE CARDIOVASCULAR ISSUES OF COXIBS	1017
	M. Hoxha , C. Buccellati, V. Capra, C. Cena, A. Sala, M. Bertinaria, G. Rovati (Italy)	
188	THE USE OF N-ACETYLCYSTEINE IN PATIENTS WITH ACUTE CORONARY SYNDROME AND DIASTOLIC LEFT VENTRICULAR DYSFUNCTION, IN ACCORDANCE WITH THE LEVEL OF HIGH-SENSITIVITY C-REACTIVE PROTEIN.	1018
	A. Nizomov , B. Toshev, J. Berdiqulov (Uzbekistan)	
189	THREE TIMES A WEEK AND FIVE TIMES A WEEK WALKING EXERCISE FREQUENCIES ARE EQUALLY EFFECTIVE IN IMPROVING WALKING CAPACITY IN EXPERIMENTAL PERIPHERAL ARTERY DISEASE	1019
	M. Pellegrin , J. Lavier, K. Bouzourene, L. Mazzolai (Switzerland)	
190	SONODYNAMIC THERAPY OF THE RABBIT CAROTID ARTERY NEOINTIMAL HYPERPLASIA USING LOW- LEVEL COMBINED ELECTROHYDRAULIC SHOCK WAVES AND ULTRASONIC WAVES ACCOMPANIED BY PROTOPORPHYRIN IX ADMINISTRATION	1020
	H. Mehrad , B. Mahvi (Iran)	
191	A NOVEL COMPOUND (D-47), THE HYPOLIPIDEMIC EFFECTS AND THE MECHANISM IN AN ANIMAL MODEL OF HYPERCHOLESTEROLEMIA (WHHLM1 RABBIT)	1021
	S. Tamura, Y. Yu, T. Nakagawa, R. Nagasaka, T. Tsunoda, K. Ogawa, M.O. Tori, T. Koike, M. Shiomi (Japan)	
192	NOVEL ROLE OF BERBERINE IN LOX1-MEDIATED ENDOTHELIAL DYSFUNCTION	1022
	A. Cicero, C. Caliceti , P. Rizzo, R. Ferrari, F. Fortini, G. Aquila, J. Shehu, E. Leoncini, L. Zambonin, B. Rizzo, M. Guardigli, A. Roda, S. Hrelia (Italy)	
193	EXPERIENCE OF TAKAYASU`S ARTERITIS SURGICAL TREATMENT	1023
	A. Pokrovskiy, A. Zotikov, V. Kulbak , E. Burtceva (Russia)	
194	DOWN-REGULATION OF THE CHEMOKINE (C-C MOTIF) RECEPTOR 9 (CCR9) CONTRIBUTES TO THE ATHEROSCLEROSIS-LOWERING ACTIVITY OF THE ANGIOTENSIN-CONVERTING ENZYME INHIBITOR CAPTOPRIL	1024
	J. Abd Alla , A. Langer, U. Quittner (Switzerland)	
195	INCIDENCE OF VALVULAR HEART DISEASE AFTER COMBINATION OF DOPAMIN AGONISTS WITH STATINS	1025
	E. Giyazitdinova , B. Muinjonov, G. Rakhimbayeva, Y. Musayeva (Uzbekistan)	
196	HYPOLIPIDEMIC EFFECT OF RHEOPHERESIS AND RESTORATION OF RETINAL PHOTORECEPTOR JUNCTION	1026
	M. Blaha, E. Rencova, H. Langrova, M. Lanska, A. Stepanov, V. Blaha (Czech Republic)	

Board #		
197	REMNANT CHOLESTEROL REDUCTION BY EZETIMIBE AND SIMVASTATIN DOES NOT AFFECT BILIARY LIPID CONCENTRATION IN GALLSTONE PATIENTS	1027
	M. Eriksson , O. Ahmed, U. Gustafsson, K. Littman, S. Sahlin, C. Pramfalk, P. Parini (Sweden)	
198	CROSS-CLASS SERINE PROTEASE INHIBITOR SERP-2 BLOCKS LIVER ISCHEMIA REPERFUSION INJURY	1028
	S. Ambadapadi , H. Chen, J. Fuentes, S. Morshed, J. Davids, B. Marques, A. Lucas (USA)	
199	STATIN THERAPY REDUCES PHOSPATE LEVELS IN DIALYSIS PATIENTS: RESULTS FROM THE EPIDEMIOLOGICAL VITAMIN K ITALIAN STUDY (VIKI STUDY)	1029
	C. Panzavolta , L. Benvegnù, A. Aghi, M. Biolo, S. Giannini, M. Noale, G. Tripepi, M. Plebani, N. Veronese, P. Messa, M. Rossini, M. Gallieni, S. Sella, F. Fabris, E. Manzato, L. Previato, S. Bertocco, A. Zambon, M. Fusaro, S. Zambon (Italy)	

Dyslipidemias: Coagulation

200	PLASMA ADVANCED OXIDIZED PROTEIN PRODUCTS PROMOTE PLATELET-ENDOTHELIAL CROSSTALK AND ENDOTHELIAL TISSUE FACTOR EXPRESSION	1030
	G. Marsche , A. Heinemann, L. Pasterk (Austria)	
201	PLASMA FIBRINOGEN IS AN IMPORTANT CLINICAL MARKER FOR PROSPECTIVE ALL-CAUSE MORTALITY IN THE LIFEWAYS CROSS-GENERATION COHORT STUDY	1031
	R. Somerville , K. Viljoen, S. McKey, A. Shrivastava, J. Mehegan, R. Segurado, C. Murrin, C. Kelleher (Ireland)	
202	ADJUSTING FOR THE INFLUENCE OF THE HEMATOCRIT LEVEL IMPROVES THE PROGNOSTIC VALUE OF THE VERIFYNOW P2Y12 ASSAY	1032
	J.W. Suh , Y.G. Kim, Y.S. Cho, T.J. Youn, I.H. Chae (Republic of Korea)	
203	PLATELET-ASSOCIATED TISSUE FACTOR AS A NEW MECHANISM INVOLVED IN THE PROTHROMBOTIC PHENOTYPE OF STABLE ANGINA PATIENTS WITH TYPE-2 DIABETES MELLITUS (T2DM)	1033
	L. Rossetti, P. Canzano, M. Mapelli, D. Trabattoni, F. Santilli, G. Davi, A. Lualdi, E. Tremoli, M. Camera (Italy)	
204	IMPACT OF TYPE-2 DIABETES MELLITUS (T2DM) ON THE PLATELET TRANSCRIPTOME PROFILE IN STABLE ANGINA (SA) PATIENTS	1034
	L. Rossetti, M. Brambilla, P. Canzano, L. Piacentini, E. Bono, M. Mapelli, D. Trabattoni, A. Lualdi, G. Colombo, E. Tremoli, M. Camera (Italy)	

Board #		
205	NTEGRIN α IIb β 3 AS POTENTIAL BIOMARKER OF HIGH ON-TREATMENT PLATELET REACTIVITY TO CLOPIDOGREL IN PATIENTS WITH AN ACUTE CORONARY SYNDROME	1035
	A. Gkourogianni , M. Tsoumani, I. Ntallas, D. Tsoukatos, I. Goudevenos, A. Tselepis (Greece)	
206	THE COMBINATION OF N-ACETYLCYSTEINE WITH FIBRINOLYTIC THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME.	1036
	A. Nizomov (Uzbekistan)	
207	FEASIBILITY OF TARGETING THROMBUS USING FOCUSED-ELECTROHYDRAULIC SHOCK WAVES ACCOMPANIED BY SIMULTANEOUSLY B-MODE ULTRASOUND IMAGING IN THE RABBIT MODEL OF COMMON CAROTID ARTERY ATHEROTHROMBOTIC OCCLUSION	1037
	H. Mehrad (Iran)	
208	NON-INVASIVE TREATMENT OF THE RABBIT CAROTID ARTERY ATHEROTHROMBOTIC OCCLUSION USING COMBINED ND:YAG LASER AND PULSED- FOCUSED ULTRASOUND ACCOMPANIED BY THROMBOLYTIC AGENT ADMINISTRATION	1038
	H. Mehrad , A. Akrami (Iran)	
209	PROTHROMBOTIC PHENOTYPE IN HYPERTENSION: CONTRIBUTION OF MEGAKARYOCYTE- AND PLATELET-ASSOCIATED TISSUE FACTOR EXPRESSION IN STROKE-PRONE RATS	1039
	M. Brambilla, P. Gelosa, L. Rossetti, L. Castiglioni, P. Canzano, S. Luigi, E. Tremoli, M. Camera (Italy)	
210	SILENCING ANTICOAGULANT PROTEIN C CAUSES SPONTANEOUS ATHEROTHROMBOSIS IN APOE KNOCKOUT MICE	1040
	A.B. Ouweneel , M. Heestermans, R.A.F. Verwilligen, M. Van Eck, B.J.M. Van Vlijmen (Netherlands)	

Dyslipidemias: Endothelial Dysfunction

211	LOW-FLOW MEDIATED CONSTRICTION INCORPORATED INDICES AS INDICATORS OF CARDIOVASCULAR RISK IN SMOKERS	1041
	N. Norioka , Y. Takemoto, M. Kobayashi, A. Makuuchi, J. Yoshikawa, Y. Yamazaki, Y. Kamiyama, T. Shuto, M. Yoshiyama (Japan)	
212	ENDOTHELIAL SHEAR RATE IN PATIENTS WITH CAROTID ATHEROSCLEROSIS	1042
	V. Genkel , A. Salashenko, O. Alekseeva, M. Denisenko, I. Shaposhnik (Russia)	
213	ANALYSIS OF BIOLOGICAL, STRUCTURAL AND FUNCTIONAL MARKERS OF ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH ARTERIAL HYPERTENSION, TREATED WITH ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS	1043
	M. Andor , V. Buda, C. Cristescu, M. Voicu, L. Suci, C. Muntean, M. Tomescu (Romania)	

Board #		
214	INFLUENCE OF CARBOHYDRATE METABOLISM DISORDERS ON STRUCTURAL AND FUNCTIONAL PROPERTIES OF THE LARGE ARTERIES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS	1044
	N. Burko , L. Salyamova, Y. Tomashevskaya, V. Oleynikov (Russia)	
215	THE PROGNOSTIC IMPORTANCE OF ENDOTHELIAL DYSFUNCTION IN METABOLIC SYNDROME WITH CORONARY ARTERY DISEASE	1045
	T. Ueda (Japan)	
216	VASCULAR AGE - A HELPFUL TOOL IN ASSESSING CARDIOVASCULAR RISK	1046
	A. Dumitrescu , S. Mosteoru, L. Gaita, R. Pleava, D. Gaita (Romania)	
217	REMOTE ISCHEMIC PRECONDITIONING AND ENDOTHELIAL FUNCTION IN HEALTHY VOLUNTEERS	1047
	N. Ryazankina , M. Vagida, V. Manchurov, A. Lebedeva, A. Arakelyan, J.C. Grivel, L. Margolis, E. Vasilieva, A. Shpektor (Russia)	
218	THE ENDOTHELIAL FUNCTION IMPROVEMENT ON STATIN THERAPY IN TYPE 2 DIABETES ASSOCIATED WITH TNF α G(308)A AND G(238)A POLYMORPHIC MARKERS	1048
	N. Lebedeva , O.K. Vikulova, A.G. Nikitin, M.S. Shamkhalova, M.V. Shestakova (Russia)	
219	BENEFICIAL EFFECT OF AZILSARTAN AND AMLODIPINE ON ENDOTHELIAL FUNCTION IN HYPERTENSIVE PATIENTS	1049
	T. Nishida , M. Ayaori, K. Shiotani, H. Uto-Kondo, M. Sasaki, T. Komatsu, Y. Endo, M. Ito, M. Ishizuka, M. Sakurada, K. Ikewaki (Japan)	
220	CIRCULATING PROGENITOR CELLS IN HYPERTENSIVE SUBJECTS: EFFECTIVENESS OF A TREATMENT WITH OLMESARTAN IN IMPROVING CELL NUMBER AND MIRS PROFILE BESIDES EXPECTED PHARMACOLOGICAL EFFECTS	1050
	G. Mandraffino , C.O. Aragona, E. Imbalzano, V. Cairo, F. Mamone, M.A. Sardo, A. Saitta (Italy)	

Genetics, Nutrition, Biomarkers: Genetics, Gene Regulation

221	A CASE OF SEVERE CHYLOMICRONAEMIA SYNDROME, IN A PATIENT WITH NORMAL LIPOPROTEIN LIPASE ACTIVITY, DUE TO A PREVIOUSLY UNIDENTIFIED MUTATION IN THE GPIIIBP1 GENE	1051
	P. Downie , G. Bayly (United Kingdom)	
222	MOLECULAR ANALYSIS OF GENES INVOLVED IN LIPOPROTEIN LIPASE DEFICIENCY IN SLOVAK PATIENTS WITH FAMILIAL CHYLOMICRONEMIA	1052
	D. Gabcova , D. Stanikova, M. Huckova, V. Bzduch, J. Stanik, I. Klimes, K. Raslova, D. Gasperikova (Slovakia)	

Board #		
223	DISSECTION OF CLINICAL AND GENE EXPRESSION SIGNATURES OF FAMILIAL VS MULTIFACTORIAL CHYLOMICRONEMIA D. Gaudet , D. Brisson, K. Tremblay (Canada)	1053
224	A NOVEL HOMOZYGOUS MUTATION IN <i>GPD1</i> LEADING TO SEVERE HYPERTRIGLYCERIDEMIA J. Levels , R. Piña-Aguilar, J. Peter, G.M. Dallinga-Thie (Netherlands)	1054
225	IDENTIFICATION AND CHARACTERIZATION OF TWO NOVEL MUTATIONS IN THE LPL GENE CAUSING TYPE I HYPERLIPOPROTEINEMIA P. Pingitore , S.M. Lepore, C. Pirazzi, R.M. Mancina, B.M. Motta, L. Valenti, K.E. Berge, K. Retterstøl, T.P. Leren, O. Wiklund, S. Romeo (Sweden)	1055
226	STATINS UPREGULATE MICRORNA-122 IN HEPG2 CELLS A. Etxebarria , X. Moreno, A. Benito-Vicente, S. Jebari, U. Galicia, H. Ostolaza, C. Martin (Spain)	1056
227	THE HYPERTRIGLYCERIDEMIC EFFECT OF APOC3 3'UTR VARIANT SST1 IS NOT MEDIATED BY A HEPATIC OR INTESTINAL MIRNA REGULATION M. Dancer , C. Marçais, C. Caussy, M. Di filippo, P. Moulin, S. Charrière (France)	1057
228	PLASMA LIPOPROTEINS OF PATIENTS WITH GENETIC LAL DEFICIENCY ARE ENRICHED IN CHOLESTERYL ESTERS: RELEVANCE OF CHOLESTEROL ESTERIFICATION BY LCAT M. Gomasaschi , L. Arnaboldi, F. Abello, C. Pavanello, F. Zimetti, E. Favari, L. Calabresi, O. Guardamagna (Italy)	1058
229	LYSOSOMAL ACID LIPASE DEFICIENCY IN GREECE: A RARE INBORN ERROR OF METABOLISM PRESENTING WITH DYSLIPIDAIMIA AND LIVER DISEASE E. Drogari , V. Mollaki, H. Christomanou, K. Stamatelopoulos, N. Manolaki (Greece)	1059
230	WILL FAMILIAL HYPERCHOLESTEROLAEMIA COHORTS HIDE MANY MORE LYSOSOMAL ACID LIPASE DEFICIENCY PATIENTS? J.R. Chora , A.C. Alves, A.M. Medeiros, C. Mariano, G. Loubarinhas, A. Guerra, H. Mansilha, M. Bourbon (Portugal)	1060
231	SCREENING OF LYSOSOMAL ACID LIPASE DEFICIENCY IN PATIENTS WITH SEVERE DYSLIPIDEMIA AND PREMATURE CORONARY HEART DISEASE O. Azevedo , N. Marques, H. Antunes, P. Azevedo, M. Oliveira, D. Bento, J. Guedes, B. Marmelo, R. Faria, E. Correia (Portugal)	1061
232	GENETIC VARIANTS OF ABO BLOOD GROUP WITH CORONARY ARTERY DISEASE AMONGST INDIANS P. Chawla , T. Ashavaid, C. Ponde, R. Rajani, A. Deshpande, R. Sawant (India)	1062
233	GP1B P.P16L POLYMORPHISM IS NOT ASSOCIATED WITH ALTERED LIPID PHENOTYPES AND CIMT PROGRESSION- A PLIC STUDY A. Dhyani , A. Baragetti, K. Garlaschelli, F. Pellegatta, L. Grigore, D. G.Norata, A.L. Catapano (Italy)	1063

Board #		
234	NFE2L2 RS2364723 CC GENOTYPE SIGNIFICANTLY INCREASED THE RISK OF CARDIOVASCULAR DISEASE: A CASE-CONTROL STUDY IN AN ARSENIASIS-ENDEMIC AREA IN TAIWAN T. Chia-Yin , C. Hung-Yi, H. Fang-I (Taiwan)	1064
235	THE GG GENOTYPE OF VITAMIN D METABOLISM-RELATED GENE DHCR7 RS12785878 IS MORE PREVALENT IN THE INDIANS AND ASSOCIATED WITH HIGHER OXIDATIVE STRESS INDEX IN SINGAPORE R. Dalan , H. Liew, L.L. Goh, X. Gao, D. Chew, B.O. Boehm (Singapore)	1065
236	ASSOCIATION OF THE HETEROPLASMY LEVEL OF MUTATION IN GENE <i>MT-CYB</i> WITH CAROTID ATHEROSCLEROSIS IN WOMEN V. Sinyov, M. Sazonova, M. Chicheva, N. Nikitina, I. Sobenin, A. Orekhov (Russia)	1066
237	SINGLE NUCLEOTIDE POLYMORPHISMS AT THE HYDROXY-METHYL-GLUTARYL-COA REDUCTASE GENE LOCUS SIGNIFICANTLY PREDICT CARDIOVASCULAR EVENTS IN CORONARY PATIENTS WITH TYPE 2 DIABETES A. Leihnerer , A. Muendlein, C. Saely, E. Kinz, P. Rein, A. Vonbank, P. Fraunberger, H. Drexel (Austria)	1067
238	RS6922269 MARKER AT THE <i>MTHFD1L</i> GENE PREDICT CARDIOVASCULAR MORTALITY IN MALES AFTER ACUTE CORONARY SYNDROME J. Hubacek , V. Stanek, R. Poledne, V. Adamkova, J. Pitha (Czech Republic)	1068
239	PHENOTYPE OF VULNERABLE ATHEROSCLEROTIC PLAQUES SHOWS STRONG ASSOCIATION WITH SINGLE NUCLEOTIDE POLYMORPHISM ALLELES OF COMMON RISK VARIANTS FOR CORONARY ARTERY DISEASE R. Furtmair , C. Kuehn, C. König, A. Ekici, L. Klinghammer, S. Achenbach, A. Reis, M. Tauchi, B. Dietel (Germany)	1069
240	GENETIC DETERMINATION OF THE ATHEROSCLEROTIC PLAQUE STABILITY I. Goncharova, M. Golubenko, O. Makeeva, V. Kashtalap , N. Tarasenko, A. Markov, V. Puzyrev (Russia)	1070
241	MAY THE TRANSCRIPTIONAL ACTIVITY OF TRANSFORMING GROWTH FACTOR BETA 1 GENE BE A MARKER FOR EARLY STAGES FOR CORONARY ATHEROSCLEROSIS? J. Dąbek, M. Bałus, J. Piotrkowicz, J. Głogowska-Ligus, Z. Gąsior (Poland)	1071
242	ASSOCIATION OF SERUM CAROTENOID CONCENTRATION WITH SINGLE NUCLEOTIDE POLYMORPHISMS IN <i>APOE</i> , <i>BCMO1</i> , <i>NPC1L1</i> , <i>CD36</i> , <i>GSTP1</i> , <i>ABCG5</i> , <i>FABP1</i> , <i>FABP2</i> AND <i>LIPC</i> GENES A. Mazeikiene , D. Karciauskaite, N. Burokiene, Z. Daunoravicius, Z.A. Kucinskiene, V. Kucinskas (Lithuania)	1072
243	A TOOL FOR QUANTITATIVE MEASUREMENT OF PROATHEROGENIC HETEROPLASMIC MUTATIONS OF MITOCHONDRIAL DNA I. Sobenin , K. Mitrofanov, A. Orekhov (Russia)	1073

Board #		
244	CREATION OF CYBRID LINES OF MONOCYTE ORIGIN WITH HIGH HETEROPLASMY LEVEL FOR MITOCHONDRIAL GENOME MUTATION M.1555G>A	1074
	M. Sazonova, V. Sinyov, A. Ryzhkova, T. Shkurat, N. Demakova, N. Nikitina, I. Sobenin, A. Orekhov (Russia)	
245	DETECTION OF THRESHOLD HETEROPLASMY LEVEL OF MTDNA IN LYPOFIBROUS PLAQUES OF HUMAN AORTIC INTIMA	1075
	A. Ryzhkova, M. Sazonova, V. Sinyov, E. Galitsyna, V. Barinova, N. Nikitina, I. Sobenin, A. Orekhov (Russia)	
246	PROATHEROGENIC MUTATIONS OF MITOCHONDRIAL DNA IN PATIENTS WITH METABOLIC SYNDROME	1076
	I. Sobenin , M. Sazonova, V. Orekhova, A. Zhelankin, A. Orekhov, A. Postnov (Russia)	
247	MITOCHONDRIAL DNA MUTATIONS ASSOCIATED WITH CAROTID ATHEROSCLEROSIS: NGS DATA	1077
	I. Sobenin , A. Zhelankin, Z. Khasanova, V. Orekhova, A. Orekhov, A. Postnov (Russia)	
248	ROLES OF ORPHAN NUCLEAR RECEPTORS IN CARDIAC HYPERTROPHY	1078
	G.H. Eom , D.H. Kwon, S. Shin, Y.U. Lee, E. Kim, N. Choe, Y.S. Nam, H. Kook (Republic of Korea)	
249	ROLE OF GENETIC POLYMORPHISMS AT THE ADIPONECTIN GENE IN REGULATION OF ADIPONECTIN GENE EXPRESSION AND CIRCULATING ADIPONECTIN LEVELS	1079
	L. Kedenko , W. Patsch, I. Kedenko, S.M. Patsch, S. Coassin, F. Kronenberg, F. Krempler, B. Paulweber, C. Lamina (Austria)	
250	LOW LDL-CHOLESTEROL, <i>PCSK9</i> AND <i>HMGCR</i> GENETIC VARIATION, AND RISK OF NEURODEGENERATIVE DISEASE: A MENDELIAN RANDOMIZATION STUDY	1080
	M. Benn , B. Nordestgaard, R. Frikke-Schmidt, A. Tybjærg-Hansen (Denmark)	
251	RELATIONSHIP BETWEEN CIRCULATING MICRORNA-30C WITH LIPOPROTEINS, THEIR CIRCULATORY TRAFFICKING AND EFFECT OF STATINS	1081
	R. Sodi , J. Eastwood, L. Denby, I. Godber, M. Caslake, C.J. Packard (United Kingdom)	
252	HYPERGLYCEMIA INCREASES MICRORNAS IN CIRCULATING HDL FROM ACUTE CORONARY SYNDROME PATIENTS AND MODULATES MIRNA PROCESSING MACHINERY IN HUMAN MACROPHAGES	1082
	L.S. Niculescu , N. Simionescu, G.M. Sanda, M.G. Carnuta, C.S. Stancu, A.C. Popescu, R.M. Popescu, A. Vlad, D.R. Dimulescu, M. Simionescu, A.V. Sima (Romania)	

Board #		
253	IS PLASMA MICRORNA-1909-5P A NEW POTENTIAL BIOMARKER FOR ACUTE MYOCARDIAL INFARCTION	1083
	E. Coskunpinar, H.A. Cakmak , A.K. Kalkan, N. Ozan Tiryakioglu, T. Araz, Z. Ongen (Turkey)	
254	DOES THE GENE EXPRESSION OF NUCLEAR FACTOR KAPPA B IN PATIENTS WITH EARLY STAGES OF CORONARY ATHEROSCLEROSIS DIFFERS FROM HEALTHY INDIVIDUALS	1084
	J. Dąbek, M. Batys, J. Głogowska-Ligus, J. Piotrkowicz, Z. Gašior (Poland)	
255	ENDOTOXIN STRESS-INDUCED APOLIPOPROTEIN E GENE DOWNREGULATION IN MACROPHAGES IS REDUCED BY METFORMIN	1085
	E.V. Fuior, S. Stavri, V.G. Trusca, I.F. Tudorache, M. Simionescu, D. Kardassis, A.V. Gafencu (Romania)	
256	DNA METHYLATION AND COPY NUMBER EVENTS IN ATHEROSCLEROTIC LESIONS	1086
	M. Nazarenko , A. Markov, A. Sleptcov, I. Lebedev, N. Skryabin, O. Barbarash, V. Puzyrev (Russia)	
257	GENE THERAPY: CASE STUDY ON THE FIRST LIPOPROTEIN LIPASE DEFICIENCY PATIENT TREATED WITH ALIPOGENE TIPARVOVEC IN GERMANY	1087
	U. Kassner , T. Hollstein, M. Wühle-Demuth, I. Demuth, E. Steinhagen-Thiessen (Germany)	
258	MAJOR ADIPOKINES AND -420 C>G RESISTIN GENE POLYMORPHISM AS PREDICTORS OF ACUTE ISCHEMIC STROKE SEVERITY AND IN-HOSPITAL OUTCOME	1088
	S. Bouziana, K. Tziomalos , A. Goulas, T.A. Vyzantiadis, A. Panderi, A. Hatzitolios (Greece)	
259	PPAR-ALPHA GENE HAPLOTYPES, ARSENIC EXPOSURE AND RISK OF CARDIOVASCULAR DISEASE	1089
	F.I. Hsieh , S.H. Lin, C.F. Huang, H.Y. Chiou (Taiwan)	

Genetics, Nutrition, Biomarkers: Nutrition

260	ABNORMAL BALGHAM MUNZIQ, A UIGHUR HERBAL MEDICINE FORMULA, HAS BEEN RECENTLY SHOWN TO POSSESS EXTENSIVE CARDIOVASCULAR PHARMACOLOGICAL ACTIVITIES	1090
	D. Xilifu, A. Nurmuhammat , U. Halmurat (China)	
261	EFFECTS OF RAMADAN FASTING ON BIOLOGICAL PARAMETERS IN PATIENTS WITH CARDIOVASCULAR RISK FACTORS	1091
	K. Bouzid , W. Hmadi, Y. Molahedh, H. Ben Ahmed, A. Bartkiz, H. Baccar, J. Abdelmoula (Tunisia)	

Board #		
262	INCREASING ADHERENCE OF CONSUMERS TO DIET & LIFESTYLE CHANGES TO LOWER (LDL) CHOLESTEROL: THE ACT STUDY T.E. SIALVERA , P. Farajian, E.A. Trautwein, A. Papadopoulou, S. Efstathiou, G. Goumas, I. Dimakopoulos, K. Papavasiliou, A. Koutsouri, A. Zampelas (Greece)	1092
263	NUTRITIONAL MODULATION OF THE TOXICITY OF ENVIRONMENTAL POLLUTANTS: IMPLICATIONS IN ATHEROSCLEROSIS B. Hennig , M. Petriello (USA)	1093
264	DIETARY POLYUNSATURATED FATTY ACID AND FRAMINGHAM RISK SCORE : ANALYSIS OF THE KOREA NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (KNHAENS 2013) N.S. Joo , B. Choi, S.I. Jung (Republic of Korea)	1094
265	VITAMIN D STATUS AND BIOMARKERS OF ENDOTHELIAL ACTIVATION IN OBESE INDIVIDUALS B. Ilincic , E. Stokic, M. Djeric, N. Eremic, D. Popovic, Z. Stosic (Serbia)	1095
266	EFFECTS OF VITAMIN E OR LIPOIC ACID SUPPLEMENTATION ON FASTING OXYPHYTOSTEROL CONCENTRATIONS IN SUBJECTS WITH IMPAIRED GLUCOSE TOLERANCE OR TYPE II DIABETES S. Baumgartner , R.P. Mensink, G. Haenen, A. Bast, C. Binder, O. Bekers, C. Husche, D. Lütjohann, J. Plat (Netherlands)	1096
267	EFFECTIVENESS OF A LOW GLYCEMIC INDEX SOLUBLE PLANT POWDER, AS A LOW-CALORIE REPLACEMENT MEAL, IN OVERWEIGHT AND OBESE PATIENTS R. Volpe , A. Bianco, F. Pacioni, E. Schiavetto (Italy)	1097
268	SUSTAINED NUTRITIONAL COUNSELING IMPROVES DIETARY INTAKE IN PARENTS AND THEIR CHILDREN OVER 5 YEARS: THE PEP FAMILY HEART STUDY P. Schwandt , E. Liepold, M. Heinzl-Gutenbrunner, T. Bertsch, G.M. Haas (Germany)	1098
269	SPANISH OBESE CHILDREN AND BIOCHEMICAL PARAMETERS : NON-HEALTHY NUTRITIVE PATTERNS C. Rodriguez-Leal, B. Ruiz-Estevez, E. Segura, I. Tinoco-Racero, N. Caro, C. Perez, I. Garcia-Campanario, A. Perez, M. Quezada-Feijoo, A. Mangas, R. Toro (Spain)	1099
270	LONG-TERM MAGNESIUM SUPPLEMENTATION IMPROVES ARTERIAL STIFFNESS IN OVERWEIGHT AND OBESE ADULTS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INTERVENTION STUDY P.J. Joris , J. Plat, S.J.L. Bakker, R.P. Mensink (Netherlands)	1100
271	THIRTEEN YEAR FOLLOWUP OF MANAGING PATIENTS WITH KNOWN CORONARY ARTERY DISEASE USING A LECTIN-LIMITED, HIGH DOSE OLIVE OIL AND POLYPHENOL RICH DIET S. Gundry , J. Epstein (USA)	1101

Board #		
272	SERUM CONTENT OF OLEIC ACID IS ASSOCIATED WITH HIGHER PLATELET-, ENDOTHELIAL- AND LEUKOCYTE-DERIVED CIRCULATING MICROPARTICLES IN NORWEGIAN NORMOLIPIDEMIC ELDERLY PATIENTS AFTER AN ACUTE MYOCARDIAL INFARCTION G. Chiva-Blanch , V. Bratseth, K. Laake, P. Myhre, H. Arnesen, S. Solheim, E. Berg-Schmidt, L. Badimon, I. Seljeflot (Spain)	1102
273	PLANT STANOL SUPPLEMENTATION LOWERS CETP-MASS, BUT NOT CETP-ACTIVITY, IN HEALTHY SUBJECTS C. Talbot , J. Plat, A. Ritsch, R. Mensink (Netherlands)	1103
274	PLASMA FAT-SOLUBLE VITAMIN AND CAROTENOID CONCENTRATIONS AFTER PLANT STEROL AND PLANT STANOL ESTER CONSUMPTION – A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS S. Baumgartner , R. Ras, E. Trautwein, R.P. Mensink, J. Plat (Netherlands)	1104
275	HAZELNUT-ENRICHED DIET IMPROVES LIPID PROFILE, FATTY ACID COMPOSITION OF ERYTHROCYTES MEMBRANE AND MARKERS OF OXIDATIVE STRESS IN CHILDREN WITH PRIMARY DYSLIPIDEMIA: A RANDOMIZED CONTROL TRIAL V. Deon , C. Del Bo', A. Bosusco, S. Vendrame, M. Porrini, P. Simonetti, O. Guardamagna, P. Riso (Italy)	1105
276	PLASMA PLANT STEROLS AND PLANT STEROL INTAKE VARY ACROSS PLANT-BASED DIETARY PATTERNS AMONG ADULTS FROM NORTH AMERICA D. Luetjohann , K. Jaceldo-Siegl, R. Sirirat, E. Haddad (Germany)	1106
277	LOW-FAT DIETARY TREATMENT ENRICHED WITH SOY PROTEIN IN CHILDREN AFFECTED WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: RESULTS FROM A RANDOMIZED-CONTROLLED PILOT STUDY O. Helk , K. Widhalm (Austria)	1107
278	ANGIOGRAPHIC AND ANTIOXIDANT CHANGES AFTER SUPPLEMENTATION WITH <i>HERACLEUM PERSICUM</i> EXTRACT: RESULTS OF A RANDOMIZED CONTROLLED TRIAL A. Sahebkar, Y. Panahi , H. Taghipour (Iran)	1108
279	DO DIET AND EXERCISE INFLUENCE IN AN ATHLETIC POPULATION?: NEW CLUES OF THE ENTERO-INSULAR AXIS C. Rodriguez-Leal, V. Aragon, I. Tinoco-Racero, E. Segura, B. Ruiz-estevez, E. Sanchez-Orellana, C. Perez, M. Monsalvo Hernando, N. Caro, A. Perez, I. Garcia-Campanario, A. Mangas, R. Toro (Spain)	1109
280	EVALUATION OF ACTUAL CONSUMPTION OF PULSE REDUCING DRUGS IN PATIENTS AFTER ACUTE CORONARY SYNDROME T. Chudinovskikh, E. Tarlovskaya (Russia)	1110

Board #		
281	EFFECTS OF RAMADAN FASTING ON CLINICAL AND BIOCHEMICAL PARAMETERS FOR TYPE 2 DIABETICS K. Bouzid , Y. Molahedh, W. Hmaid, N. Mchirgui, A. Bartkiz, E. Talbi, N. Ben Abdallah, A. Bahlous, J. Abdelmoula (Tunisia)	1111
282	COMPARISON OF EFFECTS OF DIABETIC ENTERAL NUTRITION AND STANDARD ENTERAL NUTRITION ON POSTPRANDIAL LEVEL OF GLYCEMIA, FREE FATTY ACIDS AND GLUCAGON-LIKE PEPTIDE-1. J. Visek , A. Ticha, L. Sobotka, V. Blaha (Czech Republic)	1112
283	REGULATION OF HYPOTHALAMIC GENE EXPRESSION BY DNA METHYLATION IS INFLUENCED BY PARENTAL DIET DURING PREGNANCY AND LINKED TO OFFSPRING'S RISK OF OBESITY I. Khurana, A. Kaspi, M. Ziemann, T. Block , T. Connor, B. Spolding, A. Cooper, P. Zimmet, A. El-Osta, K. Walder (Australia)	1113
284	INORGANIC NITRATE DOES NOT AFFECT GLUCOSE AND INSULIN REGULATION BUT LOWERS OXIDATIVE STRESS IN OBESE ADULTS DURING ACUTE HYPERGLYCAEMIA A. Ashor (United Kingdom)	1114
285	EFFECT OF DIFFERENT ORAL GLUCOSE LOADS ON THE ANTIOXIDANT, INFLAMMATORY AND PLATELET RESPONSE OF HEALTHY VOLUNTEERS A. Mikellidi , D. Papadopoulou - Pozatzidou, E. Bacht, C. Xenaki, S. Antonopoulou, C. Demopoulos, T. Nomikos (Greece)	1115
286	INCREASED BILE ACID AND CHOLESTEROL SYNTHESSES AND PCSK9 IN MORBID OBESITY ARE RAPIDLY NORMALIZED FOLLOWING ACUTE CALORIC RESTRICTION S. Straniero , F. Rosqvist, D. Edholm, M. Sundbom, U. Risérus, M. Rudling (Sweden)	1116
287	SUPPRESSION OF DNA DAMAGE BY DIETARY SUPPLEMENT WHICH CONTAINS PLANT EXTRACTS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL L. Gavriil , C. Argyrou, I. Malagaris, E. Fragopoulou (Greece)	1117
288	IMPACT OF OIL AND PROTEINS DERIVED FROM ANTARCTIC KRILL ON ATHEROSCLEROSIS DEVELOPMENT IN APOEKO MICE C. Parolini , F. Deller, G.S. Ganzetti, S. Manzini, M. Busnelli, M.S. Ramsvik, B. Bjorndal, I. Bruheim, R.K. Berge, G. Chiesa (Italy)	1118
289	INVESTIGATION OF CHIOS MASTIC GUM EFFECT ON METABOLIC PROFILE IN STREPTOZOTOCIN-INDUCED DIABETIC MICE A. Tzani , I. Georgiadis, L.M. Korou, P. Konstantopoulos, G. Agrogiannis, I. Vlachos, I. Doulamis, N. Katsilambros, D. Perrea (Greece)	1119
290	ANTI-HYPERLIPIDEMIC POTENTIAL OF <i>EMBLICA OFFICINALIS</i> IN HIGH FAT FED RATS: UP-REGULATION OF PPARS B. Variya , S. Patel, A. Bakrania (India)	1120

Board #		
291	ENDOTOXIN AND OMEGA-3 FATTY ACIDS EFFECTS ON ENDOTHELIAL OCCLUDIN EXPRESSION IN RAT HEART J. Dienova, K. Frimmel, L. Okruhlicova (Slovakia)	1121
292	LOW-SALT DIET INDUCES ATHEROSCLEROSIS INDEPENDENT OF LOWERING BLOOD PRESSURE IN HYPERTENSIVE MICE S. Catanozi, F. Fusco, D. Gomes, K. Bispo, V. Toledo, D. Barbeiro, V. Capelozzi, L. Furukawa, A.P. Velosa, W. Teodoro, J. Heimann, E. Quintao, M. Passarelli, E. Nakandakare (Brazil)	1122
293	LIQUID FRUCTOSE SUPPLEMENTATION IN WESTERN DIET-FED C57BL/6N MICE CAUSES LIVER CHOLESTEROL LOADING WITHOUT CHANGING CALORIE INTAKE AND BODY WEIGHT M. Baena , G. Sangüesa, M. González, M. Alegret, N. Roglans, J.C. Laguna (Spain)	1123
294	THE IMPACT OF DIETARY SUPPLEMENTATION OF <i>VERNONIA CALVOANA</i> LEAVES ON SERUM LIPID PROFILE AND HAEMATOLOGICAL INDICES IN ALBINO WISTAR RATS G. Egbung , I. Atangwho (Nigeria)	1124
295	FERULIC ACID FROM RICE BRAN ENZYMATIC EXTRACT IS RESPONSIBLE FOR ANTIOXIDANT AND ANTI-INFLAMMATORY ACTIVITIES C. Perez Ternero , B. Bermudez Pulgarin, A. Macia, M.J. Motilva, M.D. Herrera, M. Alvarez de Sotomayor (Spain)	1125
296	POTENTIAL PROTECTIVE EFFECTS OF DUNALIELLA SALINA ON DEHP-INDUCED MMP-2 AND MMP-9 EXPRESSION VIA MAPK, ERK1/2, AKT, AND NF-κB PATHWAYS IN VASCULAR SMOOTH MUSCLE CELLS M.F. Shih, J.Y. Cherng (Taiwan)	1126
297	RIBOSE-CYSTEINE INCREASES GLUTATHIONE-BASED ANTIOXIDANT STATUS AND REDUCES ATHEROSCLEROSIS IN APOE-DEFICIENT MICE S. McCormick , T. Kader, C. Porteous, G. Jones, N. Dickerhof (New Zealand)	1127
298	ANTIPLATELET EFFECT OF THE MAIN TRITERPENOIDS OF AN OLIVE LEAF EXTRACT M. Tsoumani , V. Kontogianni, T. Kellici, T. Mavromoustakos, I. Gerothanassis, A. Tzakos, A. Tselepis (Greece)	1128

Board #

Genetics, Nutrition, Biomarkers: Biomarkers

- 299 URINARY LIVER-TYPE FATTY ACID-BINDING PROTEIN IS ASSOCIATED WITH AORTIC STIFFNESS IN MALE CORONARY ARTERY DISEASE PATIENTS 1129
K. Paapstel, M. Zilmer, J. Eha, K. Tootsi, A. Piir, J. Kals (Estonia)
- 300 IMPACT OF ALKALINE PHOSPHATASE ON IN-HOSPITAL MORTALITY AND 1-YEAR CLINICAL OUTCOME IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION UNDERWENT PRIMARY PERCUTANEOUS CORONARY INTERVENTION 1130
P.C. Oh, K. Woong Chol, M. Jeonggeun, S. Jon, P. Hyun Woo, J. Ho-Jun, K. Tae-Hoon, P. Sang-Don, K. Sung Woo, S. Soon Yong, L. Kyoungsoon, H. Seung Hwan, A. Taehoon, S. Eak Kyun (Republic of Korea)
- 301 THE GENERATION OF MALONDIALDEHYDE-POSITIVE MICROVESICLES 1131
F. Puhm, T. Afonyushkin, C. Binder (Austria)
- 302 LEUKOARAIOSIS IS UNRELATED TO CAROTID STENOSIS OR RISK FACTORS FOR ATHEROSCLEROSIS 1132
B. Muinjonov, E. Giyazitdinova (Uzbekistan)
- 303 VARIABILITY AND TEMPORAL TREND OF VICORDER-ESTIMATED PULSE WAVE VELOCITY 1133
A.K. Mistri, **P. Connell**, T. Robinson (United Kingdom)
- 304 EVALUATION OF OXIDATIVE STRESS INDEX AND ITS CORRELATION WITH TRADITIONAL CARDIOVASCULAR RISK FACTORS, INFLAMMATION AND CAROTID INTIMA MEDIA THICKNESS IN DIABETES AND HEALTHY SUBJECTS 1134
R. Dalan, **H. Liew**, L.L. Goh, X. Gao, D.E. Chew, B.O. Boehm, M.K.S. Leow (Singapore)
- 305 PLASMA ARGININE/ADMA RATIO IS A SENSITIVE RISK MARKER FOR ATHEROSCLEROSIS: SHIMANE COHRE STUDY 1135
S. Yano, Y. Notsu, A. Nagai, T. Nabika (Japan)
- 306 THE ALANINE AMINOTRANSFERASE/ ASPARTATE AMINOTRANSFERASE RATIO PREDICTS FUTURE CARDIOVASCULAR EVENTS IN PATIENTS WITH ESTABLISHED CORONARY ARTERY DISEASE AND HOMA INSULIN RESISTANCE 1136
A. Vonbank, C. Saely, P. Rein, D. Zanolin, **A. Leiberer**, H. Drexel (Austria)
- 307 IMPACT OF AGE ON THE CARDIOVASCULAR EVENT RISK CONFERRED BY HBA1C IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE 1137
A. Vonbank, C. Saely, D. Zanolin, P. Rein, **A. Leiberer**, H. Drexel (Austria)
- 308 PROBNP STRONGLY PREDICTS FUTURE MACROVASCULAR EVENTS IN ANGIOGRAPHIED CORONARY PATIENTS WITH AS WELL AS IN THOSE WITHOUT TYPE 2 DIABETES 1138
P. Rein, C. Saely, A. Vonbank, D. Zanolin, **A. Leiberer**, H. Drexel (Austria)

Board #

- 309 THE LEVEL OF EOSINOPHIL CATIONIC PROTEIN IS CORRELATE WITH SEVERITY OF CORONARY ATHEROSCLEROSIS 1139
F. Byazrova, V. Lopukhova, V. Buza, K. Zykov, Y. Karpov (Russia)
- 310 SIMPLE MORTALITY PROGNOSTIC RISK CALCULATOR FOR PATIENTS WITH ACUTE CORONARY SYNDROME 1140
N. Zagidullin, E. Travnikova, B. Zagidullin, R. Zulkarneev, S. Zagidullin (Russia)
- 311 THE INVERSE ASSOCIATION BETWEEN PLASMA ENDOGLIN LEVELS AND THE SEVERITY OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH STABLE CAD 1141
E. Saita, K. Miura, N. Suzuki, K. Miyata, N. Ikemura, R. Ohmori, Y. Ikegami, Y. Kishimoto, K. Kondo, Y. Momiyama (Japan)
- 312 NITRIC OXIDE-RELATED CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH MAJOR DEPRESSION 1142
A. Meinitzer, S. Zelzer, H. Mangge, **G. Almer**, R. Prassl, O. Amouzadeh-Ghadikolai, C. Robier, A. Baranyi (Austria)
- 313 BRANCHED-CHAIN AMINO ACID PROFILES INDICATE CARDIO METABOLIC RISK INDEPENDENT OF BODY MASS INDEX 1143
S. Zelzer, A. Meinitzer, D. Enko, G. Almer, R. Prassl, H. Mangge (Austria)
- 314 STATUS OF NOVEL CARDIOVASCULAR RISK FACTOR AND CARDIOVASCULAR DISEASE RISK IN AN URBAN DELHI POPULATION-A PILOT STUDY 1144
V. Sharma, R. Shahrawat (India)
- 315 THE ATHEROGENIC PROFILE – PREDOMINANT LIPOPROTEIN PROFILE IN CARDIOVASCULAR DISEASE 1145
S. Prof. Dr. Oravec, K. Dr. Gruber, A. Prof. Dr. Dukat, P. Ass. Prof. Gavornik, L. Ass. Prof. Gaspar, E. Dr. Dostal (Slovakia)
- 316 IMPACT OF NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN AND NEUTROPHIL COUNTS IN THE LUDWIGSHAFEN RISK AND CARDIOVASCULART HEALTH STUDY 1146
R. Woitas, H. Scharnagl, M.E. Kleber, G.E. Delgado, T.B. Grammer, M. Pichler, B.K. Krämer, W. März, **T. Stojakovic** (Austria)
- 317 INCREASED LEVELS OF YKL-40 ARE ASSOCIATED WITH ALL-CAUSE MORTALITY IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE 1147
C.T. Herz, M.L. Tscharre, C. Höbaus, G. Pesau, F. Obendorf, R. Koppensteiner, G.H. Schernthaler (Austria)
- 318 RELATIONSHIP OF INFLAMMATORY BIOMARKERS, PTX3 WITH SEVERITY OF PERIPHERAL ARTERIAL DISEASE 1148
K. Igari (Japan)

Board #		
319	GALECTIN 3 AND THE REMODELING OF ARTERIAL WALL IN PATIENTS WITH METABOLIC SYNDROME V. Ionin , D. Brovin, E. Bazhenova, T. Karonova, E. Polyakova, O. Belyaeva, E. Baranova, E. Shlyachto (Russia)	1149
320	RELATION OF PLASMA COPEPTIN LEVELS AND WAIST CIRCUMFERENCE IN NON-DIABETIC ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION PATIENTS K. Cosansu , A. Turer Cabbar, H.A. Cakmak (Turkey)	1150
321	CORRELATION OF PIGMENT EPITHELIUM-DERIVED FACTOR WITH OXIDATIVE AND INFLAMMATORY MARKERS IN OBESE, NON-DIABETIC PATIENTS I. Juhász, I. Seres , A. Szentpéteri, E.V. Varga, S. Somodi, P. Fülöp, H. Lőrincz, G. Paragh (Hungary)	1151
322	AORTIC VALVE STENOSIS IN ASSOCIATION WITH INFLAMMATORY PROCESS AND BIOCHEMICAL MARKERS. J. Lūriņš , A. Visocka, V. Mackēvičs, P. Tretjakovs (Latvia)	1152
323	ASSOCIATIONS OF LIPOCALIN 2 WITH MARKERS OF INFLAMMATION AND OXIDANT STATUS IN OBESE NON-DIABETIC PATIENTS P. Fülöp , H. Lőrincz, S. Somodi, M. Harangi, I. Seres, G. Paragh (Hungary)	1153
324	FIRST TRIMESTER SERUM CONCENTRATIONS OF AFAMIN ARE ASSOCIATED WITH THE DEVELOPMENT OF PREECLAMPSIA AND GESTATIONAL DIABETES MELLITUS IN PREGNANT WOMEN A. Tramontana , B. Dieplinger, G. Stangl, E. Hafner, H. Dieplinger (Austria)	1154
325	IS RED BLOOD CELL GLUTATHIONE A BETTER MARKER FOR CORONARY ARTERY DISEASE THAN PLASMA GLUTATHIONE? A. Lima, R. Ferin, E. Santos, A. Fontes, S. Ferreira, C. Almeida, D. Martins, J. Baptista, M.L. Pavão (Portugal)	1155
326	CHANGES BRAIN NATRIURETIC PEPTIDE (BNP) LEVELS IMPROVE RISK PREDICTION OF SHORT-TERM MORTALITY FOLLOWING ACUTE MYOCARDIAL INFARCTION COMPARED TO GRACE SCORE: A <i>BRASILIA HEART STUDY</i> SUBANALYSIS L.S. Carvalho , L.A. Bogniotti, O.L. Almeida, J.C. Quinaglia e Silva, L. Trindade, G. Oliveira, A. Sposito (Brazil)	1156
327	GENETIC DETERMINANTS CONTROLLING LIPID DEPOSITS IN DIFFERENT WILD TYPE STRAINS OF ZEBRAFISH (<i>DANIO RERIO</i>) K. Vishnolia , K. Tarhbalouti, P. Ciba, C. Kruse, Z. Aherrahrou, J. Erdmann (Germany)	1157
328	CELL-DERIVED MICROPARTICLES AS MARKERS OF ENDOTHELIAL FUNCTION, INFLAMMATION AND COAGULATION IN PATIENTS WITH SLEEP APNEA-HYPOPNEA SYNDROME: A SYSTEMATIC REVIEW A.J. Vallejo-Vaz , R. Muñoz-Hernández, J. Villar, P. Stiefel (United Kingdom)	1158

Board #		
329	ANTIOXIDANT ENZYMES IN PATIENTS WITH ATHEROSCLEROSIS J. Bogdanska , D. Labudovic, S. Alabakovska, S. Cekovska, K. Tosheska Trajkovska, S. Jovanova (FYR Macedonia)	1159
330	THE NUMBER OF REQUESTS FOR HIGH SENSITIVE TROPONIN I MEASUREMENT AND THE NUMBER OF PATIENTS DIAGNOSED WITH ACUTE MYOCARDIAL INFARCTION L. Majnaric , M. Mikic, S. Bekic, S. Guljas (Croatia)	1160
331	CAROTID ATHEROSCLEROSIS IN A VERY ELDERLY POPULATION: ROLE OF AGEING AND OTHER CARDIOVASCULAR RISK FACTORS F. Spannella, F. Giulietti, G. Cocci, P. Giordano, M. Ricci, E. Espinosa, R. Sarzani (Italy)	1161
332	BIOMARKER DISCOVERY BY PLASMA PROTEOMICS IN FAMILIAL <i>LMNA</i> DILATED CARDIOMYOPATHY I. Izquierdo, D. De Gonzalo-Calvo, V. Llorente-Cortes, I. Rosa, R. Brugada, C. Oscar, A. Perez-Serra, J. Broncano, A. Luna, J. Vazquez-Alfageme, J.R. Gonzalez-Juanatey, A. Mangas, A. Garcia, R. Toro (Spain)	1162
333	BLOOD PRESSURE FLUCTUATIONS AS A LEADING LINK IN THE DEVELOPMENT OF COMPLICATIONS OF ATHEROSCLEROSIS A. Kebryakov , P. Bondarenko, M. Ermina, M. Ivanov, N. Kopylarova, A. Yadernaya, A. Mishchenko (Russia)	1163

Genetics, Nutrition, Biomarkers: Guidelines and Miscellaneous

334	ACC/AHA GUIDELINES SUPERIOR TO ESC/EAS GUIDELINES FOR PRIMARY PREVENTION WITH STATINS: THE COPENHAGEN GENERAL POPULATION STUDY M.B. Mortensen , B.G. Nordestgaard, S. Afzal, E. Falk (Denmark)	1164
335	PREDICTING THE IMPACT OF THE ORIGINAL AND GENERIC ROSUVASTATIN ON DIRECT MEDICAL COSTS FOR SECONDARY PREVENTION IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE A. Merezhanova, E. Tarlovskaya , B. Nechaeva, A. Semenkin, S. Malchikova (Russia)	1165
336	APPLICATION OF A MULTILEVEL HIERARCHICAL MODEL TO CORRELATE TOTAL CHOLESTEROL IN EIGHT DIFFERENT SETTINGS A. Pereira , F. Guarnieri, A.P.Q. Mello, R. Santos Filho, T.L.R. Martinez (Brazil)	1166
337	PROPOSAL OF A NEW APPROACH TO ACCESS CHOLESTEROL RANGES ACCORDING TO DIFFERENT CONDITIONS A. Pereira , F. Guarnieri, A.P.Q. Mello, R. Santos Filho, T.L.R. Martinez (Brazil)	1167

Board #

- 338 PREDICTING FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS' QUALITY OF LIFE AND SELF-ASSESSED HEALTH: ILLNESS BELIEFS, BELIEFS ABOUT MEDICATION, AND HEALTH LITERACY 1168
M. Hagger, J. Pang, G.F. Watts (Australia)
- 339 METABOLIC DISTURBANCES AND RISK OF CANCER IN THE 25 YEARS FOLLOW-UP OF THE "VENTIMIGLIA HEART STUDY" EPIDEMIOLOGICAL PROJECT. 1169
D. Noto, A.B. Cefalù, C.M. Barbagallo, A. Giammanco, F. Fayer, O. Palesano, G.I. Altieri, R. Spina, V. Valenti, M. Pagano, G. Cavera, M.R. Averna (Italy)
- 340 ESTRADIOL TREATMENTS CHANGE THE LIPID PROFILE IN NATURALLY MENOPAUSAL RATS FROM DIFFERENT AGE GROUPS: A THERAPEUTIC POTENTIAL DRUG FOR ATHEROSCLEROSIS 1170
P. Kumar, N. Baquer (India)
- 341 HYPONATREMIA : A RISK FACTOR OF OVERT HEPATIC ENCEPHALOPATHY 1171
S. Khedher, A. Maoui, K. Bouzid, S. Lahiani, A. Bartkiz, M. Salem, J. Abdelmoula (Tunisia)
- 342 HYPONATREMIA, A PREDICTING FACTOR OF MORTALITY IN CIRRHOTIC PATIENT 1172
K. Bouzid, S. Khedher, A. Maoui, S. Lahiani, A. Bartkiz, M. Salem, J. Abdelmoula (Tunisia)
- 343 ANDROGEN-DEPRIVATION THERAPY-INDUCED ATHEROSCLEROSIS IN PROSTATE CANCER: DIFFERENCES BETWEEN GNRH-AGONIST AND ANTAGONIST 1173
W. Duivenvoorden, S. Hopmans, G. Werstuck, J. Pinthus (Canada)
- 344 RELIABILITY ASSESSMENT OF DETERMINATION OF PROCALCITONIN IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS : ABOUT TWO CASES 1174
A. Bartkiz, K. Bouzid, S. Ghezaiel, S. Lahiani, S. Hammami, E. Talbi, A. Zannouri, M. Omrane, S. Barbouche, J. Abdelmoula (Tunisia)

Abstract not Registered

- 400 WHAT WOULD YOU DO IF YOU WERE WITH AN EMBRYO-LIKE GIANT THROMBUS IN THE LEFT VENTRICLE: CASE REPORT 1175
Z. Aktop, E. Coskun (Turkey)
- 401 RELATIONSHIP BETWEEN CAROTID INTIMA-MEDIA THICKNESS AND THE WEIGHT GAIN 1176
T. Alexescu, I. Cheta, M. Handru, V. Negrean, L. Ciumarnean, I. Para (Romania)
- 402 EFFECTS OF OSTEOPATHIC MANIPULATIVE TREATMENT ON VASCULAR AND AUTONOMIC FUNCTIONS IN HEART PATIENTS: A RANDOMIZED, CLINICAL TRIAL 1177
F. Amatuzzi, A. Guervazoni, V. Marães, K. Bousquet, F. Stauffer, M.A. Catai, G. Chiappa, S. Thomaz, C. Nakata, R. Jácomo, M. Lucena, G. Cipriano Jr. (Brazil)
- 403 APPLANATION TONOMETRY PROPOSE DIFFERENT PHYSIOLOGIC MECHANISMS IN CHAGASIC VERSUS ISCHEMIC HEART FAILURE 1178
A. Lima, J. Vilela-Martin, L. Giollo, A.P. Silva, M.E. Otto, S. Marianne, V. Maldaner, G. Chiappa, G. Cipriano, F. Amatuzzi, G. Cipriano Jr (Brazil)
- 404 PREVALENCE OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AND IMPACT ON ACHIEVEMENT OF LIPID TARGETS DURING CARDIAC PREVENTION AND REHABILITATION PROGRAMMES IN ITALY: THE HEREDITY REGISTRY 1179
M. Ambrosetti, **P. Faggiano**, P.L. Temporelli, R. Griffo, R. Pedretti (Italy)
- 405 PEDIATRIC IMT ASSESSMENT 1180
E. Barabesi, O. Guardamagna, F. Abello (Italy)
- 406 RISK FACTORS FOR DEVELOPING DRUG-RELATED PROBLEMS IN PATIENTS WITH CARDIOVASCULAR DISEASES ATTENDING GONDAR UNIVERSITY HOSPITAL, ETHIOPIA 1181
A. Bhagavathula, O. Abubeker, A. Elnour, A. Shehab (Ethiopia)
- 407 CLINICAL UTILITY OF DABIGATRAN IN UNITED ARAB EMIRATES. A PHARMACOVIGILANCE STUDY 1182
A. Shehab, A. Elnour, A. Bhagavathula, S. Al Nuaimi (United Arab Emirates)
- 408 A MUFA RICH-DIET MAY REDUCE LIVER FAT CONTENT IN TYPE 2 DIABETES PATIENTS THROUGH AN ENHANCED POSTPRANDIAL FAT OXIDATION 1183
L. Bozzetto, G. Costabile, G. Annuzzi, D. Luongo, D. Naviglio, V. Cicala, M. Giorgini, C. Piantadosi, E. Griffo, P. Cipriano, A. Giacco, A. Rivellese (Italy)
- 409 AN ASSOCIATION STUDY OF EARLY-LIFE ARSENIC EXPOSURE ON THE RISK OF HYPERTENSION, HYPERGLYCEMIA, AND HYPERLIPIDEMIA 1184
H.Y. Chiou, S.Y. Kuo, F.I. Hsieh (Taiwan)

- 410 NOVEL EFFECTS OF SARCOPENIC OSTEOARTHRITIS ON METABOLIC SYNDROME AND INSULIN RESISTANCE: THE NATIONAL SURVEY 1185
S.M. Chung, M.H. Hyun, H.S. Seo, D.J. Oh, C.G. Park, S.W. Rha, E.J. Kim, H.E. Lim, J.W. Kim, C.U. Choi, J.O. Na, S.K. Lee (Republic of Korea)
- 411 THE EXPRESSION OF MIR-125A-3P IN PERIPHERAL BLOOD MONONUCLEAR CELLS OF PATIENTS WITH CORONARY HEART DISEASE 1186
H.L. Dai, X.L. Yin, J. Xiao, X.F. Guang (China)
- 412 ENDOTHELIAL VASCULAR MOTOR FUNCTION IN ARTERIAL HYPERTENSIVE PATIENTS 1187
N. Demikhova, O. Chernatskaya, Y. Smilianova, O. Smilianova, L. Vynnychenko (Ukraine)
- 413 ROSUVASTATIN COMPARED TO ATORVASTATIN ON LIPID PROFILE AND APOLIPOPROTEIN LEVELS IN DYSLIPIDEMIC PATIENTS WITH ELEVATED LIPOPROTEIN (A) 1188
G. Derosa, D. Romano, A. D'Angelo, P. Maffioli (Italy)
- 414 RESPONSE TO AN ORAL FAT LOAD WITH A NON DAIRY CHEESE CREAM CONTAINING FERMENTED SOYBEAN EXTRACT SOY COMPARED TO A DAIRY CHEESE IN HEALTHY SUBJECTS 1189
G. Derosa, D. Romano, A. D'Angelo, **P. Maffioli** (Italy)
- 415 EFFECTS OF A NON DAIRY CHEESE CREAM CONTAINING FERMENTED SOYBEAN EXTRACT ON LIPID PROFILE AND LIPOPROTEINS IN DYSLIPIDEMIC PATIENTS 1190
G. Derosa, D. Romano, A. D'Angelo, P. Maffioli (Italy)
- 416 EVALUATION OF LIPID-LOWERING THERAPYPREFACINGACUTE CORONARY SYNDROME AND FATSDEPENDING ON CARDIOVASCULARRISK GROUP OF PATIENTS WITH ATRIAL FIBRILLATION 1191
Y. Dorofeeva, **E. Tarlovskaya**, S. Malcnikova (Russia)
- 417 RENOPREDICT: MULTIPLE BIOMARKER APPROACH TO IMPROVE THE PREDICTION OF MORTALITY IN DIALYSIS PATIENTS 1192
C. Drechsler, W. März, V. Krane, B. Kollerits, F. Kronenberg, C. Wanner (Germany)
- 418 PROGRANULIN MAY BE A BIOMARKER OF PERIPHERAL ATHEROSCLEROTIC DISEASE 1193
E. El Eter, H. Al Zamil, L. Al Dokhi, M. Al Omran (Egypt)
- 419 MATERNAL ENDOTHELIUM AND RISKS OF DEVELOPING CARDIOVASCULAR DISORDERS 1194
A. Fatima (Pakistan)
- 420 RELATIONSHIP BETWEEN THE LOCATION OF LESION AND THE ASSOCIATED ARRHYTHMIAS AND CONDUCTION ABNORMALITIES IN PATIENTS WITH MYOCARDIAL INFARCTION 1195
U. Ganiev, S. Khaitov, M. Kenjaev (Uzbekistan)
- 421 ASSOCIATION OF IDEAL CARDIOVASCULAR HEALTH WITH SUBCLINICAL VASCULAR STRUCTURE FUNCTION AND ELASTICITY IN THE COMMUNITY. THE PARIS PROSPECTIVE STUDY 3 1196
B. Gaye, P. Boutouyrie, G. Parati, M.C. Perier, F. Thomas, C. Guibout, B. Pannier, X. Jouent, J.P. Empana (France)
- 422 CARDIOVASCULAR DISEASE RISK ASSESSMENT: TRIGLYCERIDE/ HIGH-DENSITY LIPOPROTEIN VERSUS METABOLIC SYNDROME CRITERIARUNNING TITLE: CVD RISK ASSESSMENT: TG/HDL VERSUS METS 1197
M. Gharipour, M. Sadeghi, P. Nezafati, N. Sarrafzadegan (Iran)
- 423 CARDIOVASCULAR RISK IN CHILDREN: THE CLINICAL RELEVANCE OF EARLY AND TIMELY STRATIFICATION AND TREATMENT 1198
I. Gomes, B. Cardoso, P. Loureiro, M. Bourbon, F. Pinto (Portugal)
- 424 THE MOST COMMON CARDIOVASCULAR RISK FACTORS IN ADOLESCENTS SIGNIFICANT FOR DEVELOPMENT OF CARDIOVASCULAR DISEASES IN ADULTHOOD 1199
G. Grujic Ilic (Serbia)
- 425 CLINICAL OUTCOMES OF MULTI-VESSEL CORONARY ARTERY SPASM ARE COMPARABLE TO SINGLE VESSEL SPASM ON RECOMMENDED OPTIMAL MEDICAL TREATMENTS: KOREA VASOSPASTIC ANGINA REGISTRY DATA ANALYSIS 1200
S.H. Han, O. Pyoung Chun, S. Dong Il, H. Sung Ho, A. Youngkeun, P. Keun Ho, K. Dong Soo, Y. Tae Hyun, C. Dong Ju, S. Jung Won, K. Hyuck Moon, L. Byoung Kwon, G. Hyeon Gheol, R. Seung Woon, J. Sang Ho, B. Sang Hong (Republic of Korea)
- 426 ABNORMAL METABOLIC CONDITIONS ARE INDEPENDENT RISK FACTORS FOR INCREASED ARTERIAL STIFFNESS INDEPENDENT OF AGE AND BLOOD PRESSURE 1201
S.H. Han, H. Hyo Sang, O. Pyung Chun, K. Kwang Kwon (Republic of Korea)
- 427 THE RATIO OF SKELETAL MUSCLE MASS TO VISCERAL FAT AREA IS A MAIN DETERMINANT LINKING CIRCULATING IRISIN TO METABOLIC PHENOTYPE 1202
Y.C. Hwang, P. Cheol-Young, Y. Byung-Soo (Republic of Korea)
- 428 PLATELET RELEASE REACTIONS ARE MODIFIED IN VITAMIN D DEFICIENCY 1203
L. Kasatkina, I. Triakash (Ukraine)
- 429 RESPIRATORY FUNCTION OF LUNGS AT ISCHEMIC HEART DISEASE PATIENTS CONCOMITANT WITH TYPE 2 DIABETES MELLITUS 1204
S. Murtazaev, A. Mansurov, N. Sharapov, K. Khalikulov (Uzbekistan)
- 430 FREQUENCY OF STATIN DOWNTITRATION DURING OPEN LABEL EVOLOCUMAB TREATMENT IN THE OSLER-2 STUDIES 1205
M. Koren, Y. Ma, R. Somaratne, M. Bolognese (USA)


- 431 HIGH LYMPHOCYTES AND LOW MEAN CORPUSCULAR VOLUME ARE ASSOCIATED WITH DIABETES, TRIGLYCERIDE-TO-HIGH-DENSITY-LIPOPROTEIN RATIO AND METABOLIC SYNDROME, IN PATIENTS AT HIGH RISK OF CORONARY ARTERY DISEASE 1206
B. Li, I. Trakarnwijitr, H. Adams, J. Layland, J. Garlick, A. Wilson (Australia)
- 432 NUMBER OF BLOOD PRESSURE MEASUREMENTS NEEDED TO ESTIMATE LONG TERM VISIT-TO-VISIT SYSTOLIC BLOOD PRESSURE VARIABILITY FOR PREDICTING 10-YEAR CARDIOVASCULAR RISK 1207
H.M. Lim, Y.C. Chia, S.M. Ching (Malaysia)
- 433 PLASMA TRIMETHYLLYSINE, TRIMETHYLAMINE-N-OXIDE, CARNITINE AND INCIDENT MYOCARDIAL INFARCTION IN PATIENTS WITH STABLE ANGINA PECTORIS 1208
K.H. Løland, H. Olset, G.F.T. Svengen, H. Schartum-Hansen, E.K. Pedersen, E. Strand, P.M. Ueland, A. Svandal, Ø. Bleie, J.E. Nordrehaug, O. Nygård (Norway)
- 434 IMPACT OF INSULIN RESISTANCE ON CARDIAC AND VASCULAR FUNCTION 1209
G. Manno, S. Novo, R. Russo, D. Buccheri, S. Dell'Oglio, P. Morreale, G. Vitale, G. Novo (Italy)
- 435 ASSOCIATION OF CAROTID ATHEROSCLEROSIS WITH CORONARY ARTERY DISEASE: A RETROSPECTIVE STUDY OF 589 PATIENTS 1210
D. Migliorino, A. Mignano, S. Evola, G. Novo, E. Corrado, S. Novo (Italy)
- 436 NIGELLA SATIVA AND THYMOQUINONE REDUCE GENE AND PROTEIN EXPRESSION OF INTERLEUKIN-6 VIA NUCLEAR FACTOR KAPPA B PATHWAY 1211
F. Mohtar, **H. Nawawi**, T. Rahman, G.R.A. Froemming (Malaysia)
- 437 OXIDATIVE-ANTIOXIDATIVE CHANGES OF LDL, CORONARY HEART DISEASE. SOME ATHEROSCLEROSIS RISK FACTORS AND 7-YEAR UNFAVORABLE LONG-TERM RESULTS IN MEN POPULATION OF NOVOSIBIRSK 1212
Y. Ragino, Y. Polonskaja, S. Malyutina, M. Voevoda (Russia)
- 438 ISCHEMIC HEART DISEASE MORTALITY AND ALCOHOL CONSUMPTION IN THE FORMER SOVIET REPUBLICS: A COMPARATIVE ANALYSIS OF TRENDS 1213
Y. Razvodovsky (Belarus)
- 439 ALCOHOL AND PREMATURE CARDIOVASCULAR MORTALITY IN BELARUS 1214
Y. Razvodovsky (Belarus)
- 440 LEG MINUS ARM PULSE WAVE VELOCITY MEASURED WITH A NEW DEVICE CORRELATES WITH CAROTID FEMORAL PULSE WAVE VELOCITY 1215
S. Rico Martin, J.F. Sánchez Muñoz-Torrero, J.F. Calderón García, J.M. De Nicolás Jiménez (Spain)
- 441 LEG MINUS ARM PULSE WAVE VELOCITY MEASURED WITH A NEW DEVICE CORRELATES WITH CORONARY CALCIUM SCORE 1216
J.F. Sanchez Munoz-torrero, **S. Rico Martin**, J.M. De Nicolas Jimenez, J.F. Calderon Garcia (Spain)
- 442 THE ROLE OF TRACKING OF BCL-2 AND CASPASE-3 ACTIVITY IN PLAQUE EVOLUTION IN ISCHEMIC HEART DISEASE PATIENTS 1217
T. Ristic, V. Djordjevic, V. Cosic (Serbia)
- 443 ASSOCIATION BETWEEN 677C>T POLYMORPHISM WITHIN METHYLENETETRAHYDROFOLATE REDUCTASE GENE AND POSTSTROKE HEMIPARESIS IN POLISH PEDIATRIC PATIENTS 1218
B. Sarecka-Hujar, I. Kopyta, I. Zak, E. Emich-Widera (Poland)
- 444 CAROTID INTIMAL-MEDIAL THICKNESS ,PREVALENCE OF DOCUMENTED CORONARY AND CEREBRAL VASCULAR ATHEROSCLEROTIC DISEASES IN PATIENTS WITH ABDOMINAL AORTIC ANEURISM AND AORTO-ILIAC OCCLUSIVE DISEASE 1219
N. Sharashidze, **I. Botchorishvili**, Z. Pagava (Georgia)
- 445 ENDOTHELIAL FUNCTION ASSESSED BY PERIPHERAL ARTERIAL TONOMOMETRY IS NOT RELATED TO CARDIOVASCULAR RISK SCORE IN HEALTHY SUBJECTS 1220
Y.R. Sigurðardóttir, B.R. Stefánsdóttir, T. Aspelund, G. Þorgeirsson, V. Guðnason, L.B. Kristinsdóttir, **K. Andersen** (Iceland)
- 446 ASSESSMENT OF THE RISK OF PERIPHERAL ARTERIAL DISEASE IN PATIENTS WITH CORONARY ARTERY DISEASE 1221
K. Sirojiddin, A. Alavi, **M. Kenjaev** (Uzbekistan)
- 447 EFFECTS OF HIGH-DOSE ATORVASTATIN PRETREATMENT ON MYOCARDIAL STUNNING IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION 1222
K. Sirojiddin, D. Alimov, B. Mukhamedova, M. Kenjaev, R. Rakhimova (Uzbekistan)
- 448 EFFECT OF LOX1 RECEPTOR GENE EXPRESSION BY ORAL MGSO4 ADMINISTRATION TO CONTROL ATHEROSCLEROSIS IN STZ-INDUCED DIABETIC RAT 1223
N. Soltani, M. Fazali, F. Kharazmi, M. Kamran (Iran)
- 449 THE LEADING RISK FACTORS FOR DEVELOPMENT OF MYOCARDIAL INFARCTION IN ELDERLY PATIENTS 1224
I. Sukmanova, I. Zheltova (Russia)
- 450 GENDER-SPECIFIC RISK FACTORS OF MYOCARDIAL INFARCTION 1225
I. Sukmanova, I. Suspitsyna (Russia)
- 451 THE ROLE OF PSYCHOSOMATIC FACTORS AND HYPODYNAMIA IN THE DEVELOPMENT OF MYOCARDIAL INFARCTION IN MIDDLE AND ELDERLY WOMEN 1226
I. Suspitsyna, I. Sukmanova (Russia)

- 452 EFFECT OF ALPHA-LIPOIC ACID SUPPLEMENTATION ON OXIDATIVE STRESS MARKERS AND ANTIOXIDATIVE DEFENSE IN PATIENTS WITH DIABETIC NEUROPATHY 1227
F. Sztanek, I. Seres, H. Lőrincz, A. Molnár, G. Paragh (Hungary)
- 453 COMPARISON OF EFFECTIVENESS OF DIFFERENT ANTIPLATELET DOSES OF ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROME 1228
T.S. Tan Kurklu (Turkey)
- 454 PREVALENCE OF FAMILIAL HYPERCHOLESTEROLAEMIA IN PATIENTS WITH ISCHEMIC STROKE OR HIGH-RISK TIA 1229
T. Toell, L. Mayer, K. Willeit, M. Knoflach, S. Kiechl, J. Willeit (Austria)
- 455 INTEGRATIVE ANALYSIS OF GENE EXPRESSION NETWORK FOR ATHEROSCLEROSIS-RELATED DISEASE AND NUTRACEUTICALS SUPPLEMENTS 1230
L. Torres, A. Obregon-Gonzalez, V. Padilla-Mata (Mexico)
- 456 EVALUATING MONITORED LEVELS OF TOTAL CHOLESTEROL AND APPLICATION OF LIPID-LOWERING THERAPY IN PATIENTS WITH DIABETES MELLITUS AND ISCHEMIC HEART DISEASE IN AN ACTUALLY AMBULATORY PRACTICE 1231
F. Valikulova, **I. Fomin**, A. Vaysberg, E. Gurvich, M. Boldina (Russia)



84th EAS CONGRESS

May 29 - June 1, 2016
 Innsbruck, Austria



INDEX OF AUTHORS

www.eas2016.kenes.com

A			
Abajo, M.	774	Aguilar-Salinas, C.	945
Abd Alla, J.	1 024	Aherrahrou, Z.	1 157
Abdelmoula, J.	858, 859, 867, 909, 1 091, 1 111, 1 171, 1 172, 1 174	Ahmad, R.	485, 486, 487
Abdijalilova, S.	567, 570, 571	Ahmed, O.	89, 1 027
Abdul Rahman, T.	923	Ahmed, S.	529
Abdul Razak, S.	441, 716, 923, 965, 966	Aigner, E.	662
Abdulgamidov, M.	793	Aikawa, E.	42, 93
Abe, K.	583	Aikawa, M.	42
Abedpour Dehkordi, A.	721	Aittokallio, T.	378
Abello, F.	987, 1 058, 1 180	Ajendra, J.	377
Abeysekera, A.	933	Akhvlediani, M.	844
Abifadel, M.	946	Akin, I.	274
Abubeker, O.	1 181	Akita, N.	375
Achenbach, S.	377, 1 069	Akiyama, T.	855
Achmad, C.	576	Akrami, A.	1 038
Adam, S.	426	Akramova, D.	608
Adamcova, K.	889, 892	Aktan, M.	984
Adamek, V.	724	Akther, F.	508
Adamkova, V.	724, 939, 1 068	Aktop, Z.	1 175
Adamova, I.	687	akturk, F.	826
Adams, H.	723, 1 206	Akyol, T.	984
Adamski, J.	290	Al Dokhi, L.	1 193
Adorni, M.P.	697, 715	al mohy, Y.	798
Adrian, G.	801	Al Nuaimi, S.	1 182
Adyrkhaev, Z.	793, 906, 911	Al Omran, M.	1 193
Adzhemian, N.	606	Al Zamil, H.	1 193
Adzhiev, R.	685	Al-Banna, R.	568
Afanasieva, M.	679	Alabakovska, S.	678, 1 159
Afanasieva, O.	551, 679, 685, 686, 687	Alaeddin, A.	849
Afonyushkin, T.	1 131	Alain, V.D.	283
Afzal, S.	427, 1 164	Alavi, A.	1 221
Ager, M.	942	Albareda, M.	1 012
Aghi, A.	1 029	Albasri, A.	891, 896, 887
AGOP, M.	575	Alberico L, C.	898
Agrawal, D.	82	Alcantara, K.	522
Agrogiannis, G.	1 119	Aldamiz- Echevarria, G.	129
Aguiar, P.	360	Alegret, M.	508, 1 123
Aguilar Salinas, C.	959	Aleksandrova, K.	412
		Alekseeva, O.	1 042
		Alexandra, S.	830
		Alexescu, T.	913, 992, 1 176
		Alexiev, A.	914, 917
		Alfaro, F.	428
		Ali, A.M.	485
		Ali, M.Z.	820
		Alimov, D.	1 222
		Alkaaby, W.	666
		Allanov, R.	752
		Allaoui, F.	691
		Allen, R.	268
		Almaghraby, A.	587, 790
		Almagro, F.	358, 921, 975
		Almeida, C.	1 155
		Almeida, O.L.	1 156
		Almendros Afonso, T.K.	972
		Almer, G.	894, 1 142, 1 143
		almusawi, A.	887, 891, 896
		alnafakh, H.	887, 891, 896
		Alomar, S.Y.	849
		Alonso Moreno, F.J.	866
		Alonso, R.	945
		Alshehry, Z.	314
		Alt, K.	223
		Altamura, S.	102
		Altieri, G.I.	954, 1 169
		Altieri, P.	553
		Altunkeser, B.	984
		Alvarez de Sotomayor, M.	381, 1 125
		Alvarez-León, E.	356
		Alvarez-Llamas, G.	129
		Alves, A.C.	943, 945, 955, 985, 1 060
		Alves, R.	799
		Amadio, P.	222
		Amarchand, R.	767
		Amatuzzi, F.	1 177, 1 178
		Ambadapadi, S.	107, 1 028
		Ambrosetti, M.	1 179
		Amigó, N.	393, 434
		Amin, R.	126, 655
		Ammirati, E.	616
		Ammori, B.J.	426
		Amores-Arriaga, B.	505
		Amouzadeh- Ghadikolai, O.	1 142
		An, G.J.	512
		An, K.J.	739
		Ananthaseshan, S.	800

Anastassopoulou, J.	813	Arnaboldi, L.	450, 491, 1 058	Averna, M.	11, 121, 232, 388, 954	Baptista, J.	1 155	Bayly, G.	969, 1 051	Berbée, J.	90, 556
Andelković, K.	122	Arnesen, H.	1 102	Averna, M.R.	1 169	Baquer, N.	847, 1 170	Bays, H.	389	Berdikulov, J.	572, 1 018
Andersen, K.	1 220	Arnhard, K.	477	Ayami, S.	63	Barabesi, E.	987, 1 180	Bazhenova, E.	740, 890, 1 149	Berestetskaya, Y.	687
Andersen, O.M.	332	Arnoldi, A.	386	Ayaori, M.	693, 700, 1 049	Baragetti, A.	238, 616, 898, 1 063	Bchir, N.	867	Berg Schmidt, E.	654
Andor, M.	1 043	Arola, J.	915	Ayca, B.	777	Baragetti, I.	898	Bea-Sanz, A.M.	115	Berg-Schmidt, E.	1 102
Andrea, B.	707	Aronov, D.	982, 998	Azevedo, O.	1 061	Baral, B.	659	Bea, A.	765	Berg, G.	995
Andrea, T.	475	Arpad Faludi, A.	972	Azevedo, P.	1 061	Barale, C.	276	Bea, A.M.	971	Berge, K.E.	1 055
Andreasen, A.	654	Arrondo, J.L.R.	637	Azevedo, S.	955, 985	Baranova, E.	740, 890, 1 149	Beacham, L.	61	Berge, R.K.	363, 1 118
Andreasen, J.J.	654	Arroyo, D.	774	Azinheira, J.	843	Barany, P.	47	Becher, B.	127	Bergheanu, S.	244
Andréasson, A.C.	446	Arsenault, B.	119, 387	B		Baranyi, A.	1 142	Becher, T.	274	Bergthaler, A.	307
Andreev, V.	830	Arsiwala, T.	127	Babadjanov, B.	861	Barbagallo, C.M.	954, 1 169	Beck, W.	641	Berkovich, O.	890
Angeles-Martínez, J.	356, 528	Artemieva, N.	687	Babets, A.	577	Barbarash, O.	520, 573, 1 086	Bednarska-Makaruk, M.	956	Berliner, S.	563
Angelin, B.	336	Artemova, A.	850	Baccar, H.	858, 859, 867, 1 091	Barbeiro, D.	1 122	Beer, J.H.	127	Bermudez Pulgarin, B.	1 125
Angelino, D.	697	Artemova, N.	613	Baccara-Dinet, M.T.	463	Begum, H.	223	Behl-Gilhotra, R.	362	Bernabeu, C.	494
Angelopoulou, S.	794	Arutyunova, M.	860	Bachti, E.	1 115	Barbieri, S.	222	Behrendt, M.	446	Bernatova, I.	565, 1 015
Ann, T.	855	Arzt, C.	448	Badimon, L.	1 102	Barbouche, S.	1 174	Bekers, O.	1 096	Bernelot Moens, S.	81, 106, 547
Annucci, G.	1 183	Asai, A.	886	Baena-Fustegueras, J.A.	425	Barichello, M.	725	Bekiari, E.	617, 618	Bernelot Moens, S.J.	627
Ansheles, A.A.	947	Asaji, M.	63	Baena, M.	508, 1 123	Barinova, V.	1 075	Bekic, S.	1 160	Bernfur, K.	408
Ansmidte, O.	694	Asako, K.	457	Baeten, D.	547	Barkas, F.	432, 753, 928, 977, 978, 1 003	Bekkering, S.	106, 270, 556	Bernhard, J.	291
Anto Michel, N.	224, 470	Ascaso, J.	975	Baetta, R.	472	Barlow, C.	314, 449	Belaglia, J.	859	Bernhard, D.	477
Antonini-Canterin, F.	599	Ascaso, J.F.	358, 766, 921	Bagheri, B.	566	Barnes, E.	314	Belevich, I.	204	Bernini, F.	692, 697
Antonopoulou, S.	1 115	Ascerov, N.	793	Bahlous, A.	1 111	Barrett, P.H.R.	394, 471	Belhadj Hassen, H.	858	Berrougui, H.	110
Antonov, K.	917	Ashavaid, T.	1 062	Baila-Rueda, L.	115, 765, 971	Barros, P.	985	Bell, D.	355	Berta, E.	612
Antonucci, A.	725	Ashford, M.	289	Bairaktari, E.	709	Bartelt, A.	48	Belovol, A.	869	Bertaccini, D.	283
Antonucci, A.	725	Ashor, A.	1 114	Bakker, L.	90	Barter, P.	119	Beltowski, J.	468	Bertagnin, E.	671, 749
Antunes, H.	1 061	Aspelund, T.	1 220	Bakker, S.J.L.	1 100	Barter, P.J.	342	Beltrami-Moreira, M.	93	Berteotti, M.	616
Antunes, M.	993	Ass. Prof. Gaspar, L.	1 145	Bakrania, A.	1 120	Bartkiz, A.	867, 909, 1 091, 1 111, 1 171, 1 172, 1 174	Belyaeva, O.	1 149	Berti, A.	616
Anwar, A.	658	Ass. Prof. Gavornik, P.	1 145	Balakhonova, T.	551, 582, 679	Bartolini-Gritti, B.	307	Ben Abdallah, N.	858, 859, 867, 909, 1 111	Bertinaria, M.	1 017
Aoyama, N.	747	Asselbergs, F.W.	240	Balandina, Y.	776	Baruah, P.	40, 459	Ben Ahmed, H.	858, 859, 867, 1 091	Bertocco, S.	725, 1 029
Aprami, T.	576	Asset, G.	246	Balashenka, N.	581	Bassani Borges, J.	972	Benaiges, D.	1 012	Bertolini, S.	121
Aquila, G.	1 022	Assinger, A.	448	Balatskaya, N.	606	Bassendine, M.	369	Benczur, B.	414	Bertsch, T.	368, 438, 1 098
Aquilera, J.	434	Assmann, G.	66	Balder, W.	413	Bast, A.	1 096	Benghozi, R.	714	Beshay, M.	797
Aragon, V.	1 109	Astanina, K.	492	Balla, J.	467	Battista, S.	692	Benitez, S.	876	Besseling, J.	99, 359, 974
Aragona, C.O.	496, 506, 588, 675, 1 050	Astrakov, S.	644, 964	Ballantyne, C.	61	Baudin, B.	638	Benito-Vicente, A.	637, 985, 1 056	Betriu, À.	774
Arakelyan, A.	1 047	Astrakova, K.	644, 964	Baltatzki, M.	736	Bauer, R.	622	Benn, M.	123, 429, 1 080	Bezrodnii, V.	811
Araz, T.	1 083	Atanasovska, B.	113	Balu, N.	248	Baumann, S.	274	Benoist, J.F.	691	Bhagavathula, A.	1 181, 1 182
Arca, M.	121	Atangwho, I.	1 124	Batys, M.	1 071, 1 084	Baumgartner, J.	418	Bento, D.	1 061	Bhasin, P.	780
Arefieva, T.	551, 679	Atkin-Smith, G.	489	Balzarotti, G.	431	Baumgartner, S.	1 096, 1 104	Benvegnù, L.	1 029	Bianco, A.	1 097
Ares Jr., M.	269	Attia, N.	638	Ban, Z.	285	Bautembach-Minkowska, J.	956			Bianconi, V.	865
Argimón, J.	944	Auer, S.	662	Banach, M.	259, 672	Bawelski, M.	585			Biazzi, C.	898
Argyrou, C.	1 117	Aurelian, S.M.	609, 792	Bañares, V.	945					Bielicki, J.	641
Arisaka, O.	390	Auwerx, J.	127	Banchs, H.L.	553					Biemann, R.	412
Ariza, M.J.	428	Auzky, O.	515, 871	Bao, W.	119					Biessen, E.	704
Armitage, J.M.	51	Avdeeva, I.	590							Biessen, E.A.L.	269
		Averkova, A.	785							Bigolin, P.	725

Bilgic, E.	294
Billon-Crossouard, S.	648
Binder, C.	1 096, 1 131
Binder, C.J.	36, 39, 307
Biolo, M.	1 029
Birner-Gruenberger, R.	440
Birringer, M.	383
Bispo, K.	1 122
Bittar, R.	365
biyik, I.	826
Björkbacka, H.	290
Bjorndal, B.	1 118
Blackhurst, D.	710
Blaha, M.	1 026
Blaha, V.	976, 1 026, 1 112
Blanco-Vaca, F.	358, 384, 944
Blangero, J.	449
Blauw, L.	113
Bleie, Ø.	1 208
Bliden, K.P.	417
Block, T.	1 113
Blom, D.	976
Bobabekov, A.	851, 861
Bobbert, T.	989
Bobronnikova, L.	869
Bocskai, R.	414
Bode, .	224
Bode, C.	306, 470
Bodor, M.	612
Boehm, B.O.	1 065, 1 134
Boeing, H.	412
Boekholdt, S.M.	119, 627, 680
Boeva, O.	848
Bogdan, M.	509
Bogdanska, J.	678, 1 159
Bogniotti, L.A.	1 156
Boileau, C.	946
Boldina, M.	1 231
Bolognese, M.	1 205
Bolotov, I.	510
Bonacina, F.	222, 458
Bonaldo, A.	725
Bonavita, E.	458

Bondarenko, P.	568, 728, 783, 850, 1 163
Bonde, Y.	376
Boni, M.	849, 865
Bono, E.	1 034
Bonora, E.	312
Boodhoo, D.	536
Boon, M.	90, 111, 556
Boonen, H.	513
Boosani, C.	82
Boot, C.	988
Borén, J.	241, 10, 43, 647
Borges Jr, N.	799
Borggreffe, M.	274
Borghi, C.	380, 391, 671, 749
Bornstein, S.R.	682
Borowiec, M.	828
Borrillo, R.M.	938
Borst, J.	305
Boshtam, M.	721
Bosisio, R.	386
Bossano Prescott, E.	74, 322
Bossone, E.	599
Bosusco, A.	987, 1 105
Bot, I.	307
Botchorishvili, I.	1 219
Botet-Montoya, J.P.	921
Botha, S.	619
Botirova, L.	571
Bottazzi, B.	222
Bottiglieri, T.	277
Boucher, P.	283
Boudes, P.	244
Boudier, C.	283
Boulanger, C.M.	200
Boura, P.	617, 618
Bourantas, C.V.	399
Bourbon, M.	360, 730, 857, 901, 943, 945, 955, 959, 985, 993, 996, 1 060, 1 198
Bousquet, K.	1 177

Boutouyrie, P.	1 196
Bouziana, S.	794, 1 088
Bouzid, K.	858, 859, 867, 909, 1 091, 1 111, 1 171, 1 172, 1 174
Bouzourene, K.	1 019
Bowden, K.	455
Boya, P.	346
Boyd, M.	498
Boydens, C.	856
Boyle, J.R.	743
Boytssov, S.	629, 640, 663
Bozorboev, M.	744
Bozzetto, L.	1 183
Bozzolo, E.	616
Brænne, I.	240
Brambilla, M.	1 034, 1 039
Brambilla, S.	450
Brandon, J.	95
Brandt, A.	956
Bratseth, V.	1 102
Brea, Á.	975, 766
Breierova, E.	565, 1 015
Brenner, M.B.	88
Bridges, I.	462, 1 009
Brisson, D.	660, 1 053
Brito Jr, F.	781
Brix, S.	285
Broncano, J.	1 162
Broncel, M.	518, 828
Brouwer, I.	56
Brovin, D.	1 149
Brown, A.	349
Brown, M.J.	207
Brown, M.S.	134
Browning, M.	916
Bruckert, E.	1, 53, 69, 229, 244, 365, 946, 976
Brugada, R.	1 162
Bruheim, I.	1 118
Brunet, A.	463
Bubnova, M.	982, 998
Buccellati, C.	1 017
Buccheri, D.	1 209

Buchal, R.	517
Buchmann, N.	935, 989
Buda, V.	1 043
Bueno, M.	944
Buerger, C.	305
Bugrova, O.	613, 848
Bujo, H.	330
Bülw Eschen, R.	654
Bundalo, M.	373
Bürger, C.	128
Burger, F.	407
Burko, N.	603, 1 044
Burlachuk, V.	750
Burnett, J.	355
Burnett, J.R.	471
Burokiene, N.	1 072
Bursill, C.	704
Burtceva, E.	1 023
Busacca, P.	803
Busnelli, M.	131, 372, 511, 639, 689, 1 118
Buszko, M.	351
Buurman, W.	113
Buza, I.	513
Buza, V.	782, 1 139
Byazrova, F.	1 139
Byazrova, S.	473, 853
Byoung Kwon, L.	1 200
Byung-Soo, Y.	1 202
Bzduch, V.	1 052
C	
Cabré, C.	434
Cacciagiù, L.	995
Caceres Gestoso, A.	615
Cadamuro, J.	662
Cahill, P.	476
cai, A.	490
Cai, G.	447
Caidahl, K.	521
Cairo, V.	496, 506, 675, 1 050
Caixàs, A.	944
Cakmak, H.A.	893, 1 083, 1 150
Calabrese, G.	416
Calabresi, L.	47, 121, 650, 963, 1 058

Calabrò, P.	924, 925
Calderón García, J.F.	1 216, 1 215
Caliceti, C.	1 022
Caligiuri, G.	451, 474
Calosing, C.	118
Camejo, G.	47
Camera, M.	1 033, 1 034, 1 039
CAN, L.H.	951
CANET-SOULAS, E.	292
Cannon, C.P.	463
Canton, G.	248
Cantor, R.M.	241
Canzano, P.	1 033, 1 034, 1 039
Cao, L.L.	94
Capelozzi, V.	1 122
Capisizu, A.	609, 792
Capobianco, E.	825
Cappellano, G.	351
Capra, V.	1 017
Caramelli, B.	863
Carbone, F.	407
Cárdenas Vázquez, A.	945
Cardoso-Saldaña, G.	528
Cardoso, B.	1 198
Cardoso, G.	356
Cardouat, G.	281
Carerj, S.	599
Caretta, N.	725
Carey, A.	223
Carletti, R.	549
Carmeliet, P.	27, 140
Carnuta, M.G.	701, 1 082
Caro Gomez, N.	614
Caro, N.	888, 904, 1 099, 1 109
Carreau, V.	946
Caruso, D.	267
Caruso, S.	489
Carvalho, L.S.	1 156
Casale, M.	803
Cascales, M.D.M.	508
Casetta, I.	407
Caslake, M.	1 081
Cassorla, G.	545

Castagna, A.	626, 656
Castelnuovo, S.	963
Castelo-Branco, M.	592
Castiglioni, L.	1 039
Castillo Bernal, F.J.	835, 836, 837
Castro Jiménez, M.C.	835, 836, 837
Catai, M.A.	1 177
Catanozi, S.	698, 1 122
Catapano, A.	16, 19, 24, 26, 30, 132, 250, 252, 256, 258, 315, 321, 324, 472
Catapano, A.L.	222, 238, 347, 392, 431, 458, 554, 616, 1 063
Cattan-Lévy, L.	474
Cattaneo, F.	450
Caussey, C.	625, 1 057
Cavalca, V.	530
Cavalot, F.	276
Cavera, G.	1 169
cebe, H.	826
Cecchetti, A.	825
Cecconi, D.	626, 656
Cedó, L.	384
Cefalù, A.B.	121, 954, 1 169
Čejková, S.	535
Cekovska, S.	1 159
Cena, C.	1 017
Cenarro, A.	115, 202, 765, 971
Cermenati, G.	267
Ceska, R.	962
Chabowski, A.	1 016
Chae, I.H.	1 032
Chae, J.K.	493
Chaisri, U.	569
Chalikias, G.	657
Chalubinski, M.	518, 801, 828
Chamney, S.	650
Chan, D.	355, 471
Chan, D.C.	394
Chan, J.	357, 885

Chan, K.C.	247
Chang, S.Y.	560
Channon, K.	62
Chao, T.H.	773
Chapman, J.	4, 8, 213
Charakida, M.	719
Charania, S.	502
Charrière, S.	625, 1 057
Chasiotis, V.	736
Chatzigeorgiou, M.	762
Chatzizisis, Y.	93
Chaudhary, R.	417
Chaudhuri, S.	933
Chawla, P.	1 062
Chechetkin, A.	598, 602
Chee, Y.J.	881
Chen, C.H.	348
Chen, H.	107, 1 028
Chen, H.T.	341
Chen, Y.	524
Chen, Y.R.	453
Cheng, L.I.	1 009
Cheol-Young, P.	1 202
Chernatskaya, O.	1 187
Cherng, J.Y.	1 126
Chernyavina, A.	604, 605
Chestnutt, J.	650
Cheta, I.	1 176
Chéteveaux, M.	648
Chew, D.	1 065
Chew, D.E.	1 134
chi, Y.	524
Chia-Yin, T.	1 064
Chia, Y.C.	1 207
Chiappa, G.	1 177, 1 178
Chiara, M.	372
Chiariello, C.	626
Chicheva, M.	1 066
Chiesa, G.	131, 372, 511, 639, 689, 1 118
Chillarón, J.J.	1 012
Ching, S.M.	1 207
Chinnasamy, P.	94
Chiong, C.	881
Chiou, H.Y.	1 089, 1 184
Chiu, T.Y.	341
Chiva-Blanch, G.	1 102

Chlebus, K.	956
Chlopicki, S.	494
Chmara, M.	956
Chmelik, Z.	778
Cho, D.H.	884
Cho, H.C.	404, 564
Cho, J.Y.	738, 739, 1 004
Cho, K.H.	559, 646, 829
Cho, S.A.	738, 739
Cho, Y.K.	1 006
Cho, Y.S.	1 032
Choe, N.	350, 371, 1 078
Choi Wan, J.F.	994
Choi, B.	1 094
Choi, B.G.	1 000
Choi, B.H.	404, 564
Choi, B.M.	439
Choi, C.U.	120, 1 000, 1 185
Choi, J.H.	761
Choi, J.Y.	1 001
Choi, M.H.	120
Choi, Y.J.	244
Chong-Yang, D.	902
Chora, J.	945
Chora, J.R.	955, 1 060
Chou, C.H.	919
Chowdhury, M.M.	743
Christen, T.	293
Christie, B.	677
Christoffersen, C.	717
Christomanou, H.	1 059
Chroni, A.	652
Chrysohoou, C.	762, 846
Chuang, C.K.	210
Chudinovskikh, T.	1 110
Chung, S.M.	1 185
Chung, W.Y.	512, 1 010
Chvostova, M.	568
Ciba, P.	1 157
Cibickova, L.	635
Cicala, V.	1 183
Cicero, A.	380, 391, 1 022
Cicero, A.F.G.	671, 749

Cifani, N.	544, 549, 550
Ciffollilli, S.	383
Cigankov, V.	911
Cioroch, M.	62
Cipollari, E.	697
Cipriano Jr, G.	1 178
Cipriano Jr., G.	1 177
Cipriano, G.	1 178
Cipriano, P.	1 183
Ciumarnean, L.	1 176
Civeira, F.	115, 202, 358, 765, 766, 921, 971, 975
Clapp, W.	107
Clara, J.	48
Clouet Foraison, N.	634
Coassin, S.	1 079
Cobbaert, C.	578, 634
Cocci, G.	1 161
Cochran, B.	342
Codogno, I.	474
Colaço, I.	742, 941
Cole, A.	93
Colhoun, H.	308, 310
Colhoun, H.M.	246, 463
Colima Fausto, A.G.	959
Colli, S.	530
Colombo, G.	1 034
Coman, S.	775
Compte, M.T.	434
Conceição, R.	920
Concin, H.	770
Cong, K.	651
Connell, P.	1 133
Connor, T.	1 113
Conrad, D.H.	307
Constantin, G.	705
Constantin, G.I.	802
Constantinou, C.	688
CONTAMIN, H.	292
Conte, C.	496
Cook, E.	209
Cook, E.C.L.	664
Cooper, A.	1 113
Cooper, J.	934, 952

Corrado, E.	1 210
Corral, P.	945, 995
Corrao, G.	261
Corrêa-Giannella, M.L.	863
Corrêa-Giannella, M.L.C.	698
Correia, E.	1 061
Correig, X.	434
Corsini, A.	472, 337, 347, 419, 450, 491
Cosansu, K.	1 150
Cosentino, N.	530
Cosic, V.	1 217
Coskun, E.	1 175
Coskunpinar, E.	1 083
Cosor, O.C.	769
Cossette, M.	696
Costabile, G.	1 183
Coughlin, P.A.	743
Couture, P.	976
Craiem, D.	754
Cramb, R.	666, 930
Crasborn, M.	556
Crespin Crespin, M.	835, 836, 837
Crestani, M.	267
Cristaldi, A.	995
Cristescu, C.	1 043
Croce, K.	93
Croyal, M.	648
Cruciani, G.	383
Cruz, D.	742, 941
Cuchel, M.	430
Cuenca, N.	938
Cuesta Torres, L.F.	342
Cuevas, A.	945
Curran, J.	449
Cursaru, A.	805
Cutul, L.	222
Czarnecka, D.	931
Cziraki, A.	414
D	
D'Acerno, L.	924, 925
D'Addato, S.	380, 391, 671, 749
D'Agostini, L.	671

D'Angelo, A.	1 188, 1 189, 1 190
D'Angelo, R.	346
D'Erasmus, L.	121
D'Agostini, L.	749
da Silva Rodrigues, E.	972
Dąbek, J.	1 071, 1 084
Dadabaeva, N.	744, 752
Dafnis, I.	652
Dahl, M.	834
Dähnhardt, D.	411
Dai, H.L.	1 186
Dalan, R.	881, 1 065, 1 134
Dalla-Riva, J.	408
Dallegri, F.	407
Dallinga-Thie, G.	97, 260, 331
Dallinga-Thie, G.M.	286, 1 054
Dalton, N.	455
Damasceno, N.R.T.	814
	417
Dancer, M.	1 057
Danielsson, A.	290
Danzl, K.	477, 504
Darabi, M.	104, 711
Das, S.	676
Dascalescu, R.	609, 792
Daskalopoulou, S.S.	452
Dasseux, J.L.	714
Datta, H.	988
Dattilo, G.	803
Daunoravicius, Z.	1 072
Dauteuille, C.	104, 711
Davel, A.	827
Davi, G.	1 033
David, J.	1 028
Davidson, M.	464
de Boer, H.	269
de Boer, J.F.	804
De Boever, P.	502, 514
de Bruin, R.G.	269, 483
de Bruin, T.	464
De Fabiani, E.	267
De Faria, E.	922, 983
de Feyter, P.J.	399
De Geest, B.	126, 655

de Gonzalo Calvo, D.	202
De Gonzalo-Calvo, D.	1 162
de Graaf, J.	244, 270
de Gregorio, C.	803
De los Santos Moreno, A.	615
De Meyer, G.R.Y.	198, 201, 343
De Michele, M.	544
de Mutsert, R.	113, 293
De Nicolás Jiménez, J.M.	1 216, 1 215
de Roos, A.	113, 293
De Soysa, M.	936
De Vries, J.K.	413
de Vries, T.	399
De Vuono, S.	849, 865
de Winther, M.	556, 704
Deanfield, J.	719
Dechkhajorn, W.	569
Deev, A.	734, 735
Degoricija, V.	707
Dehoux, M.	474
Del Bo', C.	1 105
Del Core, M.	82
Del Porto, F.	544, 549, 550
Delatour, V.	634
Delbridge, L.	223
Deleanu, M.	488, 523, 701
Delgado-Coello, B.	64
Delgado, G.E.	1 146
Dell'Oca, N.	945
Dell'Oglio, S.	1 209
Dell'Oca, N.	961
Dellera, F.	131, 372, 511, 639, 689, 1 118
Demakova, N.	1 074
Dembinska-Kiec, A.	546, 1 016
DeMicco, D.	119
Demikhova, N.	1 187
Demina, E.	890
Demina, M.	911
Demir, M.	984
Demircioglu, S.	984
Demopoulos, C.	1 115

Demuth, I.	935, 1 087	Dixon, S.	401	Dritsa, V.	813	El Khoury, P.	946	Esteve, E.	944	Fellin, R.	121
Denby, L.	1 081	Djaramshi, A.	269	Drogari, E.	1 059	El-Kersh, A.	797	Estruch-Alrich, M.	876	Fellnerova, A.	939
Dengxuan, W.	902	Djeric, M.	870, 1 095	Dronca, E.	913	El-Osta, A.	35, 239, 265, 1 113	Etxebarría, A.	637, 985, 1 056	Fenyo, I.M.	527
Denisenko, M.	1 042	Djokic, V.	821	Dropinski, J.	796, 840, 841	El-Zidy Ibrahim, N.	989	Eun Seoung, L.	552	Ferin, R.	1 155
Denney, L.	667, 910	Djordjevic, V.	1 217	Drosos, I.	657	El-Zidy-Ibrahim, N.	935	Evangelakos, I.	437	Ferlin, A.	725
Dent, R.	392, 462, 1 009	Dlouha, D.	683, 939	Druina, L.	598, 602	Elbahey, M.	587, 790	Evdokimenko, A.	500, 598, 602	Fernandez-Hernando, C.	312
Deon, V.	1 105	Dobrolubov, M.	613	Du, X.J.	223	Elbaz, M.	346	Even, G.	474	Fernández-Higuero, J.A.	637
Derfler, K.	960	Doganci, S.	294	Du, Y.	339	Elbitar, S.	946	Everson, F.	514	Fernández-Miró, M.	1 012
Derosa, G.	1 188, 1 189, 1 190	Doi, M.	586	Duarte, T.	742	Elena, M.	555	Evola, S.	819, 1 210	Fernández, E.	774
Descamps, O.	976	DOKMEN, H.	951	Ducla Soares, J.L.	742, 941	Elfaleh, E.	909	Evola, V.	819	Fernandez, G.	961
Deschildre, C.	474	Dokoza Terešák, S.	707	Duijs, J.	269	Eligini, S.	530	Exarchos, T.	818	Ferrari, A.	267
Deshpande, A.	1 062	Doktorova, M.	622	Duivenvoorden, W.	1 173	Elisaf, M.	432, 709, 753, 928, 977, 978, 1 003	Ezhov, M.	606, 685, 686, 687	Ferrari, R.	1 022
Deshpande, S.	1 009	Dolezelova, E.	480, 494	Dumfarth, J.	477	Elizova, N.	532, 632	Ezhov, M.V.	947	Ferreira, G.S.	698
Després, J.P.	3, 7, 212, 214, 387	Domagala, T.	796, 840, 841, 1 008	Dumitrescu, A.	769, 1 046	Ellena, R.	651	F		Ferreira, J.	592
Dhar, I.	779	Domingo-Espin, J.	408	Dumitriu, I.E.	40, 459	Ellis, K.	355	Fabres Machado, U.	531	Ferreira, M.J.	592
Dhawan, V.	722	Domingues, C.	592	Dunaeva, A.	907	Elmou, A.	1 181, 1 182	Fabris, F.	725, 1 029	Ferreira, R.	843
Dhyani, A.	472, 554, 1 063	Dominguez, C.	972	Dunaway, C.	94	Emese, T.	475	Faccini, J.	346	Ferreira, S.	1 155
Di Bella, G.	803	Crespo Hirata, R.		Durmus, R.	984	Emich-Widera, E.	1 218	Fagg, W.S.	269	Ferrer, R.	425
DI CATALDO, V.	292	Dominguez Crespo Hirata, T.	972	Durrington, P.N.	426	Emma, K.	47	Faggiano, P.	1 179	Ferri, L.	544, 549, 550
Di Filippo, M.	1 057, 625	Donato, P.	592	Dürschmied, D.	470	Empana, J.P.	1 196	Fahey, T.	980	Ferri, N.	337, 347, 419, 472
di Gioia, C.	549	Dong Il, S.	1 200	Duta-Mare, M.C.	443	Emukhvari, M.	844	Fainardi, E.	407	Figuera, R.	944
di Giuseppe, R.	412	Dong Ju, C.	1 200	Dwivedi, O.	354	Endo, Y.	1 049	Fajkusova, L.	973	Fikrova, P.	480, 494
Di Taranto, M.D.	958	Dong Soo, K.	1 200	Dwyer, T.	758	Engberg, S.	209	Falcou, A.	544	Filatova, A.	551
Diana, S.	476	Doni, A.	222	Dybvig, A.	684	Enguita, F.	996	Falk, E.	1 164	Filipovic, N.	818
DiCioccio, A.T.	463	Donn, R.	426	E		Enikő, B.	475	Fang-I, H.	453, 1 064	Filippova, A.	497
Dickerhof, N.	1 127	Donners, M.	704	Eak Kyun, S.	1 130	Enko, D.	1 143	Faraj, T.	525	Filou, S.	688
Didangelos, T.	736	Doppler, C.	477	Eastwood, J.	1 081	Eom, G.H.	350, 1 078	Farajian, P.	1 092	Fimiani, F.	924, 925
Didenko, Y.	783	Dorel P., S.	913	Ebenbauer, B.	418	epstein, J.	1 101	Farhoudi, M.	600	Fiorelli, S.	530
Dienova, J.	1 121	Dorofeeva, Y.	1 191	Ebtehaj, S.	47, 699	Erdmann, J.	240, 1 157	Faria, F.	742, 941	Fiorini, E.	267
Dieplinger, B.	460, 882, 1 154	Dostal, E.	541, 720	Eckardt, K.U.	278	Eremic, N.	1 095	Faria, R.	1 061	Fischer, A.	333
Dieplinger, H.	17, 23, 31, 411, 1 154	Douglas, G.	62, 349	Edelberg, J.	246	Eretova, Z.	683	Farinaro, E.	67	Fischer, A.W.	88
Dietel, B.	377, 1 069	Douglas, S.	969	Edholm, D.	1 116	Eriksson, M.	89, 1 027	Fatima, A.	1 194	Fischer, M.	418
Dikkers, A.	47	Doulamis, I.	382, 1 119	Edsfeldt, A.	290	Eriksson, M.J.	521	Faus-Dader, M.J.	866	Fischer, S.	403, 682
Dimakopoulos, I.	1 092	Downie, P.	969, 1 051	EFFECTL Study Investigators, G.	461	Eriksson, P.	521	Faussner, A.	305	Fiser, A.	94
Dimitriou, T.	977, 978, 1 003	Doytcheva, P.	719	Efstathiou, S.	1 092	Ermina, M.	568, 728, 850, 1 163	Favari, E.	697, 1 058	Fitzpatrick, E.	476
Dimova, L.G.	804	Dr. Dostal, E.	1 145	Egabung, G.	1 124	EROGLU, Z.	953, 951	Favretto, S.	599	Flachs, P.	889, 892
Dimulescu, D.R.	1 082	Dr. Gruber, K.	1 145	Eggertsen, G.	376	Erridge, C.	525	Fayer, F.	954, 1 169	Fletcher, J.	545
Dincgez Cakmak, B.	893	Dragut, R.	805	Eha, J.	1 129	Erskine, N.	757	fazali, M.	1 223	Flores Le-Roux, J.A.	1 012
Dissanayake, S.	994	Drechsler, C.	1 192	Ehrenborg, E.	203	Erturk, M.	893	Febbraio, M.	223	Flugelman, M.Y.	932
Dito, R.	544, 549, 550	Dressel, A.	396	Eichmann, T.	374	Escalante, F.	959	Fedak, D.	903	Fogacci, F.	391, 671, 749
		Drettwan, D.	90	Eichmann, T.O.	284	Escolá-Gil, J.C.	384	Federico, V.	818	Föger, B.	219
		Drexel, H.	366, 731, 732, 733, 839, 879, 883, 991, 1 067, 1 136, 1 137, 1 138	Ekici, A.	1 069	Espinosa, E.	1 161	Felder, T.	662	Fomin, I.	1 231
				El Asmar, Z.	283	Essop, F.	502				
				El Bounkari, O.	291						
				El Eter, E.	1 193						

Fonseca, R.	843	Fuentes, L.	651	Garaffa, C.	924, 925	Genser, B.	699	Giyazitdinova, E.	597, 726, 787, 788, 831, 979, 1 025, 1 132	Gonzalez-Calero, L.	129
Fontes, A.	1 155	Fuertes, R.	434	Garaffa, E.	924, 925	Gentili, A.	849			Gonzalez-Juanatey, J.R.	1 162
Foody, J.	389	Fuor, E.V.	527, 1 085	Garces-Horna, V.	505	Georgiadis, I.	1 119	Gkougourelas, I.	617, 618	González-Santos, P.	428
Forbes, C.	1 009	Fujita, Y.	636	García Fuertes, D.	835, 836, 837	Georgousopoulou, E.	762, 846	Gkourogianni, A.	1 035	Gonzalez, F.J.	375
Foresta, C.	725	Fülöp, P.	435, 467, 702, 1 151, 1 153	García García, H.M.	399	Gerard, W.	449	Glazunova, A.	860	González, M.	1 123
Fort, J.M.	425	Furtmair, R.	1 069	García León, A.	384	Gerdes, N.	128, 305	Glei, M.	383	Goodwin, M.	694
Fortini, F.	1 022	Furukawa, L.	1 122	García Arnés, J.	428	Gergei, I.	396	Glerup, S.	332	Goossens, P.	704
Fortunato, G.	958	Furusyo, N.	579, 610, 727, 755, 756, 905	García-Campanario, I.	1 099, 1 109	Gerothanassis, I.	1 128	Głodzik, J.	585	Górska, J.	546, 1 016
Foryst-Ludwig, A.	285	Fusaro, M.	1 029	García-Casares, N.	428	Gesheff, M.G.	417	Ġogowska-Ligus, J.	1 071, 1 084	Gordts, P.	44, 46
Fotiadis, D.	818	Fusco, F.	1 122	García-García, I.	938	Ghabili, K.	817	Godber, I.	1 081	Gorzdelak-Pabis, P.	518
Fotiadis, D.I.	399	Futema, M.	952	García-Vaz, E.	114	Ghaleb, Y.	946	Göderle, L.	307	Gorzdelak, P.	801, 828
Fourie, C.M.	619	G		García, A.	1 162	Ghanaati, H.	580, 607	Goebel, G.	503	Goswami, N.	502, 514
Fournier, N.	691	Gabbasov, Z.	473, 853	García, I.	904	Gharipour, M.	1 197, 806	Goedecke, J.	710	Gottschling, K.	333
Fraass, U.	396	Gabcova, D.	1 052	Garcia, D.	745	Gheysens, O.	655	Goedeke, L.	312	Goudevenos, I.	1 035
Fragopoulou, E.	1 117	Gabriel, D.	827	Garjani, A.	566	Ghezzi, M.	725	Goeritzer, M.	284, 622	Goulas, A.	1 088
Fragoso, J.M.	356	Gabrielyan, D.	850	Garlanda, C.	222, 458	Ghoneem, A.	587	Goettsch, C.	42	Goumas, G.	1 092
Fragouli, S.	382	Gabrielyan, L.	850	Garlaschelli, K.	238, 616, 898, 1 063	Ghorashi, S.	817	Goh, L.L.	1 065, 1 134	Gouni-Berthold, I.	669
France, M.	426	Gaetano, C.	218, 221	Garlick, J.	723, 1 206	Ghosh Laskar, M.	336	Gojazadeh, M.	817	Gouveia, C.	843
Franceschini, G.	650	Gafane, L.	619	Garnier, J.M.	283	Giacco, A.	1 183	Gojkovic-Bukarica, L.	821	Govorin, A.	807
Franck, G.	93	Gafarov, V.	795	Garolera, M.	938	Giacobbe, C.	958	Gojković, T.	436, 741, 874	Gracia, M.	754, 774
Franco-Cereceda, A.	521	Gafarova, A.	795	Garzillo, C.	781	Giammanco, A.	1 169	Goldberg, R.	757	Græsdal, A.	684
Frank, S.	374, 422, 499, 707	Gafencu, A.V.	527, 1 085	Gasbarrino, K.	452	Giannella Neto, D.	863	Goldstein, J.A.	401	Graham, I.	319
Franz, R.	48	Gagulin, I.	795	Gasco, A.	491	Giannini, S.	1 029	Goliasch, G.	541	Graier, W.F.	284
Franzese, C.J.	417	Gaita, D.	769, 1 046	Gasior, Z.	1 071, 1 084	Gibbs, J.	976	Golledge, J.	362	Grallert, H.	313
Frascaroli, C.	276	Gaita, L.	769, 1 046	Gasko, R.	635	Gieger, C.	313	Golubenko, M.	1 070	Grammer, T.	396, 937
Fraser, B.	758	Galabova, G.	245	Gaspar, G.	857	Gijbels, M.	704	Gomaraschi, M.	47, 386, 1 058	Grammer, T.B.	409, 1 146
Fraunberger, P.	1 067	Galicia, U.	1 056	Gaspar, L.	541	Gilham, D.	118	Gomes, A.	592	Granata, A.	450
Freiberger, T.	962, 973	Galimskaya, V.	589, 590	Gasperikova, D.	1 052	Gill, S.	897	Gomes, D.	1 122	Grandi, E.	380, 671
Frias, M.	710	Galitsyna, E.	1 075	Gast, K.B.	293	Gillard, J.	349	Gomes, D.J.	698	Gratsiansky, N.	735
Fried, S.	281	Gall, J.	365	Gaston, A.T.	474	Gillery, P.	634	Gomes, E.I.	983	Grau, J.	944
Frikke-Schmidt, R.	237, 1 080	Gallagher, J.	114	Gaudet, D.	59, 244, 247, 300, 353, 660, 669, 1 053	Gimenez-Lopez, I.	505	Gomes, I.	1 198	Grechanyk, N.	497
Frimmel, K.	565, 1 015, 1 121	Galli, F.	383			Gingell, R.	936, 990	Gomes, M.	270	Greco, D.	692, 715
Frisdal, E.	365	Gallieni, M.	1 029	Gautier, E.L.	104	Ginsberg, H.	714	Gomez -Villarejo, D.	904	Green, S.	673
Fritsch, H.	22	Gallivan, A.	952	Gavriil, L.	1 117	Giollo, L.	1 178	Gomez, M.F.	114	Grenkowtiz, T.	935
Fritsche, A.	412	Galy, B.	102	Gavrilova, N.	629, 640, 663	Giordano, P.	1 161	Gonçalves, C.	799	Greter, M.	127
Fritz, J.	770	Gandra, S.R.	392, 1 009			Giorgini, M.	1 183	GONCALVES, F.	522	Greve, J.W.	113
Froemming, G.A.	485, 486, 487	Ganesan, M.	986	Gaye, B.	1 196	Giovannini, M.	671, 749	GONÇALVES, I.	290	Griffin, J.	969
Froemming, G.R.A.	1 211	Ganiev, U.	1 195	Gebhard, C.	696	Gipe, D.A.	247	Gonçalves, L.	592	Griffo, E.	1 183
Froio, A.	511	Ganiyev, U.	571	GELOEN, A.	292	Giral, P.	365	Goncharova, I.	1 070	Griffo, R.	1 179
Froněk, J.	562, 535	Ganzetti, G.S.	131, 372, 511, 639, 689, 1 118	Gelosa, P.	1 039	Giralt, M.	434	González García, J.R.	959	Grigore, L.	238, 616, 898, 1 063
Fruttero, R.	491			Genest, J.	714	Girona, J.	393	González Marines, D.	959	Grigorie, M.	705
Fruituoso, J.	730, 901	Gao, X.	881, 1 065, 1 134	Genis, A.	514	Giulietti, F.	1 161			Grimm, M.	351
Fu, J.	5, 9, 113	Gapon, L.	538, 557	Genkel, V.	1 042	Giuseppe Danilo, N.	238, 898			Gritskevich, A.	906, 911
Fuentes, J.	1 028			Gennaro, A.	818					Grivel, J.C.	548, 1 047

Groen, A.K.	210, 622	Gurvich, E.	1 231	Harvey, D.	952	Hernandez, M.	522	Hong, S.P.	1 001	Huisman, H.W.	619
Gromova, E.	795	Gustafsen, C.	332	Haschke-Becher, E.	662	Hernández, M.P.	478	Hong, T.J.	761	Huitema, L.	704
Grönlund, C.	596	Gustafsson, P.	203	Hashida, T.	1 002	Herrera, M.D.	381, 1 125	hongyu, W.	809	Hukkanen, M.	915
Groop, L.	354	Gustafsson, U.	1 027	Hatsukami, T.	248	Herz, C.	507, 772	Hoogenboezem, M.	481	Hulett, M.	489
Groothoff, J.	968	Gutiérrez-Cardo, A.	428	Hattori, T.	899	Herz, C.T.	771, 1 147	Hoogeveen, R.	677	Humphries, S.	238, 934
Grosu, L.	805	Guyer, K.E.	417	Hatzitolios, A.	617, 618, 736, 1 088	Herz, J.	41, 91, 283, 469	Hooper, A.	355	Humphries, S.E.	952
Gruca, A.	1 016	Gyrasis, C.	399	Hatzitolios, I.A.	794	Hetjens, S.	274	Hopmans, S.	1 173	Hung-Yi, C.	453, 1 064
Gruchala, M.	956	H		Haupt, C.	708	Heywood, S.	223	Hoppstaedter, J.	492	Hung, M.Y.	455, 673
Grufman, H.	290	Ha, K.H.	729	Havik, S.	547	Hiebert, S.W.	267	Hörauf, A.	377	Hunter, W.	82
Grujić Ilić, G.	1 199	Haas, G.M.	368, 438, 1 098	Havulinna, A.S.	410	Hilgendorf, I.	224, 306, 470	Hori, M.	949	Hur, S.K.	420
Grune, J.	285	Haase, M.	448	Hayashi, J.	579, 610, 727, 755, 756, 905	Hilvo, M.	131, 275, 639	Horinek, A.	962	Hurme, R.	275, 639
Gu, J.	654	Habibinejad, H.	1 011	Hayashi, T.	484, 838, 854	Hinterreiter, F.	882	Horn, J.	651	Hurt-Camejo, E.	47
Guaita, S.	393	Haddad, E.	1 106	Hayes, P.D.	743	Hippe, D.	248	Horner, D.S.	372	Husche, C.	1 096
Guang, X.F.	1 186	Haenen, G.	1 096	He, B.	83	Hiraoka, Y.	1 002	Host, L.	283	Husebye, E.S.	249
Guaraldi, F.	958	Haerdtner, C.	306	Heeren, J.	88, 331, 333, 334	Hirata, H.	700	Hottiger, M.O.	127	Hussain, M.M.	622
Guardamagna, O.	958, 987, 1 058, 1 105, 1 180	Hafner, E.	1 154	Heestermans, M.	1 040	Hirata, K.	338	Hou, J.	873	Hutcheson, J.	42
Guardigli, M.	1 022	Hagemeyer, C.	223, 273	Heikkilä, H.	354	Hirayuki Hirata, M.	972	Hou, L.	342	Hutchings, A.	942
Guarini, P.	626, 656	Hagger, M.	1 168	Heikkilä, T.	690	Hisakawa, N.	561	Hovingh, G.K.	119, 286, 359, 392, 627, 680, 974, 976	Huth, C.	411
Guarnieri, F.	981, 1 166, 1 167	Hahn, R.T.	492	Heimann, J.	1 122	Hjellestad, I.D.	249	Hou, J.	873	Hutten, B.	968
Guðnason, V.	1 220	Haikal, A.	910	Hein, L.	306	Hmaldi, W.	1 091, 1 111	Hovigh, K.	331	Huttl, M.	661
Guedes, J.	1 061	Hakimjavadi, R.	476	Heine, M.	88, 333	Ho-Jun, J.	1 130	Hovland, A.	466, 864	Huynh, K.	314
Guerado Espinosa, I.	835, 836, 837	Hakovirta, H.	423	Heinemann, A.	1 030	Ho, H.H.	348	Howanietz, M.T.	771	Hwang, S.H.	738, 739
Guerin, M.	365	Hale, A.	62	Heinle, H.	821	Ho, J.	426	Hoxha, M.	1 017	Hwang, Y.C.	1 202
Guerra, A.	1 060	Halliday, C.	118	Heinonen, S.	446	Ho, Y.C.	348	Hrelia, S.	1 022	Hyeon Gheol, G.	1 200
Guerrasio, A.	276	Hallström, S.	499	Heintjes, E.	760	Höbaus, C.	507, 771, 772, 1 147	Hryachkova, O.	573	Hyo Sang, H.	1 201
Guerrini, U.	458	Halmurat, U.	1 090	Heinz, K.	477	Hobbs, H.	32	Hrzenjak, A.	374	Hyuck Moon, K.	1 200
Guertin, M.C.	696	Halon, D.A.	932	Heinzel-Gutenbrunner, M.	1 098	Hobkir, J.	916	Hsieh, F.I.	1 089, 1 184	Hyun Woo, P.	1 130
Guervazoni, A.	1 177	Haltmayer, M.	882	Helk, O.	960, 1 107	Hoefler, G.	284, 622	Hsin-Chiao, W.	453	Hyun, M.H.	1 000, 1 185
Guibout, C.	1 196	Hama, S.	426	Henkel, V.V.	947	Hoeke, G.	90	Hsu, L.W.	105, 1 014	I	
Guillas-Baudouin, I.	104	Hamed, W.	797	Hennig, B.	385, 1 093	Hoeksema, M.	704	Hsu, P.L.	445	Iaconi, M.	549, 550
Guizoni, D.	827	Hammad, B.	587, 790	Henstridge, D.	223	Hoes, A.A.W.	317, 326	Hu, M.	357, 885	IBAROLLA, D.	292
Gulevskaya, T.	500, 500, 598, 602	Hammami, S.	1 174	Hentze, M.W.	102	Hoffman, J.	385	Hua-Long, L.	902	Ibarretxe, D.	393
Guljas, S.	1 160	Han, S.H.	1 200, 1 201	Heras, M.	393	Hoffmann, M.M.	409	Huang, C.F.	1 089	Ibe, N.	641
Gulkevych, O.	811	Handru, M.	1 176	Herder, C.	411	Hofker, M.	113	Huang, C.F.	1 089	Iborra, R.T.	698
Gunasekar, P.	82	Hanna, E.	650	Hereder, A.	129	Høgh, A.	834	Hubacek, J.	724, 939, 962, 1 068	Ibrahim, Z.	923
Gundry, S.	519, 1 101	Harada-Shiba, M.	121, 344, 390, 949, 976	Herings, R.	760	Hoh, B.P.	681	Hubacek, J.A.	871	Idzior-Waluś, B.	903, 931, 912
Guo, W.	534	Harada, A.	338	Hermann, M.	649	Hohensinner, P.	418	Huber, K.	418, 541	Igari, K.	1 148
Gurbel, P.A.	417	Harangi, M.	435, 467, 612, 702, 1 153	Hernandez Flores, T.	959	Hollstein, T.	989, 1 087	Hübner, M.	377	Igelseder, B.	503
Gurevich, V.	400	Hargrave, G.	498	Hernández-Mijares, A.	866	Holmes, E.	988	Huby, T.	104	Igländ, J.	957
Gurevich, V.S.	718, 947	Harrison, S.C.	743			Holven, K.B.	957	Huckova, M.	1 052	Ijäs, P.	354
Gurlek, A.	715	Hart, L.	969			Honarpour, N.	465, 976	Hudiakova, N.	842	Ikaida, M.	620
Gurses, K.M.	294, 715	Hartgers, M.L.	359, 974			Hong, B.	339, 695	Hughes, A.D.	312	Ikeda, Y.	561
Gursky, O.	630, 708	Hartvigsen, K.	307			Hong, S.J.	738, 739, 1 004	Hughes, L.	988	Ikegami, Y.	537, 1 141
								Hughes, S.G.	669	Ikemura, N.	537, 1 141
								Hui, D.	331	Ikewaki, K.	693, 700, 1 049
										Ikhlef, S.	110

Ikonen, E.	915
Iлина, N.	606
Ilicic, B.	870, 1 095
Illyes, M.	414
Ilyin, A.	860, 900
Imamura, S.	621
Imbalzano, E.	496, 506, 588, 675, 803, 1 050
Ina, K.	484, 838, 854
Inazu, A.	948
Inci Coskun, E.	893
Ingrassia, V.	954
Inoue, Y.	855
Ionin, V.	1 149
Iqbal, J.	622
Irina, O.	538
Irino, Y.	338
Isermann, B.	412, 669
Ishida, T.	338
Ishizuka, M.	1 049
isikssacan, N.	826
Ismail, N.H.	485
Ismail, Z.	965
Isomäki, A.	915
Ito, H.	586
Ito, M.	1 049
Ito, Y.	620
Ivandaev, A.	793, 906, 911
Ivanoshchuk, D.	832, 929, 940, 964
Ivanov, M.	568, 728, 783, 850, 1 163
Ivanova, O.	548, 555
Ivanova, R.	914, 917
Iwaniec, T.	840, 841, 1 008
Izquierdo, I.	1 162

J

Jaceldo-Siegl, K.	1 106
Jacob-Lenet, M.P.	474
Jacobs, F.	126
Jácomo, R.	1 177
Jafari Dinani, N.	721
Jafari, R.	918
Jakic, B.	351
Jalkanen, J.	423

Jalkanen, S.	423
James, R.	710
Janabaev, B.	851, 861
Janczura, M.	796, 840, 841, 1 008
Jänis, M.	131
Jannes, C.	945
Janovska, P.	889
Jarauta, E.	765, 971
Jargin, S.	808
Jaroch, J.	599
Jasik, P.	903
Jauhiainen, M.	623, 111, 286, 354, 378, 384, 442, 652, 690
Jay-Christian, H.	476
Jayaraman, S.	630, 708
Jazet, I.	90
Jean-Charles, G.	555
Jebari, S.	1 056
Jelev, D.	917
Jelić Ivanović, Z.	122
Jelić-Ivanović, Z.	436, 741, 874
Jeney, V.	475
Jenkinson, F.	988
Jensen, E.	389
Jensen, G.B.	427
Jensen, S.L.	332
Jenty, M.	283
Jeon, S.M.	1 004
Jeong, S.J.	420, 444
Jeonggeun, M.	1 130
Jezkova, K.	494
Ji-Yan, C.	902
Jianbin, Z.	902
Jiang, L.	489
Jiang, Y.	822, 824
Jiang, Y.D.	764
jjinbo, L.	809
Jinga, M.	805
Jingwen, L.	337
Jiyan, C.	490
Jo, Y.H.	560
Johansson, J.	118
Jokitalo, E.	204
Joksic, J.	122
Jon, S.	1 130

Jones, A.F.	666
Jones, G.	1 127
Jones, J.	889
Jones, R.	362
Jönsson-Rylander, A.C.	446
Jonung, T.	249
Joo, H.J.	738, 739, 1 004
Joo, N.S.	1 094
Joosten, L.	106, 270
Joosten, S.	556
Jörg, H.	48
Jørgensen, A.B.	237
Joris, P.J.	1 100
Josa-Laorden, C.	505
Jouent, X.	1 196
Jovanova, S.	678, 1 159
Ju Won, S.	552
Juhász, I.	1 151
Jukema, J.W.	245, 269, 293
Jukema, W.	113, 446, 578
Jula, A.	354
Julius, U.	403, 682
Julve, J.	384, 425, 944
Jumaa, H.	307
Jung Won, S.	1 200
Jung, C.H.	405, 737
Jung, S.I.	1 094
Juno, C.	245
Jurado, M.A.	938
Justiniano, H.	283
K	
Ka Wah, L.	952
Kaaroud, H.	909
Kader, T.	1 127
Kaiser, P.	789
Kajani, S.	534
Kakaletsis, N.	794
Käkelä, R.	378
Kakino, A.	636
Kalbousi, S.	638
Kaili, J.	522
Kalimanovska-Oštrić, D.	741, 874
Kalkan, A.K.	1 083

Kalkavouri, A.	736
Kalminaovska Oštrić, D.	122
Kals, J.	1 129
Kamenihina, I.	454
Kamiyama, Y.	1 041
Kammoun, H.	223
Kamphuisen, P.W.	413
Kamran, M.	1 223
Kang, B.G.	1 004
Kang, D.O.	120
Kanjuh, V.	821
Kanthasamy, V.	897
Kapoor, S.	780
Kapusta, M.	903, 912, 931
karakaya, O.	826
Kararigas, G.	76
Karasek, D.	635
Karatzas, K.	794
Karavia, E.	688
Karbiener, M.	894
Karciauskaite, D.	1 072
Kardassis, D.	130, 206, 437, 527, 1 085
Kari, A.	220
Karimova, M.	209
Karlafti, E.	736
Karlsson, T.	367
Karolina, R.	801
Karonova, T.	1 149
Karpe, F.	85, 86, 89
Karpov, A.	454, 526, 542
Karpov, Y.	782, 1 139
Karppinen, S.M.	915
Kasatkina, L.	1 203
Kaser, S.	503
Kashtalap, V.	573, 1 070
Kasichayanula, S.	976
Kasim, S.	923
Kasim, S.S.	966
Kasimdjanova, G.	744
Kasimov, U.	851, 861
Kaski, J.C.	40, 459
Kaspi, A.	1 113
Kassner, U.	935, 989, 1 087

Kastelein, J.	119, 244, 390
Kastelein, J.J.	463
Kastl, S.	541
Katano, H.	593
Katarzyna, G.	801
Kathiresan, S.	946
Katkó, M.	702
Kato, Y.	579, 610, 727, 755, 756, 905
Katsilambros, N.	1 119
Katsilambros, .	382
Kaudewitz, D.	312
Kauhanen, D.	275
Kaun, C.	418, 720
Kawakami, K.	855
Kawasaki, M.	642
Kawase, R.	63, 395, 653
Kawashiri, M.A.	948
Kaya Kocabas, E.	953
Kaya, E.	294
Kayikcioglu, M.	953
Kayikcioglu, M.	951, 984
Kaynar, L.	984
Kazan, H.	269
Kazdova, L.	421, 661, 877, 895
Kebyakov, A.	728, 1 163
Kedenko, I.	1 079
Kedenko, L.	411, 503, 662, 1 079
Keenan, A.	889
Kelleher, C.	1 031
Kellici, T.	1 128
Kenjaev, M.	567, 570, 571, 1 195, 1 221, 1 222
Kenjaev, S.	570
Kenny, R.A.	980
Kerr, A.	62
Kershaw, E.	285
Kessler, T.	240
Keun Ho, P.	1 200
Keun-Hwa, J.	552
Keyserling, C.	714
Khaitov, S.	1 195
Khalikulov, K.	1 204
Khalil, A.	110
Khallou-Laschet, J.	474

Khan, F.	114, 289
Khanal, M.P.	659
Kharazmi, F.	1 223
Khasanova, Z.	1 077
Khaw, K.T.	627, 680
Kheder, R.	916
Khedher, S.	1 171, 1 172
Khessairi, N.	859
Khiri, K.	858, 859, 867, 909
Khokhlov, L.	750
Khokhlov, R.	750
Khoury, É.	247
Khromova, A.	591, 603
Khurana, I.	239, 1 113
Kianpour, P.	918
Kiechl, S.	312, 411, 1 229
Kiemer, A.K.	492
Kikas, P.	657
Kikuchi, H.	457
Kim, B.	751
Kim, B.W.	761
Kim, C.G.	398
Kim, C.J.	999
Kim, D.J.	729
Kim, D.W.	398
Kim, E.	1 078
Kim, E.J.	120, 1 000, 1 185
Kim, E.M.	350, 371
Kim, H.C.	729
Kim, H.J.	1 004
Kim, H.K.	120
Kim, H.L.	512, 1 010
Kim, H.S.	1 010
Kim, J.M.	552
Kim, J.W.	120, 1 000, 1 185
Kim, J.Y.	559
Kim, K.C.	404, 564
Kim, K.S.	1 001
Kim, M.A.	512, 999, 1 010
Kim, M.H.	398
Kim, M.J.	404, 560, 564
Kim, N.H.	120

Kim, S.	405, 444, 493, 737	Kobayashi, J.	621	Koshurnikova, M.	582	Kruse, C.	1 157	Kyounghoon, L.	1 130	Larsson, M.	601
Kim, S.G.	398	Kobayashi, M.	1 041	Kostaki, S.	794	Krychtiuk, K.	541	Kypreos, K.	688	Laskaris, A.	846
Kim, S.H.	512, 1 010	Kobayashi, T.	63, 395	Kostara, C.	709	Kubalska, J.	956	Kyselak, O.	950	Lass, A.	284
Kim, S.M.	631	Kocabas, E.K.	951	Kostner, G.	135, 263, 960	Kubo, T.	338	Kyung-Hyun, C.	631	Laufs, U.	50, 381, 624
Kim, W.H.	493	Kochueva, M.	869	Kotoulas, C.	813	Kucinskas, V.	1 072	L		Laura, T.	118
Kim, Y.C.	1 004	Kocourkova, L.	1 005	Kotseva, K.	73, 116, 769	Kucinskiene, Z.A.	1 072	La Spada, M.P.	954	Lauridsen, B.	211
Kim, Y.G.	1 032	Kocyigit, D.	294, 715	Kotula-Horowitz, K.	796, 840, 841, 1 008	Kuehn, C.	1 069	Laajala, T.D.	378	Laurila, P.P.	111
Kim, Y.O.	439	Koenig, W.	397	Kotur-Stevuljevic, J.	436	Kühn, C.	377	Laake, K.	1 102	Laurinavicius, A.	920
Kim, Y.S.	493, 564	Kofoed, K.	211	Koike, T.	1 021	Kuiper, J.	307, 760	Laakso, M.	241	LAVENNE, F.	292
Kimura, S.	456	Koib, T.	1 021	Kolb-Lenz, D.	443	Kuivenhoven, J.A.	241, 287, 331, 413	Laaksonen, R.	131, 275, 639	Lavie, G.	932
Kimura, Y.	457	Kolb, D.	622	Kolb, D.	622	Kukharchuk, V.V.	947	Labib, M.	933	Lavier, J.	1 019
Kingwell, B.	223, 314, 362	Koliakos, G.	736	Kollerits, B.	411, 1 192	Kulbak, V.	1 023	Labrador-Barba, E.	866	Lavoie, J.M.	643
Kintscher, U.	285	Komatsu, T.	693, 1 049	Koutoulakis, E.	813	Kulik, A.	584	Labudovic, D.	678, 1 159	Lawrence, T.	704
Kinz, E.	1 067	Kondo, K.	537, 1 141	Koutouri, A.	1 092	Kulikowski, E.	118	Lacabra-Blasco, I.	505	Lawson, A.J.	666
Kirchmair, R.	422	König, C.	1 069	Kouznetsova, T.	768	Kulkarni, H.	449	Lackman, I.	745	Lawson, N.	482
Kiriazis, H.	223	Konno, S.	899	Kovalyov, L.	454	Kumar, P.	847, 1 170	Layland, J.	723, 1 206	Layland, J.	723, 1 206
Kiriyama, M.	338	Konnov, M.	734, 735	Kovalyova, M.	454	Kumar, S.	449	Lazarczyk, M.	800	Lazarczyk, M.	800
Kirsch, A.	422, 499	Kono, H.	457	Kovanen, P.	65, 96, 111, 230, 354, 378	Kume, N.	1 002	Lazzarato, L.	491	Lazzarato, L.	491
Kirschner, A.	503	Kono, S.	461	Kovanen, P.T.	204	Kumon, Y.	561	LE BARS, D.	292	LE BARS, D.	292
Kiseleva, T.	606	Konstantin, D.	418	Kowala, M.	449	Kuo, S.Y.	1 184	le Cessie, S.	293	le Cessie, S.	293
Kishimoto, Y.	537, 1 141	Konstantinides, S.	657	Kozhanova, A.	793, 906, 911	Kupchynskaya, O.	811	Lagerstedt, J.	408	Lagerstedt, J.	408
Kiss, A.	789	Konstantopoulos, P.	382, 1 119	Kozhevnikov, D.	400, 728	KURATA, A.	577	Laguna, J.C.	508, 1 123	Laguna, J.C.	508, 1 123
Kiss, M.	307	Kontogianni, V.	1 128	Koziolova, N.	604, 605	Kurilshikov, A.	832	Lahiani, S.	858, 859, 867, 909, 1 171, 1 172, 1 174	Lahiani, S.	858, 859, 867, 909, 1 171, 1 172, 1 174
Kitslaar, P.H.	399	Kontush, A.	104, 711	Kozireva, A.	728	Kurtoglu, E.	984	Lahoz, C.	766, 921, 975	Lahoz, C.	766, 921, 975
Kivelä, A.	495	Kooijman, S.	111, 210	Kozlov, K.	510	Kurtz, C.	465, 976	Lai, H.Y.	105	Lai, H.Y.	105
Kjellmo, C.A.	864	Kook, H.	350, 371, 1 078	Kozlov, S.	473, 853	Kuryata, A.	497	Lalive, P.	407	Lalive, P.	407
Kleber, M.E.	396, 409, 1 146	Kook, T.	371	Králková Lesná, I.	515, 562, 535	Kurzejamska, E.	800	Lamari, A.	803	Lamari, A.	803
Kleijnen, J.	1 009	Koolwijk, P.	481	Králková, A.	562, 535	Kutikova, L.	359, 760	Lamb, H.	113	Lamb, H.	113
Klephortova, I.	860	Kopecky, C.	699	Krämer, B.K.	1 146	kutkiene, S.	784	Lamb, H.J.	293	Lamb, H.J.	293
Klesareva, E.	551, 679	Kopecky, J.	889, 892	Kraml, P.	517, 558	Kuznetsov, V.	538, 557	Lambert, G.	119, 209, 645	Lambert, G.	119, 209, 645
Klevstig, M.	647	Koplyarova, N.	1 163	Krane, V.	1 192	Kuznetsova, T.	997	LAMBERTON, F.	292	LAMBERTON, F.	292
Klimes, I.	1 052	Koppensteiner, R.	507, 771, 772, 1 147	Krapf, C.	351	Kuzniewski, M.	903	Lamina, C.	411, 1 079	Lamina, C.	411, 1 079
Klinghammer, L.	1 069	Kopru, C.	294	Kratky, D.	279, 284, 335, 443, 622	Kuzuya, M.	484, 838, 854	Lamiquiz-Moneo, I.	971	Lamiquiz-Moneo, I.	971
Kloch-Badetek, M.	931	Kopyta, I.	1 218	Krempf, M.	648	Kvantaliani, T.	844	Lamiquiz-Moneo, I.	115, 765, 921	Lamiquiz-Moneo, I.	115, 765, 921
Klopfleisch, R.	285	Kopytova, A.	740	Krempler, F.	1 079	Kvapil, M.	871	Lammertyn, L.	619	Lammertyn, L.	619
Ktosiewicz-Latoszek, L.	956	Korbelius, M.	335	Krishnan, A.	767	Kvarnstrom, M.	464	Lamminmäki, U.	690	Lamminmäki, U.	690
Klotsche, J.	396	Koren, M.	462, 1 205	Kristensen, T.	211	Kvetnoi, I.	510	Landlinger, C.	245	Landlinger, C.	245
Klouras, E.	753, 928, 977, 978, 1 003	Koricanac, G.	373	Kristiansen, K.	889	Kwang Kwon, K.	1 201	Langer, A.	1 024	Langer, A.	1 024
Kluge, S.	383	Korkusuz, P.	294	Kristinsdóttir, L.B.	1 220	Kwang-Yeol, P.	552	Langrova, H.	1 026	Langrova, H.	1 026
Knezl, V.	565	Kormi, I.	410	Krizak, J.	565, 1 015	Kwok, S.	426	Langslet, G.	244	Langslet, G.	244
Knoflach, M.	1 229	Korneva, V.	997	Kronenberg, F.	18, 28, 241, 278, 295, 309, 411, 1 079, 1 192	Kwon, D.H.	350, 371, 1 078	Lanska, M.	1 026	Lanska, M.	1 026
Ko, A.	241	Korou, L.M.	382, 1 119	Kroon, J.	81, 481	Kwon, H.M.	665	Lanska, V.	724	Lanska, V.	724
Ko, J.	493	Koseki, M.	63, 395, 653	Krott, L.M.	88	Kwon, S.U.	763	Lappegård, K.T.	466, 864	Lappegård, K.T.	466, 864
				Kruger, R.	619	Kwon, S.W.	665	Larsson, L.	89	Larsson, L.	89

Lee, Y.U.	350, 371, 1 078	Lim, H.M.	1 207	Lörincz, H.	435, 467, 612, 702, 1 151, 1 153, 1 227	Machado, U.F.	698	Malinska, H.	421, 661, 877, 895	Margolis, L.	548, 555, 1 047
Leguina-Ruzzi, A.	478	Lim, W.H.	512, 1 010	Lorkowski, S.	383	Machida, T.	621	Mallat, Z.	307	mariani, P.	865
Lehti, S.	204	Lima, A.	1 155, 1 178	Lorza, E.	827	Macia, A.	1 125	Maljutina, S.	1 212	Marianne, S.	1 178
Leighton, B.	446	Limon, J.	956	Loßnitzer, D.	274	Macic-Dzankovic, A.	706	Mamareli, V.	813	Mariano, C.	943, 993, 1 060
Leisherer, A.	366, 731, 732, 733, 839, 879, 883, 991, 1 067, 1 136, 1 137, 1 138	Limongelli, G.	924, 925	Loubarinhas, G.	1 060	Maciej, B.	801	Mamarelis, I.	813	Marin, R.	725
Leitersdorf, E.	714	Lin, S.H.	1 089	Loureiro, P.	1 198	Maciejczyk, M.	585	Mamone, F.	496, 506, 675, 1 050	Marinova, C.	914, 917
Leitges, M.	704	Lin, Y.C.	445	Lövgren, J.	690	Mackêvičs, V.	1 152	Mancas, S.	769	Markov, A.	1 070, 1 086
Lek, M.	641	Lindahl, M.	408	Lu, R.	693	MacRae, L.	268	Manchenko, O.	860	Markova, I.	421, 661, 877
Leoncini, E.	1 022	Lindau, A.	306	Lu, Y.J.	822	Madder, R.D.	401	Manchurov, V.	1 047	Markus, H.	48
Leopold, C.	622	Lindholm, B.	47	Lualdi, A.	1 033, 1 034	Madero, M.	713	Mancina, R.M.	1 055	Marlena, B.	801
Leow, M.K.S.	1 134	Lindholt, J.S.	834	Lucas, A.	107, 1 028	Madreiter-Sokolowski, C.T.	284	Mandaffino, G.	496, 506, 588, 675, 1 050	Marmelo, B.	1 061
Lepore, S.M.	1 055	Lindqvist, P.	595, 596	Lucena, M.	1 177	Madsen, L.	889	Manea, V.	862	Marmontel, O.	625
Leren, T.P.	957, 1 055	Lindsberg, P.	204, 354	Lucius, B.	359, 760	Madsen, P.	332	Maneerat, Y.	569	Maroto, A.S.	129
Lesnik, P.	104, 365	Liorda, E.	736	Luczak, E.	518, 801	Maegdefessel, L.	264, 266	Manfredi, A.A.	616	Marott, S.	429
Letourneur, D.	79, 271	Liptak, B.	565	Ludger, S.	48	Maffioli, P.	1 188, 1 189, 1 190	Manfredi, M.	626	Marques	972
Levels, J.	1 054	Lira, A.	462	Luetjohann, D.	1 106	Mafra, J.M.	857	Mangas, A.	888, 904, 1 099, 1 109, 1 162	Gonçalves, R.	
Levin, L.	757	Lisa M., C.	48	Luginova, Z.	582	Magaña Torres, M.T.	959	Mangels, N.	333	Marques, B.	1 028
Levin, M.	647	Littman, K.	1 027	Luigi, S.	1 039	Magaña-Torres, T.	945	Mangelsdorf, D.	139	Marques, N.	1 061
Ley, K.	38, 125	Liu, C.	695	Luirink, I.	390, 968	Magdalena, C.	801	Mangge, H.	894, 1 142, 1 143	Marsche, G.	374, 440, 707, 1 030
Lhomme, M.	104, 711	Liu, C.S.	341	Luna, A.	1 162	Magné, J.	203	Mannarino, E.	865	Martin-Campos, J.M.	944
Li Tin, S.P.	994	Liu, D.	362	Luna, P.	667	Magni, P.	337, 386	Manno, G.	1 209	Martin-Lorenzo, M.	129
Li, B.	723, 1 206	Liu, H.	809	Lundbye-Christensen, S.	654	Magnoni, M.	616	Manolaki, N.	1 059	Martin, C.	637, 985, 1 056
Li, J.	524	Liu, J.	248	Lundstrom, T.	464	Magnussen, C.	758	Manolio, T.	34	Martin, R.	244
Li, M.	524	Liu, P.	695	Luongo, D.	1 183	Magomedov, R.	783	Mansilha, H.	1 060	Martinelli, N.	626, 656
Li, S.	545	Liu, P.Y.	105, 1 014	Lupattelli, G.	849, 865	Mahvi, B.	1 020	Mansurov, A.	1 204	Martinez-Marin, M.	505
Li, Y.	278	Liu, Q.	524	Lūriņš, J.	1 152	Mai, A.	267	Mantovani, A.	222, 458	Martinez-Marin, R.	505
Li, Y.H.	773	Liu, X.	822, 823, 824	Lüscher, T.	719	Maistry, T.	759	Manzato, E.	121, 725, 1 029	Martinez-Ramirez, M.	713
Li, Z.	273	Liu, Y.	426, 902	Lüscher, T.F.	127	Majnaric, L.	967, 1 160	Manzini, S.	131, 372, 511, 639, 689, 1 118	Martinez-Vea, A.	434
Liamis, G.	753, 977, 978	Liwén, L.	490	Lutgens, E.	128, 302, 303, 305, 556	Majumder, A.A.S.	820	Manzurov, A.	222, 458	Martinez, L.O.	101, 281
Libby, P.	93, 306	Llorté-Cortés, V.	1 162, 202	Lütjohann, D.	1 096	Makarenkova, K.	929, 940	Mantovani, A.	222, 458	Martinez, M.	774
Liberopoulos, E.	753, 928, 977, 978, 1 003	Llorente-Cortés, V.	1 162, 202	Luukkonen, P.	915	Makeeva, O.	1 070	Manzurov, A.	222, 458	Martinez, P.J.	129
Licata, V.	954	Lo Gullo, A.	496, 506, 675	Lysne, V.	779	Makino, H.	949	Manzurov, A.	222, 458	Martinez, T.L.R.	981, 1 166, 1 167
Lichtenstein, A.H.	2, 6, 379	Lo W.Y.	810	Lysunets, T.	786	Makri, E.	617, 618	Manzurov, A.	222, 458	Martinotti, S.	626
Licon-Rashid, M.	717	Łoboz-Grudziń, K.	599	M		Maksimow, M.	423	Manzurov, A.	222, 458	Martins, D.	1 155
Liem, A.	760	Logunova, N.	782	Ma, R.	885	Makuuchi, A.	1 041	Manzurov, A.	222, 458	Martynov, S.	860
Liepold, E.	368, 438, 1 098	Logvinenko, A.	811, 812	Ma, X.	83	Malagaris, I.	1 117	Manzurov, A.	222, 458	Maryukhnich, E.	548
Liew, H.	1 065, 1 134	Løland, K.H.	1 208	Ma, Y.	1 205	Malchikova, S.	1 165	Manzurov, A.	222, 458	März, W.	396, 406, 409, 624, 937, 1 146, 1 192
Lim, D.S.	738, 739, 1 004	Lombardi, M.	491	Maas, R.	278	Malcnikova, S.	1 191	Manzurov, A.	222, 458	Mas-Oliva, J.	64
Lim, H.E.	1 000, 1 185	Long, R.	267	Mabuchi, H.	948	Malczewska-Malec, M.	546, 546, 1 016	Manzurov, A.	222, 458	Masana, L.	121, 393, 944
		López, G.I.	995	Macchi, C.	337	Maldaner, V.	1 178	Manzurov, A.	222, 458	Mase, M.	593
		Lopez, L.R.	277, 417	Mach, F.	58, 60, 407	Maldonado, N.	42	Manzurov, A.	222, 458		
		Lopukhova, V.	1 139	Machado-Lima, A.	531, 698	Malik, V.	216	Manzurov, A.	222, 458		
		Loegger, A.	209	Machado, F.	961			Manzurov, A.	222, 458		

Masenko, V.	526, 542, 853
Mashele, N.	502
Masson, G.	93
Mastorakos, G.	382
Masuda, D.	395, 653, 845
Mata, P.	945
Matas, L.	944
Matchin, Y.	686
Mateo-Gallego, R.	115, 765, 766, 921, 971
Mateva, L.	914, 917
Mathisen, M.	864
Matikainen, N.	241
Matmurotov, Q.	851, 861
Matsuda, H.	395, 653
Matsuzawa, Y.	20, 361
Matter, C.M.	127
Matz L., R.	283
Maurer, G.	418, 541
Mauri, M.	938, 944
Mavromoustakos, T.	1 128
Mawson, T.	93
Mayer, G.	643
Mayer, L.	1 229
Mayos, J.	944
Mayr, M.	312
Mazeikiene, A.	1 072
Mazzolai, L.	1 019
Mc Crimmon, R.	114
Mc Neilly, A.	114
McAhren, S.	449
McCann, A.	779
McCormick, S.	112, 1 127
McCullough, P.A.	277
McDaniels, K.	704
McGillcuddy, F.	534, 694
Mchirgui, N.	1 111
McKendrick, J.	392
McKey, S.	1 031
McLoughlin, E.	719
McParland, J.	430
McWherter, C.	244
Md Yasin, M.	216, 965, 966
Meakin, P.	789
Medbury, H.	545
Medeiros Bastos, G.	972
Medeiros, A.M.	360, 943, 945, 955, 985, 1 060
Mehegan, J.	1 031
Mehrad, H.	580, 600, 607, 611, 1 020, 1 037, 1 038
Meikle, P.	223, 314, 362, 449, 658
Meiler, S.	128, 305
Meinitzer, A.	511, 1 142, 1 143
Meisinger, C.	411
Meitinger, T.	240
Mekala, A.P.	536
Mele, L.	692
Melki, A.	867
Mellett, N.	314
Mellgren, G.	363, 367
Mello, A.P.Q.	814, 981, 1 166, 1 167
Melnichenko, A.	632, 633
Melnikov, I.	473
Melnikov, M.	830
Mels, C.M.	619
Méndez-Acevedo, K.	64
Mensink, R.	340, 1 103
Mensink, R.P.	103, 1 096, 1 100, 1 104
Menzel, J.	412
Merezhanova, A.	1 165
Messa, P.	1 029
Messika-Zeitoun, D.	474
Messner, B.	477
Metelskaya, V.	629, 640, 663
Metso, J.	384, 623, 652
Mezzano, D.	478
Miarka, P.	903, 912
Michael, L.	449
Michalis, L.K.	399
Michel, J.B.	474
Michell, D.	268
Mickiewicz, A.	956
Mieth, M.	278
Migliorino, D.	1 210
Mignano, A.	1 210
Mijovic, R.	870
Mika, P.	584, 585
Mikellidi, A.	1 115
Mikhaleva, O.	900
Mikic, M.	1 160
Milaciu, M.	992
Milano, G.	450
Milanova, M.	791
Milicua, J.C.G.	637
Milionis, H.	432
Miljkovic, M.	436
Miller, D.	61
Miñambres, I.	876
Ming, X.	479
Mele, L.	692
Minicocci, I.	121
Ministrini, S.	865
Minniti, M.E.	47
Mintz, G.S.	83
Miranda, M.	127
Mirchi, M.	817
Miroshnikova, V.	740, 890
Mishchenko, A.	1 163
Misiano, G.	954
Mistri, A.K.	1 133
Mitish, V.	793
Mitro, N.	267
Mitrofanov, K.	1 073
Mitroshkin, M.	686
Miu, P.	673
Miura, K.	537, 1 141
Miwa, K.	338
Miyamoto, Y.	949
Miyashita, K.	621
Miyata, K.	537, 1 141
Miyazawa, T.	886
Miyoshi, T.	586
Mlih, M.	283
Mo, F.E.	445
Mo, Z.C.	822, 823, 824
Mocan, M.	509
Moeton, M.	209
Mohd Ismail, A.	716
Mohd Kasim, N.A.	441, 485, 487, 716, 923, 965, 966
Mohd Mokhsin, N.A.	681, 716, 965, 966
Mohd Nasir, N.	716, 923
Mohd Nor, F.	681
Mohtar, F.	1 211
Mohtashami, R.	918
Mokhort, T.	852
Mokhtar, S.S.	681
Mokhtari-Dizaji, M.	580, 607
Molahedh, Y.	1 091, 1 111
Mollaki, V.	1 059
Molnár, Á.	1 227
Mombelli, G.	963
Momiyama, Y.	537, 1 141
Monier, S.	711
Monsalvo Hernando, M.	614, 1 109
Monsalvo-Hernando, M.	888
Monsalvo, M.	615
Montani, J.P.	479
Montecucco, F.	407
Mora-Brugués, J.	384
Morales, C.	944
Morbini, M.	380, 391
Moregola, A.	458
Moreno, X.	1 056
Mori, K.	338
Mori, M.	948
Mori, T.A.	471
Moriarty, P.	667, 910
Moriarty, P.M.	668
Moriconi, A.	865
Morihara, R.	583
Morlotti, B.	386
Morreale, P.	1 209
Morris, A.	95, 385
Morshed, S.	107, 1 028
Mortensen, M.B.	1 164
Morvan, M.	474
Moschen, A.R.	312
Moschetta, A.	205, 208
Mospan, M.	811
Mosteoru, S.	769, 1 046
Mostoslavsky, R.	127
Motazacker, M.M.	241, 286, 331
Motilva, M.J.	1 125
Motta, B.M.	1 055
Moulin, P.	242, 625, 1 057
Moura, V.	522
Mousavi, F.	566
Moxon, J.	362
Mucher, E.	346
Muckenthaler, M.	102
Mueller, P.	95
Mueller, T.	882
Muendlein, A.	366, 731, 839, 991, 1 067
Muid, S.	441, 485, 923
Muinjonov, B.	597, 726, 787, 788, 831, 979, 1 025, 1 132
Mukhamedova, B.	1 222
Mukhamedova, M.	572
Mulder, M.	717
Mullan, R.	650
Müller, G.	403
Munakata, M.	899
Mundal, L.	957
Mundra, P.	314
Muñoz-Hernández, R.	1 158
Muñoz, M.	434
Muntean, C.	1 043
Muntoni, S.	121
Murakami, K.	338
Murakami, M.	621
Muro, A.F.	554
Murphy, C.	980
Murrin, C.	1 031
Murtazaev, S.	1 204
Musayeva, Y.	1 025
Musikhina, N.	538, 557
Mussbacher, M.	448
Mut-Vitcu, G.	769
Muthuramu, I.	126, 655
Muxel, R.	241
Muzalevskaia, M.V.	718
Myhre, P.	1 102
Mysliwiec, M.	956
N	
Na, J.O.	1 000, 1 185
Nabika, T.	703, 1 135
Nabrozidis, A.	428
Nachtigal, P.	480, 494
Naderi, G.A.	721
Naeimi Kararoudi, M.	865
Naessen, T.	601
Nafakhi, H.	887, 891, 896
Nagai, A.	703, 1 135
Nagao, M.	886
Nagasaka, R.	1 021
Nagel, F.	789
Nagel, G.	770
Nagornova, K.	613
Nagy, E.V.	612
Nahapetyan, H.	346
Nahon, K.	90
Nahrendorf, M.	93
Nair, D.	952
Najib, S.	281
Naka, K.K.	399
Nakagawa, T.	1 021
Nakajima, K.	621
Nakamura, K.	586
Nakandakare, E.	1 122
Nakandakare, E.R.	531, 698
Nakanishi, C.	948
Nakano, Y.	583
Nakata, C.	1 177
Nakatani, K.	395
Nakaya, N.	461
Nakayama, T.	456
Nam, Y.S.	1 078
Nan, R.	805
Narain, R.	815, 816
Narayanaswami, V.	641, 651
Nascimento, T.	781
Nasias, D.	437
Näslund, U.	596
Natale, F.	924, 925
Naumenko, E.	852
Naumov, V.	454, 526, 542
Navarova, J.	565, 1 015
Naviglio, D.	1 183

Nawawi, H.	441, 485, 486, 487, 681, 716, 923, 965, 966, 1 211
Nawrot, T.	502
Nayeri, H.	721
Nazarenko, M.	520, 1 086
Nechaeva, B.	1 165
NEDELICIUC, I.	575
Neely, D.	369, 988
Negi, P.	690
Nègre-Salvayre, A.	711
Negrean, V.	913, 992, 1 176
Neimark, A.	740
Nekaies, Y.	638
Nekrasova, T.V.	718
Nelson, J.	209
Nelson, J.K.	664
Nemeckova, I.	480, 494
Neroev, V.	606
Neskudla, T.	871
Nestel, P.	314, 658
Nestvold, T.	864
Netea, M.	106, 270
Neville, M.	89
Nezafati, P.	1 197
Nezami, N.	817
Nezic, D.	821
Ngo Sock, E.T.	643
Nguyen, S.D.	204, 378
Ni, C.W.	482
NICA, A.S.	574
Nicholls, S.	61
Nicoletti, A.	474
Niculescu, L.S.	701, 1 082
Nielen, T.	270
Nielsen, S.	369
Nieves, J.	553
Nikiforov, N.	532
Nikitin, A.	868
Nikitin, A.G.	1 048
Nikitin, Y.	768
Nikitina, N.	1 066, 1 074, 1 075
Nikitskaya, E.	548, 555
Nikkola, E.	241
Nikolaev, M.	740
Nikolic, S.	870
Nikolova, A.	791
Nilsen, R.M.	249
Nilsson-Wolanin, O.	408
Nilsson, J.	290
Nilsson, S.K.	88
Ning, T.	902
Nishida, M.	63, 395, 653
Nishida, T.	693, 1 049
Nishiuchi, J.	561
Nizomov, A.	567, 570, 571, 572, 1 018, 1 036
Njølstad, P.R.	363, 367
Noale, M.	1 029
Nobécourt, E.	645, 648
Noels, H.	291
Noeva, E.	551
Noguchi, H.	456
Nohara, A.	948
Nolasco, P.	522
Nolte, I.M.	413
Nony, S.	625
Norata, D.G.	431, 554
Norata, G.D.	222, 301, 458, 616, 1063
Nordestgaard, B.	75, 211, 227, 237, 254, 429, 669, 1 080
Nordestgaard, B.G.	123, 427, 1 164
Nordrehaug, J.E.	1 208
Norioka, N.	1 041
Noto, D.	121, 954, 1 169
Notsu, Y.	703, 1 135
Novakova, D.	724
Novakovic, R.	821
Novikova, A.	568
Novikova, L.	454
Novitskaya, A.	573
Novo, G.	1 209, 1 210
Novo, S.	819, 1 209, 1 210
Novoa, J.M.	494
Ntallas, I.	1 035
Nugraha, F.	576
Nurmuhammat, A.	1 090
Nussbaum, K.	127
Nusshold, C.	499
Nygård, O.	275, 779, 1 208
Nygård, O.K.	363, 367
Nyman, E.	596
O	
O'Reilly, M.	534, 694
Obendorf, F.	1 147
Oberkersch, R.E.	416
Obregon-Gonzalez, A.	1 230
Obrowsky, S.	335, 622
Odegova, A.	746
Ogawa, K.	1 021
Ogundipe, T.	514
Ogura, M.	344, 700, 949
Oguz, S.H.	715
Oh, D.J.	120, 1 000, 1 185
Oh, G.T.	420, 444
Oh, P.	392
Oh, P.C.	1 130
Ohama, T.	395, 653
Ohguro, T.	561
Ohmori, R.	537, 1 141
Ohta, N.	949
Ohta, T.	390
Ohta, Y.	583
Ohtake, A.	390
Oikawa, S.	461, 886
Okada, T.	63, 390, 395, 653
Okazaki, M.	653
Okruhlicova, L.	565, 1 015, 1 121
Okutan, H.	984
Okuyan, E.	777
Oldoni, F.	331
Oleynikov, V.	589, 590, 591, 603, 1 044
Oliveira, G.	1 156
Oliveira, H.	827
Oliveira, M.	843, 1 061
Olivieri, O.	626, 656
Oliyarnyk, O.	421, 661, 877
Olkkonen, V.	111, 286, 495
Olset, H.	1 208
Omote, Y.	583
Omrane, M.	1 174
Onda, A.	457
Ongen, Z.	1 083
Ooi, E.M.	394
Öörni, K.	47, 100, 204, 378
opan, S.	826
Opie, L.	710
Oppitz-Plörer, C.	21
Opris, S.	705, 802
Orășan, O.	992
Oravec, S.	541, 720
Ordóñez Llanos, J.	630
Ordóñez-Llanos, J.	876
Orehhov, A.	532, 632, 633, 1 066, 1 073, 1 074, 1 075, 1 076, 1 077
Orehhova, V.	1 076, 1 077
Orera-Peña, M.L.	866
Orgera, G.	550
Orhan, B.	833
Orlov, P.	929, 940
Oscar, C.	1 162
Ose, L.	957
Osipova, I.	557
Osokina, A.	551
Ossoli, A.	650
Oster, D.	492
Osto, E.	719
Ostolaza, H.	637, 1 056
Ottino, J.	938
Otto, M.E.	1 178
Ouestati, I.	858, 859, 867, 909
Ouguerram, K.	648
Ouweneel, A.B.	1 040
Ovsyannikova, A.	832
Ozan Tiryakioglu, N.	1 083
Ozcebe, O.	984
Ozerova, I.	629, 640, 663
Ozmen, F.	294
Ozsvar-Kozma, M.	307
P	
Paapstel, K.	1 129
Pacifico, A.	121
Pacioni, F.	1 097
Packard, C.	49
Packard, C.J.	1 081
Padilla-Mata, V.	1 230
Padroni, M.	407
Pagano, M.	1 169
Pagava, Z.	1 219
Pagel, P.	90
Paiva, A.	827
Pajukanta, P.	241
Palesano, O.	954, 1 169
Palmen, J.	238
Palmisano, S.	671, 749
Palo, S.	706
Palomar Muñoz, C.	614
Palominos, M.	478
Palotie, A.	241
PALTINEANU, B.	539, 628
Panagiotakos, D.	762, 846
Panahi, Y.	918, 1 108
Panchal, A.	667
Panderi, A.	1 088
Panetta, D.	818
Pang, J.	355, 471, 1 168
Pannier, B.	1 196
Panov, D.	795
Panteleeva, A.	740, 890
Pantoura, M.	617, 618
Panzavolta, C.	1 029
Panzoldo, N.B.	983
Paone, S.	489
Papadopoulou - Pozatzidou, D.	1 115
Papadopoulou, A.	1 092
Papadopoulou, S.L.	399
Papavasiliou, K.	1 092
Para, I.	992, 1 176
Paragh, G.	435, 467, 612, 702, 1 151, 1 153, 1 227
Parati, G.	1 196
Pardina, E.	425
Parhofer, K.G.	394
Parikova, A.	683
Parini, P.	47, 89, 203, 370, 1 027
Park, C.G.	120, 1 000, 1 185
Park, C.Y.	405, 737
Park, D.G.	512
Park, J.H.	738, 739, 1 004
Park, J.Y.	405, 737
Park, K.C.	404, 564
Park, K.H.	404, 564
Park, K.S.	564
Park, M.	594
Park, S.H.	420
Park, Y.W.	1 001
Parnet, P.	645
Parodi, O.	818
Parolini, C.	131, 372, 511, 639, 689, 1 118
Parra, E.S.	983
Parvu, M.	775
Pashos, E.	430
Pasqualini, L.	865
Passarelli, M.	531, 698, 1 122
Pasterk, L.	1 030
Pasterkamp, G.	311
Patankar, J.V.	622
Patel, M.	104
Patel, S.	1 120
Patel, V.	545
Patsch, S.M.	1 079
Patsch, W.	662, 1 079
Pattison, J.	455
PATURET, A.	292
Paul, J.L.	691
Paulweber, B.	68, 272, 411, 503, 662, 1 079
Paulweber, M.	503
Pauwels, B.	856
Pavanello, C.	121, 386, 963, 1 058
Pavão, M.L.	1 155
Pavlaki, M.	657
Pavlouskova, J.	973
PAYZIN, S.	951

Pchelin, I.	842	Perez, A.	888, 1 099, 1 109	Pingitore, P.	1 055	Polyakova, E.	1 149	Proietta, M.	544, 549, 550	Ragino, Y.	644, 832, 929, 940, 964, 1 212
Pchelina, S.	740, 890	Perez, C.	888, 904, 1 099, 1 109	Pinthus, J.	1 173	Polyakova, V.	510	Przepiorkowska-Hoyer, B.	903	Rahimian, R.	508
Pedersen, E.K.	1 208	Peric, M.	821	Pinto, F.	1 198	Pompilio, G.	450	Pu, J.	83	Rahman, T.	441, 485, 486, 487, 681, 716, 820, 965, 966, 1 211
Pedersen, E.R.	363, 367	Perier, M.C.	1 196	Pinto, P.R.	698	Ponde, C.	1 062	Puhm, F.	1 131	Rahmat, R.	441, 923
Pedrelli, M.	47, 203	Perin, M.A.	781	Pintus, P.	121	Pongratz, T.	541	Pujato, M.	94	Rainer, S.	335
Pedretti, R.	1 179	Perkmann, T.	307	Piotrkowicz, J.	1 071, 1 084	Poon, I.	489	Pulakazhi Venu, V.K.	554	Rajani, R.	1 062
Pedro-Botet, J.	766, 1 012	Perrea, D.	382, 1 119	PIRAQUIVE AGUDELO, J.	292	Pop, C.	862	Putatov, U.	851, 861	Rajkovic, J.	821
Pedro-Botet, J.C.	975	Perrotta, S.	549, 550	Pirazzi, C.	1 055	Pop, L.	862	Pulikal, A.	815	Rakhimbayeva, G.	1 025
Pego, M.	592	Perségol, L.	711	Pirhonen, J.	286, 915	Popeijus, H.	340	Purnomowati, A.	576	Rakhimov, R.	752
Peinado-Onsurbe, J.	425	Persson, A.	290	Pirildar, S.	984	Popeijus, H.E.	103	Pussinen, P.J.	410	Rakhimova, R.	1 222
Pelikanova, T.	871	Pertsoulis, N.	545	Plrisi, M.	599	Popescu, A.C.	1 082	Puzdriak, P.	728, 783	Ramakrishnan, L.	712
Pellegatta, F.	1 063	Perveen, I.	529	Pischon, T.	412	Popescu, H.	805	Puzyrev, V.	520, 1 070, 1 086	Ramaswami, U.	934
Pellegrin, M.	1 019	Pery, T.	888	Pistrosch, F.	403	Popescu, R.M.	1 082	Pyanikin, S.	906	Ramirez, C.M.	312
Pellegrini, N.	697	Pes, G.	121	Pitha, J.	515, 683, 1 068, 871	Popova, A.B.	947	Pyatchenkov, M.	501	Ramli, A.S.	965, 966
Pello, E.	768	Pesau, G.	1 147	Pithova, P.	871	Popovic, D.	1 095	Pylaeva, E.	551, 679	Ramsvik, M.S.	1 118
Pelosi, G.	818, 825	Petelina, T.	538, 557	Pitsavos, C.	762, 846	Pordy, R.	247, 463	Pyoung Chun, O.	1 200	Ranzato, E.	626
Peloso, G.	946	Peter, J.	1 054	Plana, N.	358, 393, 766, 921, 944, 975	Porrini, M.	1 105	Pyung Chun, O.	1 201	Raptis, N.	617, 618
PENA, C.	539, 540, 574, 628	Peter, K.	273, 402	Plat, J.	103, 340, 704, 1 096, 1 100, 1 103, 1 104	Porteous, C.	1 127	Pyush, M.	658	Ras, R.	1 104
Penco, S.	963	Peters, A.	313, 411	Plätenik, J.	517, 558	Posadas-Romero, C.	356, 528	Q		Rasente, Y.	416
Peng, H.	341	Petersen, C.M.	332	Pleava, R.	769, 1 046	Posadas-Sánchez, R.	356, 528	Qin, J.	524	Raslova, K.	1 052
Peng, X.S.	822, 823, 824	Peterson, K.L.	455	Plebani, M.	1 029	Postnov, A.	655, 1 076, 1 077	Quartuccio, S.	588	Rather, R.	722
Penning-van Beest, F.	760	Petrek, M.	1 005	Plevin, R.	498	Potekhina, A.	551, 679	Que, X.	455	Rathmann, W.	411
Peralta, J.	449	Petrides, F.	119	Plösch, T.	804	Potočková, J.	517, 558	Quezada-Feijoo, M.	1 099	Rathouska, J.	494
Pereira-Flores, K.	478	Petriello, M.	385, 1 093	Pocovi, M.	358	Potočnjak, I.	707	Quinaglia e Silva, J.C.	1 156	Rato, Q.	993
Pereira, A.	943, 945, 981, 1 166, 1 167	Petrini, J.	521	Podesser, B.K.	789	Pouwer, M.	245, 446	Quintao, E.	1 122	Raut, M.	659
Pereira, J.	478	Petrkova, J.	1 005	Podpalov, V.	581	Povlsen, G.K.	513	Quintao, E.C.R.	698	Ray, K.	61
Pérez Cuellar, M.	630	petrulioniene, Z.	784	Poelz, W.	882	Pozzi, C.	898	Quitterer, U.	1 024	Ray, K.K.	253
Pérez Guerrero, P.	615	petrylaite, M.	784	Pogorelova, O.	551, 679	Prabhakaran, D.	767	Qureshi, A.R.	47	Raz, O.	563
Pérez Isla, L.	945	Petersson, K.	690	Poirier, S.	98	PRADA, G.	540, 574	R		Razny, U.	546, 1 016
Pérez Ternero, C.	381, 1 125	Pfaffenberger, S.	541	Pojskic, B.	706	PRADA, S.	540, 574	Raal, F.	465	Razvodovsky, Y.	1 213, 1 214
Pérez Calahorra, S.	115, 358, 765, 766, 921, 975	Pfeiffer, L.	313	Pojskic, L.	706	Prager, M.	720	Raal, F.J.	976	Real, J.T.	358
Pérez Calvo, J.	505	Phillips, H.	942	Pokrovskiy, A.	1 023	Pramfalk, C.	89, 1 027	Rabelink, T.J.	269, 483	Reaven, P.D.	45, 117
Pérez-Hernández, N.	528	Piacentini, L.	1 034	Pokrovsky, A.	793, 906, 911	Prasongsukarn, K.	569	RABES, J.P.	946	Reblova, K.	973
Pérez-Hernández, N.	356	Piantadosi, C.	1 183	Pokrovsky, S.	679, 685, 686, 687	Prasst, R.	199, 894, 1 142, 1 143	Rached, F.	781, 920	Rebnord, E.W.	363
Pérez-Marques, F.	667	Piccinocchi, G.	924, 925	Poledne, R.	535, 562, 1 068	Praveen, P.A.	767	Rader, D.	430	Reda, A.	797
Pérez-Méndez, O.	713	Pichler, M.	1 146	Poli, A.	692	Pravenec, M.	421, 877	Radovic, B.	284, 443	Reddy, K.S.	767
Pérez-Pérez, A.	876	Piemontese, A.	692	Polis, A.	389	Pregartner, G.	707	Radulian, G.	805	Redezuk, G.	983
Pérez-Ruiz, M.R.	971	Pieper, L.	396	Polizzi, G.	819	Prehn, C.	290	Radulović, B.	707	Redmond, E.	476
Pérez-Serra, A.	1 162	Piepoli, M.	316, 318, 325	Polonskaja, Y.	1 212	Previato, L.	1 029	Radulović, S.	499	Redpath, G.	112
		Pieterman, E.	446	Polus, A.	546	Princen, H.	446	Radwan, M.	82	Regmi, P.	659
		Pieterman, E.J.	245			Princen, H.M.G.	245	Raggi, P.	714	Reiber, J.H.C.	399
		Pietrzycka, A.	903			Prins, J.	269			Reim, S.	128
		Pihlajaniemi, T.	915			Prof. Dr. Dukat, A.	1 145				
		Piir, A.	1 129			Prof. Dr. Oravec, S.	1 145				
		Piña-Aguilar, R.	1 054								
		Ping-Yan, C.	902								

Rein, P.	366, 731, 732, 733, 839, 883, 991, 1 067, 1 136, 1 137, 1 138
Reis de Azevedo Rabello, F.	863
Reis, A.	1 069
Reischl, E.	313
Reiz, B.	240
Religa, P.	800
Ren, K.	822, 823, 824
Rencova, E.	1 026
Renker, M.	274
Rensen, P.	90, 111, 113, 556
Rensen, P.C.N.	210, 293
Rensen, S.	113
Rentz, T.	827
Ress, C.	503
Ressia, A.	961
Retterstøl, K.	957, 1 055
Revníc, C.R.	539, 540, 574, 628
REVNIC, F.	539, 540, 574, 628
Reyes, X.	945, 961
Rha, S.W.	120, 1 000, 1 185
Rhainds, D.	696
Rhéaume, E.	696
Rhee, K.S.	493
Riascos-Bernal, D.	94
Ricci, .	337
Ricci, C.	419
Ricci, M.	1 161
Ricci, M.A.	849, 865
Richart, A.	223
Rico Martin, S.	1 215, 1 216
Riesmeyer, J.	61
Riga, M.	794
Riksen, N.	106, 270, 556
Riksen, N.P.	669
Ring-Dimitriou, S.	662
Ring, M.	521
Ringdal Pedersen, E.	275
Rinnerthaler, M.	662
Rioja, J.	428
Ripatti, S.	111, 235, 236
Risérus, U.	1 116
Riško, P.	517, 558
Riso, P.	1 105
Ristic, T.	1 217
Ritsch, A.	109, 340, 1 103
Rivas, A.	630
Rivellese, A.	1 183
Rizzo, B.	1 022
Rizzo, P.	1 022
Robier, C.	1 142
Robinson, J.G.	246, 463
Robinson, T.	1 133
Rocchiccioli, S.	818, 825
Roche, H.	694
Rocio, T.	888
Roda, A.	1 022
Roden, M.	411
Rodriguez -Rosety, M.	888
Rodríguez Cubero, A.	835, 836, 837
Rodríguez-de Miguel, M.	866
Rodríguez-Leal, C.	888, 904, 1 099, 1 109
Rodríguez-Pérez, J.M.	356, 528
Rodríguez-Rosety, M.	904
Roeters van Lennep, J.	106, 121, 717
Rogers, M.	42
Roglans, N.	508, 1 123
Rohrer, L.	345
Rolando, B.	491
Romano, D.	1 188, 1 189, 1 190
Romanovskaya, E.	589, 590
Romeo, S.	1 055
Romero, E.	938
Romeu, M.	434
Romijn, F.	578
Roncales-García Blanco, F.	505
Ronda, N.	697, 715
Ros, E.	975
Rosa, I.	1 162
Rosa, R.	796, 1 008
Rosendaal, F.	113
Rosendaal, F.R.	293
Rosenson, R.S.	392
Rostoniec, E.	584, 585
Rosqvist, F.	1 116
Ross, J.	1 009
Rossell, J.	425
Rossetti, L.	1 033, 1 034, 1 039
Rossi, N.	996
Rossini, M.	1 029
Rosticci, M.	380, 391, 749
Roth, A.	407
Roth, E.M.	463
Rothe, M.	285
Rotllan, N.	312
Rovati, G.	1 017
Roversi, G.	407
Roy, A.	712, 767
Rubio-Gracia, J.	505
Rudling, M.	336, 376, 1 116
Rufinatscha, K.	503
Rui, L.	531
Ruiz-Estevez, B.	1 109, 904, 1 099
Ruiz-Laiglesia, F.	505
Rull, A.	630
Ruotolo, G.	61
Rus, H.	536
Rus, V.	536
Ruscica, M.	337, 386, 431
Russo, I.	276
Russo, R.	1 209
Rusu, E.	805
Rusu, F.	805
Rutten, J.	270
Ruuth, M.	378
Rvatcheva, A.	542
Ryan, R.O.	87, 288
Ryazankina, N.	1 047
Rye, K.A.	104, 119, 342, 704
Rymar, O.	832
Rynkiewicz, A.	956
Ryu, J.K.	1 001
Ryzhkova, A.	1 074, 1 075
S	
Sabanovic, S.	967
Saburova, O.	473, 853
Sachdev, V.	622
Sadeghi, M.	806, 1 197
Sádevirta, S.	915
Saely, C.	366, 731, 732, 733, 839, 879, 883, 991, 1 067, 1 136, 1 137, 1 138
Saemann, M.D.	699
Sáenz-Aranzúbia, P.	358
Saez, C.G.	478
Safarova, M.	686
Sag, S.	984
Sagitov, I.	745
Saheb, S.	244
Sahebkar, A.	672, 918, 1 108
Sahlin, S.	1 027
Sairyo, M.	395, 653
Saita, E.	537, 1 141
Saitta, A.	496, 506, 588, 675, 1 050
Sakata, Y.	63, 395, 653
Sakellarios, A.	399, 818
Sakly, M.	638
Sakri, F.H.	716
Saksi, J.	354
Sakurada, M.	1 049
Sala, A.	1 017
Salakhidinov, S.	567
Salashenko, A.	1 042
Salatzki, J.	285
Salcioglu, O.	984
Saleh, Y.	587, 790
Salem, M.	1 171, 1 172
Salerno, A.	827
Salim, V.	677
Salinas, M.	93
SALMAN, N.	951
Salomaa, V.	410
Salvadori, P.A.	818
Salvayre, R.	711
Salyamova, L.	591, 603, 1 044
Salzmann, K.	503
Salzmann, M.	448
Samani, N.J.	240
Samoka, A.	587, 790
Samperiz-Legarre, P.	505
Sampietro, T.	976
Sanak, M.	1 016
Sanchez Lopez, Y.	959
Sánchez Muñoz-Torrero, J.F.	1 216, 1 215
Sánchez Quesada, J.L.	630
Sánchez-Hernández, R.M.	975, 358, 921
Sanchez-Marteles, M.	505
Sanchez-Orellana, E.	1 109
Sánchez-Quesada, J.L.	384, 876
Sanda, G.M.	488, 523, 701, 1 082
Sandhu, M.S.	680
Sang Ho, J.	1 200
Sang Hong, B.	1 200
Sang-Don, P.	1 130
Sangüesa, G.	508, 1 123
Sanjana, N.	262, 352
Sant'Anna Melo, E.	863
Santer, D.	789
Santer, P.	312
Santilli, F.	1 033
Santoro dos Santos Pereira, S.	863
Santos Filho, R.	981, 1 166, 1 167
Santos, D.	384
Santos, E.	1 155
Santos, F.	843
Santos, M.	592
Santos, R.	920, 945, 976
Sanz-Bescos, C.	505
Sapozhnikova, I.	878
Saraiva, C.	843
Sarantopoulos, A.	617, 618
Sardo, M.A.	496, 506, 675, 1 050
Sarecka-Hujar, B.	1 218
Sarrafzadegan, N.	806, 1 197
Sarzani, R.	1 161
Sasaki, J.	461
Sasaki, M.	693, 1 049
Sasiela, W.	247
Sasiela, W.J.	246
Sassolas, A.	625
Satoh, N.	620
Satta, N.	407
Sattar, N.	1 013
Sausen, G.	93
Savolainen, M.	378
Savopoulos, C.	736, 794
Savostyanov, K.	785
Sawamura, T.	636
Sawant, R.	1 062
Sayfutdinov, R.	613, 848
Sazonova, M.	532, 1 066, 1 074, 1 075, 1 076
Scarinzì, P.	725
Schaefer, A.K.	789
Schaeffer, C.	283
Schalij, M.	578
Schaltenberg, N.	48
Scharfmann, R.	645
Scharin Täng, M.	647
Scharnagel, H.	396
Scharnagl, H.	374, 409, 624, 1 146
Schartum-Hansen, H.	367, 1 208
Schatz, U.	682
Schauer, S.	284
Scheicher, B.	622
Scheideler, M.	894
Scheja, L.	88, 108
Schernthaner, G.H.	507, 771, 772, 1 147
Schiavetto, E.	1 097
Schiffmann, R.	277
Schilcher, I.	374, 499
Schlager, S.	284, 443
Schlein, C.	88
Schmid, J.A.	448
Schmidinger, B.	649

Schmidt, B.	396
Schmidt, N.	396, 937
Schmitz, C.	291
Schmölz, L.	383
Schneider, M.	278, 772
Schneider, W.	241
Schneider, W.J.	133, 649
Schnitzler, J.	81
Schoepf, U.J.	274
Schofield, J.D.	426
Scholler, E.	283
Schratter, G.	894
Schreier, L.	945, 995
Schulze, M.B.	412
Schunkert, H.	33, 240
Schutte, A.E.	619
Schwab, U.	378
Schwandt, P.	368, 438, 1 098
Schwarzova, L.	939, 962
Scopece, A.	450
Scotti, I.	616
Scrimali, C.	954
Scrylev, S.	500, 598, 602
Sedova, E.	510
Segura, E.	888, 904, 1 099, 1 109
Segurado, R.	1 031
Sehar, N.	667, 910
Seifert, R.	367
Sekerkova, A.	562
Seleem, M.	587, 790
Selice, R.	725
Selimovic, H.	706
Seljeflot, I.	1 102
Sella, S.	1 029
Semenkin, A.	1 165
Semenova, E.	998
Semenova, I.	740, 890
Seo, H.S.	120, 1 000, 1 185
Seo, J.B.	512, 1 010
Sequeira Duarte, J.	843
Seraceni, S.	407
Serban, M.C.	672

Seres, I.	435, 467, 612, 702, 1 151, 1 153, 1 227
Sergienko, I.V.	947
Serrano Jr, C.V.	781
Serruys, P.W.	399
SERUSCLAT, A.	292
Seung Hwan, H.	1 130
Seung Woon, R.	1 200
Seyedikhosroshahi, S.A.	611
Shaari, S.A.	681
Shahrawat, R.	1 144
Shakhtshneider, E.	644, 832, 929, 940, 964
Shalaby, A.	797
Shalaeva, A.	744
Shalaeva, E.	752, 851, 861
Shaligram, S.	508
Shalimova, A.	869
Shamkhalova, M.	860, 868, 900
Shamkhalova, M.S.	1 048
Shapira, C.	932
Shapira, I.	563
Shaposhnik, I.	1 042
Sharapov, N.	1 204
Sharashidze, N.	1 219
Sharifi, M.	952
SHARMA, M.	112
Sharma, S.	815, 816
Sharma, V.	880, 1 144
Sharpe, L.	209
Shchinova, A.	551, 679
Shchipakin, V.	500
Shehab, A.	1 181, 1 182
Shehu, J.	1 022
Shelkov, G.	400
Shelley, E.	980
Sheng, Q.	268
Sherbakova, E.	907
Shestakova, M.	860, 868, 900
Shestakova, M.V.	1 048
Shih, M.F.	1 126

Shimizu, M.	579, 610, 727, 755, 756, 905
Shimizu, R.	1 002
Shin, S.	350, 371, 1 078
Shinohata, R.	621
Shiomi, M.	1 021
Shiotani, K.	693, 1 049
Shipman, K.	930
Shipman, K.E.	666
Shiqun, C.	902
Shiri-Sverdllov, R.	113
Shishkin, A.	842
Shiue, L.	269
Shkurat, T.	1 074
Shlomin, V.	783
Shlyachto, E.	1 149
Shogenova, M.	454, 526, 542
Shokouhi, B.	817
Shpektor, A.	548, 555, 1 047
Shrivastava, A.	1 031
Shuto, T.	1 041
Shuto, Y.	886
Si, S.	695
Siahmansur, T.	426
SIALVERA, T.E.	1 092
Sibinga, N.	94
Siebel, A.	223
Siepi, D.	849
Sifuentes Diaz, E.	614, 615
Sigurðardóttir, Y.R.	1 220
Sijbrands, E.	717
Silva, A.P.	1 178
Silva, I.T.	814
Silva, K.S.	698
Silva, R.	592
Sima, A.V.	488, 523, 701, 1 082
Simental-Mendía, L.E.	672
Simes, J.	314
Simic-Ogrizovic, S.	436
Simionescu, M.	523, 527, 701, 1 082, 1 085
Simionescu, N.	1 082
Simmelbauer, A.	102

Simon, A.	754
Simonelli, S.	650
Simonetti, P.	1 105
Simonova, Z.	776
Simonyi, G.	1 007
Sinelli, M.	491
Singh, A.	712
Singh, N.	655
Singh, S.	712
Siniscalo, J.	378
Sinke, R.	331
Sinyov, V.	1 066, 1 074, 1 075
Sirenko, O.	786
Sirirat, R.	1 106
Sirojiddin, K.	1 221, 1 222
Sironi, M.	222
Sirtori, C.	121, 963
Sirtori, C.R.	131, 386, 639, 689
Sisic, I.	706
Skeldal, S.	332
Skilton, M.	758
Škop, V.	421, 661, 895
Skoumas, I.	762, 846
Skroblin, P.	312
Skryabin, N.	520, 1 086
Sleptcov, A.	520, 1 086
Smiianova, O.	1 187
Smiianova, Y.	1 187
Smit, N.	578
Smith, W.	619
Smyth, S.	95
So, W.Y.	885
Sobenin, I.	532, 633, 1 066, 1 073, 1 074, 1 075, 1 076, 1 077
Sobotka, L.	1 112
Söderlund, S.	241
Sodi, R.	1 081
Softeland, E.	249
Sohrabi, B.	566
Sokolov, A.	501
Sol, W.M.P.J.	483
Soler, C.	944
Soler, J.	434
Solheim, S.	1 102

Solnica, B.	546, 1 016
Solovieva, E.	582
Soltani, N.	1 223
Somaradne, R.	462, 1 205
Somerville, R.	1 031
Sommariva, E.	450
Somodi, S.	1 151, 1 153
Song, H.C.	439
Song, K.H.	884
Soon Yong, S.	1 130
Sopic, M.	122
Soran, H.	426, 462, 976
Sorin Nicu, B.	509
Soronen, J.	111
Sorrentino, V.	664
Sorsa, T.	410
Soska, V.	950
Sotnikova, R.	1 015
Soyal, S.	662
Soyal, T.	294
Spang, J.	492
Spannella, F.	1 161
Spanou, M.	794
Spasojević Kalimanovska, V.	122
Spasojević-Kalimanovska, V.	436, 741, 874
Speidl, W.	541, 720
Sperlongano, S.	924, 925
Speziali, G.	656
Spina, R.	954, 1 169
Spira, D.	935, 989
Spitz, C.	128, 305
Spolding, B.	1 113
Sposito, A.	1 156
Stadiotti, I.	450
Stadlbauer, V.	440
Staessen, J.	768
Staffler, G.	245
Stählman, M.	647
Stamatelopoulos, K.	1 059
Stanciu, O.	609, 792
Stancu, C.S.	488, 523, 701, 1 082
Staneek, V.	1 068
Stangl, G.	1 154

Stangl, H.	415
Stanik, J.	1 052
Stanikova, D.	1 052
Stanisz, A.	796, 840, 841
Stankovic, A.	373
Starodubtseva, I.	543
Staudacher, G.	503
Stauffer, F.	1 177
Stavek, P.	515, 871
Stavri, S.	1 085
Stef, M.	358
Stefan K., N.	48
Stefanadis, C.	762, 846
Stefanovic, A.	436
Stefánsdóttir, B.R.	1 220
Stein, E.A.	465, 976
Steinberg, A.	244
Steinhagen-Thiessen, E.	669, 935, 989, 1 087
Stender, S.	211
Stenvinkel, P.	47
Stepanov, A.	1 026
Stern, C.	477
Stevens, A.	426
Stewart, F.	650
Steyrer, E.	328
Stiefel, P.	1 158
Stimjanin, E.	706
Stitzel, N.	946
Stivala, S.	127
Stöckl, D.	411
Stoekenbroeck, R.M.	680
Stojkovic, S.	418
Stojakovic, T.	374, 409, 624, 1 146
Stokic, E.	870, 1 095
Stoll, M.	945, 961
Stone, G.W.	399
Stosic, Z.	870, 1 095
Stover, C.	916
Stramba-Badiale, M.	431
Strand, E.	363, 367, 1 208
Straniero, S.	1 116
Straußfeld, E.	291
Stravinsky, J.	827

Straznicky, N.	658	Svobodova, M.	889, 892	Tang, Z.L.	822, 823, 824	Theodorou, K.	704	Toro, R.	614, 904, 1 099, 1 109, 1 162	Trzeciak, J.	584
Strelow Thurow, H.	972	Swartz, E.	93	Tankovskiy, V.	606	Thiersé, D.	283	Torres-Courchoud, I.	505	Tsai, W.C.	516, 773, 919
Strijdom, H.	502, 514	Sweeney, M.	118	Tantry, U.S.	417	Thiessen, E.S.	14, 668	Torres, L.	1 230	Tscharre, M.L.	1 147
Stroes, E.	13, 77, 81, 106, 299, 464, 547, 714	Swiader, A.	346	Tarasenko, N.	1 070	Thomaidis, A.	657	Toseska-Trajkovska, K.	678	Tschöp, M.	298
Stroes, E.S.	669	Swier, V.	82	Tardif, J.C.	244, 696	Thomas, F.	1 196	Tosheska Trajkovska, K.	1 159	Tselepis, A.	928, 1 035, 1 128
Stroes, E.S.G.	392, 627, 1 009	Swift, C.	277	Tardivel, S.	691	Thomaz, S.	1 177	Toshev, B.	572, 1 018	Tselios, K.	617, 618
Strohmaier, S.	770	Swirski, F.	93	Tarhbalouti, K.	1 157	Thompson, P.	314	Toth, P.	389	Tselmin, S.	403, 682
Stroniawska-Woźniak, M.	956	Swirski, F.K.	306	Tarlarini, C.	963	Thorand, B.	411	Touqui, L.	704	Tseng, H.C.	533
Stryeck, S.	443	Syed, A.	426	Tarlovskaya, E.	746, 878, 1 110, 1 165, 1 191	Thymiakou, E.	130	Tousoulis, D.	762	Tsiantoulas, D.	307
Stulnig, T.	231	Sysi-Aho, M.	275	Tarlovskaya, Y.	776	Tibolla, G.	347, 431, 472	Trabtoni, D.	1 033, 1 034	Tsimihodimos, V.	432, 709
Stumpf, C.	377	Szentimrei, R.	435	Tartari, S.	222	Ticha, A.	1 112	Tragante do Ó, V.	240	Tsimikas, S.	455, 627, 668, 669, 670, 673, 674, 680
Su, C.H.	348	Szentpéteri, A.	435, 702, 1 151	Tarzamni, M.K.	817	Tichy, L.	962, 973	Trakarnwijitr, I.	723, 1 206	Tsunoda, T.	1 021
Suarez-Tembra, M.	975	Sztanek, F.	1 227	Tas, S.	704	Tietge, U.	47, 699	Tramontana, A.	1 154	Tsunev, N.	811
Suchanek, P.	515	T		Taskinen, M.	84, 217	Tietge, U.J.F.	804	Tran, H.	757	Tsubeuf, E.	104
Suciu, L.	1 043	Ta, H.	273	Taskinen, M.R.	111, 241, 387, 463	Tikka, A.	623	Trapani, G.	588	Tuckwell, K.	1 013
Sudjana, P.	576	Tabet, F.	119, 342	Tatomir, A.	536	Tilg, H.	312, 503	Trautwein, E.	1 104	Tudorache, I.F.	527, 1 085
Sugihara, H.	886	Taborsky, M.	1 005	Tauchi-Brück, M.	377	Timina, I.	906, 911	Trautwein, E.A.	1 092	Tuimala, J.	354
Suh, J.W.	1 032	Tada, H.	948	Tauchi, M.	1 069	Timmerman, I.	481	Travnikova, E.	1 140	Tuomi, T.M.	354
Suhre, K.	297	Tae Hyun, Y.	1 200	Taurino, M.	544, 549, 550	Tinoco Racero, I.	615	Trayhurn, P.	849	Turer Cabbar, A.	1 150
Sukhova, G.	93	Tae-Hoon, K.	1 130	Tavares Bello, C.	843	Tinoco-Racero, I.	888, 1 099, 1 109	Trbušić, M.	707	turhan caglar, F.N.	826
Sukmanova, I.	1 224, 1 225, 1 226	Taehoon, A.	1 130	Tavintharan, S.	994	Tinoco, I.	904	Tregubov, A.V.	718	Turnbull, A.V.	622
Sullivan, D.	314	Taghipour, H.	1 108	Tawakol, A.	78, 80	Tiran, B.	707	Tremblay, K.	353, 660, 1 053	Tuseddo, J.C.	995
Sullivan, D.R.	471	Taherkhanchi, B.	566	TBA, T.	320, 433	Tishko, V.	501	Trentini, A.	222, 530, 1 033, 1 034, 1 039	Tybjærg-Hansen, A.	237, 211, 427, 429, 1 080
Sulowicz, W.	903	Takahashi, A.	949	Tegla, C.A.	536	Titze, S.	278	Trescher, K.	789	Tzakos, A.	1 128
Sumino, H.	621	Takemoto, Y.	1 041	Tejedor, M.T.	971	Tixeira, R.	489	Tretjakovs, P.	1 152	Tzani, A.	382, 1 119
Sun, J.	248	Takiguchi, S.	693	Tell, G.	275	Toell, T.	1 229	Tribuntseva, L.	750	Tziakas, D.	657
Sun, W.	677	Talbi, E.	1 111, 1 174	Tell, G.S.	363, 367	Toh, R.	338	Trieb, M.	440	Tziomalos, K.	617, 618, 794, 1 088
Sun, Y.T.	516	Talbot, C.	340, 1 103	Tellis, C.	928	Tokgözoglu, L.	72, 255, 294, 296, 715, 984	Triebswetter, S.	908	U	
Sundbom, M.	1 116	Tallada Iborra, R.	531	Temizhan, A.	984	Toledo, V.	1 122	Trikash, I.	1 203	Uboldi, P.	554
Sung Ho, H.	1 200	Tallgren, T.	690	Temporelli, P.L.	1 179	Toma, L.	488, 701	Trikha, D.	722	Ueda, T.	1 045
Sung Woo, K.	1 130	Talmud, P.J.	238	Teng, Z.	349	Tomas, L.	290	Trindade, L.	1 156	Ueland, P.	779
Sung, H.R.	564	Talukdar, S.	88	Teodoro, W.	1 122	Tomashevskaya, Y.	1 044	Tripepi, G.	1 029	Ueland, P.M.	367, 1 208
Sunkara, M.	385	Tam, C.	885	Teoh, Y.P.	936, 990	Tomassini, J.	389	Tripoten, M.	551, 679	Ulbricht, C.	757
Suo, R.	823	Tam, L.	62	Teplov, A.	906	Tomescu, M.	1 043	Tritapepe, L.	549, 550	Ulianova, I.	860
Suoniemi, M.	639	Tamanaha, T.	949	Terrand, J.	283	Tomilova, D.	782	Trivella, M.G.	818, 825	Ulmer, H.	770
Susekov, A.	582	Tamás, F.	1 007	Terrin, M.	725	Tomlinson, B.	357, 885	Trnovska, J.	421, 661, 895	Umarov, A.	608
Suspitsyna, I.	1 225, 1 226	Tamborino, C.	407	Terzhakovec, A.	389	Tondo, C.	450	Trojak, A.	912	ungan, I.	826
Sutcliffe, M.	349	Tami, J.	669, 670	Tervahartiala, T.	410	Toni, D.	544	Trompet, S.	293	Urazgildeeva, S.	400, 718
Suwa, J.	875	Tamura, S.	1 021	Tesloianu, D.	575	Tonkin, A.	314	Trusca, V.G.	527, 1 085	Usenko, T.	740, 890
Suzuki, N.	537, 1 141	Tan Kurklu, T.S.	1 228	Tesmenitsky, Y.	93	Tootsi, K.	1 129			Usui, S.	621
Svardal, A.	363, 1 208	Tanaka, N.	338	Tetik Vardarli, A.	953	Tori, M.O.	1 021				
Svetlikov, A.	400	Tanaka, Y.	579, 610, 727, 755, 756, 905	Thakkar, H.	712	Torii, H.	1 002				
Svardal, A.	363, 1 208	Tanashyan, M.	500, 598, 602	Thaler, B.	418						
Svingen, G.F.T.	363, 367, 1 208	Tang, L.	465, 976								

Utermann, G.	234	van Tuijl, J.	106	Vesa, S.C.	913	Vonbank, A.	366, 731, 732, 733, 839, 879, 883, 991, 1 067, 1 136, 1 137, 1 138	Watts, G.F.	394, 471, 672, 926, 927, 1 168	Witztum, J.L.	455, 627, 668, 669, 670, 673, 680
Utkina, E.	687	Van Veldhoven, P.	655	Vianello, D.	725, 987	Vrablik, M.	243, 962, 778	Weber-Boyvat, M.	286	Wohlfahrt, P.	515
Uto-Kondo, H.	693, 700, 1 049	van Vlijmen, B.J.M.	1 040	Vickers, K.	268	Vrieling, F.	556	Weber, C.	128, 305	Woitas, R.	1 146
Uusitupa, M.	378	van Zonneveld, A.J.	269, 483	Vihervaara, T.	275, 378	Vriz, O.	599	Weber, J.	127	Wojciechowska, W.	931
V		Vandendaele, L.	856	Viklicky, O.	683	Vuilleumier, N.	364, 407	Webster, I.	502	Wojdan, K.	518, 801, 828
Vagida, M.	1 047	Vanoli, D.	595, 596	Vikulova, O.	868, 900	Vujic, N.	284, 335	Weers, P.	641, 651	Wojta, J.	418, 541, 720
Valdivielso, J.M.	774	Varava, A.	911	Vikulova, O.K.	1 048	Vynnychenko, L.	1 187	Wegscheider, M.	443	Wolf, D.	224, 470
Valdivielso, P.	766	Varbo, A.	123	Vila Belmonte, A.	766, 975	Vyzantiadis, T.A.	1 088	Weijers, E.M.	481	Wong, G.	314, 362
Valenti, L.	1 055	VARDARLI, A.T.	951	Vila, À.	944	W		Weijler, A.	649	Wong, M.S.	994
Valenti, V.	954, 1 169	Varejckova, M.	480, 494	Vila, L.	944, 1 012	Wade-Martins, R.	62	Weikert, C.	412	Wong, N.	118
Valikulova, F.	1 231	Varga, E.V.	435, 1 151	Vilela-Martin, J.	1 178	Wadsack, C.	872	Weir, J.	362, 449	Wood, D.	769
Valkov, I.	917	Varga, V.E.	467, 612, 702	Viljoen, K.	1 031	Wahl, S.	313	Welsh, P.	1 013	Woong Chol, K.	1 130
Vallejo-Vaz, A.J.	1 158	Vargas-Alarcón, G.	356, 528	Villanueva	835, 836,	Wakefield, D.	107	Wen, J.T.	1 014	Worm, J.	513
van Beek, L.	556	Variya, B.	1 120	Fernández, E.	837	Waldenberger, M.	313	Werner, C.	381, 624	Worsfold, B.P.	743
van Bockxmeer, F.M.	471	Varol, S.	777	Villar, J.	1 158	Walder, K.	1 113	Werstuck, G.	1 173	Worth, G.	1 009
van Buul, J.D.	481	Varret, M.	946	Villarreal-Molina, T.	356, 528	Waldmann, E.	394	Werz, O.	383	Worthmann, A.	48
van Capelleveen, J.	286, 331, 627	Vasconcelos, C.	843	Vinaixa, M.	434	Wallert, M.	383	West, H.	758	Worthy, G.	1 009
van Dam, A.	556	Vasilieva, E.	548, 555, 1 047	Vincen, V.	712	Walus-Miarka, M.	903, 912, 931	Westcott, C.	502, 514	Woudberg, N.	710
van de Pavert, S.A.	481	Vasilkova, O.	842	Vinchi, F.	102	Wan Ahmad, 716		Whittaker, A.	273	Wu, Y.	704
Van de Voorde, J.	856	Vasilkova, V.	852	Vindis, C.	346	W.N.H.		Wick, G.	351	Wühle-Demuth, M.	1 087
van den Berg, B.M.	483	Vaslin-Reimann, S.	634	Viney, N.J.	668, 669, 670	Wan, J.	873	Widhalm, K.	960, 1 107	X	
van den Berg, S.	556	Vassalo, T.	742, 941	Virzi, J.	407	Wang, A.	248	Więcek, M.	585	Xenaki, C.	1 115
van den Hoek, A.	446	Vasudevan, A.	277	Visek, J.	1 112	Wang, C.C.	704	Wieczorek- Surdacka, E.	903	Xia, S.	669, 670
van den Munckhof, I.	270	Vatrano, M.	588	Vishnolia, K.	1 157	Wang, F.	447, 873	Wieffer, H.M.	392	Xiao, J.	1 186
van der Burgt, Y.	578	Vaudo, G.	849	Visinoni, C.	898	Wang, H.J.	810	Wiegman, A.	968	Xida, L.	490
van der Hoorn, J.W.A.	245	Vaverkova, H.	635, 962	Visocka, A.	1 152	Wang, J.M.	105	Wiegman, A.	968	Xilifu, D.	1 090
van der Krieken, S.E.	103	Vaysberg, A.	1 231	Vitale, G.	1 209	Wang, K.Y.	456	Wigren, M.	290	Xiong, S.L.	823
van der Laarse, A.	578	Vazquez Cardenas, A.	959	Vitali, C.	386	Wang, L.	339	Wiklund, O.	136, 225, 251, 1 055	Xu, Y.	695
van der Tuin, S.	113	Vazquez- Alfageme, J.	1 162	Vitverova, B.	480, 494	Wang, P.	447, 873	Y		Yadav, R.	426
van der Valk, F.M.	669	Vecera, R.	421	Vlachos, I.	382, 1 119	Wang, Q.	447	Willeit, J.	312, 411, 1 229	Yadernaya, A.	568, 728, 850, 1 163
van der Veer, E.	269	Vedie, B.	691	Vlad, A.	1 082	Wang, X.	402, 695	Willeit, K.	503, 1 229	Yagi, K.	948
van der Veer, E.P.	483	Veierød, M.B.	957	Vladimirov, S.	741, 874	Wang, Y.	113, 210	Willeit, P.	312	Yahya, R.	717
van der Vorst, E.	704	Vekić, J.	436, 741, 874	Vlaicu, S.I.	536	Wanner, C.	699, 1 192	Willems van Dijk, J.A.P.	293	Yakushiji, E.	693
Van Eck, M.	704, 1 040	Velagapudi, S.	345	Voevoda, M.	644, 795, 832, 929, 940, 964, 1 212	Wanschel, A.	827	Willems van Dijk, K.	113, 210	Yamada, K.	593
van Esch, H.	269	Veldhof, S.	399	Voevoda, M.I.	947	Wareham, N.J.	680	Willenborg, C.	240	Yamada, S.	456
Van Gaal, L.	215, 719	Velosa, A.P.	1 122	Vogt, A.	970	Wareham, N.T.	627	William, K.	248	Yamagishi, M.	948
van Gils, J.	269	Vendrame, S.	1 105	Voicu, M.	1 043	Wasag, B.	956	Williams, H.	545	Yamashita, S.	63, 395, 461, 653
van Gils, J.M.	483	Venn, A.	758	Voidazan, S.	775	Wasiak, S.	118	Wilson, A.	723, 1 206	Yamashita, T.	583
van Harmelen, V.	556	Verbeek, R.	680	VOINEA, S.	539, 628	Wasserman, S.M.	976	Wilson, R.	313	Yamazaki, Y.	1 041
van Kooten, C.	269	Verhoeven, A.	717	Volpe, R.	1 097	Waters, D.	119	Winkels, H.	128, 305	Yanagida, T.	457
van Leuven, S.I.	547	Verkade, H.J.	804	Volpi, N.	416	Wattimena, D.	717	Wittchen, H.U.	396	Yang-Yen, H.F.	341
van Rooyen, J.M.	619	Veronese, N.	1 029	von Eckardstein, A.	257, 327, 329, 345, 714	Watts, G.	355, 424	Wittenbecher, C.	412	Yang, C.M.	533
van Tits, L.J.	127	VERSET, M.	292								
		Verweij, S.	81, 106								
		Vervilligen, R.A.F.	1 040								

Yang, F.	339
Yang, H.	464
Yang, L.	95
Yang, X.	627, 673
Yang, Z.	479
Yano, S.	703, 1 135
Yarovaya, E.	629, 640
Yasuda, D.	1 002
Yayla Abide, C.	893
Yeang, C.	455, 673, 674
Yen, J.J.Y.	341
Yenercag, M.	984
Yersal, N.	294
Yet, S.F.	348
Yi, C.	210
Yi, G.H.	822, 823, 824
Yilmaz, H.	984
Yilmaz, M.	984
Yin, X.	312
Yin, X.L.	1 186
Yingling, Z.	490
Yki-Järvinen, H.	915
Ylä-Herttua, S.	37
Yogo, M.	693
Yokota, T.	375
Yokoyama, S.	375, 531, 693
yongqiang, H.	809
Yoo, J.A.	829
Yoo, J.Y.	420
Yoshida, M.	948
Yoshikawa, J.	1 041
Yoshikawa, K.	338
Yoshino, G.	855
Yoshino, H.	855
Yoshiyama, M.	1 041
Youn, T.J.	1 032
Young, J.L.	493
Youngkeun, A.	1 200
Yu, C.W.	738, 739, 1 004
Yu, T.	524
Yu, Y.	479, 1 021
Yuan, C.	248
Yue, J.	823


Yurtaev, Y.	783
Yuschak, S.	416
Yvant-Charvet, L.	124, 304
Z	
Zabakhidze, N.	844
Zafir, B.	932
Zagajewski, J.	840
Zagidullin, B.	1 140
Zagidullin, N.	745, 907, 1 140
Zagidullin, S.	745, 907, 1 140
Zagjewski, J.	1 008
Zago, V.H.	983
Zaibi, M.S.	849
Zak, I.	1 218
Zambon, A.	12, 226, 725, 987, 1 029
Zambon, S.	121, 725, 1 029
Zambonin, L.	1 022
Zamfirescu, A.	609, 792
Zamora, A.	944
Zampelas, A.	1 092
Zampetaki, A.	312
Zannis, V.	652
Zannouri, A.	1 174
Zanolin, D.	366, 731, 732, 733, 839, 879, 883, 991, 1 136, 1 137, 1 138
Zanotti, I.	692
Zateyshchikov, D.	785
Zaytsev, D.	807
Zdzienicka, A.	1 016
Zechner, R.	92, 137
Zelarayán M	961
Zelcer, N.	209, 664
Zelinskiy, V.	830
Zeljковиć, A.	436, 741, 874
Zelzer, S.	1 142, 1 143
Zeng, L.	240
Zerr, A.	283
Zhang, H.	483

Zhang, J.	339
Zhang, P.	83
Zhang, Q.H.	822, 823, 824
Zhao, S.	268
Zhelankin, A.	532, 1 076, 1 077
Zheleznyakova, A.	868
Zheltova, I.	1 224
Zhemchugov, A.	400
Zheng, H.	452
Zheng, K.H.	547
Zhetisheva, R.	454, 526, 542
Zhokhov, D.	850
Zhou, P.	447, 873
Zhu, W.	268
Zhu, Y.	653
Zhuang, L.	210
Zielinski, L.P.	743
Ziemann, M.	1 113
Zierfuss, B.	507
Zilmer, M.	1 129
Zimetti, F.	697, 715, 1 058
Zimmer, A.	622
Zimmermann, R.	282, 284
Zimmet, P.	1 113
Zirlik, A.	224, 306, 470
Zito, C.	599
Zivanovic, V.	821
Zivkovic, M.	373
Zizkova, V.	1 005
Zo, J.H.	512, 1 010
Zotikov, A.	793, 906, 911, 1 023
Zouhar, P.	889
Zsiros, N.	467, 702
Zuk, M.	956
Zulkarneev, R.	1 140
Zuraeva, Z.	900
Zvintzou, E.	688
Zykov, K.	1 139
porgeirsson, G.	1 220
omikos, T.	1 115



84th EAS CONGRESS

May 29 - June 1, 2016
Innsbruck, Austria



**RECOGNITION,
ACKNOWLEDGEMENTS AND
COMMERCIAL SUPPORT**

www.eas2016.kenes.com

PCSK9 inhibitors: a conversation on selecting the right patients

PROGRAMME

Chair: Alberico Catapano, Italy

Welcome and introduction Alberico Catapano, Italy

Who is at greatest unmet need? Michel Farnier, France

Clinical perspective Panel

How effective are PCSK9 inhibitors in reducing LDL-C? Erik Stroes, The Netherlands

Clinical perspective Panel

Which patients find it hardest to achieve recommended LDL-C levels?

- Familial hypercholesterolaemia Michel Farnier, France

- Statin intolerance: GAUSS-3 data Erik Stroes, The Netherlands

Clinical perspective Panel

Will lowering LDL-C with PCSK9 inhibitors reduce CV risk? Alberico Catapano, Italy

Closing Q&A and panel discussion Panel

Chair's summary and close Alberico Catapano, Italy

AMGEN

Cardiovascular

Amgen (Europe) GmbH
Dammstrasse 23
CH-6300 Zug
Switzerland
www.amgen.com

© 2016 Amgen Inc. All rights reserved.
EUHQ-NP-145-0216-125392a

Lunch bags will be provided

ACKNOWLEDGEMENTS

CORPORATE PARTNERS

GOLD LEVEL CORPORATE PARTNER

AMGEN

SILVER LEVEL CORPORATE PARTNER

SANOFI

REGENERON

BRONZE LEVEL CORPORATE PARTNERS

Aegerion
Pharmaceuticals

AstraZeneca

Chiesi
People and Ideas for Innovation in healthcare

Kowa

Lilly

MSD

Pfizer

JOINT BRONZE PARTNERS

BASF
The Chemical Company

RAISIO

Unilever

ACKNOWLEDGEMENTS

The Organising Committee and the EAS Executive Committee would like to express their gratitude and acknowledgement to the following companies for their generous support in the 84th EAS Congress:

PLATINUM SPONSORS



GOLD SPONSORS



SILVER SPONSORS



SPONSORS



EXHIBITORS



INDUSTRY SUPPORTED SESSIONS

SUNDAY, MAY 29, 2016

12:30-13:30

CARL VON ROKITANSKY (BRUSSEL) HALL

MEET THE EXPERTS - THE MEDICAL PUZZLE OF HOFH

Aegerion
Pharmaceuticals

Chairperson: **Cesare Sirtori, Italy**

- **Jeanine Roeters Van Lennep**, The Netherlands
- **Claudia Stefanutti**, Italy
- **Marcello Arca**, Italy

16:00-17:30

NIKOLAI N. ANITSCHKOW (TIROL) HALL

MOVING PCSK9 INHIBITION FORWARD: THE FUTURE OF EVIDENCE-BASED CV OUTCOMES IN HIGH-RISK PRIMARY AND SECONDARY PREVENTION PATIENTS

Pfizer Cardiovascular Metabolic

Chairperson: **Jean-Claude Tardif, Canada**

- 16:00 - Welcome and Introductions
Jean-Claude Tardif, Canada
- 16:05 - Case-Based Approach to Identifying High-Risk Primary and Secondary Prevention Patients
Michel Farnier, France
- 16:25 - Current Guidelines for High-Risk Patients: The Need for Evidence-Based Decision Making to Address Remaining Unmet Need
G Kees Hovingh, The Netherlands
- 16:45 - Cardiovascular Risk Reduction With PCSK9 Inhibition: Evidence-Based Long-Term CV Outcomes
Jean-Claude Tardif, Canada
- 17:05 - Panel discussion/Q&A

MONDAY, MAY 30, 2016

13:00-14:30

NIKOLAI N. ANITSCHKOW (TIROL) HALL

PCSK9 INHIBITORS: A CONVERSATION ON SELECTING THE RIGHT PATIENTS

AMGEN
Cardiovascular

Chairperson: **Alberico Catapano, Italy**

- 13:00 - Welcome and introduction
Alberico Catapano, Italy
- 13:05 - Who is at greatest unmet need?
Michel Farnier, France
- 13:15 - Clinical perspective
Panel
- 13:20 - How effective are PCSK9 inhibitors in reducing LDL-C?
Erik Stroes, The Netherlands
- 13:30 - Clinical perspective
Panel
- Which patients find it hardest to achieve recommended LDL-C levels?
- 13:35 - Familial hypercholesterolaemia
Michel Farnier, France
- 13:45 - Statin intolerance: GAUSS-3 data
Erik Stroes, The Netherlands
- 13:55 - Clinical perspective
Panel
- 14:05 - Will lowering LDL-C with PCSK9 inhibitors reduce CV risk?
Alberico Catapano, Italy
- 14:15 - Closing Q&A and panel discussion
Panel
- 14:25 - Chair's summary and close
Alberico Catapano, Italy

13:00-14:30

KARL LANDSTEINER (INNSBRUCK) HALL

LDL-CHOLESTEROL UPDATE 2016

Chairpersons: Lale Tokgözoglu, Turkey
Pepe Zamorano, Spain

13:00 - Welcome and Introduction – What's Hot 2016

Lale Tokgözoglu, Turkey
Pepe Zamorano, Spain

13:10 - The Clinical Reality – Attaining Treatment Targets in 2016

Lale Tokgözoglu, Turkey

13:20 - What Do Recent Combination Studies Teach Us? – The Most Recent Insights

Peter Toth, USA

13:45 - Novel Findings on Genetics and Mendelian Randomization

Heribert Schunkert, Germany

14:00 - The Role of Combination Therapy – Defining Treatment Options for the Individual Patient

Pepe Zamorano, Spain

14:15 - Panel Discussion

Lale Tokgözoglu, Turkey
Pepe Zamorano, Spain

TUESDAY, MAY 30, 2016

13:00-14:30

KARL LANDSTEINER (INNSBRUCK) HALL

PCSK9 THERAPEUTICS – CAN WE REDEFINE THE CLINICAL MANAGEMENT OF HYPERCHOLESTEROLEMIA?


Chairperson: John Chapman, France

13:00 - Introduction

John Chapman, France

13:05 - PCSK9 therapeutics – the evidence so far

Eli Roth, USA

13:25 - PCSK9 therapeutics – early insights from the correlation between LDL-C and cardiovascular events

Kausik Ray, UK

13:45 - PCSK9 therapeutics - what do we have yet to learn?

Ulrich Laufs, Germany

14:05 - Panel Discussion and Q&A

John Chapman, France
Eli Roth, USA
Kausik Ray, UK
Ulrich Laufs, Germany

14:25 - Closing remarks

John Chapman, France

14:00-14:45

NIKOLAI N. ANITSCHKOW (TIROL) HALL

SPECIAL LECTURE: NOVEL CONCEPT AND CLINICAL PROOF TO ADDRESS UNMET MEDICAL NEEDS FOR THE TREATMENT OF RESIDUAL VASCULAR RISK



Chairpersons: Yuji Matsuzawa, Japan
Jean-Charles Fruchart, France

- 14:00 Welcome and Introduction
Yuji Matsuzawa, Japan
Jean-Charles Fruchart, France
- 14:05 Novel generation of Peroxisome Proliferator-Activated Receptor alpha (PPAR α) agonists: selective PPAR α modulator (SPPARM α)
Jean-Charles Fruchart, France
- 14:25 Clinical proof of concept of SPPARM α developed to be more effective and less harmful
Shun Ishibashi, Japan

14:10-14:55

CARL VON ROKITANSKY (BRUSSEL) HALL

CETP INHIBITION – WHAT'S HOT IN 2016?



Chairperson: Alberico Catapano, Italy

- 14:10 Opening by the chair
Alberico Catapano, Italy
- 14:15 The pharmacologic basis: Recent insights into kinetics
Gisette Reyes-Soffer, USA
- 14:25 Facts, Findings & Expectations
Ulf Landmesser, Germany
- 14:35 Is there a need for a new small molecule?
Wouter Jukema, The Netherlands
- 14:45 Round Table, Q&A
Alberico Catapano, Italy

14:05-14:50

WILHELM AUERSWALD (STRASSBURG) HALL

MEET THE EXPERT: INTRODUCING SEBELIPASE ALFA, A NOVEL TREATMENT FOR LAL-D



A case-based meet-the-expert session chaired by Professor Thomas Stulnig
Experts will present cases on Lysosomal Acid Lipase Deficiency including early treatment results with Sebelipase alfa.

EDUCATIONAL GRANT

The following session is supported by an Educational Grant.

MONDAY, MAY 30, 2016

N. ANITSCHKOW HALL

18:40-19:40

KEYNOTE LECTURE



Supported by Amgen, AstraZeneca, MSD, Pfizer, Regenron and Sanofi.

Chair: Alberico Catapano (Italy)

Chair: Wolfgang J. Schneider (Austria)

18:40 How genes control cholesterol
Michael S. Brown (USA)

EXHIBITION INFORMATION

EXHIBITION MAP



EXHIBITORS LIST

Company Name	Booth #
Akcea Therapeutics	22
Alexion Pharma	2
Amgen	18
Denka Seiken	8
European Atherosclerosis Society	10 and 25
European FH Patient Network	5
FH SCORE	23
Fujifilm VisualSonics	12
Immuno-Biological Laboratories	7
Kaneka Pharma Europe	6
Meda Pharma	17
Merck MSD	1
Mercodia	24
Nebion	4
Numares Health	9
Randox	21
Sanofi Regeneron	20
Wisepress Medical Bookshop	26



YOU'VE ONLY JUST ARRIVED & ALREADY WE'RE THINKING OF YOUR NEXT TRIP

As the official airline network for EAS 2016, we'd like to thank you for choosing the Star Alliance network and hope that all goes really well for you here today.

Whilst you concentrate on the day's events, we hope you'll consider us the next time you need to attend a conference.

With over 18,500 flights a day to 1,330 airports across 192 countries, our 28 member airlines will extend a wide choice of flights to any future conference you're planning to attend. And no matter which of those airlines' frequent flyer programmes you belong to, you can earn and redeem miles across all of them.

So the next time you want to concentrate all your energies on your conference, we hope you'll decide to leave the travel arrangements to us.

LIST OF SPONSORS, SUPPORTERS & EXHIBITORS

AEGERION

Aegerion Pharmaceuticals Inc
One Main St, Suite 800
Cambridge
MA 02142
USA
<http://www.aegerion.com>

Aegerion
Pharmaceuticals

Aegerion Pharmaceuticals, headquartered in Cambridge, Massachusetts, is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company was founded in 2005 with an initial focus of bringing new therapies to patients with severe lipid disorders and is now focused on research, development, commercialization of orphan drugs for the treatment of debilitating rare diseases.

AKCEA THERAPEUTICS

55 Cambridge Parkway, Suite 100
Cambridge
02142
USA
Booth #: 22
<http://www.akceatx.com>

AKCEA
THERAPEUTICS
A subsidiary of Ionis Pharmaceuticals, Inc.

Akcea Therapeutics is a development and commercialization company focused on transforming the lives of patients with serious cardiometabolic lipid disorders. Established as a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc., Akcea's portfolio spans multiple targets and disease states using advanced RNA-targeted antisense therapeutics. Akcea's investigational pipeline includes novel drugs designed to reduce several lipid risk factors, including LDL-Cholesterol, apoC-III, triglycerides and Lp(a). Volanesorsen, Akcea's most advanced investigational drug, is in Phase 3 trials for ultra-orphan lipid disorders characterized by extremely high triglycerides and apoC-III, including familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy (FPL). www.akceatx.com.

ALEXION PHARMA

Giesshübelstrasse 30

Zürich

8045

Switzerland

Booth #: 02

<http://www.alexionpharma.eu>

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. Patients with these life-threatening diseases often have no effective treatment options, and they and their families suffer with little hope. Our goal is to deliver medical breakthroughs where none currently exist. We are driven because we know people's lives depend on our work.

**AMGEN**

DAMMSTRASSE 23

ZUG

6300

Switzerland

Booth #: 23

<http://www.amgen.com>

Amgen's Commitment to Cardiovascular Disease Amgen is dedicated to addressing important scientific questions to advance care and improve the lives of patients with cardiovascular disease. Amgen has built a robust cardiology pipeline in an effort to address a number of today's important unmet patient needs, such as high cholesterol and heart failure. About Amgen Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. Amgen has grown to be the world's largest independent biotechnology company, reaching millions of patients around the world.

**AMGEN EU HQ**

Dammstr. 23

Zug

6301

Switzerland

Booth #: 18

<http://www.amgen.com>

Amgen's Commitment to Cardiovascular Disease Amgen is dedicated to addressing important scientific questions to advance care and improve the lives of patients with cardiovascular disease. Amgen has built a robust cardiology pipeline in an effort to address a number of today's important unmet patient needs, such as high cholesterol and heart failure. About Amgen Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. Amgen has grown to be the world's largest independent biotechnology company, reaching millions of patients around the world.

**ASTRAZENECA**

SE-43183 Mölndal,

Pepparedsleden 1

Sweden

www.AstraZeneca.com

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

**BASF**

Carl-Bosch-Strasse 38

Ludwigshafen, Rhineland-Palatinate

Germany

website: <http://www.basf.com>www.newtrition.com

BASF's Nutrition & Health division develops, produces and markets a comprehensive range of products and services for the human and animal nutrition, pharmaceutical as well as flavor and fragrance industries. The division strives to contribute to a better life through improving the nutrition, health and wellbeing of people across the world. Important human nutrition products are vitamins and carotenoids, plant sterols, emulsifiers and omega-3 fatty acids. Its feed additives such as vitamins, carotenoids, enzymes and organic acids make Nutrition & Health a worldwide leader for the animal nutrition market. The division provides the pharmaceutical industry with active ingredients such as caffeine and ibuprofen, as well as excipients and custom synthesis services. Furthermore, it produces aroma ingredients such as citral, geraniol and L-menthol for the flavor and fragrance industry.

**DENKA SEIKEN CO., LTD**

Nihonbashi Mitsui Tower, 2-1-1 Nihonbashi-Muromachi

Tokyo

103-8338

Japan

Booth #: 08

<http://denka-seiken.jp>

Denka Seiken offers assays directly quantifying (without any sample pretreatment) lipid subfractions, and also latex-enhanced turbidimetric immunoassays for specific protein biomarkers to be run on automated chemistry analyzers. The range of lipid subfraction assays includes small dense LDL, HDL3, Remnant Lipoproteins and Triglycerides in LDL particles. The latex-enhanced turbidimetric immunoassays are available for Adiponectin, Lp(a), Cystatin C, hsCRP, RF, Myoglobin, IgE, Ferritin, etc.



EUROPEAN ATHEROSCLEROSIS SOCIETY

Mässans gata 18/ Box 5243

Gothenburg

40224

Sweden

Booth #: 10

<http://www.eas-society.org>

Advancing and exchanging knowledge of the causes, natural history, treatments and prevention of atherosclerotic disease.

**FH EUROPE**

7 North Road

Maidenhead

SL6 1PE

UK

Booth #: 05

<http://www.fheurope.net>

FH Europe is the European FH Patient Network, consisting of 20 European patient organisations. We actively work to secure early identification and diagnosis of FH patients to prevent early cardiovascular disease. Our vision is to identify all FH patients across Europe and for them to be optimally treated in order they may live a full and healthy life. We were founded in 2015 and have successfully achieved a number of activities, including launching a Call to Action at the European Parliament in Brussels, we contributed to videos and articles about FH, attended health care professional meetings to raise awareness of the network and held a meeting of all countries to share best practice.

**FUJIFILM VISUALSONICS**

3080 Yonge Street Suite 6100

Toronto

M4N3N1

Canada

Booth #: 12

<http://www.visualsonics.com>

FUJIFILM VisualSonics, Inc is the undisputed world leader in high-resolution, micro-ultrasound systems designed for cardiovascular research. Our Vevo systems operate at 10-70 MHz, achieving up to 30 µm resolution, 5-10 times higher than any other ultrasound system. Our small animal handling platforms captures key physiological parameters including temperature, respiration, ECG and heart rate. These are integrated in real-time with echo images and data. VisualSonics platforms combine high-resolution, real-time, in vivo imaging at reasonable cost with ease-of-use and quantifiable results.

**IMMUNO-BIOLOGICAL LABORATORIES CO., LTD. (IBL)**

1091-1 Naka Aza-Higashida,

Fujioka-Shi, Gunma

375-0005

Japan

Booth #: 07

<http://www.ibl-japan.co.jp/en/>

"LipoSEARCH" is a sophisticated comprehensive lipoprotein profiling service (using HPLC-based system) that can deliver a reliable and promising complete set of data on Cholesterol and Triglyceride profiled in 4 major classes (CM, VLDL, LDL and HDL) and 20 subclasses classified by particle size. In addition, it also can deliver number of the particles that is recognized as an important factor in recent international research of atherosclerosis and dyslipidemia. The proprietary system and service "LipoSEARCH" is operated and provided by Skylight Biotech Inc. who is owned by Immuno-Biological Laboratories Co., Ltd. located in Japan.

**KANEKA PHARMA EUROPE N.V.**

Frankfurter Straße 80-82

Eschborn

65760

Germany

Booth #: 06

<http://www.kanekapharma.com>

Kaneka Corporation is touching the lives of people all over the world with infinite possibilities of chemistry. By further enhancing our key of highly innovative technology in producing medical devices and building blocks for active pharmaceutical ingredients (API), macromolecules, fermentation and bioscience, Kaneka is exploring new possibilities beyond the traditional boundaries of chemistry. Kaneka Pharma Europe N.V. (KPE) is the independent subsidiary responsible for the European market. Lipoproteinapheresis (Lp(a), LDL), in which Kaneka is one of the pioneers since 1989, is beside the interventional products one of KPE's main business.



KOWA

6-29, Nishiki 3-chome, Naka-ku, Nagoya, Aichi 460-8625

Nagoya

460-8625

Japan

<http://www.kowa.co.jp/eng/>

Kowa Company, Ltd. (Kowa) is a privately held multinational company headquartered in Nagoya, Japan. Established in 1894, Kowa is actively engaged in various manufacturing and trading activities in the fields of pharmaceuticals, life science, information technology, textiles, machinery and various consumer products. Especially, the pharmaceutical field is positioned as the key business segment; prescription (ethical drug), Over-the-Counter (OTC) / Consumer Healthcare / Dietary supplement and Medical equipment. Moreover, the pharmaceutical R&D division is focused on research and development for cardiovascular therapeutics (dyslipidemia, type 2 diabetes and atherosclerosis), ophthalmology and anti-inflammatory agents. To visit Kowa Company, Ltd.'s website, please visit www.kowa.co.jp/eng

**MEDA PHARMA S.P.A.**

Via Valosa di Sopra, 9

Monza

20900

Italy

Booth #: 17

<http://www.meda.se>

Meda is a leading international pharma company with a broad product portfolio. The nutraceuticals developed fall into the same therapeutic categories in which Meda has a wealth of experience. The cardiovascular area of nutraceuticals is represented by Armolipid product line (patented), dietary supplements with natural substances for the control of lipids when integrated in an adequate diet for such purposes. The ingredients of Armolipid line derive from high quality natural extracts with very well documented activity. The production process follows pharmaceutical quality standards, every product is clinically tested and the results of clinical trials published in peer-reviewed international medical journals.

**MERCODIA AB**

Sylveniusgatan 8A

Uppsala


75450

Sweden

Booth #: 24

<http://www.mercodia.com>

Mercodia AB is a Swedish biotech company focusing on the development of immunoassays for research within the field of metabolic disorders. Our assays are applicable to both animal and human models and are used for research ranging from basic scientific studies to large pre-clinical and clinical phase trials. The company was founded in 1991 and is today a world-leading supplier of products to all major international markets. More than ninety percent of our production is exported from our facilities in Uppsala to approximately 100 different countries around the world.

**MSD**

2000 Galloping Hill Road

Kenilworth

07033

USA

Booth #: 01

<http://www.msd.com>

Today's MSD is a global healthcare leader working to help the world be well. MSD is known as Merck in the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. MSD. Be well. For more information, visit www.msd.com

**MYLAN**

Building 4 Trident Place Mosquito Way

Hatfield

AL10 9UL

UK

<http://www.mylan.com/>

Mylan is one of the world's leading global pharmaceutical companies. Our medicines include generic and brand name products in a variety of dosage forms and therapeutic categories, such as difficult-to-manufacture injectables, transdermal patches and HIV/AIDS antiretroviral therapies. The company has innovative research and development capabilities and is one of the world's largest active pharmaceutical ingredient manufacturers. Mylan applies one global quality standard to all of our medications regardless of where they are produced. Creating better health for a better world. That's what inspires Mylan in our mission to provide quality healthcare to the world's 7 billion people, one person at a time.



NUMARES AG

Am BioPark 9
Regensburg
93053
Germany
Booth #: 09



<http://www.numares.com>

numares HEALTH develops innovative, in vitro diagnostic (IVD) tests running exclusively on the AXINON® System. AXINON® relies on numares' proprietary MGS® technology for generating reproducible, quality controlled metabolic information using nuclear magnetic resonance (NMR) spectroscopy. The AXINON® software makes this information based on disease-specific metabolic profiles easily accessible for in vitro diagnostics. The integration of different tests into one system makes AXINON® a highly flexible tool for various diagnostic questions. The new IVD test lipoFIT-S100 (CE) determines clinically proven lipoprotein parameters such as LDL-P and sdLDL in high throughput. Further tests for various indications (e.g. nephrology, oncology) are in development.

RAISIO

P.O. Box 101,
FI-21201 Raisio,
Finland

Website: www.raisio.com

Benecol® - proven to reduce cholesterol

Raisio Group is an expert in plant-based nutrition with strong international and local food brands. Benecol® is the expert brand in cholesterol reduction and a pioneer in the cholesterol lowering functional food category.

Raisio Group produces the unique cholesterol-lowering ingredient, Plant stanol ester, and licenses the Benecol brand worldwide. Benecol products are manufactured and sold by local food companies in 30 countries on five continents.

Over 70 clinical studies support the use of Benecol as an effective, easy and safe dietary tool to lower LDL-cholesterol. The cholesterol-lowering effect of Benecol is additive to those of a healthy diet and statin medication.

**RANDOX BIOSCIENCES**

55 Diamond Road
Crumlin
BT29 4QY
UK

Booth #: 21

<http://www.randoxbiosciences.com/>

Randox Biosciences is dedicated to improving health worldwide through scientific discovery, drug development and diagnostics. We offer a range of molecular products that provide diagnostic, prognostic and predictive solutions across a variety of disease areas including cardiology (cardiac risk prediction) and inherited disease. Our Familial Hypercholesterolemia Arrays I & II enable the simultaneous detection of 40 FH-causing mutations within the LDLR, ApoB and PCSK9 genes. Utilising our award winning Biochip Array Technology for multi-analyte screening of biological samples, our assays provide a complete patient profile from a single sample for rapid, accurate diagnosis.

**REGENERON**

777 Old Saw Mill River Road
Tarrytown, NY
10591
USA

Booth #: 20

<http://www.regeneron.com>

Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for high LDL cholesterol, eye diseases, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, atopic dermatitis, pain and infectious diseases.

**SANOFI**

54, av. La Boétie
Paris
75008
France

Booth #: 20

<http://en.sanofi.com/>

Sanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY)



WISEPRESS MEDICAL BOOKSHOP

25 High Path
London
SW19 2JL
UK

Booth #: 26

<http://www.wisepress.com>

Wisepress.com, Europe's leading conference bookseller, has a range of books and journals relevant to the themes of the meeting. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers. Follow us on Twitter for the latest news @WisepressBooks.



EAS 

84th European Atherosclerosis Society Congress

MEET-THE-EXPERT SESSION

Introducing Sebelipase alfa, a novel treatment for LAL-D

Placing the spotlight on Lysosomal Acid Lipase Deficiency

A case-based Meet-the-Expert session chaired by
Professor Thomas Stulnig (Vienna, Austria)

Experts will present cases on Lysosomal Acid Lipase Deficiency
including early treatment results

31 May 2016; 14:05–14:50

Wilhelm Auerswald (Strassburg) Hall,
Congress und Messe Innsbruck, Innsbruck, Austria

EMA/UNB-LAL/16/0054



